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Summary 
There is accumulating evidence on differences in the link between types of dairy products and cardio-
metabolic health, but inconsistent findings limit the field. In my PhD project, I undertook an 
epidemiological investigation comprising inter-related but distinct themes evaluating aspects of 
nutritional, molecular and genetic epidemiology to advance scientific understanding. 
I undertook research to describe dairy consumption patterns over time by evaluating nationally-
representative data of the United Kingdom National Diet and Nutrition Survey. I observed significant 
time trends for specific dairy types and groups, which were different among different groups of 
people e.g. adults younger than 65 years or elderly people. Using data from the large Fenland 
(n~12,000) and EPIC Norfolk (n~25,000) studies, I investigated associations of total and types of 
dairy consumption with markers of metabolic risk and adiposity as potential pathways to cardio-
metabolic disease. The analyses showed differential associations of dairy types and groups mainly 
with markers of adiposity and lipidaemia. I explored the potential of objective markers to assess dairy 
consumption, by examining metabolomics profiles and blood fatty acids to identify a set of 
biomarkers predicting dairy consumption and prospective associations of the identified biomarkers 
with type 2 diabetes risk. I was able to develop and validate metabolite scores reflecting consumption 
of some dairy products and observed inverse associations between some of these scores and type 2 
diabetes incidence. I analysed genetic determinants of dairy consumption, using a genome-wide 
association study in the UK Biobank (n~500,000) and identified single nucleotide polymorphisms 
predicting milk, cheese and total dairy consumption. 
Overall, this PhD work contributed towards (1) a more precise description of dairy consumption 
patterns in the UK, (2) hypothesis formulation for potential biological pathways linking to cardio-
metabolic disease, (3) discovery of metabolite scores as potential dairy biomarkers and (4) hypothesis 
formulation for potential genetic predictors of dairy consumption. 
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There is accumulating evidence on differences in the link between types of dairy products
and cardio-metabolic health, but inconsistent findings limit the field. In my PhD project, I
undertook an epidemiological investigation comprising inter-related but distinct themes
evaluating aspects of nutritional, molecular and genetic epidemiology to advance scientific
understanding.
I undertook research to describe dairy consumption patterns over time by evaluating
nationally-representative data of the United Kingdom National Diet and Nutrition Survey.
I observed significant time trends for specific dairy types and groups, which were different
among different groups of people e.g. adults younger than 65 years or elderly people.
Using data from the large Fenland (n 12,000) and EPIC Norfolk (n 25,000) studies, I
investigated associations of total and types of dairy consumption with markers of metabolic
risk and adiposity as potential pathways to cardio-metabolic disease. The analyses showed
differential associations of dairy types and groups mainly with markers of adiposity and
lipidaemia. I explored the potential of objective markers to assess dairy consumption, by
examining metabolomics profiles and blood fatty acids to identify a set of biomarkers
predicting dairy consumption and prospective associations of the identified biomarkers
with type 2 diabetes risk. I was able to develop and validate metabolite scores reflecting
consumption of some dairy products and observed inverse associations between some
of these scores and type 2 diabetes incidence. I analysed genetic determinants of dairy
consumption, using a genome-wide association study in the UK Biobank (n 500,000)
and identified single nucleotide polymorphisms predicting milk, cheese and total dairy
consumption.
Overall, this PhD work contributed towards (1) a more precise description of dairy
consumption patterns in the UK, (2) hypothesis formulation for potential biological path-
ways linking to cardio-metabolic disease, (3) discovery of metabolite scores as potential




In revision at the Journal of Nutrition
Trichia E, Imamura F, Brage S, De Lucia Rolfe E, Griffin SJ, Wareham NJ, Forouhi N
G. Associations of types of dairy consumption with cardio-metabolic risk and adiposity:
cross-sectional findings from over 12,000 adults in the Fenland Study, UK, Journal of
Nutrition (Results from Chapter 4)
Under review by co-authors
Trichia E, Imamura F, Khaw KT, Wareham NJ, Forouhi N G. Prospective associations of
total and types of dairy products with markers of metabolic risk and adiposity: findings
from the EPIC Norfolk study, UK (Results from Chapter 5)
Under preparation
• Trichia E, Imamura F, Koulman A, Brage S, Griffin SJ, Langenberg C, Khaw KT,
Wareham NJ, Forouhi N G. Development and validation of dairy prediction models
using metabolomics in two UK cohorts and the associations of derived metabolite
scores with type 2 diabetes risk (Results from Chapters 6 and 7)
• Trichia E, Amoutzopoulos B, Imamura F, Forouhi N G. Dairy consumption patterns
and their contribution to nutrient intakes: findings from the National Diet and
Nutrition Survey 2008-2016 (Results from Chapter 2)
Analyses ongoing
Trichia E, Day FR, Imamura F, Perry J, Wareham NJ, Forouhi N G. Associations of total
and types of dairy consumption with type 2 diabetes risk: a Mendelian Randomisation
study (Results from Chapter 8)
Conference/meeting presentations
• What can metabolomics tell us about dairy consumption and its associations with
type 2 diabetes?, Oral presentation, Rank Prize Symposium, September 2018,
Grasmere, UK (Results from Chapters 6 and 7)
• Metabolomics as a tool for nutritional biomarker discovery to understand the links
between dairy consumption and type 2 diabetes, Poster presentation, Strategic
Research Review Meeting, September 2018, Institute of Public Health, Cambridge,
UK (Results from Chapters 6 and 7)
• Prospective associations of total and types of dairy products with markers of
metabolic risk in the EPIC Norfolk study, UK, Poster presentation, International
Diabetes Federation Congress, December 2017, Abu Dhabi, UAE (Results from
Chapter 5)
• Associations of dairy consumption with fat and lean mass distribution in the Fenland
study, UK, Poster presentation, European Association for the Study of Diabetes
(EASD) Annual Meeting, September 2017, Lisbon, Portugal (Results from Chap-
ter 4)
• Dairy products intake, diabetes, obesity and body composition - is there a link?, Oral
presentation, Wolfson Research Event, February 2016, Cambridge, UK (Results
from Chapter 4)
Public engagement
• European Association for the Study of Diabetes (EASD) Annual Meeting 2017
press release “Body fat mass distribution: A possible explanation for lower diabetes
risk associated with dairy food consumption” (https://www.eurekalert.org/pub_
releases/2017-09/d-bfm091117.php, https://www.sciencedaily.com/releases/2017/
09/170913193146.htm; Results from Chapter 4)
• Conversation “Dairy got the all-clear this week - but was it justified?” (https://
theconversation.com/dairy-got-the-all-clear-this-week-but-was-it-justified-77423)
• Entry to Max Perutz writing competition: "A milk-way round trip: From genes to






AUC: Area Under the Curve
BMI: Body Mass Index
CLA: Conjugated Linoleic Acid
CHD: Coronary Heart Disease
CRP: C-Reactive Protein
CVD: Cardiovascular Disease
DEXA: Dual Energy X-ray Absorptiometry
DBP: Diastolic Blood Pressure
ESI:Electrospray Ionisation
FAO:Food and Agriculture Organisation
FDR: False Discovery Rate
FFQ: Food Frequency Questionnaire
FIA: Flow Injection Analysis
FSA: Food Standards Agency
GBD: Global Burden of Disease
GGT:Gamma Glutamyl Transferase
GWAS: Genome-Wide Association Study
HbA1c: Haemoglobin A1c
HESI-II: Heated Electrospray Ionisation - II
HILIC: Hydrophilic Interaction Liquid Chromatography
HOMA-IR: Homeostasis Model Assessment for Insulin Resistance
HOMA-%B: Homeostasis Model Assessment for β -cell Function
LASSO: Least Absolute Shrinkage and Selection Operator
LDL-C: Low-Density Lipoprotein Cholesterol
LP: Lactase Persistence
LPC: Lyso-Phospatidylcholine
MRC: Medical Research Council
MS: Mass Spectrometry
MUFA: Monounsaturated Fatty Acids
NAFLD: Non-Alcoholic Fatty Liver Disease
NDNS: National Diet and Nutrition Survey
NEFA: Non-Esterified Fatty Acids
NMR: Nuclear Magnetic Reasonance
OCSFA: Odd-Chain Saturated Fatty Acid
PC: Phosphatidylcholine
PCA: Principal Component Analysis
PUFA: Polyunsaturated Fatty Acids
QC: Quality Control
RCT: Randomised Controlled Trial
ROC: Receiver Operating Characteristic
SBP: Systolic Blood Pressure
SCAT: Subcutaneous Adipose Tissue
SFA: Saturated Fatty Acids
SGD: Stochastic Gradient Descent
SM: Sphingomyelin
SNP: Single Nucleotide Polymorphism
T2D: Type 2 Diabetes
TFA: Trans Fatty Acids
TRIPOD: Transparent Reporting of a multivariable Prediction model for individual
Prognosis Or Diagnosis
UPLC: Ultra Performance Liquid Chromatography
VAT: Visceral Adipose Tissue
Table of contents
List of figures  xxii
List of tables  xxvi
1 Introduction 1
1.1 Burden of cardio-metabolic disease . . . . . . . . . . . . . . . . . . . . . 1
1.2 Dairy products and cardio-metabolic disease . . . . . . . . . . . . . . . . 2
1.3 Dietary guidelines . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5
1.4 Dairy food matrix . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6
1.5 Project aims . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 13
2 Description of dairy consumption in the UK 15
2.1 Data sources of dairy consumption in the UK . . . . . . . . . . . . . . . 18
2.2 Profiles of dairy consumers . . . . . . . . . . . . . . . . . . . . . . . . . 20
2.3 Aims . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 21
2.4 Methods . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 21
2.4.1 Study design and population . . . . . . . . . . . . . . . . . . . . 21
2.4.2 Dietary assessment . . . . . . . . . . . . . . . . . . . . . . . . . 22
2.4.3 Assessment of other factors . . . . . . . . . . . . . . . . . . . . 24
2.4.4 Statistical analysis . . . . . . . . . . . . . . . . . . . . . . . . . 24
2.5 Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 26
2.5.1 Basic characteristics . . . . . . . . . . . . . . . . . . . . . . . . 26
2.5.2 Trends in dairy consumption . . . . . . . . . . . . . . . . . . . . 28
2.5.3 Dairy consumption by sex . . . . . . . . . . . . . . . . . . . . . 38
2.5.4 Dairy contribution to nutrient intakes . . . . . . . . . . . . . . . 40
2.6 Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 48
2.6.1 Summary of results and comments . . . . . . . . . . . . . . . . . 48
2.6.2 Strengths and limitations . . . . . . . . . . . . . . . . . . . . . . 49
2.6.3 Conclusion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 50
xvii Table of contents
3 Previous evidence on dairy consumption and cardio-metabolic markers 51
3.1 Markers of body weight and composition . . . . . . . . . . . . . . . . . 53
3.1.1 Body weight . . . . . . . . . . . . . . . . . . . . . . . . . . . . 53
3.1.2 Body composition . . . . . . . . . . . . . . . . . . . . . . . . . 55
3.2 Lipid markers . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 63
3.3 Glycaemic markers . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 76
3.4 Inflammatory markers . . . . . . . . . . . . . . . . . . . . . . . . . . . . 77
3.5 Markers of hepatic function . . . . . . . . . . . . . . . . . . . . . . . . . 77
3.6 Blood pressure . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 78
3.7 Metabolic syndrome . . . . . . . . . . . . . . . . . . . . . . . . . . . . 78
3.8 Gaps in the literature . . . . . . . . . . . . . . . . . . . . . . . . . . . . 78
4 Associations of dairy consumption with cardio-metabolic markers: a cross-
sectional analysis in the Fenland Study, UK 81
4.1 Previous evidence on cross-sectional associations . . . . . . . . . . . . . 83
4.2 Study aims . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 84
4.3 Methods . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 85
4.3.1 Study design and population . . . . . . . . . . . . . . . . . . . . 85
4.3.2 Dietary assessment . . . . . . . . . . . . . . . . . . . . . . . . . 85
4.3.3 Assessment of markers of metabolic risk and adiposity . . . . . . 87
4.3.4 Assessment of socio-demographic and lifestyle factors . . . . . . 88
4.3.5 Statistical analysis . . . . . . . . . . . . . . . . . . . . . . . . . 88
4.4 Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 90
4.4.1 Descriptive characteristics . . . . . . . . . . . . . . . . . . . . . 90
4.4.2 Dairy products and body composition . . . . . . . . . . . . . . . 94
4.4.3 Dairy products and metabolic markers . . . . . . . . . . . . . . . 96
4.4.4 Additional analyses . . . . . . . . . . . . . . . . . . . . . . . . . 99
4.5 Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 100
4.5.1 Summary of results . . . . . . . . . . . . . . . . . . . . . . . . . 100
4.5.2 Markers of adiposity . . . . . . . . . . . . . . . . . . . . . . . . 101
4.5.3 Markers of metabolic risk . . . . . . . . . . . . . . . . . . . . . 102
4.5.4 Strengths and limitations . . . . . . . . . . . . . . . . . . . . . . 103
4.5.5 Conclusion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 103
5 Associations of dairy consumption with cardio-metabolic markers: a prospec-
tive analysis in the EPIC Norfolk Study, UK 105
5.1 Previous evidence on prospective associations . . . . . . . . . . . . . . . 108
5.2 Study aims . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 108
5.3 Methods . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 109
5.3.1 Study design and population . . . . . . . . . . . . . . . . . . . . 109
Table of contents xviii
5.3.2 Dietary assessment . . . . . . . . . . . . . . . . . . . . . . . . . 109
5.3.3 Assessment of markers of metabolic risk and adiposity . . . . . . 109
5.3.4 Assessment of socio-demographic and lifestyle factors . . . . . . 110
5.3.5 Statistical analyses . . . . . . . . . . . . . . . . . . . . . . . . . 110
5.4 Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 111
5.4.1 Descriptive characteristics . . . . . . . . . . . . . . . . . . . . . 111
5.4.2 Dairy products and anthropometric markers . . . . . . . . . . . . 117
5.4.3 Dairy products and metabolic markers . . . . . . . . . . . . . . . 117
5.4.4 Longitudinal analyses . . . . . . . . . . . . . . . . . . . . . . . 120
5.4.5 Additional analyses . . . . . . . . . . . . . . . . . . . . . . . . . 126
5.5 Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 130
5.5.1 Summary of results . . . . . . . . . . . . . . . . . . . . . . . . . 130
5.5.2 Findings in context of previous evidence . . . . . . . . . . . . . . 130
5.5.3 Longitudinal analyses . . . . . . . . . . . . . . . . . . . . . . . 132
5.5.4 Strengths and limitations . . . . . . . . . . . . . . . . . . . . . . 133
5.5.5 Conclusion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 134
6 Biomarkers of dairy consumption: Part I 135
6.1 Measurement error in dietary assessment . . . . . . . . . . . . . . . . . . 138
6.2 Nutritional biomarkers . . . . . . . . . . . . . . . . . . . . . . . . . . . 139
6.3 Odd-chain and trans-16:1n-7 fatty acids as biomarkers of dairy consumption140
6.4 Limitations of fatty acids as candidate dairy biomarkers . . . . . . . . . . 142
6.5 Use of metabolomics for the identification of novel nutritional biomarkers 145
6.6 Metabolomics in epidemiology and nutrition research . . . . . . . . . . . 146
6.7 Previous studies on the exploration of dairy biomarkers using metabolomics146
6.8 Study aims . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 150
6.9 Methods . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 150
6.9.1 Study design and population . . . . . . . . . . . . . . . . . . . . 150
6.9.2 Metabolite and fatty acid measurement . . . . . . . . . . . . . . 151
6.9.3 Metabolite annotation . . . . . . . . . . . . . . . . . . . . . . . 155
6.9.4 Dietary assessment . . . . . . . . . . . . . . . . . . . . . . . . . 155
6.9.5 Statistical analysis . . . . . . . . . . . . . . . . . . . . . . . . . 155
6.10 Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 160
6.10.1 Descriptive characteristics . . . . . . . . . . . . . . . . . . . . . 160
6.10.2 Metabolite matching between the two cohorts . . . . . . . . . . . 161
6.10.3 Discovery of metabolites predicting dairy consumption . . . . . . 169
6.10.4 Effect of adjusting for diet on discovery results . . . . . . . . . . 172
6.10.5 Internal validation . . . . . . . . . . . . . . . . . . . . . . . . . 172
6.10.6 External validation . . . . . . . . . . . . . . . . . . . . . . . . . 174
xix Table of contents
6.10.7 Predictive value of the metabolite scores in addition to C15:0,
C17:0 and trans-16:1n-7 . . . . . . . . . . . . . . . . . . . . . . 175
6.11 Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 181
6.11.1 Summary of results . . . . . . . . . . . . . . . . . . . . . . . . . 181
6.11.2 Findings in context of previous evidence . . . . . . . . . . . . . . 181
6.11.3 Biological interpretation . . . . . . . . . . . . . . . . . . . . . . 182
6.11.4 Strengths and limitations . . . . . . . . . . . . . . . . . . . . . . 183
6.11.5 Conclusion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 184
7 Biomarkers of dairy consumption: Part II. Associations with type 2 diabetes185
7.1 Previous evidence . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 188
7.2 Study aims . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 189
7.3 Methods . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 189
7.3.1 Study design and population . . . . . . . . . . . . . . . . . . . . 189
7.3.2 Development of metabolite scores and metabolomics analyses . . 189
7.3.3 Diabetes case ascertainment . . . . . . . . . . . . . . . . . . . . 189
7.3.4 Statistical analysis . . . . . . . . . . . . . . . . . . . . . . . . . 190
7.4 Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 190
7.4.1 Descriptive characteristics . . . . . . . . . . . . . . . . . . . . . 190
7.4.2 Associations of metabolite scores with type 2 diabetes risk . . . . 192
7.5 Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 199
7.5.1 Summary of results and overall interpretation . . . . . . . . . . . 199
7.5.2 Findings in the context of previous evidence . . . . . . . . . . . . 199
7.5.3 Interpretation and potential mechanisms . . . . . . . . . . . . . . 200
7.5.4 Strengths and limitations . . . . . . . . . . . . . . . . . . . . . . 201
7.5.5 Conclusion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 201
8 Genetic predictors of dairy consumption 203
8.1 Lactase persistence . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 206
8.2 Mendelian randomisation . . . . . . . . . . . . . . . . . . . . . . . . . . 210
8.3 Study aims . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 211
8.4 Methods . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 212
8.4.1 Study design and population . . . . . . . . . . . . . . . . . . . . 212
8.4.2 Genotyping . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 212
8.4.3 Dietary assessment and data processing . . . . . . . . . . . . . . 212
8.4.4 Statistical analysis . . . . . . . . . . . . . . . . . . . . . . . . . 219
8.5 Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 221
8.5.1 Description of dairy outcomes . . . . . . . . . . . . . . . . . . . 221
8.5.2 Positive control analysis . . . . . . . . . . . . . . . . . . . . . . 221
8.5.3 Genome-wide association studies . . . . . . . . . . . . . . . . . 222
Table of contents xx
8.5.4 Exploratory work on biological interpretation . . . . . . . . . . . 228
8.6 Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 234
8.6.1 Summary of results . . . . . . . . . . . . . . . . . . . . . . . . . 234
8.6.2 Interpretation and previous evidence . . . . . . . . . . . . . . . . 234
8.6.3 Strengths and limitations . . . . . . . . . . . . . . . . . . . . . . 235
8.6.4 Implications and recommendations for future research . . . . . . 236
8.6.5 Conclusion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 237
9 Discussion 239
9.1 Summary of results and links to PhD aims . . . . . . . . . . . . . . . . . 239
9.2 Interpretation of findings . . . . . . . . . . . . . . . . . . . . . . . . . . 240
9.2.1 Potential biological mechanisms . . . . . . . . . . . . . . . . . . 240
9.2.2 Epidemiological considerations . . . . . . . . . . . . . . . . . . 247
9.3 Strengths and limitations . . . . . . . . . . . . . . . . . . . . . . . . . . 253
9.4 Implications for public health . . . . . . . . . . . . . . . . . . . . . . . 254
9.5 Suggestions for future research . . . . . . . . . . . . . . . . . . . . . . . 255
9.6 Conclusions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 256
References 257
Appendix A Supplemental results 285
A.1 Chapter 2 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 285
A.2 Chapter 4 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 289
A.3 Chapter 5 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 299
A.4 Chapter 6 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 317
A.5 Chapter 8 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 358
Appendix B Glossary of genetic terms 363

List of figures
1.1 Top risk factors for disability adjusted life years (DALYs) globally . . . . 2
1.2 Eatwell Guide 2016, Public Health England, UK . . . . . . . . . . . . . 7
1.3 Macronutrient composition of full-fat and low-fat milk. . . . . . . . . . . 9
1.4 Macronutrient composition of full-fat and low-fat yoghurt. . . . . . . . . 10
1.5 Macronutrient composition of high-fat and low-fat cheese. . . . . . . . . 11
1.6 Macronutrient composition of butter. . . . . . . . . . . . . . . . . . . . . 12
1.7 Mindmap of the PhD . . . . . . . . . . . . . . . . . . . . . . . . . . . . 14
2.1 Milk consumption in the UK, Global Dietary Database . . . . . . . . . . 19
2.2 National Diet and Nutrition Survey timeline . . . . . . . . . . . . . . . . 22
2.3 Time trends of total, high- and low-fat dairy consumption among adults
<65 years . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 29
2.4 Time trends of total, high- and low-fat dairy consumption among elderly
≥65 years . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 30
2.5 Time trends of total, full- and low-fat milk consumption among adults <65
years . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 31
2.6 Time trends of total, full- and low-fat milk consumption among elderly
≥65 years . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 32
2.7 Time trends of total, full- and low-fat yoghurt consumption among adults
<65 years . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 33
2.8 Time trends of total, full- and low-fat yoghurt consumption among elderly
≥65 years . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 34
2.9 Time trends of total, high- and low-fat cheese consumption among adults
<65 years . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 35
2.10 Time trends of total, high- and low-fat cheese consumption among elderly
≥65 years . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 36
2.11 Time trends of butter, cream and fermented dairy consumption among
adults <65 years . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 37
2.12 Time trends of total, high- and low-fat cheese consumption among elderly
≥65 years . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 38
xxiii List of figures
4.1 Adjusted associations of types of dairy consumption (servings/day) with
markers of body composition . . . . . . . . . . . . . . . . . . . . . . . . 95
4.2 Adjusted associations of types of dairy consumption (servings/day) with
lipid markers. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 97
4.3 Adjusted associations of types of dairy consumption (servings/day) with
glycaemic markers. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 98
4.4 Adjusted associations of types of dairy consumption (servings/day) with
markers of hepatic function. . . . . . . . . . . . . . . . . . . . . . . . . 99
4.5 Adjusted associations of types of dairy consumption (servings/day) with
systolic and diastolic blood pressure, CRP and adiponectin . . . . . . . . 100
4.6 Non-linear associations of dairy products with HbA1c, ratio of total to
HDL-C and CRP. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 100
5.1 Adjusted associations of changes in dairy consumption with changes in
anthropometric markers . . . . . . . . . . . . . . . . . . . . . . . . . . . 117
5.2 Adjusted associations of changes in dairy consumption with changes in
lipid markers. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 119
5.3 Adjusted associations of changes in dairy consumption with changes in
HbA1c, blood pressure and metabolic risk z-score. . . . . . . . . . . . . 120
6.1 Mechanism of endogenous odd-chain saturated fatty acid production from
propionate. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 144
6.2 Flow diagram of the inclusion process of participants in the discovery,
internal and external validation sets . . . . . . . . . . . . . . . . . . . . . 151
6.3 Heatmaps of the top elastic net signals in the discovery set from three sets
of analyses . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 171
6.4 Receiver operating characteristic (ROC) curves for dairy prediction models
in the internal validation set using the 82 overlapping metabolites . . . . . 173
8.1 Global distribution map of lactase persistence (LP) and the -213910*T allele207
8.2 Global distribution map of milk consumption in 2010, Global Dietary
Database . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 208
8.3 Milk contribution to the total amount of food consumed in the UK and
China in 2010, Global Dietary Database . . . . . . . . . . . . . . . . . . 209
8.4 Comparison of Mendelian randomisation with randomised controlled trials 211
8.5 Dietary assessment timeline and number of participants in each repeated
assessment in the UK Biobank . . . . . . . . . . . . . . . . . . . . . . . 213
8.6 Algorithm for the estimation of milk consumption from coffee as assessed
from Oxford WebQ . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 215
8.7 Algorithm for the estimation of milk consumption from tea as assessed
from Oxford WebQ . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 215
List of figures xxiv
8.8 Algorithm for the estimation of milk consumption from cereals as assessed
from Oxford WebQ . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 216
8.9 Manhattan plots from GWAS on total dairy products, milk consumed as
drink or added to cereals and cheese in the UK Biobank . . . . . . . . . . 223
8.10 Manhattan plots from GWAS on milk consumed as drink or added to
coffee, tea or cereals, milk consumed as a drink only and yoghurt in the
UK Biobank . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 224
8.11 Linkage disequilibrium of single nucleotide polymorphisms (SNPs) with
the lead SNP, rs4988235 . . . . . . . . . . . . . . . . . . . . . . . . . . 227
A.1 Receiver operating characteristic (ROC) curves for dairy prediction models
in the internal validation set using all the 174 metabolites . . . . . . . . . 347

List of tables
1.1 Directions of associations between total and types of dairy products and
cardio-metabolic disease outcomes as reported from meta-analyses of
prospective cohort studies . . . . . . . . . . . . . . . . . . . . . . . . . . 3
1.2 Content of selected micronutrients in 100 g of dairy food for selected dairy
types . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 13
2.1 Re-allocation of the start day of diary reporting for a subset of four days
out of the seven completed by adults in the National Diet and Nutrition
Survey (NDNS) 2000/01. . . . . . . . . . . . . . . . . . . . . . . . . . . 23
2.2 Basic characteristics of participants <65 years and ≥65 years in each
survey year of the National Diet and Nutrition Survey (NDNS) . . . . . . 27
2.3 Means, SE, median and IQR of total and types of dairy products within
consumers and percentage of consumers among men and women <65 years
and ≥65 years in the old survey years and the first 8 years of the rolling
programme of the National Diet and Nutrition Survey (NDNS) (2008-2016) 39
2.4 Percentage of the contribution of total and types of dairy products to total
energy and macronutrient intakes in the first 8 years of the National Diet
and Nutrition (NDNS) rolling programme (2008-2016) . . . . . . . . . . 41
2.5 Percentage of the contribution of total and types of dairy products to
micronutrient intakes in the first 8 years of the National Diet and Nutrition
(NDNS) rolling programme (2008-2016) . . . . . . . . . . . . . . . . . . 45
3.1 Directions of associations reported in meta-analyses of randomised con-
trolled trials (RCTs) or prospective cohort studies for total and types of
dairy consumption and cardio-metabolic markers . . . . . . . . . . . . . 57
3.2 Observational studies examining the prospective associations between
dairy consumption and anthropometric markers in multivariable models . 60
3.3 Characteristics of randomised controlled trials (RCTs) on the effects of
butter consumption on total cholesterol stratified by the fat intake category
of the comparison group . . . . . . . . . . . . . . . . . . . . . . . . . . 66
xxvii List of tables
3.4 Characteristics of randomised controlled trials (RCTs) on the effects of but-
ter consumption on low-density lipoprotein cholesterol (LDL-C) stratified
by the fat intake category of the comparison group . . . . . . . . . . . . . 68
3.5 Characteristics of randomised controlled trials (RCTs) on the effects of but-
ter consumption on high-density lipoprotein cholesterol (HDL-C) stratified
by the fat intake category of the comparison group . . . . . . . . . . . . . 70
3.6 Characteristics of randomised controlled trials (RCTs) on the effects of
butter consumption on triglycerides stratified by the fat intake category of
the comparison group . . . . . . . . . . . . . . . . . . . . . . . . . . . . 72
4.1 Definitions of dairy groups . . . . . . . . . . . . . . . . . . . . . . . . . 86
4.2 Descriptive characteristics of socio-demographic, behavioural and clinical
factors for the top and bottom categories of milk, yoghurt and cheese
consumption (g/d), as well as in the total sample of the Fenland study . . 91
4.3 Descriptive characteristics of dietary factors for the top and bottom cate-
gories of milk, yoghurt and cheese consumption (g/d), as well as in the
total sample of the Fenland study . . . . . . . . . . . . . . . . . . . . . . 92
5.1 Descriptive characteristics of total and types of dairy products at baseline,
first follow-up and the change between baseline and first follow-up in the
EPIC-Norfolk study (n=15,612) . . . . . . . . . . . . . . . . . . . . . . 112
5.2 Descriptive characteristics of markers of metabolic risk and adiposity
at baseline, first follow-up, second follow-up and the change between
baseline and first follow-up in the EPIC-Norfolk study (n=15,612) . . . . 113
5.3 Descriptive characteristics of socio-demographic, behavioural, clinical
and non-dairy dietary factors at baseline, first follow-up and the change
between baseline and first follow-up in the EPIC-Norfolk study . . . . . . 114
5.4 Descriptive statistics of socio-demographic, behavioural, clinical and di-
etary factors by milk, yoghurt and cheese consumption at baseline: the
EPIC-Norfolk study . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 115
5.5 Longitudinal associations of the repeated measures of total and types of
dairy products at baseline (1993-1997) and first follow-up (1998-2000)
with the repeated measures of the markers of body weight and composition
at the first and the second (2004-2011) follow-up in the EPIC-Norfolk study122
5.6 Longitudinal associations of the repeated measures of total and types of
dairy products at baseline (1993-1997) and first follow-up (1998-2000)
with the repeated measures of lipid markers at the first and the second
(2004-2011) follow-up in the EPIC-Norfolk study . . . . . . . . . . . . . 123
List of tables xxviii
5.7 Longitudinal associations of the repeated measures of total and types of
dairy products at baseline (1993-1997) and first follow-up (1998-2000)
with the repeated measures of HbA1c, blood pressure and a z-score for
metabolic risk at the first and the second (2004-2011) follow-up in the
EPIC-Norfolk study . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 124
5.8 Stratified results by age for significant interactions in associations of the
change in total and types of dairy products with the change in cardio-
metabolic markers from baseline to the first follow-up after a mean of 3.7
years in the EPIC-Norfolk study . . . . . . . . . . . . . . . . . . . . . . 127
5.9 Stratified results by sex for significant interactions in associations of the
change in total and types of dairy products with the change in cardio-
metabolic markers from baseline to the first follow-up after a mean of 3.7
years in the EPIC-Norfolk study . . . . . . . . . . . . . . . . . . . . . . 128
5.10 Stratified results by BMI for significant interactions in associations of
the change in total and types of dairy products with the change in cardio-
metabolic markers from baseline to the first follow-up after a mean of 3.7
years in the EPIC-Norfolk study . . . . . . . . . . . . . . . . . . . . . . 129
6.1 Previously published crude correlations or adjusted associations of fatty
acids C14:0, C15:0, C17:0 and trans-16:1n-7 with total and high-fat dairy
products . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 143
6.2 Discovery studies of potential novel biomarkers of dairy consumption
using metabolomics . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 149
6.3 Comparison of characteristics of the three main penalised regression methods158
6.4 Predictors included in the models for the prediction of dairy consumption 159
6.5 Descriptive characteristics of socio-demographic, lifestyle and clinical
factors in the discovery and validation set of the Fenland study and the
external validation set of the EPIC Norfolk diabetes case cohort study . . 162
6.6 Metabolite matching between the targeted metabolomics platform (Biocrates)
in the Fenland study and the untargeted platform (Metabolon) in the EPIC
Norfolk diabetes case-cohort study . . . . . . . . . . . . . . . . . . . . . 163
6.7 Parameters used in the elastic net models in the discovery set for the
different set of metabolites . . . . . . . . . . . . . . . . . . . . . . . . . 170
6.8 R2 of elastic net linear regression models of continuous dairy outcomes in
the internal validation set of the Fenland study . . . . . . . . . . . . . . . 174
6.9 Areas under the curve (AUC) for logistic regression models of the dairy
outcomes against the metabolite scores adjusted for socio-demographic
and lifestyle factors in the internal and external validation sets . . . . . . 175
xxix List of tables
6.10 Areas under the curve statistics of the logistic models with or without
the fatty acids C15:0, C17:0, trans-16:1n-7 and the metabolite score (82
metabolites) for total and types of dairy products in the internal validation
set of the Fenland study . . . . . . . . . . . . . . . . . . . . . . . . . . . 177
6.11 Likelihood ratio tests for the models with or without the fatty acids and
the metabolite score in the fatty acid set (internal validation set, n=4,246)
of the Fenland study . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 178
6.12 Beta coefficients (b), 95% CIs and p-values of the metabolite score and
the three fatty acids from logistic prediction models of dairy consumption. 179
7.1 Descriptive characteristics of socio-demographic, lifestyle, clinical and
dietary factors in the EPIC Norfolk diabetes case cohort study . . . . . . 191
7.2 Metabolites included in the top metabolite scores for total and types of
dairy consumption from elastic net regression models using metabolomics
data in the discovery set of the Fenland study . . . . . . . . . . . . . . . 194
7.3 Hazard ratios of type 2 diabetes per 1 SD of metabolite scores significantly
predicting dairy consumption in the incident diabetes case-cohort set nested
within the EPIC Norfolk study . . . . . . . . . . . . . . . . . . . . . . . 195
7.4 Hazard ratios of type 2 diabetes per 1 SD of metabolite scores not signifi-
cantly predicting dairy consumption in the incident diabetes case-cohort
set nested within the EPIC Norfolk study . . . . . . . . . . . . . . . . . . 196
7.5 Hazard ratios of type 2 diabetes per 1 SD of metabolite scores significantly
predicting dairy consumption in the OCSFA subset of the incident diabetes
case-cohort set nested within the EPIC Norfolk study . . . . . . . . . . . 197
7.6 Hazard ratios of type 2 diabetes per 1 SD of metabolite scores not signifi-
cantly predicting dairy consumption in the OCSFA subset of the incident
diabetes case-cohort set nested within the EPIC Norfolk study . . . . . . 198
8.1 Lactose content in 100 g of different types of dairy products . . . . . . . 210
8.2 Assumptions for the estimation of milk added to coffee, tea and cereals as
assessed from the Oxford WebQ in the UK Biobank . . . . . . . . . . . . 217
8.3 Number of consumers and non-consumers for binary dairy phenotypes
and mean±SD for the continuous dairy phenotypes in the UK Biobank
subsets used for the genome-wide association studies (GWAS) . . . . . . 222
8.4 Positive control results for the associations of the lactase persistence single
nucleotide polymorphism (rs4988235) with milk and total dairy consump-
tion in subsets of all ethnicities or white people only in the UK Biobank . 222
8.5 Single nucleotide polymorphisms (SNPs) significantly associated with
milk, yoghurt, cheese and total dairy consumption from genome-wide
association studies in the UK Biobank . . . . . . . . . . . . . . . . . . . 225
List of tables xx
8.6 Functional annotation and corresponding genes for the genome-wide asso-
ciation study (GWAS) top single nucleotide polymorphism (SNP) hits of
dairy phenotypes in the UK Biobank . . . . . . . . . . . . . . . . . . . . 226
8.7 Information on genes, which include the top single nucleotide polymor-
phism (SNP) hits from the genome-wide association studies (GWAS) on
the dairy phenotypes in the UK Biobank . . . . . . . . . . . . . . . . . . 229
8.8 Traits associated with the top SNP hits from phenome-wide association
studies (PheWAS) in the UK Biobank . . . . . . . . . . . . . . . . . . . 232
A.1 Means and SE of total and types of dairy products within consumers and
percentage of consumers among adults <65 years and ≥65 years in the old
survey years and the first 8 years of the rolling programme of the National
Diet and Nutrition Survey (NDNS) (2008-2016) . . . . . . . . . . . . . . 286
A.2 Median and inter-quartile range (IQR) of total and types of dairy products
within consumers and percentage of non-consumers among adults <65
years in the year 2000/2001 and the first 8 years of the rolling programme
of the National Diet and Nutrition Survey (NDNS) (2008-2016) . . . . . 287
A.3 Means and SE of total and types of dairy products (kcal/2000 kcal) within
consumers and percentage of consumers among adults <65 years and ≥65
years in the old survey years and the first 8 years of the rolling programme
of the National Diet and Nutrition Survey (NDNS) (2008-2016) . . . . . 288
A.4 Associations of total and types of dairy consumption with clinical markers
of body weight and composition from multiple linear regression models . 290
A.5 Associations of total and types of dairy consumption with markers of body
composition assessed with Dual Energy X-Ray Absorptiometry (DEXA)
from multiple linear regression models . . . . . . . . . . . . . . . . . . . 292
A.6 Associations of total and types of dairy consumption with lipid markers
from multiple linear regression models . . . . . . . . . . . . . . . . . . . 294
A.7 Associations of total and types of dairy consumption with cardio-metabolic
markers after adjustment for dairy nutrients . . . . . . . . . . . . . . . . 296
A.8 Associations of total and types of dairy consumption with glycaemic
markers from multiple linear regression models . . . . . . . . . . . . . . 297
A.9 Associations of total and types of dairy consumption with markers of
hepatic function from multiple linear regression models . . . . . . . . . . 300
A.10 Associations of total and types of dairy consumption with blood pressure,
CRP and adiponectin from multiple linear regression models . . . . . . . 302
A.11 Associations of total and types of dairy consumption with metabolic syn-
drome z-score from multiple linear regression models . . . . . . . . . . . 304
xxxi List of tables
A.12 Associations of the change in total and types of dairy consumption with
the change in markers of body weight and composition from baseline to
the first follow-up after a mean of 3.7 years in the EPIC-Norfolk study . . 306
A.13 Associations of the change in total and types of dairy consumption with
the change in lipid markers from baseline to the first follow-up after a
mean of 3.7 years in the EPIC-Norfolk study . . . . . . . . . . . . . . . . 309
A.14 Associations of the change in total and types of dairy consumption with
the change in HbA1c, blood pressure and a z-score for metabolic risk from
baseline to the first follow-up after a mean of 3.7 years in the EPIC-Norfolk
study . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 312
A.15 Results from the complete-case analyses for the associations of the change
in total and types of dairy consumption with the change in markers of body
weight and composition from baseline to the first follow-up after a mean
of 3.7 years in the EPIC-Norfolk study . . . . . . . . . . . . . . . . . . . 314
A.16 Results from the complete-case analyses for the associations of the change
in total and types of dairy consumption with the change in lipid markers
from baseline to the first follow-up after a mean of 3.7 years in the EPIC-
Norfolk study . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 315
A.17 Results from the complete-case analyses for the associations of the change
in total and types of dairy consumption with the change in HbA1c, blood
pressure and a z-score for metabolic risk from baseline to the first follow-up
after a mean of 3.7 years in the EPIC-Norfolk study . . . . . . . . . . . . 316
A.18 Metabolite concentrations in the discovery and internal validation sets
of the Fenland study and the external validation set of the EPIC Norfolk
diabetes case-cohort study . . . . . . . . . . . . . . . . . . . . . . . . . 318
A.19 Coefficients of predictors in decreasing order of magnitude of the absolute
values for total and types of dairy products as derived from elastic net
logistic prediction models in the discovery set of the Fenland study with
all 174 metabolites included . . . . . . . . . . . . . . . . . . . . . . . . 321
A.20 Coefficients of predictors in decreasing order of magnitude of the absolute
values for milk and total dairy products as derived from elastic net linear
prediction models in the discovery set of the Fenland study with all 174
metabolites included . . . . . . . . . . . . . . . . . . . . . . . . . . . . 327
A.21 Coefficients of predictors for total and types of dairy products as derived
from logistic and linear prediction models without penalisation in the
discovery set of the Fenland study with all 174 metabolites included . . . 333
List of tables xxxii
A.22 Coefficients of predictors in decreasing order of magnitude of the absolute
values for total and types of dairy products as derived from elastic net
logistic prediction models in the discovery set of the Fenland study with
the 82 overlapping metabolites with the diabetes case-cohort set nested
within the EPIC Norfolk study . . . . . . . . . . . . . . . . . . . . . . . 337
A.23 Coefficients of predictors in decreasing order of magnitude of the absolute
values for milk and total dairy products as derived from elastic net linear
prediction models in the discovery set of the Fenland study with the 82
overlapping metabolites with the diabetes case-cohort set nested within
the EPIC Norfolk study . . . . . . . . . . . . . . . . . . . . . . . . . . . 340
A.24 Coefficients of predictors for total and types of dairy consumption as
derived from logistic and linear prediction models without penalisation in
the discovery set of the Fenland study with the 82 overlapping metabolites
with the diabetes case-cohort sub-study of the EPIC Norfolk study . . . . 342
A.25 Coefficients of predictors in decreasing order of magnitude of the absolute
values for total and types of dairy consumption as derived from elastic net
logistic prediction models in the discovery set of the Fenland study with
the 82 overlapping metabolites and the odd-chain saturated fatty acids with
the diabetes case-cohort set nested within the EPIC Norfolk study . . . . 344
A.26 Coefficients of predictors in decreasing order of magnitude of the absolute
values for milk and total dairy consumption as derived from elastic net
linear prediction models in the discovery set of the Fenland study with the
82 overlapping metabolites and the odd-chain saturated fatty acids with
the diabetes case-cohort set nested within the EPIC Norfolk study . . . . 348
A.27 Coefficients of predictors for total and types of dairy consumption as
derived from logistic and linear prediction models without penalisation* in
the discovery set of the Fenland study with the 82 overlapping metabolites
and the odd-chain saturated fatty acids with the diabetes case-cohort set
nested within the EPIC Norfolk study . . . . . . . . . . . . . . . . . . . 350
A.28 Areas under the curve in the discovery and internal validation sets for the
different dairy prediction models . . . . . . . . . . . . . . . . . . . . . . 352
A.29 Areas under the curve (AUC) for models of logistic regression of the dairy
outcomes against the metabolite scores adjusted for socio-demographic
and lifestyle factors in the internal and external validation sets (odd-chain
saturated fatty acid subsample) . . . . . . . . . . . . . . . . . . . . . . . 353
A.30 Areas under the curve of the logistic models with or without the fatty acids
C15:0, C17:0, trans-16:1n-7 and the metabolite score (174 metabolites)
for total and types of dairy products . . . . . . . . . . . . . . . . . . . . 354
xxxiii List of tables
A.31 Areas under the curve of the logistic models with or without the odd-chain
saturated fatty acids C15:0, C17:0 and the metabolite score (82 metabolites)
for total and types of dairy consumption in the external validation set of
the EPIC Norfolk diabetes case-cohort study) . . . . . . . . . . . . . . . 355
A.32 Change in the ranking of top metabolite signals (>absolute mean+2SD)
after adjusting for dietary factors in the set of 174 metabolites . . . . . . 356
A.33 Change in the ranking of top metabolite signals (>absolute mean+2SD)
after adjusting for dietary factors in the set of 82 overlapping metabolites 357
A.34 Associations of top hits from the genome-wide association studies on total
dairy products, milk, yoghurt and cheese with all dairy phenotypes in the
UK Biobank . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 359
Chapter 1
Introduction
1.1 Burden of cardio-metabolic disease
According to the most recent Global Burden of Disease reports of 2016 (GBD 2016),
cardiovascular disease (CVD) is still the leading cause of death worldwide, and also in
the UK with the ischaemic heart disease in the first place and stroke in the third place
(with lung cancer in the second place)[1]. The International Diabetes Federation, in their
latest release of the Diabetes Atlas, reported that the number of adults with type 2 diabetes
(T2D) worldwide almost tripled from 151 million in 2000 to 425 million in 2017[2]. The
prevalence of T2D in the UK was 5.9% in 2017[2]. According to the latest GBD 2016
report on disease risk factors, low dietary quality is the second risk factor globally for
disability adjusted life years following child and maternal malnutrition (Figure 1.1)[3]. It
is also the leading risk factor in countries of middle or middle-high socio-demographic
index[3]. High body mass index (BMI) is the seventh top risk factor globally, fifth among
countries of middle or middle-high socio-demographic index and fourth among countries of
high socio-demographic index (Figure 1.1)[3]. Mortality increased by 11.2% and disability
adjusted life years increased by 8.6% from 2006 to 2016 due to suboptimal diet, while
increases due to high BMI were 28.6% for both over this decade[3].
The substantial contribution of cardio-metabolic disease to the global mortality and the
interplay between nutrition, metabolic risk factors, and cardio-metabolic disease suggest
that studying the role of nutrition in relation to disease endpoints, but also intermediate
endpoints is of high importance. The World Health Organisation suggests 12 steps to
healthy eating for the prevention of non-communicable diseases e.g. CVD, T2D, can-
cer and obesity (http://www.euro.who.int/en/health-topics/disease-prevention/nutrition/
a-healthy-lifestyle). These steps include the consumption of fruit, vegetables, whole grains,
replacement of saturated fatty acids (SFAs) with unsaturated fat, replacement of fatty
meat with lean meat, fish, beans and legumes, consumption of low-fat dairy products and
low consumption of sugar and salt. Dairy products comprise a widely consumed food
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Fig. 1.1 Top risk factors for disability adjusted life years (DALYs) globally, based on the
latest report of the Global Burden of Disease (GBD) 2016. Adapted from Gakidou et al[3]
group, which has been linked with bone health and prevention of hip fractures[4], and also
cardio-metabolic health, but with substantial heterogeneity in research evidence[5].
1.2 Dairy products and cardio-metabolic disease
After a literature search and extraction of relevant papers from references, I identified at
least 17 systematic reviews with meta-analyses of prospective cohort studies evaluating
associations of total and types of dairy products with cardio-metabolic disease[6–22]
including mortality (n=5 meta-analyses of 2-29 studies)[7, 13, 14, 20, 22], CVD (n=8
meta-analyses of 3-29 studies)[6, 7, 9, 10, 14, 15, 20, 22], coronary heart disease (CHD;
n=8 meta-analyses of 3-29 studies)[6, 7, 9, 10, 13–15, 20], stroke (n=10 meta-analyses of
3-18 studies)[6, 9–11, 13–15, 17, 20, 22] and T2D (n=8 meta-analyses of 3-21 studies)[8,
12, 14, 16, 18, 19, 21, 22]. I extracted information on the direction of associations reported
from these meta-analyses and summarised it in Table 1.1.
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Table 1.1 Directions* of associations between total and types of dairy products and
cardio-metabolic disease outcomes as reported from meta-analyses of prospective
cohort studies
Type of dairy products Author Year Ref. CVD CHD Stroke T2D Mortality
Milk Guo 2017 [7] ↔ ↔ ↔
Alexander 2016 [10] ↔ ↔ ↔
de Goede 2016 [11] ↓
Gijsbers 2016 [12] ↔
Mullie 2016 [13] ↔ ↔ ↔
Hu 2014 [17] ↓
Aune 2013 [18] ↔
Gao 2013 [19] ↔
Soedamah-Muthu 2011 [20] ↓ ↔ ↔ ↔
Elwood 2010 [22] ↓ ↓
Full-fat milk de Goede 2016 [11] ↑
Gijsbers 2016 [12] ↔
Aune 2013 [18] ↔
Gao 2013 [19] ↔
Tong 2011 [21] ↔
Low-fat milk de Goede 2016 [11] ↔
Gijsbers 2016 [12] ↔
Aune 2013 [18] ↓
Gao 2013 [19] ↓
Yoghurt Guo 2017 [7] ↔ ↔ ↔
Wu 2017 [9] ↔ ↔ ↔
Alexander 2016 [10] ↔ ↔ ↔
de Goede 2016 [11] ↔
Gijsbers 2016 [12] ↓
Qin 2015 [15] ↔ ↔
Chen 2014 [16] ↓
Aune 2013 [18] ↓
Gao 2013 [19] ↓
Tong 2011 [21] ↓
Cheese Chen 2017 [6] ↓ ↓ ↓
Guo 2017 [7] ↓ ↔ ↔
Alexander 2016 [10] ↔ ↓ ↓
de Goede 2016 [11] ↔
Gijsbers 2016 [12] ↔
Qin 2015 [15] ↔ ↓
Hu 2014 [17] ↓
Aune 2013 [18] ↓
Gao 2013 [19] ↓
Butter de Goede 2016 [11] ↔
Pimpin 2016 [14] ↔ ↔ ↔ ↓ ↔
Qin 2015 [15] ↔ ↔
Hu 2014 [17] ↔
Elwood 2010 [22] ↔
Ice-cream Gijsbers 2016 [12] ↓
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Table 1.1 (continued)
Type of dairy products Author Year Ref. CVD CHD Stroke T2D Mortality
Cream Gijsbers 2016 [12] ↔
Hu 2014 [17] ↔
Fermented dairy products Guo 2017 [7] ↓ ↔ ↔
de Goede 2016 [11] ↔
Gao 2013 [19] ↔
High-fat dairy products Guo 2017 [7] ↔ ↔ ↔
Alexander 2016 [10] ↔
de Goede 2016 [11] ↓
Gijsbers 2016 [12] ↔
Qin 2015 [15] ↔ ↔
Chen 2014 [16] ↔
Aune 2013 [18] ↔
Gao 2013 [19] ↔
Soedamah-Muthu 2011 [20] ↔
Tong 2011 [21] ↔
Low-fat dairy products Guo 2017 [7] ↔ ↔ ↔
Alexander 2016 [10] ↓
de Goede 2016 [11] ↓
Gijsbers 2016 [12] ↓
Qin 2015 [15] ↔ ↓
Chen 2014 [16] ↔
Aune 2013 [18] ↓
Gao 2013 [19] ↓
Soedamah-Muthu 2011 [20] ↔
Tong 2011 [21] ↓
Total dairy products Guo 2017 [7] ↔ ↔ ↔
Schwingshackl 2017 [8] ↓
Alexander 2016 [10] ↔ ↔ ↓
de Goede 2016 [11] ↔
Gijsbers 2016 [12] ↓
Qin 2015 [15] ↓ ↔ ↓
Chen 2014 [16] ↔
Hu 2014 [17] ↓
Aune 2013 [18] ↓
Gao 2013 [19] ↓
Soedamah-Muthu 2011 [20] ↔
Tong 2011 [21] ↓
Elwood 2010 [22] ↓ ↓ ↓
*↔: no association, ↑: positive association/increase in risk, ↓: inverse association/decrease in risk
Abbreviations: CVD: Cardiovascular disease; CHD: Coronary heart disease; T2D: Type 2 diabetes
Total and types of dairy products were not associated with all-cause mortality[7, 13,
14, 20, 22].
Results on associations with CVD were consistently null for yoghurt[7, 9, 10], fer-
mented dairy products[7], low-fat[7] and high-fat dairy products[7], but mixed for milk[7,
10, 20, 22], cheese[6, 7, 10] and total dairy products[7, 10, 15] indicating inverse or null
associations. Specifically, the latest meta-analyses for milk showed null associations with
CVD[7, 10] and included five additional studies[7] compared to the older meta-analyses,
which showed inverse associations[20, 22]. The latest meta-analyses for cheese and car-
diovascular disease showed inverse associations[6, 7] and included six additional studies
compared to a former meta-analysis, which showed null associations[10].
Associations between dairy products and risk of CHD were consistently null for
milk[7, 10, 13], yoghurt[7, 9, 10, 15], butter[14, 15], fermented[7], high-fat[7, 10, 15, 20]
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and total[10, 15, 20] dairy products, while results for cheese[6, 7, 10, 15] and low-fat dairy
products[7, 10, 15, 20] showed either inverse or null associations.
No associations were reported between yoghurt[9–11, 15], butter[11, 14, 15, 17],
cream[17] or fermented dairy products[11] and risk of stroke, while inverse associations
were reported between low-fat dairy consumption and risk of stroke[11, 15]. Either null
or inverse associations were reported between milk[10, 11, 13, 17, 20], cheese[6, 10, 11,
15, 17], high-fat[11, 15] or total[10, 11, 15, 17, 22] dairy products and stroke incidence.
However, most of the meta-analyses indicated that cheese was associated with a lower
stroke incidence by a range of 6% to 13%[6, 10, 15, 17] and total dairy consumption was
associated with a lower risk of stroke by a range of 9% to 21%[10, 15, 17, 22].
Finally, null associations were reported between full-fat milk[12, 18, 19, 21], cream[12],
fermented[19] or high-fat[12, 16, 18, 19, 21] dairy products and T2D risk and inverse
associations were consistently reported between yoghurt (risk reduction range: 9% -
18%)[12, 16, 18, 19, 21] or butter (4% risk reduction per 45 g/day)[14] and T2D risk.
Findings were more mixed for milk (low-fat[12, 18, 19] or total milk[12, 18, 19, 22]),
cheese[12, 18, 19] or dairy products (low-fat[12, 16, 18, 19, 21] or total dairy products[8,
12, 16, 18, 19, 21, 22]) and T2D risk. Most of the meta-analyses on total milk showed
null associations with T2D risk[12, 18, 19]. The meta-analyses also reported an 18% risk
reduction from higher consumption of low-fat milk[18, 19] and 8% from higher consump-
tion of cheese[18, 19]. The risk reduction was 4% - 12% per 200 g daily consumption of
low-fat dairy products[12, 18, 19, 21] and 3% - 7% per 200 g daily consumption of total
dairy products[8, 12, 18, 19, 21, 22].
The diversity of the results among the different types of dairy products and the sig-
nificant heterogeneity observed in some of the meta-analyses[11–13, 16, 19] raise two
key issues: one on what the contributing mechanisms and pathways to disease incidence
are; the other on the methodological aspects of relevant studies such as the observational
study design and the measurement error of self-reported methods of dietary assessment.
Understanding these key issues could further elucidate the link between dairy consumption
and cardio-metabolic health and enhance appropriate translation to public health messages
about dairy consumption. This is even more relevant for dairy types such as yoghurt or
cheese, for which evidence is more limited compared with total dairy products.
1.3 Dietary guidelines
The results of the meta-analyses reviewed above indicate that total and types of dairy
products including their high-fat alternatives were associated with either a reduction or no
change in the risk of cardio-metabolic disease outcomes. Yet, dietary guidelines continue to
recommend the consumption of low-fat dairy products over their high-fat versions[23, 24].
For example, the latest release of the Eatwell Guide by Public Health England in 2016,
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recommends the daily consumption of some dairy products, with a preference for low-fat
products (Figure 1.2)[23]. This apparent discrepancy between the evidence from meta-
analyses of prospective studies and the dietary guidelines can be understood in the context
of the classical diet-heart hypothesis[25].
According to this hypothesis, SFA food sources, such as dairy products, are thought
to be associated with a higher cardiovascular risk, because SFA intake has been associ-
ated with higher cholesterol levels[25]. However, this hypothesis has been increasingly
controversial. For instance, a meta-analysis of prospective cohort studies failed to report
any association between SFA intake and total or cardiovascular mortality, risk of CHD,
stroke or T2D[26]. This meta-analysis did not take into account nutrient substitutions,
which is an important consideration in the context of an isocaloric diet. Evidence from a
meta-analysis of 11 prospective cohort studies[27], a meta-analysis of eight randomised
controlled trials (RCTs)[28], and a meta-analysis of 15 RCTs[29], which did account for
isocaloric nutrient substitution, showed that substitution of SFAs with polyunsaturated
fatty acids (PUFA) leads to lower risk of CHD. Specifically, pooled results from the RCTs
showed a 10% CHD risk reduction from the substitution of 5% energy from SFA with 5%
energy from PUFA [RR=0.90 (95% CI: 0.83, 0.97)][28]. It is of note that no significant risk
change was observed for substitution with monounsaturated fatty acids (MUFA) [27–29],
carbohydrates or protein[29].
Overall SFA intake does not seem to be harmful for cardio-metabolic health, when
considered alone, but there is a coronary benefit if it is replaced with PUFA. Based on this
type of evidence, the World Health Organisation and the Scientific Advisory Committee
on Nutrition drafted a public consultation document on evidence and recommendations
for SFA intake[30]. This document recommends SFA intake reduction and maintenance
to less than 10% energy and replacement of SFAs with PUFA, but the existing evidence
was identified as of low or moderate quality[30]. Though the topic of the health effects of
SFAs remains contentious, two specific issues are relevant in the context of dairy products:
(1) whether the diet-heart hypothesis in case of dairy products is valid and, (2) whether
it would be more appropriate to reach conclusions after accounting for the dairy "food
matrix" rather than a single nutrient (SFA).
1.4 Dairy food matrix
The food matrix is defined by the United States Department of Agriculture as "the nutrient
and non-nutrient compounds of foods and their chemical relationships" (https://definedterm.
com/a/definition/197890). Using a more holistic approach by studying the overall dairy
food matrix instead of individual nutrients might provide a better insight into the link
between dairy consumption and cardio-metabolic health. Dairy products comprise a very
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Fig. 1.2 Eatwell Guide 2016, Public Health England, UK[23]
diverse food group with different dairy types varying by nutrient content (e.g. fat), form
(e.g. solid, semi-solid, liquid) and processing (e.g. fermentation).
All dairy products are derived from milk, which is defined by Codex Alimentarius as
"the normal mammary secretion of milking animals intended for consumption as liquid
milk or further processing"[31]. Milk processing can result in products with very different
food matrices.
According to Codex Alimentarius, yoghurt is the fermented milk product, which is pro-
duced by the starter symbiotic cultures of Streptococcus Thermophilus and Lactobacillus
delbrueckii subsp. bulgaricus, while alternate culture yoghurt is produced by cultures of
Streptococcus Thermophilus and any Lactobacillus species[31]. This process results in a
nutritional profile of yoghurt with less water than milk and thus higher nutrient density with
also higher bioavailability. Yoghurt contains lower amounts of lactose, which is also more
effectively digested than that from milk due to the presence of lactic acid bacteria[32].
Cheese is a food item with many distinct subtypes. Codex Alimentarius defines general
standards for cheese, but also standards for groups of cheese e.g. cheese in brine, unripened
cheese including fresh cheese, extra hard grating cheese and specific standards for each type
of cheese falling within these groups e.g. mozzarella, cheddar, edam etc[31]. According to
the general standards, for a milk product to be considered cheese, the ratio of whey protein
to casein should not exceed that of milk and it should be produced through the coagulation
of milk protein[31].
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Butter is a product with a minimum fat content of 80%, maximum fat content of 90%
and a maximum water content of 16%[31].
The heterogeneity of the different dairy types is evident from the pie charts of Fig-
ures 1.3- 1.6. The water contribution to the total food weight is about 15% for butter and
increases to 37% for high-fat cheese, 82-87% for yoghurt and 87-89% for milk.
In terms of fat content, butter has the highest (82%), followed by high-fat cheese (35%),
whereas the fat content of the rest of dairy types is below 4%. From the total fat in different
dairy types, SFA is consistently the main contributor constituting 62-66% of total dairy
fat, followed by 22-24% of MUFA, whereas trans fatty acids (TFA) contribute by just
2-4%. The most abundant TFA is vaccenic acid, but trans fat also consists of conjugated
linoleic acid and trans-palmitoleate[33]. For most of the dairy products, contribution of
different fatty acids is consistent, with a few exceptions due to different processing. For
example, MUFA and TFAs contribute less than 0.1% to total fat of low-fat cottage cheese.
The majority of SFAs consists of long-chain fatty acids with 13 carbon atoms or more
(62-79%), of which 1.3-1.9% is C15:0 and 0.8-1.1% is C17:0. Medium chain fatty acids
(6-12 carbon atoms) constitute 10-16% of dairy SFAs, while short chain fatty acids (up to
5 carbon atoms) constitute 5-6.5%. It should be noted that this is a simplified presentation
of the nutrient composition of dairy products, especially for fat, as milk contains over 400
different fatty acids, but most of them are in trace amounts[33]. In addition, fat in dairy
products takes several different forms. The majority of it is in the form of triglycerides
(98%), but there is also diacylglycerol (<2%), cholesterol (<0.5%), phospholipids (1%)
and free fatty acids (0.1%)[33]. Part of triglycerides are surrounded by the milk fat globule
membrane, which also contains some lipid classes such as phospholipids[34]. Depending
on the process of homogenisation, the milk fat globule membrane in butter might be mostly
absent[34].
Concerning protein, cheese has the highest content (25%), followed by yoghurt (5-6%)
and milk (3.5%), whereas the contribution to the weight of butter is just 0.6%. Casein
constitutes 80% of milk protein and whey constitutes 20%.
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Fig. 1.3 Macronutrient composition of full-fat and low-fat milk. Source: McCance and
Widdowson’s Food Composition Tables[35]. The food item selected to represent full-fat
milk composition was "Milk, whole, pasteurised, average" (food code:12-596) and the item
selected for low-fat milk composition was "Milk, semi-skimmed, pasteurised, average"
(food code: 12-313) Abbreviations: LCFA: Long-chain fatty acids; MCFA: Medium-chain
fatty acids; MUFA: Monounsaturated fatty acids; SCFA: Short-chain fatty acids; SFA:
Saturated fatty acids; TFA: Trans fatty acids
Finally, carbohydrates do not contribute more than 8% to the weight of dairy products,
when there are no added sugars. The highest contribution of carbohydrates to the total food
weight is for yoghurt (7.8%), followed by milk (4.6%) and some types of low-fat cheese
(3.3%), while for butter and other types of cheese, it is 0.6% or lower. Carbohydrates in
milk, cheese and butter are mainly lactose, whereas in yoghurt 60% of the carbohydrates
are lactose and 40% are galactose due to the action of the lactic acid bacteria.
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Fig. 1.4 Macronutrient composition of full-fat and low-fat yoghurt. Source: McCance and
Widdowson’s Food Composition Tables[35]. The food item selected to represent full-fat
yoghurt composition was "Yoghurt, whole milk, plain" (food code: 12-184) and the item
selected for low-fat yoghurt composition was "Yoghurt, low fat, plain" (food code: 12-379).
Abbreviations: LCFA: Long-chain fatty acids; MCFA: Medium-chain fatty acids; MUFA:
Monounsaturated fatty acids; SCFA: Short-chain fatty acids; SFA: Saturated fatty acids;
TFA: Trans fatty acids
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Fig. 1.5 Macronutrient composition of high-fat and low-fat cheese. Source: McCance and
Widdowson’s Food Composition Tables[35]. The food item selected to represent high-fat
cheese composition was "Cheese, Cheddar, English" (food code: 12-346) and the item
selected for low-fat cheese composition was "Cheese, cottage, plain, reduced fat" (food
code: 12-550). Abbreviations: LCFA: Long-chain fatty acids; MCFA: Medium-chain fatty
acids; MUFA: Monounsaturated fatty acids; SCFA: Short-chain fatty acids; SFA: Saturated
fatty acids; TFA: Trans fatty acids
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Fig. 1.6 Macronutrient composition of butter. Source: McCance and Widdowson’s Food
Composition Tables[35]. The food item selected to represent butter composition was
"Butter, unsalted" (food code: 17-661). Abbreviations: LCFA: Long-chain fatty acids;
MCFA: Medium-chain fatty acids; MUFA: Monounsaturated fatty acids; SCFA: Short-
chain fatty acids; SFA: Saturated fatty acids; TFA: Trans fatty acids
Information on the micronutrient content of dairy types is presented in Table 1.2.
Full-fat and low-fat yoghurt contain higher amounts of minerals compared with full-fat
and low-fat milk. Butter has the lowest mineral content, whereas cheese has the highest
calcium, magnesium, phosphorus and zinc content of all the dairy types. Regarding vitamin
content, butter contains the highest amount of fat-soluble vitamins i.e. vitamin A, vitamin
D and vitamin K, followed by cheese. Cheese has the highest content of vitamin B12.
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Table 1.2 Content of selected micronutrients in 100 g of dairy food for selected dairy types †
Minerals (mg) Vitamins (µg)
Dairy products ‡ Potassium Calcium Magnesium Phosphorus Zinc Vitamin A Vitamin D Vitamin B12 Vitamin K1
Full-fat milk 157 120 11 96 0.5 38 0.6
Low-fat milk 156 120 11 94 0.4 20 0.9
Full-fat yoghurt 280 200 19 170 0.7 32 0.2
Low-fat yoghurt 228 162 16 143 0.6 8 0.1 0.3 0.03
High-fat cheese 75 739 29 505 4.1 388 0.3 2.4 4.7
Low-fat cheese 161 127 13 171 0.6 17 0.6
Butter 27 18 2 23 0.1 1060 0.9 0.3 7.4
†Information extracted from the McCance and Widdowson’s Food Composition Tables[35]
‡ The food items selected from the Food Composition Table to represent the different dairy types are "Milk, whole, pasteurised, average"
(food code: 12-596) for full-fat milk, "Milk, semi-skimmed, pasteurised, average" (food code: 12-313) for low-fat milk, "Yoghurt, whole milk,
plain" (food code: 12-184) for full-fat yoghurt, "Yoghurt, low fat, plain" (food code: 12-379) for low-fat yoghurt, "Cheese, Cheddar, English"
(food code: 12-346) for high-fat cheese, "Cheese, cottage, plain, reduced fat" (food code: 12-550) for low-fat cheese and "Butter, unsalted"
(food code: 17-661) for butter
The complexity of the dairy food matrix, but also its heterogeneity across different dairy
types suggest the need for an in depth investigation of the links between dairy consumption
and cardio-metabolic health using a multi-disciplinary approach.
1.5 Project aims
The overall aim of this PhD was to develop an understanding of the associations of total and
types of dairy products with cardio-metabolic health by incorporating aspects of nutritional,
molecular and genetic epidemiology. A mindmap of the specific sub-aims of the PhD and










































































































































































































































































































































































































































































































































































































































































































































































































































Description of dairy consumption in the
UK
Summary
Background and aims: Monitoring of consumption patterns is important to inform public
health policies. In the UK, individual level consumption data from a representative UK
sample are available only from the National Diet and Nutrition Survey (NDNS). The
dairy information available from the NDNS reports includes milk and its fat alternatives,
cheese categorised into cheddar, cottage and other cheese, one group for yoghurt, fromage
frais and other dairy desserts and butter, but consumption levels do not include content
of these dairy types in composite foods. The aims of this study were to describe dairy
consumption patterns over time and their contribution to nutrient intakes also accounting
for their consumption from composite foods and recipes.
Methods: We evaluated data of adults from the old surveys of NDNS (1994/1995 for
elderly, 2000/2001 for adults <65 years) and the rolling programme years (2008/2009 to
2015/2016), which constitute random and representative samples of the UK population.
Diet was assessed with weighed 4-day or 7-day (2000/2001) food diaries in the old surveys
and estimated 4-day food diaries in the rolling programme. We disaggregated composite
foods into food ingredients to derive more precise estimates. Time trends of weighted
consumption (g/day) of total, high-fat and low-fat dairy products (milk, yoghurt, cheese,
butter) were reported among dairy consumers for adults <65 years and elderly participants
≥65 years. Dairy contribution to nutrients across the different survey years was estimated.
Results: A range of 420-597 adults <65 years were included in each rolling programme
year, while 1,723 adults were included in year 2000/2001 (mean age range: 40.1-41.3
years; 38.1-45.7% women). For elderly adults, a range of 87-184 participants were
included in each rolling programme year, and 1,733 participants were included in the
1994/1995 survey (73.2-76.6 years; 35.7-49.1% women). Total dairy consumption did not
significantly change among adults <65 years (242.6-245.0 g/day) or among the elderly
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adults (302.8-285.9 g/day) over the period of 20008/2009 to 2015/2016. Low-fat dairy
products were consumed consistently in greater amounts (almost 3-fold higher) than high-
fat dairy products. Elderly adults had significantly lower consumption of high-fat dairy
products over time from 119.1±16.5 g/day in 2008/2009 to 53.1±6.2 g/day in 2015/2016
(p=0.002). The consumption of low-fat dairy products did not significantly change for
either age group over time.
Milk was consistently the largest contributor to total dairy consumption for both groups.
While consumption of total and low-fat milk did not change over time, consumption of
full-fat milk decreased by 8.6 g/day for adults <65 years and by 81.1 g/day for elderly
people over the 8-year period. Yoghurt consumption did not significantly change (mean
range: 37.8-45.4 g/day for adults <65 years and 39.4-64 g/day for elderly participants), but
the percentage of elderly yoghurt consumers increased from 19.5% in 1994/1995 to 46.4%
in 2015/2016. No large changes were observed for mean cheese consumption (24.1-27.5
g/day for adults <65 years; 19.8-25.1 g/day for elderly people) or butter consumption
(6.4-8.2 g/day for adults <65 years; 7.9-11.2 g/day for elderly people).
Total dairy consumption contributed 13.5-14.6% to total energy intake. For macronutri-
ents, total dairy consumption contributed 24.4-25.8% to total fat, 40.2-42.2% to saturated
fat, 16.2-17.7% to cis-monounsaturated fat, 51-62.1% to trans fat, 5.1-5.7% to carbohy-
drate, and 17.7-19.1% to protein. For micronutrients, total dairy consumption contributed
24.3-32.1% to vitamin A, 11.4-13.3% to vitamin D, 39.4-41.8% to vitamin B12, 48.4-
50.5% to calcium, 14.5-15.8% to potassium, 12.3-13.7% to magnesium, 25.7-27.8% to
phosphorus and 19.8-21.5% to zinc. Of the subtypes, high-fat cheese was the highest dairy
contributor to total and types of fat, and vitamin A, while low-fat milk was the highest
contributor to the other nutrients.
Conclusion: In this study of NDNS data, we reported updated consumption levels
for total dairy products (low- and high-fat), milk (low- and full-fat), cheese (low- and
high-fat) and butter, and their contribution to nutrient intakes further accounting for their
consumption in the context of composite foods and recipes. We additionally reported
consumption of low- and full-fat yoghurt, which was previously reported as part of the
group "yoghurt and dairy desserts". The importance and variability of the dairy food
matrix is evident when considering the high contribution of dairy products to intakes of the
healthful vitamins and minerals, as well as to intakes of saturated and trans fat. Research
into the mechanisms of action of the dairy food matrix on health in combination with close
monitoring of consumption levels in the population will inform policy-related decisions.
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What is already known
• Monitoring consumption patterns is important to inform public health policies.
In the UK, individual level consumption data from a representative sample
are available only from the National Diet and Nutrition Survey (NDNS).
• Current NDNS reports include consumption of total dairy products (low- and
high-fat), milk (low- and full-fat), cheese (cheddar, cottage, other) and butter.
Yoghurt consumption is reported as part of the group "yoghurt, fromage frais
and other dairy desserts". These consumption levels do not account for the
dairy content in composite foods and recipes.
What this research adds
• After accounting for dairy consumption as part of composite foods, total and
low-fat dairy consumption in the UK did not significantly change from 2008
to 2016, while high-fat dairy consumption decreased from 119.1 g/day to 55.1
g/day among elderly people.
• Of the high-fat dairy products, cheese and butter consumption did not change
over the 8 years, but full-fat milk consumption decreased by 8.6 g/day among
adults <65 years and 81.1 g/day among elderly people.
• Yoghurt consumption did not change, but the percentage of elderly yoghurt
consumers increased from 19.5% in 1994/1995 to 46.4% in 2015/2016.
• Total dairy consumption contributed by approximately 15% to total energy,
monounsaturated fat and potassium, 20% to protein and zinc, 25% to total
fat, vitamin A and phosphorus, 40% to saturated fat and vitamin B12, 50% to
calcium and 55% to trans fat intake.
Publication
Trichia E, Amoutzopoulos B, Imamura F, Forouhi N G. Dairy consumption patterns and
their contribution to nutrient intakes: findings from the National Diet and Nutrition Survey
2008-2016 (Manuscript under preparation)
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From a public health perspective, it is very important to monitor the food intakes of a
population in order to identify the main contributors to dietary intake and ensure that the
intakes are within appropriate ranges, which have been shown to promote health. This is
especially of interest for foods like dairy products, which contain diverse components, with
known benefit for bone health, and also related to cardio-metabolic health (sections 1.1
and 1.2). Reporting of trends of dairy consumption over time can inform public health
agencies and policymakers on potential deviations from dietary recommendations, so that
they can implement appropriate public health interventions. The implementation of the
intervention and the choice of the target population will be based on the profile and the
characteristics of the consumers and non-consumers in a demographic, socioeconomic
and lifestyle context. For example, according to a study with data from a national food
and health survey in Australia in 2010-2011, 1.2% of the participants reported avoiding
dairy consumption due to a diagnosed disease (e.g.coeliac disease), 15.3% avoided dairy
consumption because of unpleasant symptoms without any medical diagnosis and 5.8%
avoided dairy consumption without reporting any symptoms[36]. This behaviour was
associated with a participant profile characterised by younger age, being a woman, higher
worry of illness and higher receptiveness to alternative medicine[36]. This paradigm
suggests the need to establish a clear rationale and structure of dietary guidelines and
investigate the consumption patterns within a population.
2.1 Data sources of dairy consumption in the UK
The food balance database from the United Nations Food and Agricultural Organisation
(FAO; http://www.fao.org/faostat/en/#data/FBS), which includes the per capita food avail-
ability, had been the main source of global dietary data until about 10 years ago. Although
these data can give rough estimates of food consumption patterns and trends across time
and different countries, they have several limitations, as they do not provide individual
food consumption data, which are necessary for more precise estimates. To fill these gaps,
the Global Dietary Database was launched as part of the data collected for the 2010 Global
Burden of Diseases (GBD) project[37]. This database provides individual level dietary
data for 11 food groups in 1990, 2005 and 2010 across 193 countries worldwide from
publicly available data, data collected for the 2010 GBD project or data collected within
the scope of the Global Dietary Database (https://www.globaldietarydatabase.org/).
Concerning dairy consumption in the UK, this database includes consumption levels
only for milk as aggregated from 24 data sources. As seen in Figure 2.1, according to
these data, milk contributes the most to the total amount of food consumed compared with
other food groups and it has slightly decreased over the 20-year period.
While this database is useful, it includes information only for milk and not for yoghurt,
cheese and butter or total dairy consumption. As a proxy for consumption, there are several
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Fig. 2.1 Milk contribution to the total amount of food consumed in the UK in 1990 and 
2010, Global Dietary Database (https://www.globaldietarydatabase.org/country-
comparisons. html, date of access: 9 June 2018) 
data sources related to dairy products in the UK. For example, the Dairy Division of the 
Agriculture and Horticulture Development Board (AHDB) provides data related to dairy 
farms, which concern milk yield, supply and flow, dairy products production, dairy trade and 
household level consumption (https://dairy.ahdb.org.uk/). Furthermore, the Department of 
Environment, Food and Rural Affairs releases statistics on the production and supply of dairy 
products, which at least partly overlaps with the data from AHDB (https://www.gov. 
uk/government/organisations/department-for-environment-food-rural-
affairs/about/statistics). A combination of data from these sources and WHO/FAO statistics 
was used by Hobbs et al. to obtain a picture of the trends of dairy consumption over 
decades[38]. According to these data, full-fat milk consumption decreased from 
approximately 140 l/capita/year in 1970 to approximately 20 l/capita/year in 2010. On the 
contrary, low-fat milk appeared in 1980s and started increasing to reach a plateau of 
approximately 60 l/capita/year in mid 1990s[38]. 
For detailed individual level dietary information on consumption levels of any food 
in a representative UK sample, the National Diet and Nutrition Survey (NDNS) is the 
most suitable source. However, the dietary data processing has not been done to such an 
extent yet so as to get the detail that is provided by the 4-day diaries used in the survey. 
As a result, there are limitations in the survey reports to date. NDNS has reported 
specifically consumption of milk (whole, semi-skimmed, 1% fat, skimmed), cheese 
(cheddar, cottage, 
Pie charts removed for copyright reasons. Copyright holder is Tufts University. 
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other), butter (including ghee and spreadable butter) and yoghurt included in the group
"yoghurt, fromage frais and other dairy desserts". Thus yoghurt consumption is not
discriminated from consumption of dairy desserts and not categorised into low- and full-fat
and cheese is categorised into cheddar and other cheese and not into low- and high-fat.
It is of note that the reported consumption levels do not include disaggregated data of
composite foods and recipes.
2.2 Profiles of dairy consumers
Several studies have investigated potential correlates of dairy consumption[39–51]. Sub-
stantial differences in dairy consumption by ethnicity and country of origin have been
reported, which makes of interest the ethnicity and country-specific description and investi-
gation of dairy consumption. Ethnicity is an important factor due to the higher prevalence
of lactose intolerance in certain ethnic groups compared to others, as will be elaborated
in Chapter 8. Country of origin is also an important factor as total dairy consumption
is lower in developing countries, even though it has been increasing at a higher rate[45].
Also among developed countries in Europe, country-specific differences in dairy con-
sumption have been reported, as well as country-specific interactions in associations of
socio-demographic factors with dairy consumption[43].
Evidence on specific types of dairy products highlights variation in consumption
by several characteristics. For example, men reported higher milk consumption than
women in two studies of African American populations[48] and in one study of a UK
population[42], while women reported higher low-fat milk consumption than men in a
study in Norway[39]. Higher milk consumption has also been associated with lower
socioeconomic position in a Finnish study[41], while higher consumption of low-fat
milk has been related to a higher[40] or a lower[44] socioeconomic position based on
occupation, higher income[40] or higher educational level[49]. Higher consumption of full-
fat milk has also been related to lower[40, 46] or higher[44] socioeconomic position based
on occupation or income. Higher yoghurt consumption has been consistently reported
among women[43, 47, 50], people with higher educational level[47] and income[50] and
people who overall adopt healthy lifestyle behaviours including higher compliance with
a healthy dietary pattern characterised by higher consumption of fruit, vegetables[51,
52], legumes, nuts[52], lean meat and whole grains and lower alcohol consumption[51],
higher physical activity levels[47, 51], no smoking[50, 51] and better sleep quality[51].
Cheese consumption has also been correlated with a higher socioeconomic status based
on occupation[40, 41, 46], higher educational level[40, 42, 47] and higher income[40],
whereas results for sex are more inconsistent, with some studies having reported higher
consumption among men[48] and others among women[39]. Finally, for butter, some
studies reported higher consumption among men[43, 44] and there was heterogeneity in
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butter consumption and socioeconomic position with both a positive[44] and an inverse
association[41] previously reported.
2.3 Aims
So far, individual data on consumption of milk (low- or full-fat), yoghurt (low- or full-
fat), cheese (low- or high-fat), and butter and their contribution to nutrient intakes, also
accounting for the dairy types consumed as part of composite foods and stratified by
demographic factors are not available.
The aims of this study were
1. To describe consumption levels of the main total, low- and high-fat types of dairy
products i.e. milk, yoghurt, cheese and butter in a representative UK sample over
time and report any trends observed.
2. To describe consumption of total and types of dairy products stratified by age groups
and sex in the UK.
3. To describe the contribution of total and types of dairy products to relevant macro-
and micronutrient intakes over time in the UK.
2.4 Methods
2.4.1 Study design and population
The UK NDNS was launched in 1992 by the Ministry of Agriculture, Fisheries, and
Food and the Department of Health. In 2000, the Food Standards Agency (FSA) and the
Department of Health continued the survey with the help of the Social Survey Division
of the Office for National Statistics and the Medical Research Council (MRC) Elsie
Widdowson Laboratory formely known as MRC Human Nutrition Research. This initiative
includes the old surveys started in 1992 with children and continued in 1994/1995 with
elderly people (65 years and older) and 2000/2001 with adults and the rolling programme
years, which started in 2008 and are repeated every year in participants older than 1.5
years[53]. The NDNS rolling programme is now co-funded by Public Health England
of the Department of Health and FSA and conducted by NatCen Social Research, Elsie
Widdowson Laboratory and University College London Medical School (only for years
1-4). From 2019, the MRC Epidemiology Unit will be responsible for the survey.
A pilot study was conducted in 1994 for the survey of the year 1994/1995, in 1999 for
the survey of 2000/20001 and in 2007 for the rolling programme. The survey was approved
by the Multi-centre Research Ethics Committee (years 1-4 of the rolling programme), the
Cambridge South NRES Committee (years 5-8 of the rolling programme) and the National
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Health Service Local Research Ethics Committees of the areas included in the sample (all
years). All participants or their proxies provided written informed consent. A timeline of
the survey is shown in Figure 2.2.
Fig. 2.2 National Diet and Nutrition Survey timeline, ∥ denotes a time gap of more than
one year
Households were selected with multi-stage random probability sampling. The first
stage was the primary sampling units derived from the postal sectors and the second stage
was the Government Office Region. Invitations were sent to the households selected
randomly from the Postcode Address File within primary sampling units and interviewers
also approached the invited households that did not respond. Eligible individuals were
identified from each household who accepted the invitation and only one adult was selected
per household or one adult and one child in the rolling programme, also accounting for
the target age and sex groups, which were needed to complete a representative sample as
defined from census data. Pregnant or breastfeeding women were excluded. If a postal
code belonged to an institution, it was excluded from the study, but for the years 1994/1995,
a small sub-sample of the elderly sample was recruited from institutions too, which were
randomly selected.
The target sample size of the rolling programme was approximately 1,000 participants
(500 children and 500 adults) each year. The response rates were 85% in 1994/1995,
61% (47% for the 7-day diary) in 2000/20001, 64% for years 1-4, 63% for years 5-6 and
60% for years 7-8 of the rolling programme. Weights were generated based on sampling
probabilities of region, age and sex groups to compensate for any divergence from sample
representativeness due to the selection of households and people within household and
non-response. Participants were interviewed over four periods of three months across the
whole year, to account for seasonality.
2.4.2 Dietary assessment
Diet was assessed in the NDNS with multiple-day food diaries. In 1994/1995, participants
used a 4-day weighed diary or a 4-day estimated diary if weighing was a reason for dropout
from the study. Four-day weighed diaries showed no substantial differences in intakes
compared to 7-day weighed diaries, but had higher participant compliance in the 1994
2.4 Methods 23
pilot study. In 2000/20001, participants completed 7-day weighed food diaries. In case of
eating out, participants were asked to keep a descriptive diary and then interviewers would
purchase the foods described in the reported amounts and weigh them. Institutionalised
people in 1994/1995 were further assisted by the interviewers who visited them once daily
to weigh one meal (different meal each day) and the rest of the meals were reported in a
descriptive diary. Relevant information was also obtained from the care providers.
In the rolling programme, participants completed 4-day estimated food diaries, based
on better performance of the 4-day estimated diary compared to a 24-hour recall on four
non-consecutive days in the pilot study. Participants were instructed to complete the diary
during two weekdays and two weekend days in the year 1 of the rolling programme. The
instructions changed for the rest of the years, so that all days of the week are equally
represented. In order to generate estimates that are as comparable as possible, the data
from the year 2000/2001 were adjusted to include four out of the seven days of reporting,
because although the mean intakes should not substantially change, the variation and
the percentage of consumers of certain foods are expected to be different and thus not
comparable. The four days were selected so that each day of the week is included equally
in the derived sample, the days are consecutive and where possible the first four days are
selected from the seven days reported. Based on these criteria the number of days for each
day of the week re-allocated is shown in Table 2.1.
Table 2.1 Re-allocation of the start day of diary reporting for a subset of four days out of
the seven completed by adults in the National Diet and Nutrition Survey (NDNS) 2000/01.
Table adapted from NDNS report.
Original start day Re-allocated start day
Total
Sunday Monday Tuesday Wednesday Thursday Friday Saturday
Sunday 56 56
Monday 121 121
Tuesday 246 66 67 379
Wednesday 246 23 26 71 366
Thursday 190 158 348
Friday 125 154 279
Saturday 175 175
Total 246 246 246 246 247 247 246 1724
Composite foods were disaggregated into food ingredients, which are contained in the
FSA standard recipes database[54]. Nutrient intakes were estimated using year-specific
Nutrient Databanks, which were based on McCance and Widdowson’s Food Composition
Tables[35], but were updated from the survey data each year adding information from
new food analyses, food manufacturers, food labels and homemade recipes. In the rolling
programme, the DINO (Diet-In-Nutrients-Out) system and a Microsoft Access analysis
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system were used for the dietary data processing. Nutrient intakes were corrected for the
water loss during cooking and/or processing.
2.4.3 Assessment of other factors
Socio-demographic factors (age, sex, ethnicity, occupation) were assessed with an interviewer-
administered questionnaire. BMI was calculated by dividing the weight (Soehnle Quantra-
tronic digital scale 7300, 7306 in the old surveys; Soehnle, Seca 850, Seca 870, Tanita
THD-305 in the rolling programme) by the square of height (kg/m2).
2.4.4 Statistical analysis
We reported consumption of milk (low- and full-fat), yoghurt (low- and full-fat), cheese
(low- and high-fat), butter, cream, fermented dairy products (sum of yoghurt and cheese),
low-fat dairy products (sum of low-fat milk, total yoghurt, low-fat cheese and low-fat
cream), high-fat dairy products (sum of full-fat milk, high-fat cheese, high-fat cream and
butter) and total dairy products.
Day-level data were aggregated using weights, which were calculated so that weekend
days are given a lower weight than weekdays depending on the total number of diary days
completed. So if someone completed one day, they were given the weight 1*5/7=0.71 if it
was a weekday and the weight 1*2/7=0.29 if it was a weekend day. If they completed two
days, they were given 2*5/7=1.43 for weekdays or 2*2/7=0.57 for weekends. For three
completed days, they were given a weight of 3*5/7=2.14 for weekdays or 3*2/7=0.86 for
weekend days and finally for 4 completed days, they were given a weight of 4*5/7=2.86
for weekdays or 4*2/7=1.14 for weekends.
Due to the high number of non-consumers for some dairy types, statistics were esti-
mated within consumers and the percentage of consumers was reported. Due to the skew-
ness of the consumption of total and types of dairy products, the median and inter-quartile
range in addition to the mean and its standard error were estimated. Dairy consumption
was reported in g/day.
Consumption levels are presented stratified by age with 65 years as the cut-off point for
all the survey years, because the old surveys assessed adults <65 years and elderly people
with age ≥65 years in different years. In addition, combined consumption levels for all
the years stratified by sex are presented and combined consumption levels for the rolling
programme years only stratified by BMI are presented.
Statistics were calculated after the data were set as survey data using the sampling
weights and accounting for the two-stage sampling design. Significance of time trends
was derived from linear regression models including dairy consumption within consumers
and the survey year and logistic regression models including dairy consumption (yes or
no) and the survey year. Due to the different methods used for the dietary assessment in
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the old surveys (weighed food diaries) and the rolling programme years (estimated food
diaries), significance of time trends is reported only for the rolling programme years for
the consumption within consumers, but for all the years for the percentage of consumers,
which is expected to be independent of the dietary assessment method. Years are presented
throughout the results as survey years e.g. 2008/2009, 2009/2010 and not as chronological
years e.g. 2008, 2009, because each survey year covered all seasons within two different
chronological years.
The percent contribution of the different types of dairy products for each year of the
rolling programme was estimated for nutrients including: intake of total energy, total
fat, saturated fat, cis-monounsaturated fat, trans fat, carbohydrates, total sugars, protein,
vitamin A, vitamin D, vitamin B12, calcium, potassium, magnesium, phosphorus and zinc.
All analyses were conducted using Stata 14.2 (College Station, TX: StataCorp LP,
2015).
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2.5 Results
2.5.1 Basic characteristics
Basic characteristics of adults and elderly participants for each survey year are presented
in Table 2.2. By design, the old survey years included more participants than the rolling
programme years. The rolling programme years included 420-597 adults, whereas year
2000/2001 included 1,723 adults <65 years. For elderly participants, the rolling programme
years included 87-184 participants and year 1994/1995 included 1,733 participants.
The mean age was consistent across years ranging from 40.1 years in 2013/2014 to
41.3 years in 2011/2012 for adults, and from 73.2 years in 2012/2013 to 76.6 years in
1994/1995 for the elderly. Likewise, the percentage of women ranged from 38.1% in
2013/2014 to 45.7% in 2010/2011 for adults, and from 35.7% in 2015/2016 to 49.1% in
1994/1995 for elderly participants.
The percentage of people in the high BMI category (>30 kg/m2) increased overall over
time starting from 21.1% in 2000/2001 and reaching 24.5% in 2015/2016 after peaking
at 30.3% in 2011/2012 for adults. Among the elderly group, the prevalence of high BMI
(≥30 kg/m2) increased from 14% in 1994/1995 to 24.5% in 2015/2016 after peaking at
32% in 2013/2014.
Most of the participants completed all the four days of the food diaries with percentages
ranging from 81.7% in 2000/2001 to 99.2% in 2008/2009 for adults, and from 96% in
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2.5.2 Trends in dairy consumption
UK time trends of the percentage of consumers and average consumption levels within
consumers for total and types of dairy products are presented from 2000/2001 to 2015/2016
for adults younger than 65 years, and from 1994/1995 to 2015/2016 for elderly adults older
than 65 years in Figures 2.3- 2.12. The corresponding statistics (mean, standard error,
median, interquartile range) are presented in Tables A.1- A.2.
Total, low- and high-fat dairy consumption
The percentage of adult consumers or elderly consumers of total and high-fat dairy prod-
ucts did not significantly change from 2000/2001 or 1994/1995 respectively to 2015/2016
with levels higher than 99.8% throughout the whole period (p>0.05; Figures 2.3, 2.4). Low-
fat dairy consumers <65 years significantly decreased from 99.3% in 2000/2001 to 98.2% in
2015/2016 (p=0.04; Figure 2.3), but the change for elderly participants was not significant
(Figure 2.4). A decrease was observed in consumption of total and high-fat dairy products
from 2000/2001 (287.8±5.3 and 85.1±3.2 g/day respectively) to 2008/2009 (242.6±9 and
73.2±5.9 g/day respectively), but no significant change was observed from 2008/2009
to 2015/2016 (p>0.05). Low-fat dairy consumption was consistently higher compared to
high-fat dairy consumption with 205.3±5.2 g/day in 2000/2001 to 181.8±9.9 g/day in
2015/2016 for low-fat dairy products and 85.1±3.2 g/day in 2000/2001 to 66.7±4.9 g/day
in 2015/2016 for high-fat dairy products (Figure 2.3). For elderly consumers, although
total and low-fat dairy consumption did not significantly change over the 8-year rolling
programme period, high-fat dairy consumption significantly decreased from 167.6±5.5
g/day in 1994/1995 and 119.1±16.5 g/day in 2008/2009 to 53.1±6.2 g/day in 2015/2016
(p=0.002; Figure 2.4).
Milk consumption
Milk was consistently the largest contributor to total dairy consumption across the years,
even though the percentage of total and low-fat milk consumers significantly decreased
among adults (p=0.01 and p=0.0004 respectively), maintaining levels above 98.5% for
total milk and 97% for low-fat milk (Figure 2.5). On the contrary, the percentage of
full-fat milk consumers did not change significantly (p>0.05), but fluctuated within a
range of 72 to 80% (Figure 2.5). Within adult consumers, average total and low-fat
milk consumption did not significantly change (p>0.05; Figure 2.5), but full-fat milk
consumption significantly decreased from 68.8±3.8 g/day in 2000/2001 and 55.3±7.2
g/day in 2008/2009 to 46.7±5.8 g/day in 2015/2016 (p=0.01; Figure 2.5). Among elderly
people, the percentage of full-fat milk consumers significantly decreased from 87.9% in
1994/1995 to 73.5% in 2015/2016 (p<0.0001), while no substantial trends were observed
for percentages of total or low-fat milk consumers (Figure 2.6). Within elderly consumers,
consumption of total and low-fat milk did not significantly change over the 8-year period
(p>0.05), but full-fat milk consumption significantly decreased from 165.6±6 g/day in
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Fig. 2.3 Time trends of the percentage of consumers and the consumption levels within
consumers of total, high- and low-fat dairy products among adult participants <65
years in the old survey (2000/2001) and the rolling programme years (2008-2016) of the
National Diet and Nutrition Survey (NDNS) in the UK. P for trend is estimated for years
2008/2009-2015/2016 only for consumption within consumers, but for all the years for
the percentage of consumers. ∥ denotes a time gap of more than one year between the old
surveys and the rolling programme.
1994/1995 and 114.2±19.4 g/day in 2008/2009 to 33.1±7.8 g/day in 2015/2016 (p=0.02;
Figure 2.6).
Yoghurt consumption
Yoghurt consumption patterns did not significantly change for adults <65 years (Fig-
ure 2.7). In the most recent survey year, 2015/2016, 48.1% of adults <65 years consumed
yoghurt (average consumption: 45.4±3.7 g/day). While consumption within consumers
did not change also for participants ≥65 years, the percentage of consumers of total, full-fat
and low-fat yoghurt significantly increased from 19.5% to 46.4%, 13.8% to 29.8% and
13.5% to 34.4% respectively over the 12-year period (Figure 2.8).
Cheese consumption
The percentage of adult total and low-fat cheese consumers did not significantly
change, whereas the percentage of high-fat cheese consumers increased from 78.4% in
2000/2001 to 80.9% in 2015/2016 (Figure 2.9). Within adult consumers, total cheese
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Fig. 2.4 Time trends of the percentage of consumers and the consumption levels within
consumers of total, high- and low-fat dairy products among elderly participants ≥65
years in the old survey (1994/1995) and the rolling programme years (2008-2016) of the
National Diet and Nutrition Survey (NDNS) in the UK. P for trend is estimated for years
2008/2009-2015/2016 only for consumption within consumers, but for all the years for
the percentage of consumers. ∥ denotes a time gap of more than one year between the old
surveys and the rolling programme.
consumption significantly slightly decreased from 27.5±1.5 in 2008/2009 to 24.1±1.4
g/day in 2015/2016, but no significant change was observed for high- or low-fat cheese
consumption separately (Figure 2.9). The percentage of elderly consumers of total cheese
and high-fat cheese significantly increased from 71.3% to 76.8% and 69.6% to 75.5%
respectively from 1994/1995 to 2015/2016, but the percentage of consumers of low-fat
cheese did not significantly change (Figure 2.10). No significant 8-year trend was observed
for cheese consumption within elderly people ≥65 years (Figure 2.10).
Butter consumption
Consumption patterns for butter both among adults <65 years and elderly people
≥65 years did not significantly change over the 8-year period. No significant changes
were observed within consumers. In the most recent survey year of 2015/2016, butter
consumption was 8.1±0.5 g/day and 7.9±0.8 for adults <65 years and elderly people
respectively (Figures 2.11, 2.12).
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Fig. 2.5 Time trends of the percentage of consumers and the consumption levels within
consumers of total, full- and low-fat milk among adult participants <65 years in the
old survey (2000/2001) and the rolling programme years (2008-2016) of the National Diet
and Nutrition Survey (NDNS) in the UK. P for trend is estimated for years 2008/2009-
2015/2016 only for consumption within consumers, but for all the years for the percentage
of consumers. ∥ denotes a time gap of more than one year between the old surveys and the
rolling programme.
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Fig. 2.6 Time trends of the percentage of consumers and the consumption levels within
consumers of total, full- and low-fat milk among elderly participants ≥65 years in the
old survey (1994/1995) and the rolling programme years (2008-2016) of the National Diet
and Nutrition Survey (NDNS) in the UK. P for trend is estimated for years 2008/2009-
2015/2016 only for consumption within consumers, but for all the years for the percentage
of consumers. ∥ denotes a time gap of more than one year between the old surveys and the
rolling programme.
2.5 Results 33
Fig. 2.7 Time trends of the percentage of consumers and the consumption levels within
consumers of total, full- and low-fat yoghurt among adult participants <65 years in
the old survey (2000/2001) and the rolling programme years (2008-2016) of the National
Diet and Nutrition Survey (NDNS) in the UK. P for trend is estimated for years 2008/2009-
2015/2016 only for consumption within consumers, but for all the years for the percentage
of consumers. ∥ denotes a time gap of more than one year between the old surveys and the
rolling programme.
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Fig. 2.8 Time trends of the percentage of consumers and the consumption levels within
consumers of total, full- and low-fat yoghurt among elderly participants ≥65 years in
the old survey (1994/1995) and the rolling programme years (2008-2016) of the National
Diet and Nutrition Survey (NDNS) in the UK. P for trend is estimated for years 2008/2009-
2015/2016 only for consumption within consumers, but for all the years for the percentage
of consumers. ∥ denotes a time gap of more than one year between the old surveys and the
rolling programme.
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Fig. 2.9 Time trends of the percentage of consumers and the consumption levels within
consumers of total, high- and low-fat cheese among adult participants <65 years in the
old survey (2000/2001) and the rolling programme years (2008-2016) of the National Diet
and Nutrition Survey (NDNS) in the UK. P for trend is estimated for years 2008/2009-
2015/2016 only for consumption within consumers, but for all the years for the percentage
of consumers. ∥ denotes a time gap of more than one year between the old surveys and the
rolling programme.
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Fig. 2.10 Time trends of the percentage of consumers and the consumption levels within
consumers of total, high- and low-fat cheese among elderly participants ≥65 years in
the old survey (1994/1995) and the rolling programme years (2008-2016) of the National
Diet and Nutrition Survey (NDNS) in the UK. P for trend is estimated for years 2008/2009-
2015/2016 only for consumption within consumers, but for all the years for the percentage




The percentage of cream consumers significantly decreased for both age groups. No
significant changes were observed within consumers. In 2015/2016, cream consumption
was 5.7±0.4 and 7.4±1.1 g/day for adults <65 years and elderly people respectively
(Figures 2.11, 2.12).
Fermented dairy consumption
Fermented dairy consumers ≥65 years significantly increased from 74.6% in 1994/1995
to 82.8% in 2015/2016 (Figure 2.12). No significant changes were observed within
consumers. In 2015/2016, fermented dairy consumption was 47±2.5 and 52.6±5.9 for
adults <65 years and elderly people respectively (Figures 2.11, 2.12).
Fig. 2.11 Time trends of the percentage of consumers and the consumption levels within
consumers of butter, cream and fermented dairy products (sum of yoghurt and cheese)
among adult participants <65 years in the old survey (2000/2001) and the rolling pro-
gramme years (2008-2016) of the National Diet and Nutrition Survey (NDNS) in the
UK. P for trend is estimated for years 2008/2009-2015/2016 only for consumption within
consumers, but for all the years for the percentage of consumers. ∥ denotes a time gap of
more than one year between the old surveys and the rolling programme.
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Fig. 2.12 Time trends of the percentage of consumers and the consumption levels within
consumers of butter, cream and fermented dairy products (sum of yoghurt and cheese)
among elderly participants ≥65 years in the old survey (1994/1995) and the rolling
programme years (2008-2016) of the National Diet and Nutrition Survey (NDNS) in the
UK. P for trend is estimated for years 2008/2009-2015/2016 only for consumption within
consumers, but for all the years for the percentage of consumers. ∥ denotes a time gap of
more than one year between the old surveys and the rolling programme.
2.5.3 Dairy consumption by sex
Overall, men consumed more total dairy products (264.3±4.6 g/day for <65 years and
321.4±6 g/day for ≥65 years) than women (234.1±3.2 for <65 years and 319.6±4 g/day
for ≥65 years) over the 8-year period from 2008/2009 to 2015/2016 (Table 2.3). This
difference was attributed mainly to a higher consumption of milk compared to women.
Conversely, women <65 years consumed more low-fat yoghurt (38.1±1.4 g/day) than
men (34.5±1.8 g/day) of the same age category. Women ≥65 years also consumed more
total yoghurt (both low- and full-fat; 50.2±1.9 g/day) than elderly men (42.2±2.7 g/day;
Table 2.3). Men <65 years consumed slightly higher amounts of total and high-fat cheese
than women of the same age group, whereas women consumed higher amounts of low-fat


























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































40 Description of dairy consumption in the UK
2.5.4 Dairy contribution to nutrient intakes
Total energy and macronutrient intakes
Table 2.4 shows the contribution of total and types of dairy products to macronutrient
intakes in the total sample and within dairy consumers for each of the years of the rolling
programme. The contribution of total dairy consumption to total energy intake ranged
from 13.5% in 2011/2012 to 14.6% in 2009/2010 with most of it coming from high-fat
dairy products (from 8.3% in 2011/2012 to 9.4% in 2009/2010). Of the subtypes, low-fat
milk was the highest contributor to total energy intake overall (from 3.9% to 4.4%) and
high-fat cheese was the highest contributor within consumers (from 4.3% to 4.9%).
Total dairy products contributed by 24.4%-25.8% to total fat intake, 40.2%-42.2%
to saturated fat intake, 16.2%-17.7% to cis-monounsaturated fat intake, 51%-62.1% to
trans fat intake, 5.1%-5.7% to carbohydrate intake, 12.7%-13.8% to total sugar intake
and 17.7%-19.1% to protein intake. Specifically for the contribution to trans fat intake,
it seems that there is a linear increase from 51% in 2008/2009 to 62.1% in 2015/2016.
Of dairy subtypes, the highest contributor to total, saturated, cis-monounsaturated and
trans fat was high-fat cheese both overall (7.6-8.6%, 12.8-14.8%, 5.2-5.9% and 16-22.2%
respectively) and among consumers only (9.4-10.9%, 15.7-18.9%, 6.3-7.5% and 21.2-
27.9% respectively). The highest dairy contributor to carbohydrate, total sugar and protein
intake was low-fat milk both overall (3.4-4%, 8.5-9.8% and 7.7-9% respectively) and














































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































44 Description of dairy consumption in the UK
Micronutrient intakes
Table 2.5 presents the contribution of total and types of dairy products to micronutrient
intakes overall and within dairy consumers for each survey year of the rolling programme.
Total dairy consumption contributed to intakes of vitamin A by 24.3-32.1%, vitamin D by
11.4-13.3%, vitamin B12 by 39.4-41.8%, calcium by 48.4-50.5%, potassium by 14.5-15.8%,
magnesium by 12.3-13.7%, phosphorus by 25.7-27.8% and zinc by 19.8-21.5%.
The highest dairy contributor to vitamin A intakes both overall (7.8-11%) and among
consumers only (11-19.8%) was high-fat cheese. For vitamin D, vitamin B12, calcium,
potassium, magnesium, phosphorus and zinc, low-fat milk contributed the most both overall
and among consumers only. Specifically, among all (overall) survey participants including
consumers and non-consumers, low-fat milk contributed to micronutrient intakes as follows:
vitamin D, 3.8-5.2%; vitamin B12, 21.4-25.6%; calcium, 23.5-26.3%; potassium, 9.3-
10.4%; magnesium, 6.9-7.9%; phosphorus, 12.9-14.8% and; zinc 8-9.4% among consumers
and non-consumers. Similarly, low-fat milk also contributed the most to micronutrients as
follows: vitamin D, 3.8-5.6%; vitamin B12, 22.9-26.8%; calcium, 25.2-27.4%; potassium,




































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































48 Description of dairy consumption in the UK
2.6 Discussion
2.6.1 Summary of results and comments
Dietary consumption data at a national level in the UK with the NDNS has enabled the
examination of trends in dairy consumption over an 8-year period from 2008 to 2016
and comparison with the older surveys from 1994/1995 and 2000/2001. There have been
notable shifts in dairy consumption and some clear patterns have emerged.
Overall, milk was the highest contributor to total dairy consumption consistently over
time constituting about 80% of total dairy products in adults <65 years and about 85%
in elderly adults. It is noted that low-fat milk consumption was consistently higher than
full-fat milk over time contributing approximately 80% to the total milk consumption
among adults <65 years. Commensurate with this, full-fat milk consumption continued the
decreasing trend observed in earlier years through food supply and availability data[38],
dropping by 8.6 g/day among adults <65 years and by 81.1 g/day among elderly people
over the 8-year period of 2008-2016. The percentage of elderly consumers of full-fat
milk dropped by 14.4% over the 22-year period of 1994-2016. In contrast, the percentage
of elderly consumers of total, full-fat and low-fat yoghurt increased by 26.9%, 16% and
20.9% respectively over the same 22-year period. Smaller increases were observed for the
percentages of high-fat cheese consumers and smaller decreases for the percentages of
cream consumers in both age groups. Differences of consumption levels between men and
women were small.
Total dairy consumption contributed on average approximately 14% to total energy
intake, 25% to total fat, 5.5% to carbohydrate, and 18% to protein. Of the macronutrient
subtypes, total dairy consumption contributed 41% to saturated fat, 17% to monounsatu-
rated fat, 55% to trans fat, and 13% to sugars.
Of the micronutrients, total dairy consumption contributed approximately 25% to
vitamin A, 10% to vitamin D, 40% to vitamin B12, 50% to calcium, 15% to potassium,
13% to magnesium, 27% to phosphorus, and 21% to zinc.
The highest dairy contributor to total fat and its types was cheese followed by butter.
For carbohydrates, sugars and protein, the highest contributor was milk. For micronutrients,
the highest dairy contributor was low-fat milk except for vitamin A, for which the highest
dairy contributor was high-fat cheese.
The highest dairy contribution to macronutrient intakes was observed for saturated
fat (approximately 41%) and for trans fat (approximately 50%), which are the main
macronutrients of concern for cardio-metabolic risk (as appraised in section 1.3). The
contribution of dairy products to saturated fat intake is in agreement with that reported
from the TRANSFAIR study, which consisted of chemical analysis of approximately 100
foods from 14 European countries and also from the use of purchase data or consumption
data (individual or household level) to derive food contributions to nutrient intakes[55].
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Specifically for the UK, this study used household level consumption data from the National
Food Survey 1997 and reported a contribution of dairy products to saturated fat intake of
38.8%[55]. However, for trans fat, dairy consumption contributed 24.7%[55], while in
our analysis we observed a much greater (2-fold higher) contribution of approximately
50%, which actually increased from 51% contribution to trans fat intake in 2008/2009 to
62.1% in 2015/2016. It can be assumed that the increased contribution of dairy to trans
fat intake in the recent years, as reported in this PhD, is a consequence of the voluntary
decrease of the industrial trans fat content by the food industry in the UK because of the
reported harmful effects of industrial trans fat on health[56], while at the same time the
ruminant trans fat intake might not have considerably changed. Indeed, in the most recent
report on trans fat content of foods from the Department of Health, it was observed that the
industrial trans fat content of foods was significantly decreased compared to that observed
in foods 20 or 30 years ago[57].
It is of note that some descriptive statistics reported in the official reports of NDNS
differ from the statistics I reported here. For example, the contribution of milk and milk
products, as well as butter to saturated fat intake of people 19-64 years was reported to
be 27% previously[53], while this analysis reported 41% and the numbers were similar
both among consumers only and in the total sample. The biggest difference was for butter,
for which prior report was of a 5% contribution, while I reported a 15% contribution to
saturated fat intake. Such difference is expected if we consider that we estimated dairy
consumption also accounting for dairy content in composite foods and recipes. Butter is
an ingredient used very often in recipes, so whether we account for recipes or not should
make a large difference in the estimation of butter consumption levels.
2.6.2 Strengths and limitations
This descriptive study has several strengths. First, we used data from NDNS, which
includes a representative sample from the UK, so that we can generalise the results of our
study to a national level with confidence. Since the start of the rolling programme in 2008,
there are annual data available, which enabled us to look at consumption trends over time.
We further contributed to the precision of the consumption levels by incorporating in our
analysis dairy products consumed as part of composite foods and recipes. This was an
enhancement and an important contribution, since it made a big difference to nutrients
such as saturated fat, for which butter is a high contributor, but also a frequent ingredient
in recipes.
However, this PhD analysis has also some limitations. The rolling programme started
in 2008, so we could only investigate trends over 8 years, while it is of greater interest to
investigate trends over decades. Even the availability of the old survey data did not allow for
the investigation of trends in consumption patterns, because of the different methodology
used (weighed vs estimated food diary), but it only allowed the description of trends of
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the percentage of dairy consumed, which should be equally captured irrespective of the
dietary assessment method used. As a result, trends of dairy consumption for years earlier
than the NDNS rolling programme in the UK are available only as an approximation from
household level consumption data or national level dairy supply/availability/production
data.
2.6.3 Conclusion
The healthfulness of yoghurt has been consistently supported from previous evidence,
whereas the saturated fat content of full-fat milk has been used as the reason to recommend
lower consumption of full-fat milk and a preference towards low-fat milk and dairy products
in general[23]. These recommendations are reflected in the consumption levels and trends
observed in our study from a representative UK sample with a continuous decrease over
time in the consumption of full-fat milk and an increase in the consumption of yoghurt.
However, evidence regarding saturated fat intake from specific food sources such as dairy
products has started to change.
The importance and variability of the dairy food matrix is evident when considering
the contribution of dairy products to nutrient intakes. Dairy products contribute more
than a quarter to vitamin A, vitamin B12, calcium, and phosphorus intakes, which are
important nutrients for health, but also to saturated and trans fat intakes, which have been
linked to potential harmful effects on health. The balance of effects from these nutrients
is what defines the final effect of dairy products as food entities on health. Research into
the mechanisms of action of the dairy food matrix on health in combination with close
monitoring of consumption levels in the population will contribute to informed formulation
of dietary guidelines and design of effective public health interventions.
Chapter 3
Previous evidence on dairy consumption
and cardio-metabolic markers
Summary
The differential associations observed between different dairy types and cardio-metabolic
disease outcomes (section 1.2) pose the question as to what the underlying pathways for
such associations are, which might further explain the observed heterogeneity. Biological
pathways to cardio-metabolic disease might be related to a number of factors including
adiposity, lipidaemia, glycaemia, inflammation, hepatic function and blood pressure.
Evidence from randomised controlled trials (RCTs) supports favourable effects of
total dairy consumption on body weight and composition under conditions of energy
restriction. Specifically, total dairy consumption decreased body weight, total fat mass,
waist circumference, abdominal fat and visceral adipose tissue and increased lean mass in
RCTs. Results on specific dairy types are limited.
Concerning lipid markers, there is established evidence from RCTs that butter increases
total, low-density lipoprotein (LDL-C) and high-density lipoprotein cholesterol (HDL-C)
when compared with other types of fat, whereas null effects on blood lipids were reported
for total, high-fat or low-fat dairy products. Cheese decreased LDL-C and HDL-C when
compared with butter. Evidence on other dairy types is sparse.
RCTs have failed to report any effects of total, low-fat or high-fat dairy products on
glycaemic markers including fasting blood glucose, insulin, haemoglobin A1c (HbA1c)
or the homoestasis model assessment for insulin resistance (HOMA-IR). As for other
markers, evidence on specific dairy types is sparse.
Fermented dairy consumption decreased inflammatory markers overall in RCTs, but
low-fat or high-fat dairy consumption did not have an effect on C-reactive protein (CRP).
The number of studies on specific dairy types is limited, and there are no studies on
associations between dairy consumption and markers of hepatic function.
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Finally, evidence from RCTs indicates a beneficial effect of fermented milk on systolic
(SBP) and diastolic (DBP) blood pressure, but no effects for total, low-fat or high-fat dairy
products. Milk, total and low-fat dairy products have been associated with a lower risk of
hypertension in prospective cohort studies.
Overall, although there are many studies on associations of dairy consumption with
cardio-metabolic risk markers, the evidence is not sufficient or consistent to draw conclu-
sions on associations of different dairy types with a spectrum of cardio-metabolic markers.
The inconsistency in the definition of dairy products as a food group and the limitations of
the studies that have been conducted so far suggest the need for more research to elucidate
the link between dairy consumption and cardio-metabolic disease.
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Cardio-metabolic diseases are multifactorial and thus the investigation of biological
pathways including adiposity, glycaemia, lipidaemia, inflammation, hepatic function and
blood pressure could elucidate the role of dairy products in their pathogenesis. There is an
extensive literature on associations of total and types of dairy consumption with several
cardio-metabolic markers. However, the evidence synthesis is not very straightforward
because different studies have investigated associations of different dairy types or groups
with different markers resulting in sparse evidence on associations between certain dairy
types and certain cardio-metabolic markers. In this chapter, evidence on associations
of total and types of dairy products with cardio-metabolic markers from randomised
controlled trials (RCTs) and prospective cohort studies is presented.
3.1 Markers of body weight and composition
3.1.1 Body weight
Randomised controlled trials
Meta-analyses of RCTs show differential effects of dairy products on body weight
depending on whether the interventions applied energy restriction or not[58]. After
I searched meta-analyses on associations of dairy consumption with cardio-metabolic
markers, I summarised the results for total, low- and high-fat dairy products in Table 3.1.
A meta-analysis of 37 RCTs reported an overall null effect of a mean 2.6±1 serv-
ings/day of total dairy consumption on body weight during a mean 7.7±7.9 months of
intervention[58]. After stratification by energy restriction status, the same meta-analysis
reported an increasing effect of total dairy consumption on body weight in trials without
energy restriction [b=0.36 kg (0.01, 0.7)], but a decreasing effect in trials with energy
restriction of 500 kcal/day on average [-0.64 kg (-1.05, -0.24)] in the intervention groups
compared to the control[58].
The distinction of trials based on the application of energy restriction or not is not
sufficient to describe the independent effects of dairy consumption on body weight. Instead,
it is important to know whether an experiment is isocaloric, thus whether the intervention
and control foods contain the same amount of energy in order to distinguish the effect of
energy from the effect of dairy consumption. During no energy restriction, it is even more
important to address this issue, because if the intervention is compared with the habitual
diet, then we have increased energy intake in the intervention group, so the increasing
effects of the intervention on body weight might be the result of the increase in energy
intake rather than a net effect of dairy products. A meta-analysis of 27 RCTs, which
included only RCTs with energy restriction, identified and reported that the allocation of
intervention and control foods was isocaloric, so it seems reasonable to assume that trials
with energy restriction have applied isocaloric interventions to the two trial arms[59]. Of the
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27 RCTs included in this meta-analysis, 15 overlapped with the more recent meta-analysis
reported above[58] and of the remaining 12 RCTs, six allocated an intervention of casein
or whey protein and five allocated an intervention of total (n=2) or types (n=4) of dairy
products[59]. This meta-analysis also reported a decreasing effect of dairy consumption
on body weight with a larger magnitude [-0.92 kg (-1.62, -0.2)][59]. The effect was even
more pronounced among women [-1.16 kg (-1.66, -0.66)], but it was attenuated to null
in case of mutli-component interventions that included resistance training[59]. Likewise,
older meta-analyses on the effect of dairy consumption on body weight with most of the
included studies overlapping with the aforementioned meta-analyses reported null effects
when examining trials with and without energy restriction together[60–62]. There were
weight decreasing effects when examining trials with energy restriction only[61, 62].
Under no energy restriction, both low- and high-fat dairy products increased body
weight in another meta-analysis of RCTs[63]. Meta-analyses on types of dairy products
are not available, because most of the interventions included total dairy products, often
giving the option to participants to select the type of preference based on a specific calcium
intake that they aimed to achieve and usually suggesting a minimum amount of milk to be
consumed[58]. Some interventions included milk in different forms (fluid or powder), of
different fat content or of different processing (whey protein or casein mixture)[58, 59].
Prospective cohort studies
Since the average duration of RCTs is limited to approximately 8 months, evidence
from prospective cohort studies can inform on longer term associations between dairy
consumption and body weight or BMI. The majority of the prospective cohort studies have
examined body weight rather than body mass index (BMI) in real-life settings. Prospective
cohort studies have reported null[64–66], positive[66] or inverse[67–69] associations be-
tween total dairy consumption and body weight after adjustment for total energy intake. It
can be assumed that adjustment for energy intake in observational studies is equivalent to
the application of an isocaloric experiment in RCTs to assess the association of dairy con-
sumption with body weight independent of total energy intake. However, in observational
studies, we should also accommodate the possibility of residual confounding due to the
use of the subjective measure of dietary assessment.
Similar results have been reported for high-fat dairy consumption with null[67, 70],
positive[66] or inverse[66, 69] associations with body weight. For low-fat dairy products
null associations with body weight have been more consistently reported[66, 67, 69–
71]. For the main dairy types, prospective analyses resulted in either null (milk[67, 70,
72], yoghurt[73], cheese[65, 67, 70, 71]) or inverse (milk[65, 72], yoghurt[65, 67, 70],
cheese[68, 72]) associations. The heterogeneity of these results from the prospective cohort
studies will be further explored in Chapter 5. After a literature search, I have summarised
the magnitude and variance of these associations in Table 3.2.
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3.1.2 Body composition
Randomised controlled trials
Some of the studies investigating associations between dairy consumption and body
weight, also examined associations with measures of body composition (Table 3.1). Five
meta-analyses of RCTs showed that total dairy consumption decreased body fat mass
in energy restriction trials[58–62] and two of them showed null effects in trials with no
energy restriction[58, 62]. For example, the meta-analysis that included the most RCTs
(n=27) reported a decrease of 1.24 kg in body fat mass after an intervention with a mean
of 2.7±1 dairy servings/day during 5.1±3.1 months[59].
Three meta-analyses of RCTs reported that total dairy consumption increased lean
mass in energy restriction trials[58, 59, 61], although in one of them the effect was not
significant[58], but dairy consumption did not change lean mass in trials with no energy
restriction as reported by one of the meta-analyses[58]. For example, the meta-analysis
with the highest number of RCTs (n=27), reported that an average of 2.9 dairy servings/day
increased body lean mass by 0.36 kg over an average period of 4.2 months[59].
Measures of body fat and lean mass distribution are peripheral fat and appendicular
lean mass. Since the association between abdominal fat and cardio-metabolic disease
has been shown to be even stronger, compartments of abdominal fat including visceral
adipose tissue (VAT) and subcutaneous adipose tissue (SCAT) are also measured[74].
VAT or intraperitoneal fat is the part of the adipose tissue in the abdominal area, which
surrounds the organs, and SCAT is the part of the adipose tissue, which is accumulated
under the skin[74]. The equipment to measure abdominal fat is often expensive (computer
tomography, magnetic resonance imaging, dual energy X-ray absorptiometry), so most
of the studies measure waist circumference (sometimes also the ratio of waist to hip
circumference) as a proxy for fat mass distribution[74]. Meta-analyses of RCTs have
reported decreasing effects of total dairy consumption on waist circumference in trials
with energy restriction[58, 61], but null effects in trials without energy restriction[58]. In
accordance with the effects on body fat mass reported from the meta-analyses, one 6-month
and one 12-month cross-over RCT, which did not apply energy restriction, reported null
effects of four low-fat dairy servings on abdominal fat when compared with one or two
servings[75, 76]. Conversely, in two trials with energy restriction dairy consumption
decreased abdominal fat[77, 78], whereas in one trial with energy restriction no effect was
observed[79]. One of the trials, which examined VAT, also observed a decrease with higher
dairy consumption[78].
Prospective cohort studies
Evidence on associations of dairy products with waist circumference from prospective
cohort studies, after adjustment for total energy intake[64, 65, 71], BMI[68, 80, 81] or
both[67] shows null associations for cheese[65, 67, 68, 71], low-fat[71, 80] and total
dairy products[64, 67, 68], but inverse associations for yoghurt[65, 67] and high-fat dairy
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products[67, 80]. In addition, a prospective observational analysis of data from the
PREDIMED trial (3.2 years of follow-up) reported null associations with central adiposity
for all dairy types and groups studied apart from yoghurt and its sub-types, for which
inverse associations were found[82].
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3.2 Lipid markers
Randomised controlled trials of butter
There is a large number of studies on the associations between butter and blood lipids,
because of the hypothesis that it increases blood cholesterol due to its high content of
saturated fatty acids. Despite this large literature, it is challenging to draw conclusions
as there is no meta-analysis of these RCTs so far. A simple synthesis of results would
be subject to heterogeneity related to control groups, intervention duration and intensity,
study design, sample size, country of origin, participants’ gender, specific characteristics
of the study sample e.g. postmenopausal women, hypercholesterolaemic individuals or
individuals with metabolic syndrome. A meta-analysis is beyond the scope of the present
PhD project, but a qualitative appraisal of the literature is presented.
Previous meta-analysis
The only meta-analysis published on this topic was by Zock and Katan in 1997 on 20
clinical trials published between 1957 and 1995. This meta-analysis examined the effects
of a 10% energy substitution of hard and soft margarine with butter on total, low-density
lipoprotein (LDL-), and high-density lipoprotein cholesterol (HDL-C), total-to-HDL-C
ratio and triglyceride levels[87]. Butter increased total and LDL-C compared to both types
of margarine and the increase was more pronounced when soft margarine was used as
the control group (increase by 0.25 and 0.20 mmol/l of total and LDL-C respectively)
than when hard margarine was used (increase by 0.19 and 0.11 mmol/l of total and
LDL-C respectively)[87]. HDL-C and total-to-HDL-C ratio increased only when butter
substituted hard margarine (increase by 0.02 mmol/l and 0.20 respectively), while no effect
on triglyceride levels was observed when butter substituted either type of margarine[87].
Literature search
From a literature search in PubMed from 1980 to 2016 and extraction of relevant studies
from references of other papers, 56 RCTs, which use butter either in the intervention or
as a control and examine effects on blood lipids, were identified. Of those, 35 RCTs
remained[88–122] after exclusion of 21 RCTs because either they used butter as part of
both the intervention and the control group to compare the effects of other fat sources
(n=11), or the intervention did not include solely butter (n=5), or they were included in the
meta-analysis by Zock and Katan published in 1997 (n=3) or the intervention or control
group was not of interest (n=2).
Description of identified studies
Among the 35 eligible RCTs, the majority of the trials are cross-over studies (n=27)[88–
95, 97, 99, 101, 102, 104–115, 117, 118, 120] with a mean sample size of 43±42. Most
of the studies included both men and women (n=26)[88–90, 92, 94–96, 98, 100, 102, 105–
108, 110–112, 114–122], seven studies included men only[97, 99, 101, 103, 104, 109, 113]
and two studies women only[91, 93]. Nine of the trials are postprandial studies[90, 93, 97,
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101, 105, 106, 108, 109, 113], three had a duration of less than one month[92, 96, 103],
16 had a duration between one and three months[89, 91, 94, 95, 98, 100, 102, 104, 110–
112, 114, 116, 119, 121, 122] and seven had a duration between three and six months[88,
99, 107, 115, 117, 118, 120]. Eight studies were done in Australia and New Zealand[90,
92, 102, 115–119], 10 in northern Europe[89, 93, 94, 97, 99, 100, 106, 111, 113, 121, 122],
six in southern Europe[91, 95, 101, 104, 108, 109], five in the United States[105, 110,
112, 114, 120] and five elsewhere[88, 96, 98, 103, 107]. Thirteen out of the 35 studies did
not include individuals from the general population, but included hypercholesterolemic
individuals (n=4)[111, 116–118], individuals with metabolic syndrome (n=1)[98] or type
2 diabetes (n=3)[96, 106, 108].
High diversity was also observed concerning the food items used as comparison
(control) groups in RCTs on the effect of butter on blood lipids. In order to make a
qualitative summary synthesis of the results, it was considered reasonable to classify
the comparison groups according to the intervention content of different fatty acids
(monounsaturated fatty acids –MUFA-, polyunsaturated fatty acids -PUFA-, saturated
fatty acids –SFA- and trans fatty acids –TFA-). The category of high MUFA content
includes olive oil (n=12)[89, 91, 93, 95, 101, 104, 106, 109, 113, 119, 120, 122], rape-
seed oil (n=3)[99, 113, 121], palm oil (n=1)[113], argan oil (n=1)[96] and soft mar-
garine (n=3)[98, 105, 107]. The category of high PUFA content includes sunflower oil
(n=4)[90, 97, 109, 113], soybean oil (n=2)[110, 120], safflower oil (n=3)[115, 118, 119],
unsaturated margarine (n=4)[100, 114, 117, 121] and walnuts (n=2)[101, 104]. The cat-
egory of high SFA content included coconut oil (n=3)[115, 118, 122] and cocoa butter
(n=1)[120] and the category of high TFA content included hard margarine (n=5)[107, 110–
112, 114] and a canola oil and PUFA blend enriched with TFAs (n=1)[116]. The com-
parison groups which included less SFA than butter such as cheese (covered in the next
paragraph), milk (n=2)[92, 108] and the habitual diet (n=10)[89, 91, 94, 96, 98, 101–
104, 116], cannot be classified in any of the aforementioned categories and constitute a
separate category. Habitual diet as a comparison group is a special case, as its content
might be characterised by a higher heterogeneity. Certain comparison groups such as
carbohydrates (n=1)[119], and interesterified linseed and rapeseed oil that are high both
in PUFA and MUFA[93] do not belong to any of the aforementioned categories and they
have not been included in separate categories, as the number of relevant trials identified is
insufficient.
Qualitative evidence synthesis
Based on this classification, overall, LDL-C increased when butter substituted food
sources of MUFA[88, 89, 95, 99, 101, 104–107, 109, 113, 119–122] or PUFA[88, 100, 105,
110, 114, 115, 117, 118, 120, 121], or TFA[87, 107, 112, 114, 116]. Results are conflicting
for lower SFA intake showing increase[88, 89, 91, 94, 102, 102, 103] or no effect[96,
98, 101, 104, 116] on LDL-C. For HDL-C, there was no effect when butter substituted
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food sources of MUFA[87–89, 93, 95, 99, 101, 105, 107, 120–122], an increasing effect
when it substituted hard margarine[87] and mixed effects when it substituted PUFA food
sources[88, 90, 105, 110, 114, 115, 117, 118, 120, 121] or the habitual diet[91, 94, 96,
98, 101, 102, 104] in most of the studies. Total cholesterol increased when PUFA food
sources[88, 100, 105, 110, 114, 115, 117, 118, 120, 121] or food items with generally
lower SFA content[89, 91, 94, 102–104, 116, 120] were substituted with butter. For
MUFA, results were conflicting showing no[91, 93, 95, 101] or increasing effects on total
cholesterol[87–89, 95, 99, 105, 107, 120–122]. Most of the trials reported null effects on
triglycerides when butter replaced any fat sources[87, 89–91, 93–99, 101, 102, 104, 105,
107–110, 113–117, 120–122].
Some characteristics of the 35 studies included in this qualitative evidence synthesis
are presented in Tables 3.3-3.6.
It is recommended for future research that a meta-analysis of the RCTs examining
the effects of butter on blood lipids, is conducted to obtain quantitative effects and to
account for all sources of heterogeneity. The last meta-analysis of part of these RCTs was
conducted in 1997 by Zock and Katan[87], thus an updated meta-analysis is needed.
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Evidence on other dairy types
Total dairy consumption did not exert any effects on total cholesterol in four RCTs[77–
79, 123], but exerted an increasing effect in one RCT[124] when compared with habitual
consumption under an isocaloric experiment and a decreasing effect in another RCT
when compared with a diet lower in dairy products under no energy restriction[125]. The
effects on total cholesterol reported by four RCTs for low-fat dairy consumption were
null[75, 76, 126, 127]. Evidence on dairy types in relation to total cholesterol and the ratio
of total to HDL-C from RCTs and prospective cohort studies is limited.
RCTs reported null effects of total dairy consumption on LDL-C[77–79, 123, 124] or
HDL-C[77–79, 124]. A meta-analysis of nine RCTs without energy restriction indicated
null effects of low- and high-fat dairy consumption on LDL-C or HDL-C[63] (Table 3.1).
Cheese consumption had a decreasing effect on total cholesterol, LDL-C and HDL-C,
but no effect on triglycerides, when compared with butter consumption, even though the
intervention and control group had the same intake of PUFA/SFA ratio, as reported in a
meta-analysis of five RCTs[83] (Table 3.1). In the same publication, through a narrative
review of RCTs on the effect of cheese on blood lipids when compared with tofu consump-
tion (n=4) or a modified cheese with a higher PUFA/SFA ratio (n=3), cheese increased
total cholesterol and LDL-C overall and had no effect on HDL-C and triglycerides[83].
Interventions of dairy types are limited.
Associations on total dairy consumption and LDL-C reported from prospective cohort
studies are null[64, 81], and the same holds for most associations with HDL-C[68, 81, 82,
128].
Null associations have also been reported between cheese and HDL-C[68, 71, 82, 129],
whereas evidence on associations between other dairy types and LDL-C or HDL-C from
prospective cohort studies is sparse. No effect on fasting triglycerides, was reported
from interventions of total[77, 78, 123, 124] or low-fat dairy products[75, 76, 126, 127]
and most of the prospective cohort studies also reported null associations for total dairy
consumption[64, 68, 81, 82, 128].
The number of studies on associations between specific dairy types and triglycerides is
limited. Specifically for yoghurt, there have been several RCTs examining its effect on the
lipid profile, but there is a high variability in the type of yoghurt used, as many of them
did not involve conventional yoghurt, but yoghurt with additional microbial species[130].
A review of such studies concluded that despite this heterogeneity most studies showed
beneficial effects of the different types of yoghurt on the lipid profile, which is not though
very informative for the effect of conventional yoghurt[130].
Evidence on associations of total and types of dairy products consumption with
apolipoprotein A1 (ApoA1), ApoB and non-esterified fatty acids (NEFA) is sparse.
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3.3 Glycaemic markers
Glucose
Evidence from RCTs does not show any effect of total dairy consumption on fasting
blood glucose[77–79, 123–125]. In a meta-analysis of eight RCTs, no effect on fasting
blood glucose was reported from interventions of low-fat or high-fat dairy products[63]
(Table 3.1). The number of interventions of dairy types also examining fasting blood
glucose is limited. Results from prospective cohort studies for total and low-fat dairy
consumption are conflicting, showing null[82, 128, 131, 132] or inverse[64, 71, 81, 82,
131] associations, while associations are consistently null for cheese consumption[71, 82,
131, 132]. Studies on associations of other dairy types and fasting blood glucose, as well
as on dairy consumption and postprandial glucose, are sparse.
Haemoglobin A1c
For haemoglobin A1c (HbA1c), there seems to be a tendency towards a null association
with total dairy consumption as reported in prospective cohort studies[81, 131, 132]. For
the association with dairy types the available studies are few, and evidence from RCTs is
sparse, so no meaningful conclusion can be drawn.
Insulin
Most of the RCTs reported null effects of total dairy consumption on fasting insulin[77–
79, 123, 124]. The number of interventions of dairy types examining postprandial insulin
are insufficient to draw conclusions. The number of prospective cohort studies for such
associations is even more limited.
Indices for insulin resistance
Homeostasis Model Assessment for Insulin Resistance (HOMA-IR) is highly correlated
(r=0.88) with euglycemic clamp, which is considered the gold standard for the measurement
of insulin sensitivity[133]. The index is estimated as shown in equation (3.1).
HOMA− IR = FastingPlasmaGlucose∗FastingPlasmaInsulin
22.5
(3.1)
Homeostasis Model Assessment for β -cell function (HOMA-%B) is a less frequently





RCTs reported null[79, 123] or decreasing[124, 125] effects of total dairy consumption
on HOMA-IR and null effects of low-[63] or high-fat[63] dairy consumption. Evidence on
dairy types and evidence from prospective cohort studies, as well as for HOMA-%B, is
sparse and thus inconclusive.
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3.4 Inflammatory markers
In a systematic review of 52 controlled trials and prospective cohort studies (78 results
extracted), Bordoni et al. created an inflammation score from the studies identified. This
score was positive for a study if the results indicated a beneficial effect/association of
dairy consumption on inflammatory markers, negative if the results indicated an increasing
effect/association, or zero for null effects/associations[134]. The higher the absolute
value of the score, the more criteria the study met among a range of 12 criteria. These
criteria related to the study design (controlled trial, randomisation), the results (effect
magnitude, sustainable effects, dose-response effects) and the interpretation (biological
plausibility, clinical significance)[134].The most frequently investigated inflammatory
markers were C-reactive protein (CRP; n=51), interleukin-6 (n=44) and tumour necrosis
factor α (n=36)[134].
The findings of this systematic review indicated statistically significant anti-inflammatory
effects of dairy consumption (n=61), which were more pronounced in persons with
metabolic disease (n=24)[134]. No effects were indicated among people with gastroin-
testinal disorders (n=8) and pro-inflammatory effects were observed among people with a
reported milk allergy (n=6)[134]. When results were stratified by dairy fat content, both
low-(n=20) and high-fat (n=35) dairy consumption exerted anti-inflammatory effects with
more pronounced effects for low-fat dairy[134].
Stratification by fermentation status, showed that only fermented dairy products (n=16)
had a significant anti-inflammatory effect[134]. Despite the significant effects/associations,
it should be noted that the magnitude of the effects was low. In another meta-analysis of six
RCTs, low- and high-fat dairy consumption was not associated with CRP[63] (Table 3.1),
whereas results for dairy types and results from prospective cohort studies are insufficient
to draw conclusions.
3.5 Markers of hepatic function
According to my literature search, there are no studies available on the association
between dairy consumption and markers of hepatic function. However, there is some
evidence, which supports the generation of a hypothesis that dairy consumption could be
associated with hepatic function. Liver function tests i.e. gamma-glutamyl transferase
(γ-GT), aspartate aminotransferase (AST), and alanine transaminase (ALT)[135, 136], and
non-alcoholic fatty liver disease (NAFLD)[137] have been reported to be associated with
incident type 2 diabetes. De novo lipogenesis is an underlying pathway for NAFLD[138],
which may be linked to cardio-metabolic disease through liver fat accumulation[139].
Diet provides the substrates for de novo lipogenesis i.e. fat and carbohydrates, but can
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also be associated with NAFLD through obesity, insulin resistance, hyperlipidaemia and
inflammation[140].
3.6 Blood pressure
Dairy consumption did not have an effect on systolic blood pressure (SBP) in a meta-
analysis of eight RCTs[84] (Table 3.1). Similar results were reported for low- and high-fat
dairy consumption and SBP or diastolic blood pressure (DBP) in a meta-analysis of seven
RCTs with no energy restriction[63] (Table 3.1). In another meta-analysis of 14 RCTs
investigating the effect of probiotic fermented milk, the pooled result indicated a decrease
in SBP and DBP with a more pronounced effect among hypertensive individuals[85]
(Table 3.1). In observational research, two meta-analyses of prospective cohort studies
concluded that total dairy products[84, 86], low fat-dairy products[86] and milk[86]
were associated with a 3-4% lower risk of elevated blood pressure per 200 g/d, but null
associations were reported for high-fat dairy products (n=6)[86], yoghurt (n=4)[86] or
cheese (n=8)[86] (Table 3.1). Evidence on low- and high-fat dairy types is sparse.
In summary, fermented dairy products may play a beneficial role in the regulation of
blood pressure, while total, low-fat dairy products and milk may exert such beneficial
effects mainly within high blood pressure levels, while they do not seem to have an effect
within normal levels.
3.7 Metabolic syndrome
Metabolic syndrome, which is a cluster of risk factors of type 2 diabetes (T2D) and
cardiovascular disease (CVD) including high blood glucose, high blood pressure, high
triglycerides, low HDL-C and central overweight/obesity[141], has been reported to highly
predict mainly T2D[142], but also CVD[143]. A meta-analysis of eight prospective
cohort studies with an average follow-up of 6.7 years showed a decrease in the risk
of developing metabolic syndrome by 15% for higher compared to lower total dairy
consumption categories[144]. For types of dairy products it is not possible to reach definite
conclusions due to the limited number of available studies.
3.8 Gaps in the literature
From the literature review presented above, it becomes evident that the combinations of
dairy exposures and cardio-metabolic outcomes investigated differ across studies substan-
tially. This results in inconsistent evidence and for certain associations, especially for
specific dairy types, too sparse evidence to draw any conclusions. Even in RCTs, consid-
ered the gold standard of the hierarchy of evidence, many limitations can be identified,
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such as questionable compliance, impossible blinding, short duration, low sample size,
diversity in comparison groups, no assessment of habitual consumption or funding by the
food industry[63].
In addition, the inconsistency of the definitions of dairy groups (total, low- and high-
fat), which have been used in different studies might result in inconsistent findings. Dairy
products are a heterogeneous food group with a variety of macro- and micro-nutrients.
Thus, a consistent definition of dairy exposures is needed for the comparability of results
across studies. This inconsistency is also evident from the relevant published meta-analyses,
which pool results from studies of different dairy products, as the number of studies for each
dairy type separately is not sufficient to draw conclusions. Consequently, there is a need for
a comprehensive set of exposures, outcomes and covariates and a consistent methodology
to be used in the study of the associations of dairy products with cardio-metabolic markers
to further elucidate the link to cardio-metabolic disease.

Chapter 4
Associations of dairy consumption with
cardio-metabolic markers: a
cross-sectional analysis in the Fenland
Study, UK
Summary
Background and aims: Epidemiological evidence on associations between dairy types and
cardio-metabolic risk is inconsistent. We aimed to investigate cross-sectional associations
between total and types of dairy products and markers of metabolic risk and adiposity.
Methods: We included 12,065 adults (54% women) aged 30 to 65 years recruited
to the Fenland study between 2005 and 2015 in Cambridgeshire UK. Diet including
dairy products (milk, yoghurt, cheese, cream, butter, ice-cream) was assessed with a food
frequency questionnaire. Markers of adiposity were measured with dual energy X-ray
absorptiometry and ultrasonography. Blood pressure and circulating concentrations of
lipid, glycaemic, and hepatic markers, C-reactive protein and adiponectin were measured.
Associations between dairy consumption and these outcomes were assessed using robust
regression, adjusted for socio-demographic, lifestyle, and dietary factors including total
energy intake and body-mass index and corrected for false-discovery rate.
Results: The median (IQR) of milk, yoghurt, and cheese consumption were 293(146 -
439), 35.3 (8.8 – 71.8), and 14.6 (4.8 – 26.9) g/day, respectively. Low-fat dairy consumption
was inversely associated with visceral-to-subcutaneous fat ratio [% difference per serving
(95% CI): -2.58 (-3.91, -1.23); p=0.0002]. Habitual daily consumption per one glass of
milk was associated with 0.33 kg higher lean mass (95% CI: 0.19, 0.46; p=2.5×10-6).
High-fat dairy products were positively associated with total and low-density lipoprotein
cholesterol [0.06 mmol/l (0.03, 0.09); p=3.5×10-5 and 0.05 mmol/l (0.03, 0.08); p=7×10-6
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respectively], while low-fat dairy and milk consumption were inversely associated with
high-density lipoprotein cholesterol [-0.02 mmol/l (-0.03, -0.01); p=1.5×10-6 for both].
Other associations were not significant.
Conclusion: Our novel finding of an inverse association between low-fat dairy and
milk consumption and visceral-to-subcutaneous fat ratio suggests fat distribution as a
potential pathway for the link between dairy consumption and metabolic risk. These
findings should be confirmed in prospective and experimental studies, in other populations,
and combined with research investigating mechanisms.
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What is already known
• Dairy products have been associated with no or a lower risk of cardio-
metabolic disease endpoints.
• Evidence from randomised controlled trials supports favourable effects of
total dairy consumption on body weight and composition under conditions
of energy restriction, increasing effects of butter, but more favourable ef-
fects of cheese on blood lipipds, no effects of total dairy consumption on
glycaemia and no effects of total, high-fat or low-fat dairy consumption on
blood pressure.
• Evidence on specific dairy types, effects on other cardio-metabolic markers
such as inflammation and hepatic function and more long-term associations
of habitual dairy consumption with cardio-metabolic markers is limited.
What this research adds
• Low-fat dairy consumption was associated with lower visceral-to-
subcutaneous fat ratio by 2.58% per serving/day.
• Habitual daily consumption of one glass of milk was associated with 0.33 kg
higher lean mass.
• The cross-sectional design of this study does not allow causal inferences,
but findings are hypothesis-generating, which might be further examined in
prospective cohort studies and randomised controlled trials.
Publication
Trichia E, Imamura F, Brage S, De Lucia Rolfe E, Griffin SJ, Wareham NJ, Forouhi N
G. Associations of types of dairy consumption with cardio-metabolic risk and adiposity:
cross-sectional findings from over 12,000 adults in the Fenland Study, UK, (Manuscript in
revision at the Journal of Nutrition)
4.1 Previous evidence on cross-sectional associations
The main limitation of cross-sectional studies is the higher possibility of reverse causation
due to the weakness of this study design to fulfil the temporality requirement for causality,
as the exposure and the outcome are measured at the same time point. Certain phenotypes
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can influence people’s behaviour both in the context of actual consumption, but also in the
context of reporting their consumption and it can be assumed that the more apparent this
phenotype is, the higher the probability of behaviour change.
The most well-characterised phenotype related to change in consumption and reporting
behaviour is body mass index (BMI), as people with higher BMI might under-report or
consume lower amounts of foods perceived as unhealthy and over-report or consume
higher amounts of foods perceived as healthy[145–152]. An example could be that people
of higher BMI over-report or consume more low-fat dairy products and under-report or
consume less high-fat dairy products. For this reason, the validity of cross-sectional studies
on the associations between dairy products and body weight, BMI or obesity status could
be questionable. In addition, it might be useful for cross-sectional studies to adjust for
BMI when examining associations between dairy consumption and other cardio-metabolic
markers. Thus, for the appraisal of previous evidence on cross-sectional associations
between dairy consumption and cardio-metabolic markers, studies using body weight,
BMI or obesity status as outcomes and other studies not adjusting for BMI or another
measure of body mass were not considered. In future meta-analyses of cross-sectional
studies, it would be of interest to investigate heterogeneity of associations by adjustment
for BMI in individual studies, which is out of the scope of the present project.
Cross-sectional studies investigating associations of total and types of dairy products
with markers of body composition, lipid markers and markers of hepatic function also
adjusting for BMI are limited. Concerning glycaemic markers, results on the associations
between total dairy consumption and fasting blood glucose are inconsistent indicating
null[131, 153] or inverse[154] associations, whereas the number of studies for other
glycaemic markers and specific dairy types is limited. High-fat dairy consumption was
not associated with C-reactive protein (CRP)[154–156], while evidence on total and types
of dairy products is sparse. Results on associations between total dairy consumption and
systolic blood pressure (SBP) showed inverse[131, 154] or positive[157] associations and
for diastolic blood pressure (DBP) showed inverse associations[131, 154, 157], while for
dairy types results are limited and thus inconclusive.
4.2 Study aims
Based on the broader inconsistencies on associations of total and types of dairy products
with cardio-metabolic markers from prospective or randomised controlled trial (RCT)
evidence (Chapter 3) and that from cross-sectional studies (appraised above), this study
aimed to investigate associations of total and types of dairy products with markers of
metabolic risk and adiposity. Of special interest were associations between total and types
of dairy products and body fat mass and lean mass distribution, for which evidence is even
more limited, but they provide objective and precise markers of body composition.
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4.3 Methods
4.3.1 Study design and population
The Fenland study is a prospective cohort study with complete baseline measurements
(Phase 1; 2005-2015; n=12,434) and an ongoing Phase 2 (follow-up) since 2014. Eligible
participants were born between 1950 and 1975, were residing in Ely, Wisbech, Cambridge
or surrounding villages and were recruited through general practitioners. Exclusion criteria
included known history of diabetes, psychotic or terminal illness, inability to walk unaided,
pregnancy, or lactation. For the present, cross-sectional analysis, a sample of 12,065
participants was used after exclusion of participants with missing dietary data (n=17),
participants in the bottom and top 1% of total energy intake (n=250) and in the top 1%
of total dairy consumption (n=97) and pregnant women (n=5). The study was approved
by the Cambridge Regional Ethics Committee. All participants gave written informed
consent.
4.3.2 Dietary assessment
Participants’ diet over the last year was assessed with a 130-item semi-quantitative food
frequency questionnaire (FFQ)[158]. The FFQ consisted of two parts: the first part
included a list of items and nine frequencies from “Never or less than once/month” to “6+
per day” and the second part included questions on consumption of milk, breakfast cereals,
cooking fat, added salt and dietary supplements. The dietary data from the FFQ were
processed with the FFQ EPIC Tool for Analysis (FETA) software[159]. Dairy products
were assessed in servings/day and were categorised as previously described[160] and
shown in Table 4.1.
































































































































































































































































































































































































































































































































































































































































4.3.3 Assessment of markers of metabolic risk and adiposity
Markers of body weight, body composition, and blood pressure
Trained research staff conducted all measurements according to standardised procedures.
BMI was calculated as weight divided by height squared (kg /m2). Waist and hip cir-
cumferences were averaged from two repeated measures with a non-stretch tape. Total
body fat and its distribution (peripheral fat, visceral adipose tissue -VAT-, subcutaneous
adipose tissue -SCAT-) and lean mass and its distribution (appendicular lean mass) were
estimated with a Dual-Energy X-ray Absorptiometry (DEXA; Lunar Prodigy Advanced
fan beam scanner, GE Healthcare, Bedford, United Kingdom; GE encore software, version
14.10.022 to 16, GE Medical Systems14). Abdominal ultrasonography (LOGIQ Book
ultrasound system, and Logic eGE Healthcare with a 3C MHz-RS and 2-5 MHz 3C-RC
curved array transducers respectively), was also used to derive VAT and SCAT[161] and
to assess hepatic fat. VAT was defined as the distance from the peritoneum boundary to
the lumbar spine and SCAT as the depth from the skin boundary to the linea alba. This
method has been validated against measurements of intra-abdominal and subcutaneous
adipose tissue with magnetic resonance imaging[162]. A semi-quantitative hepatic fat
score was derived from ultrasonography using a method previously validated against the
gold standard proton magnetic resonance spectroscopy[163]. The score ranged from 3 to
12, representing the increasing degree of hepatic fat. Blood pressure was measured with
an automated sphygmomanometer (Omron, 705CP-II) three times and the average of the
measurements was used.
Biochemical analyses
A 47.2 ml blood sample was taken from every participant after an overnight fast. Fasting
and 2-hour plasma glucose were measured during a standard (75g) oral glucose tolerance
test. Haemoglobin A1c (HbA1c) was measured in whole blood. Insulin, total cholesterol,
high density lipoprotein cholesterol (HDL-C), triglycerides, apolipoprotein A1 (ApoA1),
apolipoprotein B (ApoB), non-esterified fatty acids (NEFA), alanine aminotransferase
(ALT), γ-glutamyl transferase (GGT), C-Reactive Protein (CRP) and adiponectin were
measured in serum. Low density lipoprotein cholesterol (LDL-C) was calculated from
triglycerides, HDL-C and total cholesterol using the Friedewald formula (LDL-C= Total
cholesterol – HDL-C – (Triglycerides/2.2)[164]. The Homeostasis Model Assessment
for Insulin Resistance (HOMA-IR) and HOMA for beta cell function (HOMA-%B) were
calculated using the HOMA calculator (https://www.dtu.ox.ac.uk/homacalculator/).
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4.3.4 Assessment of socio-demographic and lifestyle factors
A general questionnaire was administered for information on ethnicity, occupation, ed-
ucational level, income, marital status, smoking and medication use. Physical activity
was objectively measured over seven days using a combined heart rate and movement
sensor (Actiheart, CamNtech, Papworth, UK) and individually calibrated with a treadmill
test to derive physical activity energy expenditure[165]. This method has been previously
validated with doubly-labelled water[166].
4.3.5 Statistical analysis
Descriptive characteristics of socio-demographic, behavioural, clinical and dietary factors
were derived for the whole sample, as well as for the top and bottom categories of
milk (non-consumers and 585-732 g/d), yoghurt (non-consumers and top quartile within
consumers) and cheese (non-consumers and top quartile within consumers) consumption.
The mean and standard deviation (SD) for the continuous variables and the frequencies
and percentages of each category for categorical variables were calculated.
As primary exposures, I considered the three main dairy types i.e. milk, yoghurt and
cheese. As primary outcomes, I considered one representative marker from each of the
marker clusters of anthropometry, glycaemia, lipidaemia, inflammation, blood pressure
and hepatic function. Thus, I used the ratio of VAT to SCAT (VAT/SCAT), HbA1c,
total-to-HDL-C ratio, CRP, SBP and DBP and hepatic fat score respectively.
Positively-skewed outcome variables, (VAT/SCAT, HOMA2-IR, HOMA2-%B, fast-
ing glucose, 2-hour glucose, fasting insulin, triglycerides, NEFA, ALT, γ-GT, CRP,
adiponectin), were log-transformed. A metabolic risk z-score was calculated[167] and
used in a secondary analysis to investigate the association between dairy products and
a composite index of cardio-metabolic markers, by taking averages of z-scores of blood
pressure (average of the z-scores of SBP and DBP), HbA1c, and waist circumference and
lipids (-1 × HDL-C and log-transformed triglycerides).
Missing covariates were imputed with multiple imputation by chained equations
(MICE) under the assumption of data missing at random[168]. Multiple imputation
involved linear, logistic and predictive mean matching models according to variable dis-
tribution and 5 imputation datasets were derived. Outcome variables were accounted for
in the imputation, but only participants with non-missing observations for the outcome
variables were included in the estimation models. Imputation diagnostics (comparison
of the original and the imputed data distributions, convergence of the imputation models,
fraction of missing information, Monte Carlo errors) were performed to assess the validity
of the imputation[169].
To examine cross-sectional associations between different dairy types and cardio-
metabolic markers, robust multiple linear regression was used, deriving multiple maximum
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likelihood (MM-) estimators, which are robust against the influence of outliers[170].
Poisson regression was used for hepatic fat score, where the ordinal variable (1 to 12) was
assumed to follow a Poisson distribution (better fit in preliminary analysis than ordered
logistic or negative binomial model, based on Akaike information criteria)[171].
The initial probability of false positive findings was set to 5%. Because of the large
number of tests, false discovery rate correction was applied accounting for correlations
between tests and assuming an arbitrary correlation pattern[172]. Associations were
considered significant if they passed this correction (p<0.00025).
Associations were adjusted for potential confounders based on previous knowledge
and biological plausibility using four statistical models. In model 1, I adjusted for socio-
demographic factors including age, sex, test-site and ethnicity, total energy intake, and dairy
products other than the dairy exposure. In model 2, I further adjusted for age at completion
of full-time education, pack-years of smoking, physical activity energy expenditure (all
continuous), and education level, occupation, household income, marital status, smoking
status, hormone-replacement therapy (HRT; for women only), lipid-lowering medication,
and anti-hypertensive medication (categorical). In model 3, I further adjusted for plasma
vitamin C levels (as a marker of diet quality, reflecting fruit and vegetable intake), dietary
supplement use, and consumption of non-dairy dietary factors. In model 4, I further
adjusted for BMI to partly account for the possibility of dietary misreporting and lifestyle
confounding due to obesity status. When the outcome was lean mass, models were further
adjusted for height.
Pre-specified tests for effect modification by sex and BMI for each association were
investigated. As sensitivity analyses, I repeated regression analyses in the complete-case
dataset and with 10 imputed datasets, to examine stability of results based on five imputed
datasets in the primary analyses. To assess whether non-linear associations were present,
restricted cubic spline regressions (three knots at the 10th, 50th and 90th percentiles) were
fitted in the maximally adjusted model. For the same purpose, categorical exposures were
used with five categories including non-consumers and quartiles among consumers for
dairy types. The categories were generated from the residuals of the regression of total
energy intake against dairy products[173].
In post-hoc analyses, I examined whether the identified significant associations can be
explained by nutrients contained in dairy products including calcium, potassium, magne-
sium, phosphorus, vitamin A, vitamin B12, lactose, mono-unsaturated fat and saturated fat
from the dairy exposure one-by-one.
All analyses were conducted using Stata 14.2 (College Station, TX: StataCorp LP,
2015).
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4.4 Results
4.4.1 Descriptive characteristics
The analyses evaluated 12,065 adults (54% women) with a mean±SD age of 48.6±7.5
years. The median (IQR) dairy consumption was: milk 293(146 - 439) g/day; yoghurt 35.3
(8.8 – 71.8) g/day; and cheese 14.6 (4.8 – 26.9) g/day (Table 4.2). Almost two-thirds of
high yoghurt consumers were women. Participants of non-white ethnic background were
2-4 times less likely to consume dairy products than participants of white background.
Yoghurt and cheese consumption were positively correlated with higher socio-economic
status, educational level and income and negatively correlated with likelihood of being
current smokers.
Among dietary consumption levels, overall, low-fat dairy consumption was approx-
imately six times higher than that of high-fat dairy (Table 4.3). For dairy types, low-fat
milk and yoghurt consumption were higher than consumption of the full-fat alternatives,
but high-fat cheese consumption was higher than low-fat cheese consumption. The con-
sumption of low-fat milk, fruit, vegetables, whole-grain cereals and fish were higher in
the highest quartile of yoghurt consumption, whereas consumption of alcohol, sugar-
sweetened beverages and processed meat was lower compared to non-consumers. For
the highest quartile of milk consumption, lower consumption of fruit and vegetables and
higher consumption of potatoes, processed cereals, sweet snacks, coffee and tea were
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4.4.2 Dairy products and body composition
Habitual milk consumption was significantly associated with higher BMI with each ad-
ditional glass of milk/day associated with 0.26 kg/m2 (95% CI: 0.16, 0.36) higher BMI
(Table A.4). Similar patterns were observed for low-fat milk and low-fat and total dairy
products. Other dairy subtypes were not significantly associated with BMI.
Dairy products were not associated with the percentage of body fat (data not shown),
total fat mass, or peripheral body fat mass (Figure 4.1, Table A.5), nor were any significant
associations found between any dairy type and waist circumference or the ratio of waist to
hip circumference, as proxies for fat mass distribution.
Low-fat dairy consumption was associated with 2.6% (-3.91, -1.23) lower VAT/SCAT
ratio. A similar association was observed for VAT.
Habitual milk consumption was significantly associated with 0.33 kg (0.19, 0.46)
higher lean mass per one glass/day (Figure 4.1, Table A.5). Both full- and low-fat milk
showed similar associations (Figure 4.1, Table A.5). The association was partly attenuated
when adjusted for height, but was still significant (0.18 kg/glass of milk/day; 0.10, 0.27).
Effect modification by BMI was suggested for the association between high-fat
dairy and appendicular lean mass (p-interaction=0.0001). Among non-overweight adults
(BMI<25 kg/m2), appendicular lean mass was lower by 0.11 kg (-0.22, -0.001) per one
serving of high-fat dairy, but associations were not observed among overweight (0.05 kg;
95% CI: -0.07 to 0.18 kg) or obese adults (0.02 kg; 95% CI -0.16 to 0.20 kg).
No significant association was observed for cheese, butter, ice-cream or any other dairy
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4.4.3 Dairy products and metabolic markers
No association was found between any type of dairy products and the ratio of total to HDL-
C (Figure 4.2, Table A.6). High-fat dairy consumption was weakly positively associated
with total cholesterol [0.06 mmol/L (95% CI:0.03, 0.09) per serving/day] and with LDL-C
[0.05 mmol/l (0.03, 0.08)]. Of subtypes of high-fat dairy, butter consumption showed
similar associations. Slight attenuation of the association was observed after adjustment for
vitamin A, total, mono-unsaturated and saturated fat (Table A.7). Low-fat dairy and milk
consumption were weakly inversely associated with HDL-C [-0.02 mmol/l (-0.03, -0.01)
for both]. None of the dairy types were significantly associated with triglycerides, apoA1,
apoB or NEFA. Further adjustment for nutrients did not materially alter these findings.
Consumption of different dairy types was not significantly associated with glycaemic
markers, hepatic markers, blood pressure measures, CRP, adiponectin, or the metabolic




































































































































































































































































































































Fig. 4.4 Adjusted associations of types of dairy consumption (servings/day) with markers
of hepatic function. Statistically significant associations after correction for false discov-
ery rate are marked with an asterisk. ALT: Alanine Transaminase, GGT: Gamma-Glutamyl
Transferase
4.4.4 Additional analyses
Results were not altered when analyses with 10 imputed datasets or complete-case analyses
were done (data not shown). There was no indication of a non-linear association from
analyses with restricted cubic splines or categorical exposures after correction for multiple
testing. [Figure 4.6 as example, shows the associations between 3 main exposures (milk,
yoghurt and cheese) and 3 main outcomes (HbA1c, total-to-HDL-C ratio and CRP respec-
tively). The p-value for non-linearity was <0.05, but this was not statistically significant
after multiple test correction.
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Fig. 4.5 Adjusted associations of types of dairy consumption (servings/day) with other phys-
iologic markers including systolic and diastolic blood pressure, CRP and adiponectin.
Statistically significant associations after correction for false discovery rate are marked
with an asterisk. CRP:C-reactive protein
Fig. 4.6 Non-linear associations of dairy products with HbA1c, ratio of total to HDL-
C and CRP. The plots were selected on the basis of nominally significant non-linearity.
A. milk and HbA1c (p-nonlinear=0.015), B. yoghurt and ratio of total to HDL-C (p-
nonlinear=0.015), and C cheese and CRP (p-nonlinear=0.015). HbA1c:Haemoglobin A1c,
HDL-C:High-density lipoprotein cholesterol, CRP:C-reactive protein
4.5 Discussion
4.5.1 Summary of results
This study resulted in two novel findings. First, habitual daily consumption of one serving
of low-fat dairy products was associated with a 3% lower ratio of VAT to SCAT as a marker
of fat mass distribution, a measure which is associated with diabetes risk independently of
total fat mass[174]. Second, habitual daily consumption of 1 glass of milk was associated
with a 0.33 kg higher body lean mass.
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4.5.2 Markers of adiposity
There are no previous studies on the association between dairy consumption and VAT/SCAT.
An RCT showed a reduction in VAT among those consuming 6-7 servings of dairy products
per day compared to those consuming less than 4 servings/day[78]. A cross-sectional
study of twins reported an inverse association between low-fat fermented dairy products
and VAT[175], but I have not identified any studies of the association between dairy
consumption and SCAT.
Although total dairy consumption has been consistently associated with a lower body
fat mass in RCTs[60–62], the number of studies for dairy subtypes is limited. I found no
significant associations between any dairy type and total or peripheral fat mass or waist
circumference and waist-to-hip ratio as proxies for fat mass distribution. The direction of
the associations I observed between low-fat dairy consumption and total body fat mass,
and waist circumference was consistent with that observed in previous studies and with
that observed for VAT/SCAT in the current analysis. The higher dairy amounts used in
trials compared to the consumption levels reported in observational studies could partly
explain the lack of significance in certain associations.
Although no mechanism has been reported for an inverse association between low-fat
dairy consumption and VAT/SCAT, a plausible explanation could be that the effects of
dairy nutrients on fat mass are more pronounced in VAT than in SCAT. For example,
VAT was reported to be more metabolically active with a more efficient glucose uptake
than SCAT[176]. Relevant underlying mechanisms for these associations include higher
lipolysis and lower lipogenesis due to lower parathyroid hormone and 1,25-(OH)2 vitamin
D levels related to calcium intake[177], and possibly a combination of higher satiety with
lower appetite related to dairy protein intake[178–180]. Potential mechanisms for the
associations of dairy products with body weight and composition are discussed in more
detail in Chapter 9.
With these current analyses and specifically the observed positive association between
milk consumption and body lean mass, we extend the previous understanding on the
positive association between total dairy consumption and total lean mass[61] to include
specific dairy subtypes. Dairy products and mainly milk have been consistently associated
with bone health due to their nutrient content including calcium, phosphorous, vitamin
D and protein, which might partly explain the positive association with lean mass[181].
Another potential mechanism is the increasing effect of milk on growth hormone[182, 183],
which has been associated with a higher lean mass through a higher bone mineral density
and muscle mass[184].
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4.5.3 Markers of metabolic risk
Concerning lipid markers, I did not find an association between any dairy type and the
ratio of total to HDL-C, though I observed a positive association between high-fat dairy
and mainly butter consumption and total cholesterol and an inverse association of low-fat
dairy and mainly milk consumption with HDL-C. The association of dairy consumption
with the ratio of total to HDL-C has not been extensively studied previously, except for
butter, which increased the ratio, and total and HDL-C separately when butter replaced
hard margarine[87], but butter had no effect when it replaced olive oil or walnuts in
RCTs[89, 95, 105]. Null associations have been reported between low-fat and high-fat
dairy consumption and HDL-C[63].
My findings of a positive association of high-fat dairy and mainly butter consump-
tion with LDL-C were consistent with findings of feeding trials, in which butter in-
creased LDL-C when it substituted margarine[87], monounsaturated[89, 95, 105] or
polyunsaturated[105] fat. However, in a meta-analysis of RCTs, low- and high-fat dairy
consumption did not show an effect on LDL-C, but it is not clear whether butter was
included in the high-fat dairy group in all the studies[63].
I found no association of any dairy type with triglycerides, ApoA1, ApoB or NEFA.
With the exception of butter consumption which seems to have a neutral effect on triglyc-
eride levels when it substitutes other fat sources[89, 105], the evidence is sparse for
associations between other dairy types and the rest of the lipid markers.
As in previous research, associations between dairy consumption and glycaemic mark-
ers were null in the current study including that between low- or high-fat dairy consumption
and fasting blood glucose or HOMA-IR in RCTs[63]. Evidence on associations between
other dairy types and glycaemic markers is sparse. Dairy products have an insulinotropic
effect in short-term trials due to their protein content, but this effect does not seem to be
maintained in the long-term[185], which may explain the different findings between trials
and prospective cohort studies.
I did not observe any association between dairy types and SBP or DBP, which is in line
with prior findings from a meta-analysis of seven RCTs, which reported a neutral effect of
low- and high-fat dairy consumption on SBP and DBP[63].
I also did not find any significant association of dairy consumption with hepatic fat,
markers of hepatic function, CRP or adiponectin. While there is little research about
dairy consumption and hepatic outcomes, our finding was consistent with a 6-month RCT
showing no effect of milk consumption on hepatic fat in comparison to water[186]. The
current findings for CRP and adiponectin were in agreement with a meta-analysis of six
RCTs[63].
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4.5.4 Strengths and limitations
This study has several strengths including its large sample size (n=12,065) and the inclu-
sion of several dairy subtypes and diverse cardio-metabolic markers, which allowed the
investigation of many potential pathways for cardio-metabolic disease. By employing
DEXA and ultrasonography, we were able to use more accurate methods to assess VAT
and SCAT than previous studies that used waist circumference and waist-to-hip ratio as
proxies of central adiposity[74]. Our statistical approaches were thorough including the
adjustment for important potential confounders including objectively measured physical
activity, the derivation of estimates robust to outliers, and the handling of missing data
with multiple imputation.
This study also has limitations. The cross-sectional design increases the risk of reverse
causation and limits inference for causal association. Although the questionnaire used
was assessed for validity in a similar population[158] and we adjusted for BMI as an
established factor of dietary misreporting, we cannot exclude the possibility of error due to
dietary misreporting caused by the use of self-reported methods of dietary assessment. In
addition, the use of the food frequency questionnaire does not allow the discrimination
of dairy types e.g.cheese or yoghurt to subtypes based on processing. This leads to loss
of information, as there is a high heterogeneity among subtypes of yoghurt and cheese
based on the way they are processed and produced with very different food matrices.
Consumption of high-fat dairy products has a limited range and lower levels compared
to low-fat dairy products, which might compromise the power to detect associations for
high-fat dairy. Finally, although we adjusted our models for many potential confounders,
we cannot exclude the possibility of residual confounding.
4.5.5 Conclusion
The novel finding of an inverse association between low-fat dairy products and VAT/SCAT
suggests abdominal obesity as a potential pathway for the association of dairy consumption
with cardio-metabolic disease. The association between milk consumption and a higher
body lean mass could also be a potential explanation for the overall positive metabolic
associations of dairy consumption. These findings are important for generating robust
hypotheses and should be confirmed and further investigated in prospective studies, clinical
trials and mechanistic studies.

Chapter 5
Associations of dairy consumption with
cardio-metabolic markers: a
prospective analysis in the EPIC
Norfolk Study, UK
Summary
Background and aims: Accumulating evidence suggests that some types of dairy products
are associated with lower cardio-metabolic risk. However, relevant pathways have not
yet been investigated in long-term epidemiological studies on habitual dairy consumption
and its relationship with metabolic risk factors. The aim of this study was to investigate
prospective associations of habitual dairy consumption with markers of metabolic risk and
adiposity.
Methods: We examined associations of changes in dairy consumption (servings/day)
with parallel changes in metabolic markers using multiple linear regression in 15,612
adults followed up from 1993-1997 aged 40-78 years at baseline in the EPIC-Norfolk
study, UK.
Results: An increase in low-fat fermented dairy products was associated with a lower
increase in body weight and BMI over an average follow-up of 3.7 years. For example,
a change in yoghurt consumption was associated with a lower increase in body weight
by 0.23 kg (95% CI: -0.46, -0.01). An increase in high-fat dairy products (-0.14±1.18
servings/day) was associated with higher increases in body weight and BMI [b=0.13
(0.05, 0.21) and 0.04 (0.01, 0.07) respectively]. An increase in total dairy consumption
(0.07±1.3) was positively associated with an increase in total cholesterol [0.02 mmol/l
(0.003, 0.04)]. A similar association was observed between high-fat dairy (including
butter) consumption and LDL-C, while increasing low-fat dairy consumption (0.06±1.02)
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was inversely associated with increasing total and LDL-C. A change in full-fat milk
(-0.11±0.62) was positively associated with HbA1c (p=0.027).
Conclusion: Our results support the differential associations of dairy types with
metabolic pathways including associations of increasing low-fat fermented dairy products
with lesser increase in adiposity and of increasing high-fat dairy products with greater
increase in circulating lipids.
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What is already known
• Dairy products have been associated with no or a lower risk of cardio-
metabolic disease endpoints.
• Evidence from randomised controlled trials supports favourable effects of
total dairy consumption on body weight and composition under conditions
of energy restriction, increasing effects of butter, but more favourable ef-
fects of cheese on blood lipipds, no effects of total dairy consumption on
glycaemia and no effects of total, high-fat or low-fat dairy consumption on
blood pressure.
• Evidence on specific dairy types, effects on other cardio-metabolic markers
such as inflammation and hepatic function and more long-term associations
of habitual dairy consumption with cardio-metabolic markers is limited.
What this research adds
• Of all the cardio-metabolic markers examined, changes in dairy consumption
were associated mainly with parallel changes in markers of adiposity and
lipidaemia over 3.7 years of follow-up.
• An increase in low-fat fermented dairy products was associated with a lower
increase in body weight and BMI. For example, a change in yoghurt consump-
tion by 1 serving/day was associated with a lower increase in body weight by
0.23 kg.
• Increases of high-fat dairy consumption were associated with higher increase
of total and low-density lipoprotein cholesterol (LDL-C), while increases of
low-fat dairy consumption were associated with lower increases of total and
LDL-C.
Publication
Trichia E, Imamura F, Khaw KT, Wareham NJ, Forouhi N G. Prospective associations of
total and types of dairy products with markers of metabolic risk and adiposity: findings
from the EPIC Norfolk study, UK (Manuscript under review by co-authors)
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5.1 Previous evidence on prospective associations
Effects of total and types of dairy products on markers of metabolic risk and adiposity
have been examined in several randomised controlled trials -RCTs- (Chapter 3). Even
though RCTs are considered the gold standard for the investigation of causal associations,
they also have some limitations (Chapter 3). For instance, most of these trials used mixed
dairy products in their intervention, which makes it difficult to distinguish the net effects
of specific dairy types. In addition, their average duration is limited to a few months. For
example, the average duration of 37 RCTs included in a meta-analysis on the effects of
dairy consumption on body weight and composition was 7.7 months[58]. It is of interest
to examine long-term associations of habitual dairy consumption with cardio-metabolic
markers, since cardio-metabolic disease is a chronic disease developing over several
years. Furthermore, since cardio-metabolic disease is multifactorial, characterised by
multiple biological pathways including body composition, lipidaemia, glycaemia, and
blood pressure, it is of interest to investigate associations of total and types of dairy
products with markers related to these pathways.
Some previous prospective cohort studies have investigated associations of habitual
dairy consumption with cardio-metabolic markers, but results are sparse and inconsistent
for specific dairy types (Chapter 3). Inconsistencies in findings might be related to
differences in the definitions of dairy groups (total, low- and high-fat) and the use of the
baseline consumption (n=9)[64–66, 68, 69, 71, 73, 80, 81], repeated measures (n=2)[67,
68] or change in dairy consumption (n=3)[66, 70, 72] across different studies. Associations
of the parallel change (change across the same time points for both the exposure and the
outcome) between dietary factors and anthropometric markers were shown to be closer
to associations described in RCTs compared with associations between baseline diet
and outcome change or associations between change in diet and prospective outcome
change[187]. However, the number of studies assessing associations of parallel change is
limited[66, 70, 72] especially for dairy types[70].
5.2 Study aims
The primary aim of this study was to investigate associations of changes in total and types
of dairy products with parallel changes in markers of metabolic risk and adiposity, as
potential pathways for the association of dairy products with cardio-metabolic disease.
The secondary aim of this study was to investigate associations of the repeated measures
of total and types of dairy consumption with prospective repeated measures of markers of
metabolic risk and adiposity.
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5.3 Methods
5.3.1 Study design and population
We evaluated data from the European Prospective Investigation into Cancer and Nutrition
in Norfolk (EPIC-Norfolk) study in the UK. More information on the study design of the
whole EPIC cohort[188] and Norfolk, UK arm[189] was previously published. Recruitment
was done through general practices from 1993 to 1997 at baseline with exclusion criteria
of having terminal or malignant disease, inability to attend a local clinic, alcoholism,
psychiatric disorder, inadequate command of English or blindness. Participants were
invited for a first follow-up between 1998 and 2000 and a second follow-up between 2004
and 2011. At each time point, participants provided general information, completed a
dietary assessment and measurement of several physiological markers. From an initial
sample of 25,639, we evaluated 15,612 adults after exclusion of participants with no dietary
data at baseline or follow-up (n=673), participants censored before the first follow-up
assessment (n=8,507) and participants with implausible values of total energy intake [<800
and >4000 kcal/day for men, and <500 and >3,500 kcal/day for women[190] (n=847)].
We also excluded participants with outliers of the changes in dairy consumption and
cardio-metabolic marker for each association examined (outside the range of 3 SD from
the mean). Participant informed consent was obtained and the study was approved by the
Norwich District Ethics Committee.
5.3.2 Dietary assessment
Diet was assessed at baseline and first follow-up (1998-2000) with a 130-item semi-
quantitative food frequency questionnaire (FFQ). Validity of the FFQ was internally
assessed at baseline against 7-day diet diaries[158]. The questionnaire ascertained habitual
consumption of foods over the past year with nine frequencies ranging from “never or less
than once/month” to “6 times per day”; and additional questions on the type and amount
of milk consumed, details on breakfast cereals, fat for cooking, visible fat on meat, and
dietary supplements. The correlation coefficient between the dairy consumption from the
FFQ and that from the 7-day diary at baseline was 0.56 for milk, 0.57 for yoghurt, 0.33
for cheese and 0.54 for butter. Dietary data were processed with the FETA software[159]
, assessed in servings/day and grouped as shown in Table 4.1[160]. We considered total
milk, yoghurt and cheese as primary exposures .
5.3.3 Assessment of markers of metabolic risk and adiposity
As primary outcomes we considered changes in body mass index (BMI), waist circum-
ference, the ratio of total to high-density lipoprotein cholesterol (HDL-C), haemoglobin
A1c (HbA1c), systolic and diastolic blood pressure. BMI was defined as weight (digital
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scale, Salter, UK) divided by height squared (free-standing stadiometer). Waist and hip
circumferences were measured to the nearest 0.1cm with a D loop non-stretch fibreglass
tape to standardised protocol. Body fat was measured with bioelectrical impedance (Tanita,
UK) at the first and second follow-up. The average of two blood pressure measurements
was used (Accutorr sphygmomanometer, Datascope, UK). Non-fasting blood was collected
and lipid markers i.e. total cholesterol, HDL-C and triglycerides (RA 1000, Bayer Diag-
nostics, Basingstoke), and glycaemic markers i.e. HbA1c (Diamat ion exchange HPLC,
Bio-Rad Laboratories, Hemel Hempstead, UK) were measured. Low-density lipoprotein
cholesterol (LDL-C) was calculated using the Friedewald formula[164]. Trained research
nurses did all the assessments and the blood sampling. As part of the secondary outcomes,
the metabolic risk z-score was calculated as previously described[167] by taking averages
of z-scores of blood pressure [average of the z-scores of systolic (SBP) and diastolic
blood pressure (DBP)], HbA1c, waist circumference, -1 x HDL-C and log-transformed
triglycerides.
5.3.4 Assessment of socio-demographic and lifestyle factors
Socio-demographic factors including educational level, marital status and occupation,
medical history (disease status and medication use) and smoking status across the different
time points and baseline physical activity were assessed with the Health and Lifestyle
questionnaire[188]. Physical activity at follow-up was assessed with the EPIC physical
activity questionnaire (EPAQ2) designed based on validation studies using heart rate
monitoring after calibration with estimates derived from doubly labelled water[191].
5.3.5 Statistical analyses
The ratio of total to HDL-C, and triglycerides were not normally distributed and were
log-transformed. Missing values of the dairy exposures and covariates were imputed using
multiple imputation by chained equations (MICE) specified for continuous and categorical
variables individually[168], whereby we generated five imputed datasets.
In our primary analysis, we investigated the association of the change in dairy consump-
tion between baseline and the first follow-up with the parallel change of the markers using
multiple linear regression models. This approach was selected, because in observational
research it gave the results most biologically plausible and the closest to those from RCTs
for associations between diet and weight change[187].
As a positive control analysis, to confirm the plausibility of associations, we first
evaluated the prospective association of changes in butter consumption with changes in
LDL-C , which is a well-established association from RCTs[87].
Accounting for availability of covariates and their plausibility as confounders, we
developed regression models with three different levels of adjustment for potential con-
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founders. The first included socio-demographic factors i.e. age, sex, educational level,
age at completion of full-time education, occupational and marital status, physical activity
level, smoking status, total energy intake, medications (lipid-lowering, anti-hypertensive
and hormone replacement therapy), and follow-up duration. Mutually-exclusive dairy
products were adjusted for. The second model additionally included major food groups
and dietary supplement use. The third additionally included BMI unless the outcome was
BMI or the metabolic risk z-score. Models included baseline levels of covariates and their
changes if applicable. Baseline outcome values were not adjusted for to avoid collider bias
which could be larger than bias due to confounding of a baseline outcome[192–194].
Accounting for possibilities of both type I and type II errors, we interpreted results
before and after false-discovery rate correction (two-sided alpha=0.05)[172, 195].
In secondary analyses, we conducted a longitudinal analysis for the associations of
the repeated measures of dairy consumption from baseline and the first follow-up with
the repeated measures of the markers from the first and the second follow-up using linear
mixed models. Although this analysis is not theoretically as valid as the primary analysis,
the decision to also proceed with it was based on the assumption that the parallel change
analysis might be under-powered upon the observation that the changes in some dairy
types were very small.
Pre-specified analyses were conducted additionally to test interactions with age, sex
and BMI for all the associations. We further conducted analyses to assess robustness of
our primary findings. We applied inverse probability weighting to assess potential bias due
to healthy survivor effects or effects due to censoring over the follow-up after deriving
the probability of censoring with logistic regression[196]. To assess stability of results,
we applied multiple imputation with 10 datasets and complete-case analysis; analyses
excluding participants with prevalent type 2 diabetes and additionally with hypertension,
hyperlipidaemia or cardiovascular disease; and analyses adjusting for the baseline outcome.
For all analyses we used Stata 14.2 (College Station, TX: StataCorp LP, 2015).
5.4 Results
5.4.1 Descriptive characteristics
Participants were followed for a mean±SD of 3.7±0.7 years. The mean±SD consumption
of milk, yoghurt and cheese at baseline was 1.7±0.8, 0.3±0.4 and 0.5±0.4 servings/day
respectively. The mean±SD of their change over the follow-up was -0.06±0.70, 0.02±0.40
and -0.04±0.40 servings/day respectively for milk, yoghurt and cheese (Table 5.1).
Changes in markers of metabolic risk and adiposity and lifestyle characteristics are
presented in Tables 5.2- 5.3. For example average increases in weight and waist circum-
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ferences were by 1.3±4.0 kg and 0.8±5.5 cm. In addition, total energy intake decreased
by 88.6±478.5 kcal.
Socio-demographic, lifestyle, clinical and dietary characteristics varied by participants
consuming different types of dairy products (Table 5.4). Non-consumers of milk reported a
lower consumption of fruit, processed and whole-grain cereals, sugar-sweetened beverages
and tea, and higher amounts of artificially sweetened beverages. High yoghurt consumers
were more frequently women, of higher educational level, less frequently current smokers
and consumed more fruit, vegetables, whole-grain cereals, artificially sweetened beverages,
fruit juice and decaffeinated coffee and lower amounts of potatoes, sweet snacks and
alcohol. High cheese consumers were of higher educational level and consumed more
processed and whole-grain cereals, red meat, fruit juice and alcohol.
Table 5.1 Descriptive characteristics of total and types of dairy products at baseline, first
follow-up and the change between baseline and first follow-up in the EPIC-Norfolk study
(n=15,612)
Baseline 1st follow-up Change
Dairy products (servings/d) Mean (SD)
Milk Full-fat 0.33 (0.78) 0.23 (0.66) -0.11 (0.62)
Low-fat 1.39 (1.0) 1.43 (0.95) 0.04 (0.86)
Total 1.73 (0.82) 1.67 (0.82) -0.06 (0.71)
Yoghurt Full-fat 0.04 (0.12) 0.04 (0.14) 0.00 (0.16)
Low-fat 0.27 (0.39) 0.29 (0.41) 0.02 (0.40)
Total 0.30 (0.41) 0.33 (0.42) 0.02 (0.41)
Cheese High-fat 0.34 (0.29) 0.30 (0.27) -0.03 (0.28)
Low-fat 0.13 (0.27) 0.12 (0.26) 0.00 (0.28)
Total 0.47 (0.40) 0.43 (0.37) -0.04 (0.38)
Cream 0.07 (0.17) 0.07 (0.18) 0.00 (0.18)
Butter 0.43 (0.93) 0.44 (0.89) 0.00 (0.88)
Ice-cream 0.21 (0.28) 0.20 (0.30) -0.01 (0.30)
Fermented dairy products 0.77 (0.61) 0.76 (0.61) -0.01 (0.57)
Total dairy products High-fat 1.18 (1.41) 1.05 (1.29) -0.14 (1.18)
Low-fat 1.82 (1.18) 1.89 (1.14) 0.06 (1.02)
Total 3.22 (1.41) 3.15 (1.39) -0.07 (1.32)
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Table 5.2 Descriptive characteristics of markers of metabolic risk and adiposity at baseline,
first follow-up, second follow-up and the change between baseline and first follow-up in the
EPIC-Norfolk study (n=15,612)
Baseline 1st follow-up 2nd follow-up Change
Anthropometric markers Mean (SD)
Weight (kg) 73.0 (12.8) 74.1 (13.2) 74.1 (14.0) 1.3 (4.0)
BMI (kg/m2) 26.1 (3.7) 26.7 (4.0) 26.8 (4.3) 0.6 (1.4)
Waist circumference (cm) 87.3 (12.1) 88.0 (12.5) 94.2 (12.2) 0.8 (5.5)
Waist-to-hip ratio 0.8 (0.1) 0.8 (0.1) 0.9 (0.1) 0.0 (0.0)
Body fat (%) † - - 32.7 (11.3) 31.6 (8.1) - -
Lipid markers
Total / HDL-cholesterol 4.7 (1.6) 4.4 (1.6) 3.7 (1.1) -0.2 (1.2)
Total cholesterol (mmol/l) 6.2 (1.2) 6.1 (1.2) 5.4 (1.1) -0.1 (1.0)
HDL-cholesterol (mmol/l) 1.4 (0.4) 1.5 (0.5) 1.5 (0.4) 0.1 (0.3)
LDL-cholesterol (mmol/l) 4.0 (1.0) 3.8 (1.0) 3.2 (1.0) -0.2 (0.9)
Triglycerides (mmol/l) 1.8 (1.1) 1.9 (1.1) 1.7 (0.9) 0.1 (0.9)
Other markers
HbA1c (mmol/mol) 34.9 (8.5) 36.6 (7.3) 40.1 (6.7) 1.6 (6.1)
Systolic blood pressure (mm
Hg)
134.3 (17.9) 135.1 (18.2) 136.1 (16.7) 0.5 (14.9)
Diastolic blood pressure
(mmHg)
82.0 (11.0) 81.9 (11.2) 78.2 (9.3) -0.1 (10.5)
Metabolic risk z-score -0.02 (0.59) 0.0 (0.61) 0.0 (0.58) 0.01 (0.34)
† Body fat measurements were not available at baseline
Abbreviations: BMI: Body mass index; DBP: Diastolic blood pressure; HbA1c: Haemoglobin
A1c; HDL-C: High density lipoprotein cholesterol; LDL-C: Low-density lipoprotein cholesterol;
SBP: Systolic blood pressure; SD: Standard deviation
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Table 5.3 Descriptive characteristics of socio-demographic, behavioural, clinical and
non-dairy dietary factors at baseline, first follow-up and the change between baseline
and first follow-up in the EPIC-Norfolk study (n=15,612) †
Baseline 1st follow-up Change
Socio-demographic factors
Age (years) 58.6 (8.9) 62.1 (9.0) 3.2 (0.8)
Sex * Women 56.2 56.2
Educational level * Medium 41.9 41.9
High 14.7 14.6
Age completing education (years) § 8.7 (12.2) 8.7 (12.2) 0.0 (0.0)
Socio-economic status * Medium 16.7 16.7
High 46.7 46.7
















Energy intake (kcal/d) ∥ 2,018 (552) 1,929 (529) -88.6 (478.5)
Medications / Supplements
Lipid-lowering medication * Yes 1.5 4.7
Anti-hypertensive medication * Yes 16.4 21.8
Hormonal therapy * Yes 12.3 12.5
Dietary supplements *∥ Yes 49.6 55.5
Non-dairy food dietary factors
(g/d) ∥
Fruits 250.2 (180.4) 263.6 (187.7) 12.2 (170.9)
Vegetables 241.8 (1240.) 240.8 (123.3) -2.1 (110.8)
Potatoes 115.2 (60.5) 111.7 (59.5) -3.7 (69.3)
Legumes 60.0 (37.6) 56.0 (35.8) -3.9 (38.3)
Processed cereals 82.1 (54.1) 78.9 (49.6) -2.9 (53.0)
Whole-grain cereals 78.9 (78.0) 69.1 (73.1) -10.3 (75.1)
Poultry and eggs 37.9 (23.9) 37.5 (24.7) -0.3 (25.9)
Red meat 62.0 (40.5) 57.7 (39.5) -4.1 (42.4)
Processed meat 27.9 (22.9) 27.5 (22.3) -0.4 (21.8)
Fish 37.7 (25.8) 37.4 (25.5) -0.2 (25.4)
Sauces 19.5 (17.9) 19.3 (18.6) -0.2 (20.4)
Margarine 16.6 (16.3) 14.4 (15.1) -2.2 (16.6)
Nuts 2.5 (7.4) 2.5 (7.7) (9.2)
Sweet snacks 116.6 (84.6) 108.3 (82.3) -8.6 (72.2)
Sugar-sweetened beverages 33.1 (72.1) 33.7 (75.6) 0.9 (83.2)
Artificially sweetened beverages 36.9 (104.9) 36.0 (104.3) -0.3 (101.1)
Fruit juice 50.9 (69.1) 55.1 (72.0) 4.0 (73.7)
Regular coffee 329.5 (320.6) 298.6 (301.2) -27.9 (252.8)
Decaffeinated coffee 87.6 (207.1) 76.8 (191.7) -10.2 (187.7)
Tea 632.0 (365.2) 617.1 (360.5) -18.2 (250.6)
Alcoholic beverages 128.8 (232.2) 125.4 (221.9) -1.5 (154.7)
†Continuous variables are presented as mean(SD) and categorical variables are presented as column percentages
‡ Total percentage of missing values: 13% at baseline, 59% (49% due to missing values of the physical activity
variable) at follow-up and 60% at both when accounting for non-ovelapping missing values for all the variables
*Reference categories: sex:men; educational level: low; socio-economic status: low; physical activity: inactive;
lipid-lowering medication: no; anti-hypertensive medication: no; hormonal therapy: no; dietary supplements: no
§ Missing values <5% at baseline and follow-up









































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































5.4.2 Dairy products and anthropometric markers
Low-fat fermented dairy products i.e. yoghurt (total and low-fat) and low-fat cheese
were inversely associated with body weight and BMI (p<0.05). While body weight was
increased by 1.3±4 kg, those who increased their habitual daily yoghurt consumption by
1 serving had a lower increase in body weight by 0.23 kg (95% CI: -0.46, -0.01) in the
most adjusted model (Figure 5.1). Changes in low-fat yoghurt and low-fat cheese were
inversely associated with changes in body weight [-0.31 kg (-0.56, -0.06) and -0.64 kg
(-0.97, -0.31) respectively] and BMI [-0.23 kg/m2 (-0.36, -0.11) and -0.13 kg/m2 (-0.22,
-0.04) respectively]. Changes in high-fat dairy products, full-fat milk and high-fat cheese
were positively associated with changes in body weight, BMI, or both. For example,
an increase in high-fat dairy consumption by 1 serving/day was associated with 0.13 kg
(0.05, 0.21) higher body weight (Figure 5.1). No associations were observed between
changes in any types of dairy products and changes in waist circumference or waist-to-hip
ratio (Figure 5.1). Associations adjusted for a smaller number of covariates did not give
materially different results (Table A.12).
Fig. 5.1 Adjusted associations of changes in dairy consumption (servings/day) with changes
in anthropometric markers. BMI: Body mass index
5.4.3 Dairy products and metabolic markers
Changes in butter were positively associated with changes in LDL-C [0.05 mmol/l
(0.02, 0.07)] in the positive control analysis and also with changes in total cholesterol
(Figure 5.2).
An increase in total dairy consumption was positively associated with an increase in
total cholesterol [0.02 mmol/l (0.003, 0.04)], but not other lipids. Increasing levels of
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high-fat dairy consumption were associated with increasing LDL-C levels [0.04 mmol/l
(0.02, 0.06)]. Changes in total cheese consumption were not associated with changes in any
lipid markers but increasing habitual high-fat cheese consumption by 1 serving/day was
associated with 0.12 (0.04, 0.21) mmol/l higher total cholesterol, 0.04 mmol/l (0.01, 0.07)
higher HDL-C and 0.09 mmol/l (0.02, 0.16) higher LDL-C. An increase of 1 serving/day of
habitual low-fat dairy consumption was associated with a decrease of total and LDL-C by
0.03 mmol/l (-0.05, -0.01). Similar associations were observed for total and low-fat milk
consumption and LDL-C. An increase of habitual total and low-fat yoghurt consumption
was associated with 0.06 mmol/l (-0.12, -0.01) lower total cholesterol and 0.02 mmol/l
(-0.04, -0.01) lower HDL-C respectively.
From associations between changes in dairy consumption and changes in non-lipid
metabolic markers, only one significant association was observed between full-fat milk
and HbA1c [0.52 mmol/mol (0.06, 0.97)] (Figure 5.3). Results from models of change for
all the three different levels of adjustment used as described are presented in Tables A.12-
A.14.
Overall, although the aforementioned associations were statistically significant at the
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Fig. 5.3 Adjusted associations of changes in dairy consumption (servings/day) with changes
in HbA1c, blood pressure and metabolic risk z-score. HbA1c: Haemoglobin A1c.
5.4.4 Longitudinal analyses
In secondary analyses, results from the most adjusted longitudinal models relating repeated
measures of dairy products to repeated measures of cardio-metabolic markers at later time
points are presented in Tables 5.5- 5.7.
Results from the positive control analysis showed a positive association between butter
consumption and both LDL-C [0.32 mmol/l (0.15, 0.49)] as in the primary analysis and
additionally triglycerides [1.34 mmol/l (0.71, 1.99)] (Table 5.6).
However, some of these associations were different in comparison to the primary
results. Specifically, after correction for multiple testing, low-fat dairy consumption was
on average positively associated with body weight and BMI [0.19 kg (0.11, 0.28)] and 0.16
kg/m2 (0.1, 0.21) respectively] (Table 5.5). Similar associations were observed for milk
(total and low-fat) and yoghurt (total and low-fat) (Table 5.5). Yoghurt consumption was
also positively associated with waist circumference [0.54 cm (0.28, 0.79)] (Table 5.5). On
the contrary, high-fat dairy consumption was inversely associated with the ratio of waist to
hip circumference [-0.002 (-0.003, -0.001)] with similar associations for full-fat milk and
high-fat cheese (Table 5.5).
Milk consumption was associated with higher ratio of total to HDL-C [1.18 (0.64,
1.72)] with similar associations observed for both full-fat and low-fat milk (Table 5.6).
Low-fat dairy consumption was associated with lower HDL-C [-0.01 mmol/l (-0.02, -0.01)]
(Table 5.6). Similar associations were found for total and low-fat milk.
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Concerning the other markers of metabolic risk, no association was found between
any dairy type and HbA1c after multiple test correction (Table 5.7). High-fat cheese
consumption was inversely associated with SBP [-1.68 mmHg (-2.6, -0.77)], while full-fat
milk was positively associated with DBP [0.5 mmHg (0.21, 0.79)] (Table 5.7). Finally,
low-fat dairy consumption was positively associated with metabolic risk z-score [0.03
(0.02, 0.04)] with similar associations observed for total and low-fat milk (Table 5.7).
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5.4.5 Additional analyses
We conducted stratified analyses by age, sex and BMI, when the interactions were sig-
nificant (p<0.05) (Tables 5.8-5.10). An increase in high-fat cheese consumption was
associated with a higher increase in body weight and BMI only among participants within
the 50-60 years age group [0.87 kg (0.33, 1.41), p-int=0.037 and 0.28 kg/m2 (0.08, 0.48),
p-int=0.027 respectively] (Table 5.8). Stratified results by sex showed an inverse associa-
tion between an increase in low-fat milk and an increase in the ratio of total to HDL-C only
among men [-0.06 (-0.1, -0.02)] (p-int=0.02), whereas an increase of cheese consumption
was inversely associated with an increase in waist circumference only among women [-0.48
(-0.88, -0.08), p-int=0.009] (Table 5.9). Despite interactions with BMI being significant
(p-int<0.05), associations within strata of BMI were null (Table 5.10).
Although the magnitude or significance of the associations from the complete-case
analysis are different in certain cases, the directions of associations did not change (Ta-
bles A.15-A.17). From the main dairy types, the coefficient which substantially changed is
the one for the association between the change in yoghurt consumption and the change in
body weight, which became stronger [-0.47 kg (-0.77, -0.17); Table A.15].
Results from the specified sensitivity analyses in regards to quality of imputation,
prevalent diseases, and possible attrition bias were not substantially different compared to
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5.5 Discussion
5.5.1 Summary of results
In the pre-specified primary analysis on associations of changes in dairy consumption
with parallel changes in cardio-metabolic markers, we observed an inverse association of
changes in low-fat fermented dairy consumption, with changes in body weight and BMI
over an average of 3.7 years. In contrast, there was a positive association of changes in
high-fat dairy consumption with changes in body weight and BMI. Increasing low-fat dairy
consumption was inversely associated with an increase in both total and LDL-C, while
increasing total and high-fat dairy consumption (especially butter or high-fat cheese), was
associated with a greater increase in total cholesterol, LDL-C and HDL-C.
5.5.2 Findings in context of previous evidence
Anthropometric markers
Our results on associations between changes in dairy consumption and changes in anthro-
pometric markers only agree with some other prospective cohort studies. Results from
these studies are mixed, most of them indicating either inverse or null associations and
sparse for the different dairy types or groups they examine.
We did not find any association between the change in total or low-fat dairy consump-
tion and changes in body weight or BMI, whereas we observed a positive association be-
tween changes in high-fat dairy consumption including full-fat milk and changes in weight
and BMI. Of the previous studies on prospective associations between dairy consumption
and body weight, six investigated associations of total dairy consumption[64–69, 81], five
investigated associations of low-fat dairy consumption[66, 67, 69–71, 80] and four exam-
ined associations of high-fat dairy consumption[66, 67, 69, 80]. Results were conflicting
for total and high-fat dairy products with four of them indicating an inverse[66–69] and
five of them a null association[64–67, 70]. Null associations were reported in all the five
studies examining associations of low-fat dairy products[66, 67, 69–71, 80]. We also
observed inverse associations between changes in the consumption of low-fat fermented
dairy products i.e. total and low-fat yoghurt and low-fat cheese and changes in weight and
BMI. Our results agree with the results from three prospective studies on the association
between yoghurt and weight change[65, 67, 70]. One study did not find any association
between total or low-fat yoghurt and weight change[73].
We observed no associations between changes in any dairy type and changes in waist
circumference and the ratio of waist to hip circumference. Our results are in agreement
with the majority of the prospective studies, as null associations were reported in four out
of five studies on total dairy consumption[64, 65, 67, 68], all three studies on low-fat dairy
consumption[67, 71, 80] and all four studies on cheese[65, 67, 68, 71] in relation to the
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change in waist circumference. In contrast, inverse associations with the change in waist
circumference were reported from two studies on yoghurt[65, 67], one study on milk[65]
and one study on butter[80].
Results from RCTs are mainly available for total dairy products as most of the inter-
ventions included a mixture of the three main dairy types i.e. milk, yoghurt and cheese[58].
According to a recent meta-analysis of RCTs, an average total dairy consumption of 2.6±1
serving/day decreased body weight by 0.64 kg during an average period of 7.7±7.9 months
in 16 trials which applied energy restriction[58]. A decreasing effect was also reported for
waist circumference in trials with energy restriction[58]. The same meta-analysis, reported
an increasing effect of total dairy products on body weight in trials without any energy
restriction[58], potentially because in the case of energy restriction, the same restriction is
applied to both the intervention and the control group, whereas in the case of no energy
restriction, if the randomisation is not successful or the compliance differs between the
intervention and the control group, any effect might be due to differences in energy intake.
Potential mechanisms for an inverse association of low-fat fermented dairy products,
such as yoghurt and low-fat cheese with body weight, have been reported in relevant
studies. There is evidence that yoghurt has beneficial effects on gut function, which has
been linked to obesity and type 2 diabetes[198], owing to the fermentation process it has
gone through[199]. In addition, the content of most nutrients in yoghurt is higher than
that of milk, as yoghurt is more condensed and their bioavailability has been proposed
to be enhanced due to a lower gastric pH caused by the higher acidity of yoghurt[32].
That means that potential effects from nutrients e.g. an enhanced regulation of satiety and
appetite by dairy protein[178–180] might be more pronounced in yoghurt than in milk.
The underlying biological mechanism for the positive associations of the change in
high-fat dairy and milk consumption with the change in body weight and BMI after
adjustment for total energy intake is not clear. There is evidence of an increasing effect
of total dairy consumption on body lean mass with a simultaneous decreasing effect on
body fat mass, resulting in a decreasing total effect on body weight[58]. It is harder to
disentangle this balance of effects when examining dairy types, as the evidence is more
limited, so a potential explanation could be that for high-fat dairy products the increasing
effect on lean mass prevails over the decreasing effect on body fat mass, leading to a slight
body weight increase.
Metabolic markers and blood pressure
We did not observe any association between the change in dairy consumption and the
change in the ratio of total to HDL-C. Past evidence is limited except for butter, which
has been shown to increase the ratio when it replaces soft margarine[87] or olive oil[89].
Our results of a positive association between the change in high-fat dairy consumption
including butter and high-fat cheese and the change in total and LDL-C and HDL-C
132 Prospective associations in the EPIC Norfolk study, UK
(for high-fat cheese only) overall agree with evidence from RCTs. In a meta-analysis
of 20 clinical trials, LDL-C was reduced after replacement of butter with soft or hard
margarine[87]. Butter also increases LDL-C when it substitutes food sources of mono-[89]
or poly-unsaturated fatty acids[105].
Concerning associations of cheese consumption with lipids, a meta-analysis of five
RCTs concluded that cheese consumption over a period of 2-8 weeks results in a lower
increase in cholesterol (total, LDL, HDL) than butter of the same polyunsaturated fat to
saturated fat content[83]. In our study we observed similar associations between butter
and LDL-C (0.05 mmol/l decrease per 10 g of butter or 5.2 g of saturated fat) and high-fat
cheese and LDL-C (0.09 mmol/l decrease per 40 g of cheese or 8.67 g of saturated fat).
However, considering the nature of the FFQ, it is possible that there is measurement error
in the estimates, which could result in slightly different estimates than the true.
We also observed inverse associations of the change in low-fat dairy consumption with
the change in total (mainly due to yoghurt) and LDL-C (mainly due to milk). Evidence
on associations of other dairy products with lipids is sparse. A meta-analysis of nine
RCTs reported null effects of low- or high-fat dairy products on LDL-C or HDL-C[63].
It is not clear though whether butter was included in the high-fat dairy interventions. A
positive association between high-fat dairy products and lipids is also supported from
evidence on the effect of saturated fat on lipids. Saturated fat has been consistently reported
to increase total, LDL-C and HDL-C, when it substitutes carbohydrates[200], mono- or
poly-unsaturated fatty acids[201]. Inverse associations of low-fat dairy products with blood
lipids could be attributed to calcium, which decreases lipogenesis and increases lipolysis,
an effect which might be more pronounced in low-fat than high-fat dairy products[177].
We found null associations between the change in dairy consumption and the change
in HbA1c, except for milk which was positively associated. Overall, our results agree with
evidence from a meta-analysis of RCTs, where neither low- nor high-fat dairy products
were associated with markers of glycaemia such as fasting blood glucose or homeostasis
model assessment for insulin resistance (HOMA-IR)[63]. Evidence on other dairy products
and glycaemic markers is insufficient to draw any conclusions. Dairy products have been
characterised as insulinotropic in the short-term, an effect that they do not seem to hold
in the long-term, which potentially explains the differential results according to the study
design[185]. We did not identify any significant associations between the change in
dairy consumption and the change in blood pressure in accordance with results from a
meta-analysis of seven RCTs in normotensive people[63].
5.5.3 Longitudinal analyses
Although some of the longitudinal associations in our secondary analysis were significant
after FDR correction, some of the results from associations with anthropometric markers
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were less concordant with results from other prospective cohort studies and RCTs, while
associations with lipids were more consistent.
For example, our positive control analysis of the association between butter and LDL-C
led to a positive association, which is consistent with evidence from RCTs as described
before (section 5.5.2). An example of disagreement with past evidence is the association
between yoghurt consumption and body weight, which was positive in the longitudinal
analysis even after adjustment for energy intake and other dietary variables, but inverse in
the analysis of parallel change. As described above and according to results from other
prospective cohort studies on the association between yoghurt consumption and body
weight, either inverse[65, 67, 70] or null[73] associations were reported.
The explanation of the results from our longitudinal analyses is not clear, but I can
speculate on possible reasons. Longitudinal associations might be biased if not adjusted for
the baseline outcome e.g. baseline body weight to account for baseline differences in body
weight. However, it is not advised to adjust for baseline outcome in observational studies,
where it is often not possible to know whether the baseline exposure e.g. dairy consumption
or other factors related to the exposure has influenced the baseline outcome[192], so that
adjustment for that could lead to collider bias and spurious associations[194]. Consequently,
we trust that our main analysis of parallel change is a valid approach to assess prospective
associations, but we cannot quantify any potential bias introduced to our longitudinal
analysis. In this analysis, we showed that such biases might be stronger for anthropometric
outcomes, maybe due to a greater inherent behavioural component, which is an important
point of consideration for prospective analyses in nutritional epidemiology.
5.5.4 Strengths and limitations
This study has several strengths. The prospective design of our study reduces the proba-
bility of reverse causation bias. The repeated measures of dairy consumption and cardio-
metabolic markers at the same time points allowed us to perform an analysis of parallel
change, which has been shown to give the most biologically plausible results compared
with other analytical approaches in observational prospective cohort studies[187]. We
used a comprehensive set of types and groups of dairy products in the associations ex-
amined and we investigated multiple potential pathways for the associations between
dairy consumption and cardio-metabolic disease. We also adopted a rigorous statistical
approach including the use of multiple imputation to handle missing data and the use of
inverse probability weighting in our secondary analyses to examine the presence of healthy
survivor’s effect[202].
This study also has limitations. The observational nature of the study does not allow
us to make any causal inferences, but we can generate hypotheses to be further tested in
RCTs. Diet was assessed with an FFQ, which is a subjective, self-reported method, usually
accompanied by a degree of measurement error, which we could not quantify in the present
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study. Although the analysis of parallel change has been identified as a suitable analytical
approach to investigate associations between diet and body weight[187], the change in
dairy consumption observed in our population over the 3.7 years of follow-up might not
have been as large and variable as needed to detect some associations. Finally, although we
adjusted for several potential confounders, we cannot eliminate the possibility of residual
confounding.
5.5.5 Conclusion
The current analysis of parallel changes in dairy consumption and markers of metabolic
risk, showed differential associations with adiposity and lipidaemia for different dairy
types, which extends previous understanding. The main result of an inverse association
between an increase in low-fat fermented dairy products and an increase in body weight
is a potential pathway for the previously described association with type 2 diabetes[160].
These findings contribute to greater understanding of the differential associations of dairy
products with cardio-metabolic health and should be further confirmed in clinical settings
and other populations.
We also showed that longitudinal analyses i.e. associations between exposure at
certain time points and outcome at later time points might include bias, as shown in
previous studies, but especially for anthropometric outcomes, which are affected more by
behavioural components and are thus more prone to bias. Knowing that this analysis might
entail bias, we pre-specified the analysis of parallel change as the primary analysis and we
based our conclusions on this analysis.
Chapter 6
Biomarkers of dairy consumption: Part
I. Development and validation of
metabolite scores
Summary
Background and aims: Measurement error in self-reported dietary assessment is a well-
recognised limitation of nutritional research, and there is interest in the use of objectively
measured nutritional biomarkers independent of such errors. To improve understanding
of the links between dairy products and cardio-metabolic disease, we aimed to develop
and validate metabolite scores predicting consumption of different dairy types and to
investigate their predictive value over blood fatty acids, which have been identified as dairy
fat biomarkers.
Methods: We evaluated metabolomic profiles using the targeted Biocrates platform
among 10,281 participants of the Fenland study for the discovery (n=6,035) and validation
(n=4,246) of metabolite scores predicting each of total and types of dairy products sep-
arately, accounting for socio-demographic, lifestyle and clinical factors. In the internal
validation set, we examined how well the metabolite scores with or without phospholipid
fatty acids (C15:0, C17:0 and trans-16:1n-7, as candidate biomarkers of dairy consumption)
could predict milk, yoghurt, cheese, butter, and total dairy consumption assessed from a
food frequency questionnaire. Next, we evaluated data from an untargeted metabolomics
platform (Metabolon) among 1,440 participants of the diabetes case-cohort set nested
within the EPIC Norfolk study to externally validate the metabolite scores for prediction
of dairy consumption.
Results: The area under the curve (AUC) statistic for consumption of the selected
dairy products ranged from 0.68 to 0.81 in the internal validation (p<0.05 for prediction
by metabolite scores). Addition of the odd-chain saturated fatty acids (OCSFAs) in the
discovery analysis resulted in an AUC range of 0.72-0.84. In the external validation set,
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AUCs of 0.60, 0.62 and 0.64 respectively were observed for milk, butter and total dairy
(p<0.05 for milk only), increasing to 0.65, 0.66 and 0.77 respectively (p<0.05 for all) when
OCSFAs were included in the models. For yoghurt and cheese, AUCs were 0.69 and 0.66
respectively in multivariable models, but each of the metabolite scores did not significantly
predict each dairy type in the external validation before and after adding phospholipid fatty
acids.
Conclusions: A set of metabolites could predict milk, butter and total dairy consump-
tion with internal and external validity. External validity of yoghurt and cheese was not
confirmed. These findings indicate that the use of metabolomics is a promising approach
for the identification of novel biomarkers of dairy consumption and we recommend the
replication of our approach in other populations and the use of more sets of metabolites
and biological samples e.g. metabolites related to the gut microbiome, which might better
reflect fermented products like yoghurt and cheese.
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What is already known
• Measurement error of self-reported methods of dietary assessment is a com-
mon limitation in nutritional epidemiology.
• The use of nutritional biomarkers is independent of this measurement error.
• The odd-chain saturated fatty acids (OCSFAs; C15:0 and C17:0) and trans-
16:1n-7 have been suggested as candidate biomarkers of dairy fat, but with
limitations.
• To overcome limitations of candidate biomarkers of dairy fat, it is of interest
to identify novel biomarkers, which can be potentially achieved with the use
of metabolomics.
What this research adds
• In a discovery analysis, SM-OH C14:1 was one of the top metabolite signals
predicting all dairy types, SM C16:1 predicted milk and total dairy products,
and LPC a C17:0 predicted cheese, butter and total dairy products.
• We developed metabolite scores predicting total and each dairy type in the
discovery and internal validation set.
• In the external validation set, metabolite scores significantly predicted milk,
butter and total dairy products, but not yoghurt or cheese.
• The metabolite scores had predictive value in addition to the phospholipid
fatty acids for all the dairy types, while fatty acids had predictive value in
addition to the metabolite scores only for butter in the internal validation set.
Publication
Trichia E, Imamura F, Koulman A, Brage S, Griffin SJ, Langenberg C, Khaw KT, Ware-
ham NJ, Forouhi N G. Development and validation of dairy prediction models using
metabolomics in two UK cohorts and the associations of derived metabolite scores with
type 2 diabetes risk (Manuscript under preparation)
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6.1 Measurement error in dietary assessment
The measurement error, which accompanies the self-reported methods of dietary assess-
ment is a common limitation in nutritional epidemiology[203]. Several approaches have
been proposed to reduce and partly account for measurement error. First, adjustment of
associations between diet and any outcome for energy intake estimated from the same
dietary assessment method as the exposure -thus having correlated measurement errors-
may reduce measurement error by partly cancelling out the correlated errors [152, 204].
When the method of dietary assessment is the food frequency questionnaire (FFQ), this
only gives a crude estimate of total energy intake. However, it is still important to do the
adjustment, primarily to partly account for the confounding related to it, but also to partly
account for the correlated measurement errors[204].
In addition, dietary misreporting has been shown to be differential across methods of di-
etary assessment and groups of people. Although there is no gold standard of self-reported
dietary assessment methods, the error derived from multiple-day food diaries and 24-hour
recalls is on average smaller than that from FFQ[152, 205, 206]. If only one method of
dietary assessment is available in a study, it is not possible to address the error which is
specific to this method. However, taking into consideration several predictors of dietary
misreporting might partly account for measurement error. The most well-characterised
predictor of energy misreporting is body mass index (BMI) with under-reporters being
overall overweight or obese and over-reporters usually being underweight[145–152]. The
ability of high BMI to predict dietary under-reporting is not limited to the current status,
but extends to a high-BMI history or generally BMI fluctuations across time[149, 151].
Other proposed predictors of energy under-reporting are older age[145, 147, 148, 151],
women[147, 151, 206], high percentage of body fat[151, 206], lower education[147, 151]
and some psychosocial factors including social desirability, dissatisfaction with body
image, dieting and restrained eating[150, 151]. Energy over-reporting has been less stud-
ied, but some suggested younger age[151], men[147], current smoking[147] and low
socio-economic status[148] as predictors additionally to underweight.
In some studies, energy under-reporters also reported lower intake of total fat[148, 149,
151], saturated fat[149], carbohydrates[151], sugar[149–151], added salt[148], fibre[149,
151], frequency of snacks[148] and consumption of fried foods[148], whereas they reported
higher intakes of total protein[148–150], fibre[148], calcium[148], iron[148], vitamin
C[148], and folate[148]. Considering that dairy products are important sources of saturated
fat, protein and calcium, as we described in section 2.5.4, self-reported dairy consumption
is also prone to measurement error. In addition, some dairy types, specifically milk and
butter are included in many composite foods, which might be one additional level of
complexity and source of error. As we reported in section 2.5.4, we identified large
differences in the amounts of milk and butter consumption when we accounted for their
content in composite foods compared to previously reported estimates.
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Even if consistent efforts have been made to account for measurement error, no
universal solution has been identified so far, as it is often impossible to know all the
potential sources and correlates of error which the self-reported nature of dietary assessment
methods entails. Consequently, there have been attempts to replace this subjective element
with more objective methods of dietary assessment including the doubly labelled water
technique for the estimation of total energy intake and the identification of biomarkers of
dietary intake, which reflect nutrient intakes or food consumption.
6.2 Nutritional biomarkers
The assessment of nutritional biomarkers also entails challenges and measurement errors.
However, these are of a different nature and thus uncorrelated with the measurement errors
from the self-reported dietary assessment methods[204]. Although the use of nutritional
biomarkers overcomes the errors related to the subjective nature of the self-reported
dietary assessment, there are still some points to consider when designing or conducting a
nutritional biomarker study[204]:
• Between-person variation due to genetic, hormonal, homeostatic, metabolic and gut
microbiome-related differences, as well as the interplay between them.
• The range of intake of a nutrient or food in a population relative to the plateau that
the corresponding biomarker might reach in the biological sample.
• Lifestyle factors e.g. smoking, physical activity and alcohol consumption.
• Pathological conditions and use of medications.
• Differential bioavailability of biomarker-related food components.
• The specificity of the biomarker to a nutrient or food. Specificity is more difficult to
be achieved for foods with overlapping nutrient profiles.
• Whether a biomarker can reflect diet in an absolute way (recovery biomarkers) or
a relative way (concentration biomarkers). Ideally, a dose-response quantification
is desirable, which can be achieved with recovery biomarkers such as biomarkers
detected in 24-hour urine or doubly labelled water. However, the majority of
biomarkers are concentration biomarkers, which are still informative for ranking
individuals with low or high habitual consumption.
• The reference period of a biomarker, which depends on the kinetics of the food
component and the type of biological specimen the biomarker is stored in. When
it is of interest to assess the habitual intake of people in an epidemiological study,
biomarkers with a short half-life are useful only for foods which are consumed on a
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regular basis, so that we do not have high inter-individual variability depending on
the day of tissue collection[207].
• Differences in food production, storage, processing or preparation.
• Technical errors related to laboratory methods.
The uncorrelated errors between nutritional biomarkers and self-reported dietary assess-
ment and the useful information we can obtain from both methods, imply that biomarkers
cannot replace self-reported dietary assessment, but both are useful tools to complement
each other and used in combination.
6.3 Odd-chain and trans-16:1n-7 fatty acids as biomark-
ers of dairy consumption
Results from associations of dairy consumption with cardio-metabolic disorders are mainly
derived from studies using self-reported methods of dietary assessment, so it is of interest
to identify potential biomarkers of dairy consumption. The first studies, which explored
such biomarkers, used a hypothesis driven approach to investigate fatty acids as potential
biomarkers of the ranking of dairy consumption (concentration biomarkers). This hypothe-
sis, which included the odd-chain saturated fatty acids (OCSFAs) C15:0 (pentadecanoic
acid) and C17:0 (heptadecanoic acid), was generated from the observation that these fatty
acids are produced by microbial fermentation or microbial de novo lipogenesis in the
ruminant duodenum and are transferred to the ruminant milk, which is then consumed
by humans, but cannot be produced endogenously in the human body[208]. Before that
observation, the only use of OCSFAs was as internal standards in the chemical analyses of
fatty acids with gas or liquid chromatography[209, 210]. Instead the focus was on even-
chain fatty acids, which constitute more than 99% of fatty acids in human blood plasma
in contrast to the very small amounts of OCSFAs[208]. Likewise, OCSFAs constitute on
average 1.6% of the total saturated fat in milk, whereas C14:0, C16:0 and C18:0 constitute
11.2%, 28.9% and 11.1% respectively[35]. However, C16:0 is more abundant in meat
(e.g. 36% of the saturated fat in beef) and C18:0 is more abundant in cocoa products
(approximately 30% of total saturated fat) and meat (approximately 20% of total saturated
fat)[35], so their specificity as dairy biomarkers was questionable. In addition, coconut oil
contains more C14:0 than milk (18% of total fatty acids in coconut oil)[35], but it has been
studied as a potential biomarker of dairy fat, since it can be assumed that consumption
levels of coconut oil are on average lower than that of dairy products in certain populations.
From a literature review and citations of relevant papers, I identified 27 studies[154, 201,
211–235] examining crude correlations or adjusted associations of potential biomarkers
of dairy fat intake including C14:0 (n=12)[213, 216, 217, 220, 223–225, 228–230, 232,
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235], C15:0 (n=24)[211–220, 222–235], C17:0 (n=20)[211–220, 222, 225, 228–235],
trans-16:1n-7 (n=12)[154, 201, 217, 219, 221, 223–226, 229, 230, 232] and trans-18:1n-
7 (vaccenic acid; n=2)[217, 229]. These associations were with total dairy products
(n=16)[211–213, 215, 216, 219, 220, 222, 224–226, 228, 230, 231, 233, 235], high-fat
dairy products (n=11)[154, 201, 214, 221, 223–225, 229, 231, 232, 234], low-fat dairy
products (n=6)[201, 223–225, 231, 232], full-fat milk (n=5)[201, 218, 221, 223, 224],
low-fat milk (n=5)[201, 221, 223, 224, 231], cheese (n=5)[212, 215, 221, 226, 231],
high-fat cheese (n=3)[201, 223, 224], low-fat cheese (n=3)[201, 223, 224] and butter
(n=8)[201, 212, 218, 221, 223, 224, 227, 231] consumption, whereas for yoghurt the
number of studies identified was small[223, 231]. The first study on this hypothesis
examined the correlations of estimated dairy consumption with C15:0 and C17:0 in adipose
tissue[211]. The estimated correlations in this study were high enough (r=0.34-0.61 and
r=0.2-0.35 between total dairy consumption and C15:0 or C17:0 respectively) to generate
further interest in OCSFAs as potential biomarkers of dairy consumption[211] (Table 6.1).
When comparing results from such studies, it is important to account for the biological
sample used as different samples have different reference time periods. There is a constant
exchange of fatty acids between the different tissues from the stage right after their intake
from the diet to their introduction to the blood circulation in the form of chylomicrons,
their uptake from different tissues to their storage in the adipose tissue[236]. Due to
this constant movement, the fatty acid content of the different tissues is correlated[236].
However, according to the reference period of intake we are interested in, we might
achieve a higher correlation with dietary intake if we choose the most relevant sample,
but also the most precise method of dietary assessment. For example, it seems that dairy
consumption from multiple food diaries had overall higher correlations with blood fatty
acids than consumption from multiple 24-hour recalls[213] or FFQ[215], and intakes from
24-hour recalls in turn had higher correlations than intakes from FFQ[220] (Table 6.1).
The biological samples used in the majority of the studies to measure fatty acids are
adipose tissue, blood (total fatty acids or non-esterified fatty acids or fatty acids from
phospholipids, cholesteryl esters or triglycerides) and erythrocytes[236]. Biomarkers in
adipose tissue reflect average intake over 1 – 1.5 year, biomarkers in erythrocytes reflect
average intake over a few months -as the life cycle of erythrocytes is approximately 120
days- and biomarkers in serum and plasma samples reflect more short-term intake over a
few hours to weeks[237].
Of the studies identified (Table 6.1) , seven analysed adipose tissue samples[211,
213–216, 222, 235], four erythrocytes[217, 218, 225, 232], 23 serum or plasma sam-
ples (phospholipids, n=13[154, 201, 212, 213, 216, 219–221, 223, 224, 228, 229, 233];
cholesteryl esters, n=2[212, 213]; total plasma, n=5[217, 225, 230, 232, 234]; total serum,
n=3[215, 226, 227]; whole blood, n=1[231]). The majority of the studies assessed dairy
consumption with an FFQ, (n=20)[154, 201, 211, 214, 215, 217–228, 231, 232, 235],
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while seven studies used a food diary[211–213, 215, 216, 229, 233] and two studies used
a 24-hour recall[213, 220]. C15:0 was moderately correlated with total and high-fat dairy
consumption and this correlation was stronger than that of C17:0, while the sum of the two
biomarkers showed a slightly stronger correlation[211, 213] (Table 6.1). Correlations of
C14:0 lie on the same levels as those of C17:0. Trans-16:1n-7 was also correlated with
dairy consumption and the correlation was weaker than that of C15:0, but stronger overall
than that of C17:0. Correlations with low-fat dairy products and low-fat dairy subtypes
were overall low, ranging from -0.01 to 0.17.
6.4 Limitations of odd-chain saturated fatty acids and
trans-16:1n-7 as candidate biomarkers of dairy con-
sumption
Although results from existing studies show OCSFAs and trans-16:1n-7 as promising
biomarkers of dairy fat, there are several potential limitations of their use as dairy biomark-
ers. First, the specificity of OCSFAs as dairy biomarkers has been questioned both because
they have been associated with other foods and because they do not seem to be specific to
individual dairy types. After OCSFAs are produced in the ruminant duodenum by microbial
fermentation not only are they transferred to milk, but they are also contained in ruminant
meat[208]. Thus, the correlation with dairy consumption might be population-specific
depending also on the consumption levels of other food items, such as ruminant meat
(e.g. beef), but also fish which can be important food sources of OCSFAs when consumed
in relatively high amounts[238, 239]. OCSFAs have also been inversely correlated with
alcohol consumption[216, 218, 219, 228, 232] with correlations ranging from -0.1 for
erythrocyte C15:0[232] to -0.44 for phospholipid C15:0[216] and from -0.14 for erythro-
cyte C17:0[218] to -0.52 for phospholipid C17:0[216]. A potential explanation for these
correlations is that alcohol consumption increases the substrate for the production of the
even-chain fatty acids C16:0 and C18:0, which is acetyl-CoA through the conversion of
ethanol to acetate in liver and the subsequent conversion of acetate to acetyl-CoA[240]. Be-
cause fatty acids are measured in relative concentrations, it can be inferred that an increase
of even-chain saturated fatty acids will lead to a decrease of the relative concentrations of
other fatty acids i.e. OCSFAs.
Second, while OCSFAs and trans-16:1n-7 in contrast to even-chain saturated fatty
acids were thought not to be produced endogenously, but to be synthesised only by the
ruminant bacteria[241], there has been evidence that they may be derived from alternative
biological pathways as well. This became evident for C17:0 when it was observed that
while the ratio of C15:0 to C17:0 in milk is approximately 2:1, the same ratio in human
sample tissues overall is reversed and approximately 1:2 and thus C17:0 must be derived
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Table 6.1 Previously published crude correlations or adjusted associations of fatty acids C14:0,
C15:0, C17:0 and trans-16:1n-7 with total and high-fat dairy products
C14:0 C15:0 C17:0 Trans-16:1n-7
Dairy products Total High-fat Total High-fat Total High-fat Total High-fat
Blood
Assessment of changes †
Albani, 2015[231] - - ↑ ↑ ↑ ↑ - -
Plasma
Correlations
Yakoob,2016[232] - - - 0.26 - 0.19 - 0.24
Yakoob,2014[225] 0.08 0.05 - 0.19 - 0.12 - 0.10
Sun, 2007[217] ‡ 0.18, 0.17 - 0.28, 0.29 - 0.13, 0.13 - 0.19, 0.20 -
Assessment of changes †
Jenkins, 2017[234] - - - ↑ - ↔ - -
Abdullah, 2015[230] ↔ - ↑ - ↑ - ↔ -
Serum
Correlations
Santaren, 2014[226] - - 0.20 - - - 0.00 -
Brevik, 2005[215] § - - 0.37, 0.27 - 0.22, 0.09 - - -
Phospholipids
Correlations
Da Silva, 2014[154] - - - - - - - 0.15
de Oliveira Otto,2013[224] 0.14 0.09 0.22 0.16 - - 0.07 0.13
Mozaffarian, 2013[223] - 0.10 - 0.15 - - - 0.15
Micha, 2010[201] - - - - - - - 0.39
Saadatian-Elahi, 2009[220] ∥ 0.44, 0.25 - 0.33, 0.15 - -0.08, 0.13 - - -
Thiebaut,2009[219] - - 0.13 - 0.10 - 0.00 -
Rosell, 2007[216] 0.27 - 0.43 - 0.23 - - -
Wolk, 2001[213] # 0.41, 0.36 - 0.40, 0.46 - 0.17, 0.26 - - -
Smedman, 1999[212] - - - 0.34 - 0.00 - -
Assessment of changes †
Weitkunat, 2017[233] - - ↔ - ↔ - - -
Nestel, 2014[229] ↔ - ↑ - ↔ - ↑
Mozzafarian, 2010[221] - - - - - - - ↑
Cholesteryl esters
Correlations
Wolk, 2001[213] # 0.35, 0.39 - 0.32, 0.40 - 0.22, 0.36 - - -
Smedman, 1999[212] - - - 0.46 - 0.00 - -
Erythrocytes
Correlations
Yakoob,2016[232] - - - 0.16 - 0.13 - 0.21
Yakoob,2014[225] -0.01 0.01 - 0.07 - -0.01 - 0.09
Sun, 2007[217] ‡ 0.12, 0.11 - 0.22, 0.23 - 0.11, 0.14 - 0.18, 0.18 -
Adipose tissue
Correlations
Laursen, 2018[235] 0.34 - 0.39 - 0.25 - - -
Aslibekyan,2012[222] - - 0.34 - 0.16 - - -
Rosell, 2007[216] 0.47 - 0.52 - 0.3 - - -
Brevik, 2005[215] § - - 0.39, 0.25 - 0.06, 0.16 - - -
Baylin, 2002[214] - - - 0.31 - 0.31 - -
Wolk, 2001[213] # 0.48, 0.58 - 0.58, 0.69 - 0.20, 0.22 - - -
Wolk, 1998[211]** - - 0.61, 0.34 - 0.35, 0.20 - - -
*Five randomised controlled trials[229–231, 233, 234], eight prospective cohort studies[201, 211–213, 221, 223, 224, 232], one
case-cohort study[235], three nested case-control studies[217, 219, 225], one case-control study[222], and six cross-sectional
studies[154, 214–216, 220, 226] were included
†Changes were assessed with linear regression[221, 229–231] or t-tests [233, 234]
‡The first correlation is derived from cross-sectional data and the second from 4-year prospective data
§The first correlation is derived from 14-day food diary data and the second from food frequency questionnaire data
∥The first correlation is derived from 24-hour recall data and the second from food frequency questionnaire data
#The first correlation is derived from 21-week food diary data and the second from 14 24-hour recall data
**The first correlation is derived from four one-week food diary data and the second from food frequency questionnaire data
144 Biomarkers of dairy consumption: Part I
from an additional source to a higher extent than C15:0[242]. Even-chain fatty acids
are produced from repeated condensation of malonyl-CoA with acetyl-CoA[243]. Under
presence of propionate, a short-chain fatty acid produced by the gut microbiome, propionyl-
CoA is produced, which competes with acetyl-CoA for the condensation of malonyl-
CoA and which then produces OCSFAs as shown in Figure 6.1[233, 244, 245].Through
this mechanism, it has also been proposed that higher fibre intake might lead to higher
production of OCSFAs[233]. A second alternative pathway is α-oxidation of even-chain
saturated fatty acids C16:0 and C18:0 to produce C15:0 and C17:0 respectively[208]. This
pathway is better characterised for C17:0 from two animal studies[234]. In the first study,
infusion with C18:0 led to higher serum levels of C17:0 in rats[234]. In the second study,
supplementation with phytol, which produces phytanic acid, a substrate competing with
α-oxidation of C18:0 to produce C17:0, resulted in lower serum levels of C17:0[234].
Concerning trans-16:1n-7, it has been suggested that it is partly derived from the partial
β -oxidation of trans-18:1n-7[246].
Fig. 6.1 Mechanism of endogenous odd-chain saturated fatty acid production from propi-
onate. Figure adapted from Weitkunat et al[233]
Schematic representation of the odd-chain saturated fatty acid production removed for 
copyright reasons. Copyright holder is Karolin Weitkunat. 
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Third, technical error from the laboratory methods employed can lead to higher varia-
tion. The low levels of OCSFAs in sample tissues might lead to unstable measurements[247].
In addition, although trans-18:1n-7 is the predominant trans fatty acid in milk, human
sample contents of trans-16:1n-7 and trans-18:1n-7 are similar[217, 248]. It has been
suggested that depending on the choice of gas chromatography capillary column and the
temperature, there might be co-elution of trans-16:1n-7 and iso C17:0 -a branched-chain
fatty acid- leading to erroneously higher concentrations of trans-16:1n-7[248].
Finally, a natural source of variation by country can be different ruminant feeding
practices related to energy, fat and fibre intake of the animals[33].
In order to account for the limitations of the known potential biomarkers of dairy fat
intake, it has been attempted to identify novel biomarkers through metabolomics.
6.5 Use of metabolomics for the identification of novel nu-
tritional biomarkers
Different study designs have been employed to identify or validate a biochemical compound
as a nutritional biomarker including animal studies, observational studies and dietary
interventions[204]. The traditional method followed in these studies has been to examine
associations between food consumption or nutrient intake and one or more candidate
biomarkers under a hypothesis-driven deductive approach. Although the inductive, data-
driven approach, has been more conservatively used and has even received criticism in
the context of research quality due to the lack of an initial hypothesis, it has also been
identified as very important for the advancement of science and the generation of new
hypotheses[249]. Remarkable examples of how inductivism has contributed to scientific
advancements include Darwin’s theory of evolution and Watson and Crick’s discovery of
the DNA structure[249].
With the use of the “-omics” technologies i.e. genomics, transcriptomics, proteomics
and metabolomics, spreading in several fields of systems biology research, hypothesis-
free, exploratory analyses can be used to identify potential biomarkers of dietary intake.
Since metabolomics, which is the study of low-molecular weight metabolites (usually
<1,500 Da), is the final downstream product of the genome and thus more directly linked
to the phenotype compared to the other “-omics” approaches, it is particularly useful
for the identification of potential biomarkers[250]. The use of metabolomics has been
exponentially increasing for the last few decades due to the development of high-throughput
methods including nuclear magnetic resonance (NMR) and mass spectrometry (MS)[250].
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6.6 Metabolomics in epidemiology and nutrition research
Following this trend, the usefulness of metabolomics has been evident also in food and
nutrition research with several applications from the identification of food compounds
also including contaminants, allergens, toxins, quality and geographical origin[251] to
contributions towards personalised nutrition (identification of person’s nutritype) and the
identification of potential biomarkers of dietary intake for the advancement of dietary
assessment[252]. To identify novel nutritional biomarkers, one needs to explore that part of
the human metabolome which includes all those metabolites directly derived from foods or
produced from the ingestion and metabolism of the food consumed, also known as the food
metabolome[207]. The large number of compounds constituting the food metabolome (>
25,000) and the multiple stages of food metabolism that these compounds might be related
to, makes the characterisation of the food metabolome highly complex[207]. The fate of a
food compound can be one of the following[207]:
• Digestion in the mouth, stomach or small intestine into simple nutrients readily
available for absorption. In this case, the food compound is not a very useful
biomarker as usually the simple nutrients can be found in multiple foods or even
produced endogenously making it hard to trace their dietary source.
• Processing by the gut microbiota. In this case, the end products of the processing
might be included in the human metabolome and although some of them might be
used as dietary biomarkers, the pathways involved are more complex.
• Absorption and metabolism usually in the liver or kidneys. In this case, the com-
pound and/or its metabolites are released in the circulation or stored tissues and it is
more likely that the food compound is a more specific biomarker of a food.
According to a recent literature review of metabolomics studies for the identification of
dietary biomarkers, metabolomics has been more extensively used for the identification of
biomarkers of fruits, vegetables, meat, fish, bread, whole grain cereals, nuts, wine, coffee,
tea, cocoa and chocolate and the classification of individuals according to the dietary
pattern they mostly adhere to e.g. vegetarian, Mediterranean diet, a prudent or a Western
dietary pattern[207, 252].
6.7 Previous studies on the exploration of dairy biomark-
ers using metabolomics
So far, 12 studies on the investigation of potential novel dairy biomarkers from metabolomics
analyses have been identified[227, 229, 253–262] (Table 6.2). Of those, six have assessed
blood metabolomic profiles with MS[227, 229, 255, 259, 261] or H-NMR[254], seven
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have assessed urine metabolomic profiles with MS[256, 262] or H-NMR[253, 257, 258,
260, 262] and one study has used H-NMR in faecal samples[257] (Table 6.2). Most of the
studies were randomised controlled trials (RCTs) and two of the studies were observational
(cross-sectional[261] or nested case-control[227]). Of these studies, two included only
patients with irritable bowel syndrome[254, 255], one included children[253], one included
twins[261] and three included overweight or obese people[229, 258, 260].
Despite the metabolite signals identified from these studies as summarised in Table 6.2,
which can be used for the exploration of candidate biomarkers of dairy consumption,
several limitations can be identified. The two studies by Pedersen et al have included
patients with irritable bowel syndrome[254, 255] with limited generalisability, as the
bioavailability of nutrients in these patients might be limited due to symptoms like di-
arrhoea, which may result in limited absorption. The study by Hjerpsted et al, which
assessed potential biomarkers of cheese consumption, used butter with the same amount of
fat as a control, which automatically excludes the identification of potential biomarkers
of dairy fat[256]. The metabolite signals derived from this study were mainly products
of tryptophan or tyrosine metabolism, supporting a higher content of these amino acids
in cheese than in butter[256]. Although these amino acids might be specific to cheese
when compared with butter, they are not specific to cheese when compared with other
foods such as meat[256]. The same holds for other amino acids or products of amino acid
metabolism that were reported from other studies such as tyrosine[257, 261], phenylala-
nine, valine and trimethyl-N-aminovalerate (product of lysine or proline)[261]. In addition,
some metabolites reported are not specific to dairy products, although sensitive to dairy
consumption. Such metabolites are urinary citrate, which might be produced from the
citric acid contained in dairy products, but it may also originate from cranberry juice, grape
juice or tea and even produced endogenously[257, 260]; urinary creatinine, creatine and
urea, which are markers of protein catabolism[257, 258, 260]; urinary trimethylamine-N-
oxide, which is a gut metabolite of choline, a nutrient contained in dairy products, eggs,
fish and meat[260]; urinary 3-phenyllactic acid, which is a product of the metabolism
of lactic acid bacteria and also contained in honey as a preservative[262]; and urinary
hippurate[253, 257, 260], which is a product of the gut microbiota[263].
Some studies identified certain lipid classes[227, 229, 259, 261], such as several sh-
pingomyelins [259, 261] and phospholipids[229, 259, 261], as potential dairy biomarkers.
These metabolites could be identified as potential biomarkers of dairy fat, but since they
constitute broad lipid classes, lipids specific to dairy consumption need to be identified.
In addition, such metabolites may not be relevant for very low-fat dairy products such as
skimmed milk, for which non-lipid molecules are more likely to be potential biomarkers.
Finally, urinary lactose, galactose and galactonate as potential biomarkers of milk con-
sumption and urinary 3-phenyllactic acid as potential biomarker of cheese consumption
reported in the study by Munger et al. could be very specific for this study[262]. As
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the authors mentioned, excess amounts of lactose and galactose coming from the 600 ml
of milk used in the intervention may result in increased urinary excretion of these and
also galactonate, which might not be relevant for lower habitual consumption levels of
milk[262]. Thus, while these could be good biomarkers, they might not be useful for
dietary assessment or clinical applications in real-life settings.
Overall, single molecules in metabolomics are less likely to serve as specific biomarkers
to individual dairy types. Thus, instead of investigating single molecules as potential
biomarkers as done in previous metabolomics or nutritional biomarker studies, we aimed
to develop metabolite scores. The combination of selected molecules to create scores
might be more specific to the consumption of an individual food compared to single
biomarkers[207]. Especially since the candidate biomarkers of dairy consumption do
not discriminate between different dairy types, the use of a compound score of multiple
biomarkers may effectively reflect individual dairy types.
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6.8 Study aims
The aims of this study were to
1. Identify metabolites predicting dairy consumption using metabolomics
2. Develop and validate metabolite scores that reflect consumption of total and types of
dairy products
3. Examine whether the metabolite scores could provide predictive ability in addition
to C15:0, C17:0 and trans-16:1n-7, which have been identified as candidate dairy
biomarkers
6.9 Methods
The reporting of the process for the development and validation of the dairy prediction
models was based on the TRIPOD (Transparent Reporting of a multivariable prediction
model for Individual Prognosis Or Diagnosis) guidelines[264].
6.9.1 Study design and population
Targeted metabolomics data from the Fenland study comprised the discovery set for
the exploration of potential biomarkers of dairy consumption and development of the
metabolite scores. Untargeted metabolomics data from the EPIC Norfolk incident diabetes
case-cohort study comprised the external validation set. The discovery and validation sets
were selected to investigate associations between metabolite scores and type 2 diabetes
risk in EPIC Norfolk study (Chapter 7), for which the metabolite scores must be derived
from an independent set.
Discovery and internal validation sets
A summary of the study design is presented in Figure 6.2. In the present analysis,
we evaluated 10,281 participants from the baseline assessment of the Fenland study
(section 4.3) after exclusion of those with no metabolomics data (n=1,751), and no dietary
data (n=14), pregnant women (n=3), men with energy intake less than 800 kcal, or more
than 4,000 kcal or women with energy intake less than 500 kcal or more than 3,500 kcal
(n=200) and participants with more than the 50% of the metabolites missing (n=186). The
sample was split into two subsets: a discovery set and a validation set (internal validation).
The validation set was selected based on the availability of measurements for the fatty
acids C15:0, C17:0 and trans-16:1n-7 (n=4,246), because the third aim of this study was to
assess the additive value of the metabolite scores to models with fatty acids as candidate
dairy biomarkers and the scores would be derived ideally from an independent set. Fatty
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acids were measured in samples randomly chosen by picking every other box up to 5,000
samples covering the whole cohort (approximately 12,000 samples). The rest of the
samples constituted the discovery set (n=6,035).
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Fig. 6.2 Flow diagram of the inclusion process of participants in the discovery, internal
and external validation sets
External validation set
The external validation was performed in a diabetes case-cohort study of 1,440 participants
(initial sample: 1,503) nested within the EPIC Norfolk study (section 5.3) after exclusion
of participants who were missing dietary data at baseline or follow-up (n=44), men with
energy intake less than 800 kcal or more than 4,000 kcal or women with energy intake less
than 500 kcal or more than 3,500 kcal (n=17) and participants with more than 50% of the
metabolites missing (n=2). In the secondary analysis, where OCSFAs were also included
in the discovery, we further excluded participants with no fatty acid measurements (n=848)
leaving 592 participants for this analysis (356 incident diabetes cases and 236 non-cases).
6.9.2 Metabolite and fatty acid measurement
As mentioned (section 6.5) the two laboratory techniques for metabolomic analyses are
MS and NMR. MS is usually coupled with liquid (LC) or gas (GC) chromatography. In
large epidemiological studies, LC might be preferable, with much smaller preparation
times than that of GC, which requires a derivatisation step in the beginning, in order to
make the compounds volatile[265]. However, LC has some disadvantages compared to
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GC. For example, ion suppression, which is the unsuccessful ionisation of some molecules
due to the competition with other molecules is more common in LC than GC resulting in
GC being more sensitive especially for smaller compounds[265]. Both MS and NMR have
advantages and disadvantages and no method can assess the global metabolome. NMR
is a fast method (2-3 minutes/sample), as it does not require any prior derivatisation or
separation and it is quantitative, but it has low sensitivity, is expensive, requires relatively
large samples and cannot detect inorganic compounds[266]. Although NMR was more
popular initially, MS has been gaining more ground in epidemiological studies, due to
the lower and decreasing cost, the requirement of small samples, and its high sensitivity,
which has made it very useful also in the identification of nutritional biomarkers, which
are expected to be detected in low concentrations[265]. However, MS might have low
reproducibility, because of the variation in the pH and the column temperature and column
ageing or contamination[267]. These problems can be handled with the use of a buffer
such as formic acid or trifluoroacetic acid to maintain the pH, the use of a thermostat
and the use of a pump system to re-equilibrate the column[267]. In addition, MS is less
quantitative and slower (20-30 minutes/sample) than NMR[266]. In both of the studies,
metabolomics profiling was conducted with MS. More details on the specific methods are
presented in the following sections.
The reporting of the methods for the metabolite measurement is based on the proposed
reporting standards by the Chemical Analysis Working Group as part of the Metabolomics
Standards Initiative[268].
Metabolomics assay in the discovery and internal validation sets
Fasting blood samples were collected after an overnight fast. For the preparation of blood
plasma, blood was mixed with heparin, an anticoagulant, which does not interfere with the
analytical samples[269]. Samples were stored in -80°C in the MRC Epidemiology Unit
Biorepository Freezer until analysed. Before the analysis, the samples were removed from
the freezer, placed on roller mixers at 30 rpm to thaw for 15-20 minutes and centrifuged
for 1 minute at 2,000 rpm. Calibration standards and internal standards were also briefly
centrifuged and quality control (QC) samples were centrifuged for 5 minutes at 2,750
rpm. All vials were then shaken for 15 minutes at 1,200 rpm and vortexed and then
transferred to 96-well plates with rows A-H and columns 1-12. Derivatisation agent (50
ul) was added to all the wells. The internal standards (10 ul) were added to all wells for
quantification apart from A1, which included the blank (deionised water with phosphate
buffer saline). Positions B2-D2 contained the zero samples (blank samples with internal
standards). Positions E1-C2 contained the calibration samples, positions D2-F2 contained
the commercial QC samples, positions G2 and H12 contained the pooled QC samples and
positions H3-G12 contained the study samples. The sample processing was done on a
Hamilton STAR liquid handling station (Hamilton Robotics Ltd, Birmingham, UK).
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Targeted metabolomic profiling of 10,684 blood plasma samples was performed with a
commercial kit (Absolute IDQ p180 kit, Biocrates Life Sciences AG, Innsbruck, Austria).
Flow injection analysis (FIA) MS (AB SCIEX 5500 Qtrap mass spectrometer, Sciex Ltd,
Warrington, UK), isocratic with methanol, in positive ionisation mode was performed for
lipids and acylcarnitines , FIA-MS in negative ionisation mode was performed for hexose,
while for amino acids and biogenic amines, ultra-performance liquid chromatography MS
(UPLC-MS; Waters ltd, Machester, UK couples to ABSciex 5500 Qtrap mass spectrometer,
Sciex Ltd, Warrington, UK) was performed with a 5-minute gradient elution starting with
100% water and changing to 95% acetonitrile and 0.2% formic acid over a Waters Acquity
UPLC BEH C18 column (2.1 x 50 mm, 1.7mm).
The raw metabolomics data were processed with the MetIDQ software (provided with
the kit). The data went through checks for outliers, non-detects, peak picking, normalisation
using the QC samples (metabolite values were divided by the ratio of the mean value of
QC samples within a plate to the mean value of QC samples across all the plates) and
finally batch correction. Normalisation is very important to distinguish between biological
variation and noise due to column degradation, changes in room temperature or pH of
the mobile phase, matrix effects or the repeated use of the ion source and results can be
substantially different when it is not applied[265].
Values under detection limits were replaced with numbers randomly selected from
a uniform distribution between 0.1 and a minimum observed within batch. After ex-
clusion of 13 metabolites based on the results from the QC and the batch correction,
174 metabolites were left including amino acids (n=22), biogenic amines (n=12), acyl-
carnitines (n=40), phosphatidylcholines (PCs) (n=74), lysophosphatidylcholines (LPCs)
(n=14), sphingomyelins (SMs) (n=11) and hexose. Amino acids and biogenic amines were
quantified and expressed in absolute scale, whereas the lipids, acylcarnitines and hexose
were semi-quantified due to lack of standards and thus expressed in a relative scale.
Metabolomics assay in the external validation set
Non-fasting blood samples were collected at baseline from the 1,503 participants of the
diabetes case-cohort study nested within the EPIC Norfolk study. Samples were stored in
-80°C until one day before the analysis and overnight in liquid nitrogen the night before the
analysis. Deproteinisation was done with methanol, which has been shown to promote an
optimised extraction and deproteinisation[270], under vigorous shaking for two minutes
(Glen Mills GenoGrinder 2,000). The samples were then centrifuged and placed on a
TurboVap (Zymark) to remove the organic solvent. The order of the study samples on the
plates was randomised and QC samples (two commercial QC standards and four pooled
QC samples) were evenly distributed across the study samples. A blank sample and
internal standards, which compensate for the technical noise that might be introduced to
the analytical process[269] were also used.
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Untargeted metabolomic profiling was performed in 1,503 blood citrated plasma
samples (DiscoveryHD4® platform, Metabolon, Inc.; Waters ACQUITY UPLC, Thermo
Scientific Q-Exactive spectrometer with a heated electrospray ionization (HESI-II) source
and Orbitrap mass analyzer with 35,000 mass resolution). Samples were divided into five
fractions of which two were used for reverse phase UPLC tandem MS (MS/MS) with
positive ion mode electrospray ionization (ESI; mobile phases with 0.1% formic acid in
water and 0.1% formic acid in methanol), one was used for reverse phase UPLC MS/MS
with negative ion mode ESI (mobile phases with 6.5 mM ammonium bicarbonate in water,
pH=8 and 6.5 mM ammonium bicarbonate in 95% methanol and 5% water) , one was used
for hydrophilic interaction liquid chromatography (HILIC) UPLC MS/ MS with negative
ion mode ESI (mobile phases with 10 mM ammonium formate in 15% water, 5% methanol,
80% acetonitrile and 10 mM ammonium formate in 50% water and 50% acetonitrile)
and one was kept as a backup. The UPLC column used was a 2.1 mm x 100 mm Water
BEH C18 1.7 mm at 40°C and the HILIC column was a 2.1 mm x 150 mm Waters BEH
Amide 1.7mm at 40°C. Gradient elution with water, methanol, 0.05% pentafluoropropionic
anhydrate and 0.1% formic acid was used in all the columns.
Metabolite identification was based on the retention index, accurate mass matched to
the Metabolon internal library of metabolites within a range of ±10 ppm and the standards
used. The raw metabolomics data were processed and went through normalisation by
“block correction” i.e. setting median to 1 and adjusting each data point proportionately
and QC checks with in-house software from Metabolon, Inc. After QC procedures, 940
metabolites where quantified, of which 308 were unknown.
Approximate metabolite matching between the targeted and untargeted platforms
Due to the different assays used in the Fenland study (targeted platform) and the EPIC
Norfolk study (untargeted platform), some of the molecules included in one dataset could
not be exactly matched with similar molecules of the other dataset. Thus, in order to
perform the external validation, matching of the metabolites between the two metabolomic
platforms was performed.
Fatty acids assay
Plasma phospholipid fatty acids (38 individual fatty acids) were measured in 4,791 partici-
pants in the Fenland study and 592 participants in the EPIC Norfolk diabetes case-cohort
study. For the measurement of fatty acids, the same method was used in both studies.
Phospholipids were isolated from total plasma lipids with solid-phase extraction and then
free fatty acids were extracted with hydrolysis and derivatisation. The free fatty acids were
methylated to form fatty acid methyl-esters, which are volatile and were then used in GC
(7890N; Agilent Technologies) with a 30 m capillary column with a diameter of 0.25 mm.
Sample was processed with sequential multipurpose sampler systems (Gerstel GmbH &
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Co. KG, Mulheim an der Ruhr, Germany). One blank sample and two QC samples were
used in all the batches: one from human plasma pooled from the study samples and one
from horse plasma. Standards of all fatty acids were used for the GC calibration. Study
and QC samples were stored in -80°C before analysis. Fatty acids were identified by
comparing their retention times with those of the standards. Fatty acids were expressed in
relative amounts. More details of the methods applied were published previously[271].
6.9.3 Metabolite annotation
Nomenclature of amino acids followed the recommendations by the IUPAC-IUB Com-
mission on Biochemical Nomenclature[272]. For all the lipids, “Cx:y” indicates x carbon
atoms and y double bonds. For the acylcarnitines, x denotes the number of carbon atoms
of the carboxylic acid, which is esterified with carnitine. Thus, carnitine is denoted as C0.
For PCs there is the additional indication of “aa” when it contains two fatty acids or “ae”,
when it contains one fatty acid and one fatty alcohol. So a PC might be denoted as PC aa
Cx:y or as PC ae Cx:y. If it is an LPC, then this becomes LPC aa Cx:y or LPC ae Cx:y.
Finally, SMs are denoted as SM Cx:y or SM-OH Cx:y if it is a hydroxy-SM.
6.9.4 Dietary assessment
In both studies, an 130-item semi-quantitative FFQ was used for the dietary assessment
reflecting habitual dietary intakes over the past year. The FFQ was validated against 7-day
food diaries in the EPIC Norfolk study[158]. Participants could choose one from the nine
frequencies of dairy consumption ranging from “never or less than once/month” to “6 times
per day” and provide more details on the type and amount of milk consumed. Correlations
between the dairy consumption as reported in the questionnaires and as reported in the
7-day diaries were 0.56 for milk, 0.57 for yoghurt, 0.33 for cheese and 0.54 for butter.
Questionnaire data were processed with the FETA software[159]. Dairy outcomes included




Further metabolomic and fatty acid data pre-treatment was performed, which is an im-
portant step to emphasise biological information and interpretability[273]. This involved
log-transformation to reduce heteroscedasticity, centering by subtracting the mean to leave
only the relevant variation and auto-scaling by dividing by the standard deviation to make
the metabolites comparable[273]. Missing values were imputed using multiple imputation
with chained equations[168] and due to the low number of missing values (Tables 6.5
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and A.18), a single imputed dataset was used in subsequent analyses. Data were processed
in Stata 14.2 (College Station, TX: StataCorp LP, 2015).
Due to the skewed distributions of most of the dairy products, which did not approxi-
mate the normal distribution even after transformation, binary variables of low and high
consumers were created for milk, yoghurt, cheese, butter, and total dairy products (sum
of milk, yoghurt, cheese, cream and butter). Milk consumption, which was more fre-
quently consumed than the other dairy types, was divided into <1 serving/day and ≥2
servings/day. Yoghurt, cheese and butter consumption were divided into <1 serving/week
and ≥1 serving/day. Total dairy consumption was divided into <1 serving/day and ≥3
servings/day. The log-transformed energy densities of milk and total dairy products (in
2,000 kcal of total energy intake), which approximated the normal distribution were also
used as outcomes.
Methods for metabolomics data analysis
Metabolomics data can be analysed with the use of multiple univariate models for each
metabolite or the use of a multivariable model including all the metabolites. The use of
a multivariable method has the advantage of accounting for the correlations between the
explanatory variables i.e. the metabolites and thus their relations, which might be more
informative than the associations with each metabolite separately[274]. In addition, we
can avoid the use of multiple test correction, which in some cases may increase the risk of
false negatives[274].
Multivariable methods can be categorised into unsupervised and supervised. Unsu-
pervised methods do not get any input about which variable we would like to base our
predictions on, in contrast to supervised methods. Unsupervised methods reported in
metabolomics studies include principal component analysis (PCA), which can be used
in a hypothesis-free exploration or for dimensionality reduction, but also other machine
learning methods such as k means clustering and parallel factor analysis[275]. Although
unsupervised methods such as PCA are used widely and routinely in nutritional and other
metabolomics studies[252], they are not very useful for nutritional biomarkers identifi-
cation, because we are interested in the discrimination of the sample based on a specific
dietary consumption profile, which is not very likely the same as the discrimination that the
unsupervised methods will show[275]. Supervised methods used in metabolomics studies
include regression and its variations e.g. penalised regression, discriminant analysis meth-
ods e.g. partial least squares-discriminant analysis (PLS-DA), which is the most extensively
used method in nutritional metabolomics studies[252] or other machine learning methods
such as random forests, support vector machines and artificial neural networks[275].
All the methods have their advantages and disadvantages and the choice of a method
is often a trade-off between interpretability, easy and fast application, and flexibility. For
example, while ordinary regression is easily interpretable, in our case it might not be very
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useful. We expect high multicollinearity between metabolites, which might be handled
less effectively with the ordinary regression. PLS-DA is a method, which easily over-fits
the data, so a well-designed validation and caution with the interpretation of the results are
needed, when this method is applied[274]. Machine learning techniques can effectively
deal with high-dimensional data, they do not require assumptions that other methods
do, and they empirically have a high prediction accuracy but at the same time some of
them introduce the risk of over-fitting, are time consuming and difficult to apply and
interpret[276–281].
Regularisation or penalisation or shrinkage methods apply a penalty on the regression
coefficients leading to biased effect estimates, but simultaneously decreasing the vari-
ance introduced due to mutlicollinearity between the different explanatory variables (e.g.
metabolites)[280]. The three main types of penalised regression are the Ridge, LASSO
(Least Absolute Shrinkage and Selection Operator) and elastic net regression and a compar-
ison of their characteristics is presented in Table 6.3. The first penalised method was Ridge
regression, which applies a penalty on the sum of squares of the regression coefficients (L2
norm), keeps all the coefficients in the model (no shrinkage to zero) and applies similar
weights to highly correlated variables[282]. After Ridge regression, the LASSO regression
was introduced, which applies a penalty to the absolute values of the regression coefficients
(L1 norm), shrinks some coefficients to zero, thus dropping variables out of the model and
keeps only one out of a group of perfectly correlated variables[283]. LASSO regression
gives a better prediction accuracy than Ridge regression, because it decreases the variation
after variable selection[283]. On the other hand, this variable selection attribute makes
LASSO less stable than Ridge[283]. Another limitation of the LASSO is that the sample
size poses a restriction to the number of variables that can be selected to be kept in the
model[283]. The third main type of penalised methods among several variations of the
LASSO[284], is elastic net, which is a combination of the former two methods, as it applies
both an L1 and an L2 penalty at a ratio, which can be defined[285]. Elastic net combines
the advantages of both methods and overcomes their disadvantages, and it has been char-
acterised as the stabilised version of LASSO, as it applies equal weights on absolutely
correlated variables, without dropping them, thus giving the ability to investigate group
effects and the number of variables to keep in the model is independent of the sample
size[284]. These penalties can be used both in linear and logistic regression models.
Discovery and validation of dairy prediction models
Elastic net regression had the lowest prediction error when compared with Ridge, LASSO,
principal components, partial least squares, support vector and random forest regression
in a metabolomics study[280]. Due to its suitability for high-dimensional data with
multicollinearity, its advantages over the other penalised methods and its relative simplicity
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Table 6.3 Comparison of characteristics of the three main penalised regression
methods
Ridge LASSO Elastic Net
Penalty ∑ β 2 (L2) |β | (L1) ∑ β 2 and |β | (L1+L2)
Shrinkage to zero No Yes Yes
Perfectly correlated variables Equal weights Keeps only one in the model Equal weights
Relative prediction accuracy Lower Higher Higher
Relative stability Higher Lower Higher
Restriction on number of vari-
ables by sample size
No Yes No
Abbreviations: LASSO: Least Absolute Shrinkage and Selection Operator
compared to other machine learning methods, elastic net regression was applied for the
development of dairy prediction models.
These models were used for each dairy type specified in three sets of analyses. The
first set included all the 174 metabolites from the targeted metabolomics platform of the
Fenland study. The second set included only the 82 metabolites, which were matched with
the metabolites from the untargeted metabolomics platform of the EPIC Norfolk diabetes
case-cohort study. The third set included the 82 matched metabolites and the two OCSFAs
C15:0 and C17:0.
For binary dairy outcomes, elastic net logistic regression with a stochastic gradient
descent (SGD) classifier was used in Python Scikit Learn module v0.19.1[286]. Prior to
application, fine-tuning of the SGD algorithm was performed for all the different models
by level of adjustment (Table 6.4) using the Scikit Learn GridSearchCV function, which
used exhaustive combinations of input values for several parameters of the algorithm and
3-fold cross-validation to give the set of parameters which resulted in the best predictions.
In our case, we tuned the parameters of L1 ratio (inputs: 0.05, 0.15, 0.25, 0.35, 0.45, 0.55,
0.65, 0.75, 0.85), which defines whether the elastic net penalisation will be closer to a
Ridge or a LASSO penalty, alpha (inputs:10-15, 10-10, 10-8, 10-4, 0.001, 0.01, 1, 5, 10, 20),
which is a constant that multiplies the penalty, and the maximum number of iterations for
the model to reach convergence (inputs: 5, 50, 100, 500, 1,000). For linear dairy outcomes,
elastic net linear regression with 3-fold cross validation was used (Scikit Learn function:
ElasticNetCV).
Five different levels of adjustment were used in the models (Table 6.4). Model 1 (base
model) included age (continuous in years), sex, test site (Cambridge, Ely, Wisbech), smok-
ing status (never smoker, ex-smoker, current smoker), physical activity energy expenditure
(continuous in kj/kg/day), lipid-lowering medication (Yes, No), hormone replacement
therapy (Yes-women, No-women, Men), BMI (continuous in kg/m2). Model 2 included the
metabolites (continuous). Model 3 combined model 1 and model 2. Model 4 additionally
included educational level (low, medium, high), socioeconomic status based on occupa-
tion (low- technical/semi-routine and routine occupations; medium- lower managerial
/ intermediate occupations; high- professional/higher managerial occupations) and anti-
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Table 6.4 Predictors included in the models for the prediction of dairy consumption
Model Predictors
Discovery and validation of prediction models
Model 1 age, sex, test site, physical activity, smoking status, lipid-lowering medication, HRT, BMI
Model 2 Metabolites
Model 3 Model 1 + model 2
Model 4 Model 3 + educational level, occupational status, anti-hypertensive medications
Model 5 Model 3 + total energy intake, fruit, vegetables, cereals, red meat, processed meat, fish, margarine,
sweet snacks, SSBs, caffeinated coffee, tea, alcoholic beverages, dietary supplements
Predictive value of metabolite scores for dairy consumption in addition to C15:0, C17:0 and trans-16:1n-7
Model 1 age, sex, test site, physical activity, smoking status, lipid-lowering, HRT, BMI
Model 2 C15:0, C17:0, trans-16:1n-7 fatty acids
Model 3 Metabolite score
Model 4 Model 1 + model 2
Model 5 Model 1 + model 3
Model 6 Model 4 + total energy intake, fruit, vegetables, cereals, red meat, processed meat, fish, margarine,
sweet snacks, SSBs, caffeinated coffee, tea, alcoholic beverages, dietary supplements
Model 7 Model 1 + model 2 + model 3
Abbreviations: BMI: Body mass index; HRT: Hormone-replacement therapy; SSBs: Sugar-sweetened beverages
hypertensive medication (Yes, No). Model 5 was additionally adjusted for dietary variables
including total energy intake (kcal/day), dietary supplements (Yes, No) and intakes (g/day)
of fruit, vegetables, cereals, red meat, processed meat, fish, margarines, sweet snacks,
sugar-sweetened beverages, coffee, tea, alcoholic beverages and dairy products other than
the dairy outcome.
Metabolite scores were created from the sum of the metabolites weighted by the elastic
net coefficients. Apart from the scores with all the metabolites, we also created scores with
the top metabolites only, as the main contributors to dairy prediction and which are more
likely to be validated in an independent set without noise that the rest of the metabolites
might add. As top metabolites, we defined those that were above the mean+2*SD of the
regression coefficients. As per the TRIPOD guidelines, the same models were developed
also without any penalisation (Appendix 1 Tables A.21, A.24, A.27)[264].
The internal and external validation were performed by applying the discovery elastic
net coefficients as weights to create the metabolite scores in the internal and external
validation sets respectively and their inclusion in logistic prediction models (without
penalisation).
Assessment of the predictive value of the metabolite scores in addition to C15:0,
C17:0 and trans-16:1n-7
The subset used as the internal validation set in the previous analysis, was also used
to evaluate whether the metabolite scores have predictive value over the use of C15:0,
C17:0 and trans-16:1n-7, which have been described as candidate biomarkers of dairy
consumption. Logistic and linear regression models were developed without penalisation
with the Statsmodels v0.9.0 Python module. Seven different sets of predictors were
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used in the models (Table 6.4). We selected covariates which could potentially predict
dairy consumption or potentially confound the association between metabolites and dairy
consumption and also be relatively easily available in a clinical setting. Dietary factors
were included in secondary models, because the overall scope of this project was to
develop metabolite scores, which could be used independent of self-reported dietary data.
Model 1 included age, sex, test site, smoking status, physical activity energy expenditure,
lipid-lowering medication, hormone replacement therapy and BMI as described in the
previous analysis. Model 2 included C15:0, C17:0 and trans-16:1n-7. Model 3 included
the metabolite scores standardised. Model 4 was a combination of model 1 and model 2.
Model 5 was a combination of model 1 and model 3. Model 6 was model 4 additionally
adjusted for the same dietary variables as reported in the previous analysis. Model 7 was
the combination of model 1, model 2 and model 3. Metabolite scores including the top
metabolites only were used in secondary analyses. Further secondary analyses included
additional adjustment for C14:0 and additional adjustment of model 4 for educational level,
socioeconomic status and anti-hypertensive medication. Likelihood ratio tests were used
to statistically compare the different nested models (with or without the fatty acids and
with or without the metabolite scores).
Metrics for the evaluation of the prediction models
According to the TRIPOD guidelines, it is suggested to estimate and report primarily met-
rics for calibration or discrimination. Areas under the curve (AUC) were estimated (Scikit
Learn function: roc_auc_score) and the receiver operating characteristic (ROC) curves
(1-specificity against sensitivity) were produced for logistic prediction models (Scikit
Learn function: roc_curve). As metrics of the overall performance, R2 was calculated for
the linear models and the accuracy (Scikit Learn function:accuracy_score).




Descriptive characteristics of participants in the discovery, internal and external validation
sets are presented in (Table 6.5).
Participants in the discovery set were 46.8% women with mean (SD) age of 48.9 (7.4)
years.Almost half of the participants were of medium educational level and high socio-
economic status. Almost one third of them were current smokers with a mean (SD) BMI
of 26.9 (4.8) kg/m2. Distributions of socio-demographic, lifestyle and dietary variables
were similar between the discovery and internal validation sets.
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Participants in the diabetes case-cohort study nested within the EPIC Norfolk study
were older, of lower educational level and socio-economic status, less frequently smokers,
more frequently on anti-hypertensive medication and HRT and consumed more milk,
margarines, sweet snacks, tea and less yoghurt and red meat than participants in the
discovery and internal validation sets within the Fenland study.
6.10.2 Metabolite matching between the two cohorts
In total, we matched 82 metabolites. Exact matching was possible for 21 out of 22 amino
acids, 10 out of 12 biogenic amines and 15 out of 40 acylcarnitines, as shown in Table 6.6.
For the lipid compounds i.e. PCs, LPCs and SMs, the application of FIA-MS/MS did not
allow for differentiation of the fatty acids contained in these lipids based on number of
carbon atoms and their type of bond. For this reason, the lipids reported from the targeted
metabolomics platform are the sum of all the isobaric (same weight within a range of
±0.5 Da) and isomeric (same number of atoms, but different structure) compounds of
these lipids. Likewise, specific hexose sugars could not be identified, so their sum was
reported as hexose. On the other hand, the untargeted metabolomics platform identified
specific isobaric/isomeric compounds for some lipids, while for others, it identified sum
of compounds, but with a higher specificity than the targeted platform. Approximate
metabolite matching was performed based on the number of carbon atoms, the number of
double bonds and the molecular mass (also accounting for positive or negative ion mode).
After this process, approximate matching was possible for nine out of 14 LPCs, 17 out of
74 PCs, eight out of 11 SMs and hexose, that was matched with three sugars (Table 6.6).
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Table 6.5 Descriptive characteristics of socio-demographic, lifestyle and clinical factors in
the discovery and validation set of the Fenland study and the external validation set of the
EPIC Norfolk diabetes case cohort study*
Discovery set Internal validation set External validation set
Participants (N) 6,035 4,246 1,440
Socio-demographic factors
Age (years) 48.9 7.4 47.8 7.3 60.1 9.0
Sex (ref. Men) Women 46.8 45.5 48.9
Testsite (ref. Cambridge) † Ely 35.3 34.9
Wisbech 27.2 29.5
Educational level (ref. Low) ‡ § Medium 45.9 45.9 37.6
High 34.4 33.7 12.3
Socio-economic status (ref. Low) ‡ § Medium 19.7 19.5 16.0
High 53.8 53.2 42.1
Lifestyle factors
Smoking status (ref. Never) ‡ § Former smoker 53.9 54.2 43.0
Current smoker 33.7 32.3 12.7
Physical activity (ref. Inactive) † ‡ Energy expenditure
(kj/kg/d)




Energy intake (kcal/d) § 1,924 571 1,939 579 2023 578
BMI (kg/m2) ‡ § 26.9 4.8 26.8 4.7 27.6 4.5
Medications / Supplements
Lipid-lowering medication (ref. No) ‡ Yes 4.3 3.5 1.9
Anti-hypertensive medication (ref. No) ‡ Yes 7.2 7.2 23.6
Hormone replacement therapy (ref. No for women /
Men) ‡
Yes 2.9 2.8 16.0
Dietary supplements ‡ § Yes 41.0 42.4 54.2
Types of dairy products
Milk § Energy density 1.5 1 1.6 1.0 1.8 0.9
< 1 serving/d 38.8 37.8 21.5
≥2 serving/d 27.0 27.1 41.0
Yoghurt § < 1 serving/wk 35.6 36.6 53.5
≥1 serving/d 13.1 12.6 7.3
Cheese § < 1 serving/wk 27.9 28.0 24.8
≥1 serving/d 8.1 9.0 8.2
Butter § < 1 serving/wk 51.9 53.9 63.4
≥1 serving/d 17.8 18.3 19.4
Total dairy products § Energy density 3.0 1.4 3.0 1.4 3.1 1.4
< 1 servings/d 6.7 7.0 3.9
≥3 servings/d 39.1 39.4 43.8
Non-dairy dietary factors (g/d)
Fruits § 240.6 203.3 244.8 198.7 241.1 198.9
Vegetables § 258.1 143.2 253.4 135.5 233.1 120.3
Cereals § 169.3 100.6 169.2 96.4 154.4 85.5
Red meat § 74.2 46.7 72.9 48.4 64.3 46.0
Processed meat § 31.7 26.9 32.3 29.3 31.4 25.5
Fish § 42.9 33.4 43.2 35.4 37.2 25.5
Margarines § 7.5 10.0 7.8 10.5 17.2 16.7
Sweet snacks § 90.6 69.1 91.9 70.7 115.9 85.9
Sugar-sweetened beverages § 43.2 95.1 39.9 84.7 41.0 84.8
Coffee § 360.6 348.3 356.6 347.2 385.1 337.4
Tea § 485.7 371.2 492.3 373.2 636.2 370.0
Alcoholic beverages § 151.2 249.5 149.7 238.1 120.7 229.9
*The mean and SD is presented for continuous variables and column percentages are presented for categorical variables
†Testsite is not applicable in the EPIC Norfolk study. Physical activity was objectively assessed in the Fenland study and expressed as a continuous
variable for physical activity energy expenditure. Physical activity level was assessed with a questionnaire in the EPIC Norfolk study and categorised into
four categories.
‡Missing values for each variable were < 3% with total non-overlapping missing values of 4% across all variables in the discovery set and 6.4% in the
internal validation set




















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































6.10.3 Discovery of metabolites predicting dairy consumption
Parameters producing the best prediction in 3-fold cross-validation and used to fine-tune
the elastic net discovery models are presented in (Table 6.7). As described (section 6.9.5),
three metabolite sets were used for the development of dairy prediction models: the total
set of metabolites from the targeted metabolomics platform of the Fenland study (n=174),
the subset of the metabolites, which could be approximately matched with the metabolites
from the untargeted platform in the EPIC Norfolk study (main approach; n=82; Table 6.6)
and the subset of the overlapping metabolites with the addition of the OCSFAs (n=84).
Top metabolite signals from the main (metabolites, socio-demographic and lifestyle factors
excluding diet) logistic elastic net regression models for each approach and for each
dairy type are presented in Figure 6.3. Coefficients estimated in the logistic and linear
elastic net regression models and models without penalisation are presented in Appendix 1
(Tables A.19- A.27).
























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Fig. 6.3 Heatmaps of the top signals (>mean+2*SD of the absolute values of the elastic net
coefficients) from the discovery analysis with elastic net logistic regression models with
age, sex, test site, smoking status, physical activity, lipid lowering medication, hormone-
replacement therapy, body mass index and A) 174 metabolites or B) 82 metabolites
overlapping with the metabolites from the external validation set or C) 82 metabolites over-
lapping with the metabolites from the external validation set and the odd-chain saturated
fatty acids.
The metabolite, which contributed the most to prediction of most dairy types was
SM-OH C14:1 (Figure 6.3). In all the three analyses, SM C16:1 was the second top signal
in total and the top negative signal for total dairy products and for milk apart from the
analysis with the 82 overlapping metabolites, in which it was the third for milk. LPC a
C17:0 was one of the top metabolite signals positively predicting cheese, butter and total
dairy products in the analysis with the 174 metabolites (Figure 6.3A), and butter and total
dairy products in the analysis with the 82 metabolites (Figure 6.3B). Cis-OH-Pro was
the top (negative and in total) signal for yoghurt in the analysis with the 174 metabolites
(Figure 6.3A), but could not be matched with any metabolite from the untargeted platform
(Table 6.6). Instead, in the analysis with the 82 metabolites, trans-OH-Pro was the top
signal negatively predicting both yoghurt and cheese (Figure 6.3B).
When OCSFAs were added to the discovery analysis (Figure 6.3C), LPC a C17:0 was
one of the top metabolite signals for butter only. C15:0 was the second top signal for
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cheese and butter and the third top signal for total dairy products (positive associations),
whereas C17:0 was not identified as a top signal for any dairy type (Tables A.25, A.26).
6.10.4 Effect of adjusting for diet on discovery results
As mentioned, secondary models also included total energy intake and other dietary factors.
After adjustment for dietary factors, the ranking of some metabolites was not substantially
affected, whereas for others the difference was larger. The relevant results are shown in
Appendix 1 (Table A.32 when all 174 metabolites were included and Table A.33 when
only the 82 overlapping metabolites were included in the discovery). In both cases, SM-OH
C14:1, which came up as the top metabolite signal for most of dairy types did not change
ranking. The ranking of PC aa C18:1, which was one of the top signals for milk and
yoghurt in the set of 174 metabolites did not change much either (Table A.32). Cis-5-OH
Pro, which was the top metabolite signal for yoghurt in the set of 174 metabolites, dropped
by 14 positions after adjustment for diet (Table A.32). The same happened with trans-4-OH
Pro which was the second top signal for yoghurt and cheese (drop by 26 positions) in
the set of the 82 metabolites (Table A.33). Most of the metabolites for butter and total
dairy products did not change ranking in either set of metabolites. Specifically for total
dairy products, only SM C16:1 dropped by 161 positions and LPC a C18:0 dropped by 32
positions in both cases.
6.10.5 Internal validation
After fitting logistic regression models with the metabolite scores (total or top metabolites)
in the discovery and internal validation sets, the AUCs in the internal validation set were
lower than AUCs in the discovery set for all the models and for most of the dairy products
(Table A.28). Specifically, AUCs of the main models, which included the scores, and
socio-demographic and lifestyle (except for diet) factors, were lower by 0.01-0.02 points
and ranged from 0.68 for milk to 0.81 for total dairy products (Figure 6.4). Likewise for
linear prediction models of milk and total dairy products, in most cases R2 was lower by a
range of 0.01-0.04 in the internal validation set compared to the discovery set ranging from
0.06 for the total metabolite score of milk to 0.19 for the total metabolite score of total
dairy products (Table 6.8). R2 in the discovery and internal validation set were similar
when OCSFAs were added to the discovery models.
The largest predictive value of the metabolite score in addition to socio-demographic
and lifestyle variables in the internal validation set was observed for total dairy products
(AUC increased from 0.59 to 0.81; Figure 6.4E) and butter (AUC increased from 0.59 to
0.73; Figure 6.4D). For yoghurt the AUC increased from 0.67 to 0.7 (Figure 6.4B).
The loss of information due to the use of only the overlapping metabolites between
the targeted and the untargeted platforms did not influence the predictive ability of the
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Fig. 6.4 Receiver operating characteristic (ROC) curves and corresponding areas under the
curve (AUC) for prediction models of metabolite scores reflecting A) milk, B) yoghurt, C)
cheese, D) butter and E) total dairy consumption in the internal validation set (n=4,246)
using the 82 overlapping metabolites. Socio-demographic, lifestyle model: age, sex, test
site, smoking status, physical activity, lipid lowering medication, hormone-replacement
therapy and body mass index; Top metabolite scores include metabolites with coefficients
with absolute values >mean+2*SD
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Table 6.8 R2 of elastic net linear regression models of continuous dairy outcomes in the
internal validation set of the Fenland study
Discovery set Internal validation set
Dairy products Models N=6,035 N=4,246
Total milk Socio-demographic, lifestyle* 0.01 0.01
Metabolite score † 0.09 0.06
Top metabolite score ‡ 0.03 0.02
Socio-demographic, lifestyle, metabolite score* 0.10 0.06
Socio-demographic, lifestyle, top metabolite score* ‡ 0.04 0.03
Total dairy products Socio-demographic, lifestyle* 0.02 0.03
Metabolite score † 0.20 0.18
Top metabolite score ‡ 0.14 0.14
Socio-demographic, lifestyle, metabolite score* 0.21 0.19
Socio-demographic, lifestyle, top metabolite score* ‡ 0.15 0.16
*Socio-demographic and lifestyle factors include age, sex, test site, smoking status, physical activity, lipid lowering medication,
hormone-replacement therapy and body mass index
†Metabolite score created from the 82 metabolites overlapping with the metabolites from the external validation set
‡Top metabolite scores were derived from the top mean+2*SD of the absolute values of the elastic net coefficients from
the main models, which included age, sex, test site, smoking status, physical activity, lipid lowering medication, hormone-
replacement therapy, body mass index and the metabolites
models, as the AUCs for the models with the metabolite score, the socio-demographic and
the lifestyle factors in the internal validation set were similar to those derived from the
total set of 174 metabolites (Figure A.1).
6.10.6 External validation
As expected, AUCs in the external validation set were overall lower than those observed
in the internal validation set (Table 6.9). Among the metabolite scores derived from
the different approaches, the metabolite scores with the highest AUCs overall with also
the most significant contributions to the multivariable AUCs, were those derived from
the top signals when OCSFAs were also included in the models for milk (AUC=0.65,
p=0.005), butter (AUC=0.66, p=0.001) and total dairy products (AUC=0.77, p=0.001)
(Table 6.9). Although the contribution of the total and top metabolite scores for milk and
the top metabolite score for butter from the approach without OCSFAs were significant,
the increase in AUCs from the base model (socio-demographic and lifestyle factors) was
of small magnitude, by 0.01 point. For total dairy products, contribution to AUCs were
significant for all the approaches apart from the one corresponding to the total metabolite
score derived from the 82 overlapping metabolites.
Metabolite scores for yoghurt and cheese were not validated in the external validation
set with non-significant contribution to multivariable AUCs of 0.69 and 0.66 respectively
(p>0.05) when the 82 overlapping metabolites were used. The contribution of the metabo-
lite scores were not significant even when OCSFAs were included in the scores and
produced increases in AUCs up to 0.72 for yoghurt and 0.7 for cheese scores (Table 6.9).
Similar results were observed when the AUCs for all the models were estimated in the
OCSFA subsample of the external validation set (Table A.29).
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Table 6.9 Areas under the curve (AUC) for logistic regression models of the dairy outcomes
against the metabolite scores adjusted for socio-demographic and lifestyle factors* in the





Metabolite score † Metabolite score †
No Yes No Yes
Dairy outcome Metabolite set ‡ Number of
metabolites
N AUC AUC N AUC AUC p §
Milk overlapping ∥ 82 2,758 0.59 0.68 900 0.59 0.60 0.03
top signals from overlapping # 3 0.59 0.63 900 0.59 0.60 0.02
overlapping, OCSFAs 84 0.59 0.72 362 0.61 0.62 0.14
top signals from overlapping, OCSFAs** 2 0.59 0.66 362 0.61 0.65 0.005
Yoghurt overlapping ∥ 82 2,089 0.67 0.70 875 0.69 0.69 0.98
top signals from overlapping # 2 0.67 0.68 875 0.69 0.70 0.37
overlapping, OCSFAs 84 0.67 0.75 391 0.72 0.72 0.94
top signals from overlapping, OCSFAs** 5 0.67 0.68 391 0.72 0.72 0.98
Cheese overlapping ∥ 82 1,574 0.67 0.73 475 0.65 0.66 0.23
top signals from overlapping # 4 0.67 0.71 475 0.65 0.66 0.18
overlapping, OCSFAs 84 0.67 0.79 194 0.70 0.70 0.94
top signals from overlapping, OCSFAs** 3 0.67 0.72 194 0.70 0.70 0.36
Butter overlapping ∥ 82 3,066 0.59 0.73 1,193 0.61 0.62 0.10
top signals from overlapping # 5 0.59 0.69 1,193 0.61 0.62 0.03
overlapping, OCSFAs 84 0.59 0.76 515 0.62 0.64 0.05
top signals from overlapping, OCSFAs** 5 0.59 0.72 515 0.62 0.66 0.001
Total dairy products overlapping ∥ 82 1,969 0.59 0.81 687 0.59 0.64 0.07
top signals from overlapping # 4 0.59 0.78 687 0.59 0.68 0.003
overlapping, OCSFAs 84 0.59 0.84 282 0.61 0.74 0.01
top signals from overlapping, OCSFAs** 3 0.59 0.80 282 0.61 0.77 0.001
*Socio-demographic and lifestyle factors include age, sex, test site, smoking status, physical activity, lipid lowering medication, hormone-
replacement therapy and body mass index
†"Metabolite score-No" includes the socio-demographic and lifestyle factors; "Metabolite score-Yes" includes the socio-demographic and
lifestyle factors as well as the metabolite score
‡The metabolite set used in the discovery analysis to derive the metabolite scores
§p values of the coefficients of the metabolite score
∥Metabolites of the discovery (targeted) set approximately matched with metabolites from the external validation (untargeted) set
#Top signals defined as metabolites with absolute values of coefficients >mean+2*SD
**Top signals derived from the discovery models which included the overlapping metabolites and OCSFAs
Abbreviations: OCSFA: Odd-chain saturated fatty acid
6.10.7 Predictive value of the metabolite scores in addition to C15:0,
C17:0 and trans-16:1n-7
Table 6.10 shows the change in AUCs when we added fatty acids to the base model (No,
No -> No, Yes), the metabolite score (total or top) to the base model (No, No -> Yes,
No), fatty acids to the model with the metabolite score (Yes, No -> Yes, Yes) and the
metabolite score (total or top) to the model with fatty acids (No, Yes -> Yes, Yes). When
the metabolite score was added to the models with the fatty acids in the internal validation
set, socio-demographic and lifestyle factors, the AUC was increased by 0.02 for yoghurt
and cheese and 0.06 for milk and total dairy products. Lower increases in the AUCs were
observed when the three fatty acids were added to the models with the metabolite score,
socio-demographic and lifestyle factors, ranging from 0 for milk and total dairy products
to 0.01 for the other dairy types. Multivariable AUCs were higher by a range of 0.02 for
yoghurt and cheese to 0.05 for milk, when the top metabolite score was used in place of the
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total metabolite score. Results from the analyses including the total set of 174 metabolites
were similar (Table A.30). The likelihood ratio tests were highly significant apart from
the case where the three fatty acids were added to models with the metabolite score and
the socio-demographic and lifestyle factors, where the test was highly significant only for
butter (p=5.6 x 10-5; Table 6.11).
Overall, coefficients of the metabolite scores were highly significant both in the models
with and without the fatty acids (Table 6.12). In the models with the metabolite scores,
C15:0 was significant for milk and yoghurt only when the top metabolite score was
included, but for cheese, butter and total dairy products, it was significant both for the total
and the top metabolite scores (Table 6.12). In the same models, C17:0 was significant
only for total dairy products (continuous) when the top metabolite score was included,
while trans-16:1n-7 was significant for yoghurt (total and top metabolite score), butter
(top metabolite score) and total dairy products (binary; total and top metabolite score;
Table 6.12). These results were not replicated when the same analysis was performed in
the external validation set with no obvious additive value of the metabolite scores to dairy
prediction models including OCSFAs (Table A.31).
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Table 6.10 Areas under the curve statistics of the logistic models* with
or without the fatty acids C15:0, C17:0, trans-16:1n-7 and the metabo-
lite score (82 metabolites †) for total and types of dairy products in
the internal validation set of the Fenland study










Yes 0.68 0.68 Yes 0.63 0.64
Yoghurt Fatty acids Yoghurt Fatty acids





Yes 0.70 0.71 Yes 0.68 0.69
Cheese Fatty acids Cheese Fatty acids





Yes 0.73 0.74 Yes 0.71 0.73
Butter Fatty acids Butter Fatty acids





Yes 0.73 0.74 Yes 0.69 0.72
Total dairy products Fatty acids Total dairy products Fatty acids





Yes 0.81 0.81 Yes 0.78 0.80
*All models include age, sex, test site, smoking status, physical activity, lipid
lowering medication, hormone-replacement therapy and body mass index
†Metabolites approximately matched between the discovery (targeted) set and the
external validation (untargeted) set
‡The top metabolite score includes only the top metabolite signals defined as the
metabolites with absolute values of coefficients >mean+2*SD
























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































6.11.1 Summary of results
In this study, we developed metabolite scores for total and types of dairy products with
multivariable AUCs ranging from 0.72 for yoghurt to 0.83 for total dairy products in
the discovery set and from 0.68 for milk to 0.81 for total dairy products in the internal
validation set. We did not identify metabolites discriminating dairy types from each other,
but we consider the metabolite scores to specifically predict individual dairy types. The
metabolite SM-OH C14:1 was identified as top signal across different dairy types and
across different set of metabolites or analyses. SM C16:1 was one of the top signals
for milk and total dairy products across the different sets of metabolites, but adjustment
for other dietary factors affected its ranking substantially. LPC a C17:0 was one of the
top signals for cheese, butter and total dairy products (most consistently for butter). In
secondary analyses, C15:0 was one of the top signals for cheese, butter and total dairy
products when OCSFAs were added to the models, whereas C17:0 did not reach the top
signals for any dairy type.
In the external validation set, metabolite scores for milk, butter and total dairy products
contributed significantly to the prediction of dairy consumption. The contribution of scores
to yoghurt and cheese prediction models was not significant. The metabolite scores had
predictive value for dairy consumption in addition to the fatty acids for all the dairy types.
The fatty acids had predictive value in addition to the metabolite scores only for butter in
the internal validation set.
6.11.2 Findings in context of previous evidence
Metabolomic profiling is useful to identify potential novel biomarkers of dairy consumption
and potentially address the limitations of OCSFAs and trans-16:1n-7 as candidate dairy
biomarkers (section 6.4). In our study, we showed that metabolite scores for total and types
of dairy products had predictive value for dairy consumption in addition to OCSFAs and
trans-16:1n-7, while fatty acids had predictive value in addition to the metabolite scores
only for butter consumption. Of the dairy products, butter has the highest proportion of
saturated fat, so prediction of butter consumption with OCSFAs might be stronger than of
other dairy types. This was the case especially for C15:0, which was one of the top signals
for the prediction of butter consumption in the discovery analysis, which included OCSFAs.
On the contrary, C17:0 was not a top metabolite signal for any dairy type. Considering
that our method accounted for multicollinearity between metabolites and that C17:0 has
been proposed to be also produced endogenously by alternative pathways[208], it might be
assumed that failure to identify C17:0 as a top metabolite for dairy prediction was due to
the inclusion of other metabolites that were highly correlated with C17:0 and contributed
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more to the prediction of dairy consumption than C17:0. One of these metabolites might be
LPC a C17:0 as one of the top signals for cheese, total dairy products and more consistently
across different analytical methods for butter.
Concerning previous studies on the use of metabolomics for the discovery of potential
dairy biomarkers, the study by Pallister et al was the most comparable with our study
in terms of the biological sample (blood), the study design (cross-sectional), the dairy
products of interest (milk, butter, total dairy products) and the set of metabolites analysed
(Biocrates metabolite set)[261]. In this study, they also identified SM-OH C14:1 as one of
the top metabolites for milk, butter and total dairy products along with PC aa C28:1 for
butter and total dairy products in a UK population and they were able to replicate these
findings in an Estonian and a German population[261]. They did not report any results
for yoghurt or cheese consumption. The replication of the top signal for the part of the
analysis that was common between our study and the study by Pallister et al provides us
with an additional external validation of this part of our results.
Comparison of our results with results from other studies on discovery of dairy biomark-
ers with metabolomics is limited due to methodological differences including different bio-
logical samples (urine[253, 256–258, 260, 262], faeces[257]), application of H-NMR[254],
and use of a different set of blood metabolites[227, 229, 255, 259].
6.11.3 Biological interpretation
Interpretation of the top metabolite signals of dairy consumption depends on the discovery
set of metabolites used. The metabolites in this study included 21 amino acids, 12 biogenic
amines, 40 acylcarnitines, 88 PCs, 11 SMs and 1 hexose. Most of the metabolites we
identified as top signals for dairy prediction were lipids. When all the 174 metabolites
were included in the discovery analysis, the non-lipid top (as we defined them) metabolite
signals were interleucine for milk, cis-4-OH Pro and taurine for yoghurt and Trp for cheese.
Food composition information from the FooDB database (http://foodb.ca/) indicates that
these compounds are not specific to these dairy types. For example, taurine is included in
meat, fish, legumes among other foods (http://foodb.ca/compounds/FDB003191) and cis-4-
OH Pro is included in cheese, processed meat, garlic and several vegetables (http://foodb.
ca/compounds/FDB013511). We also observed the non-specificity of these metabolites
to dairy consumption in our data from the drop in the ranking of these metabolites after
adjustment for dietary factors.
Thus, the set of metabolites that we have used seems to reflect predominantly the fat in
dairy products. As expected, some of the top signals might not be specific to dairy types
such as SM C16:1, which was not a top metabolite after adjustment for dietary factors.
However, the top metabolite SM-OH C14:1 was more consistent across dairy products and
different analyses. This molecule represents the isobaric molecules of SM(d18:1/ 15:0)
and SM(d16:1/ 17:0), which contain OCSFAs. Information on these SMs from metabolite
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databases is limited. SMs and PCs as top signals for prediction of dairy consumption might
partly reflect the fat in the milk fat globule membrane and partly the free fat. It has been
reported that 60-70% of the polar lipids in milk i.e. phospholipids and SMs are located
in the milk fat globule membrane[34]. The majority of the phospholipids found are PCs
(35%), while SMs comprise 25% of the polar lipids of the membrane[34]. Thus, with
the metabolomics platform we used, we covered approximately 60% of these lipids. In
addition, with the inclusion of PCs and SMs we covered most of the saturated fat of the
membrane, as the majority of both lipid classes are saturated, while other lipid classes
of the membrane such as phophatidylinositols or phophatidyethanolamines are mainly
unsaturated[34].
Milk, yoghurt and cheese contain higher amounts of the milk fat globule membrane,
while butter contains lower amounts due to homogenisation[34]. However, considering the
complicated metabolic pathways and processing that the dairy lipid molecules go through
after their uptake in the organism, it is not possible to disentangle the association we
observed by identifying the specific origin of the blood lipids. For example, we observed
SM-OH C14:1 as the most consistent top signal, which contains the OCSFAs. It is not
possible with this observation alone to conclude the specific source molecules and the
extent that each of them contributes to blood SM-OH C14:1. Considering the different
forms, in which lipids are contained in dairy products (section 1.4), potential sources are
the uptake and processing of the free OCSFAs; the metabolism of dairy triglycerides; the
dairy SMs, which might be metabolised to produce free OCSFAs and then form SMs; dairy
phospholipids that contain these fatty acids or endogenous production of these fatty acids,
especially C17:0, from alternative pathways as previously described[233, 244, 245].
6.11.4 Strengths and limitations
The key strength of our study is the development of metabolite scores predictive of dairy
consumption instead of the single metabolite approach, thus increasing the probability
that the metabolite scores are more specific to dairy products, which have a complex food
matrix and share many nutrients with other foods[207]. While replication of results of
a nutritional metabolomics study in an independent study is not very common due to
the unavailability of resources and is identified as a limitation of such studies[288], we
were able not only to perform internal validation, but also external validation by using an
independent cohort despite some discrepancies due to the study design. We also applied
a machine learning method (elastic net regression), which was shown to be a flexible
and appropriate approach for our purpose leading to lower prediction errors as reported
from previous metabolomics studies[280], but has not previously been applied in other
nutritional metabolomics studies to our knowledge.
This study has also limitations. Although our primary aim was the prediction of dairy
consumption, it is also of interest to unravel the unconfounded and causal associations
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between dairy consumption and metabolites. The observational nature and the cross-
sectional design of our study imposed difficulties in identifying such associations, but
it would still be important to generate hypotheses to be examined in RCTs, which are
considered the gold standard. We have used a subjective method of dietary assessment
to investigate potential biomarkers of dairy consumption in order to use them for the
objective assessment of dairy consumption, which might introduce the measurement
errors in self-reported dietary assessment (section 6.1). In addition, following about a
decade of the use of metabolomics in nutrition, the need for studies which characterise
dose response relationships between dietary intake and biomarkers has been emphasised,
since lack of assessment of the dose response relationship is common in most nutritional
metabolomics studies[288]. However, since the availability of exploratory metabolomics
studies for the identification of potential blood biomarkers of dairy consumption is limited,
we consider our study informative for hypothesis generation for future assessment of the
dose-response relationship in feeding trials. Finally, the set of metabolites we used was
limited, missing proteins (only targeted amino acids) and lactose metabolites. Nevertheless,
with the metabolite scores we generated, we could approximate the associations between
an important part of the dairy lipid profile with part of the human lipid profile, which could
be an important predictor of cardio-metabolic disease.
6.11.5 Conclusion
To our knowledge, this is the first study to develop metabolite scores predictive of both
total and types of dairy consumption, assess their validity (internally and externally), and
show that such scores have predictive value for dairy consumption in addition to OCSFAs
and trans-16:1n-7 as candidate dairy biomarkers. External validation was successful for
milk, butter and total dairy products, but not for yoghurt and cheese. Thus, we were able to
create metabolite scores specific for discriminating between consumers and non-consumers
of milk, butter and total dairy products, but not yoghurt or cheese.
Future RCTs can further advance our findings and examine the hypotheses we gen-
erated. Studies with different sets of metabolites e.g. untargeted metabolomics and
metabolites related to gut microbiome, application of more machine learning methods
with high flexibility and prediction accuracy, but also the combination of metabolomics,
transcriptomics, epigenomics, and genomics could further contribute to the discovery of
biomarkers and a greater understanding of biological mechanisms[265]. Metabolomics
might be a useful tool for the discovery of novel nutritional biomarkers, which could po-
tentially elucidate metabolic pathways relating food consumption to disease. The novelty
of our study can contribute new evidence to the area of dairy biomarkers with the use of
metabolomics and constitute a useful approach for related future research.
Chapter 7
Biomarkers of dairy consumption: Part
II. Associations with type 2 diabetes
Summary
Background and aims: Meta-analyses of prospective cohort studies indicated heterogene-
ity in associations between different types of dairy products and type 2 diabetes (T2D)
risk. The majority of the studies use self-reported dairy consumption, with accompanying
measurement error. To improve precision in dietary assessment and hence improve epi-
demiological understanding of the links between dairy products and T2D, we aimed to
use objectively measured metabolite scores related with dairy consumption to investigate
associations with T2D risk.
Methods: We evaluated 1,440 participants of the diabetes case-cohort set nested within
the EPIC Norfolk study (641 T2D cases and 799 non-cases). Prentice-weighted Cox
proportional hazard models were used to investigate associations between standardised
metabolite scores generated in an independent cohort and T2D risk adjusting for socio-
demographic, lifestyle and clinical factors.
Results: During 16,360 person-years of follow-up, 641 T2D cases were identified.
Significant inverse associations with T2D risk were observed for the metabolite score for
milk, butter and total dairy products, which significantly predicted dairy consumption in
this cohort. For example, total metabolite scores for total dairy products, milk and butter
were associated with a 24% [HR=0.76 (0.69, 0.83)], 11% [HR=0.89 (0.82, 0.97)] and 43%
[HR=0.57 (0.52, 0.62)] lower risk of T2D in multivariable models (without adjustment
for BMI) respectively. Metabolite scores for yoghurt and cheese were not successfully
externally validated.
Conclusions: We demonstrated that metabolite scores, which could significantly
predict milk, butter and total dairy consumption, were associated with lower T2D risk.
Metabolite scores for yoghurt and cheese, which were not externally validated, were
associated with a higher or no risk. These findings indicate that our novel approach
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of the development of metabolite scores for the prediction of dairy consumption using
metabolomics is also a promising approach for the identification of objective markers of
dairy consumption, specific to individual dairy types and can open up possibilities for
understanding the pathways to disease aetiology. Further research is necessary for the
discovery of scores, which better predict certain types of dairy products such as yoghurt
and cheese, which are of great interest for their associations with cardio-metabolic disease.
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What is already known
• Different types of dairy products have been associated differently with type 2
diabetes (T2D) risk in meta-analyses of prospective cohort studies
• The majority of the studies on associations between dairy consumption and
T2D risk use self-reported methods of dietary assessment, which entail mea-
surement error
What this research adds
• Metabolite scores, which significantly predicted total dairy, milk and butter
consumption were significantly associated with a lower risk of T2D by 24%,
11% and 43% respectively in multivariable adjusted models.
• Metabolomics opens up the possibility for the elucidation of potential path-
ways linking dairy consumption to T2D risk.
Publication
Trichia E, Imamura F, Koulman A, Brage S, Griffin SJ, Langenberg C, Khaw KT, Ware-
ham NJ, Forouhi N G. Development and validation of dairy prediction models using
metabolomics in two UK cohort and the associations of derived metabolite scores with
type 2 diabetes risk (Manuscript under preparation)
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7.1 Previous evidence
Evidence from meta-analyses of prospective cohort studies indicates a heterogeneity
of associations between different types of dairy products and type 2 diabetes (T2D)
risk (Chapter 1). For example, no significant associations were reported between full-
fat milk[12, 18, 19, 21], cream[12], fermented[19] or high-fat[12, 16, 18, 19, 21] dairy
products and T2D risk. On the other hand, significantly inverse associations were con-
sistently reported overall between yoghurt[12, 16, 18, 19, 21] or butter[14] and T2D
risk. Finally, mixed associations were reported between milk (low-fat[12, 18, 19] or
total[12, 18, 19, 22]), cheese[12, 18, 19], or dairy products (low-fat[12, 16, 18, 19, 21] or
total[8, 12, 16, 18, 19, 21, 22] ) and T2D risk.
To a certain extent, this heterogeneity of associations might be attributed to true
variation due to different characteristics of different dairy types, which raises questions
about what contributed mainly to the observed associations with T2D and through which
pathways if causal effects were present. In addition to true variation, the heterogeneity of
associations might also be partly a result of differential measurement error from the self-
reported methods of dietary assessment. The use of nutritional biomarkers has the potential
to contribute towards a better understanding of the relevant pathways underpinning such
associations by reflecting specific sets of characteristics of dairy products, but also to
overcome the limitations of subjective methods of dietary assessment.
The fatty acids C15:0, C17:0 and trans-16:1n-7 are the candidate biomarkers of dairy
consumption proposed so far. By investigating associations of these fatty acids with T2D or
related endpoints, we may obtain a deeper insight into pathways linking dairy consumption
(specifically dairy fat in this case) to T2D. Results from individual prospective cohort
studies on the association of the three fatty acids with T2D risk were mixed[218, 221,
223, 226, 228, 232, 289–291] indicating inverse or null associations. The sources of this
heterogeneity of associations are not clear, but they are probably related to methodological
differences between the studies. Results of a pooling project among prospective cohort
studies within the Fatty Acids and Outcomes Research (FORCE) consortium, which used
a harmonised protocol, showed inverse associations per 10th to 90th percentile range
of C15:0 (n=16, RR=0.80, 95% CI:0.73, 0.87), C17:0 (n=13, RR=0.65, 95% CI:0.59,
0.72) and trans-16:1n-7 (n=8, RR=0.82, 95% CI: 0.70, 0.96) after adjustment of various
covariates including adiposity measures[292]. No study has reported an increase in risk
with consumption or circulating levels of these fatty acids. In summary, there is some
evidence indicating a decrease in risk of T2D with consumption or circulating levels of
odd-chain fatty acids (OCSFAs) and trans-16:1n-7, but due to the heterogeneity of results,
further investigation is needed. There is therefore an interest in the discovery and use of
more potential biomarkers of dairy consumption.
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7.2 Study aims
The primary aim of this study was to assess the associations of metabolite scores, which
were generated from metabolomics data and reflect consumption of different types of dairy
products, with T2D risk. A secondary aim of this study was to assess the associations of
metabolite scores generated from both metabolomics and OCSFAs, with T2D risk.
7.3 Methods
7.3.1 Study design and population
We evaluated 1,440 adults with available metabolomics profiles (641 incident T2D cases
and 799 non-cases, 16,360 person-years of follow-up) from the incident diabetes case-
cohort study nested within the EPIC Norfolk study, UK. This sample was derived after
exclusion of participants who were missing dietary data (n=44), men with energy intake
less than 800 kcal or more than 4,000 kcal or women with energy intake less than 500 kcal
or more than 3,500 kcal (n=37) and participants with more than 50% of the metabolites
missing (n=2). In a secondary analysis, where we generated metabolite scores using
OCSFAs in an independent cohort, participants with no fatty acid measurements were
further excluded (n=848) leaving 592 participants (356 incident T2D cases and 236 non-
cases). Details about the case-cohort study were reported in section 6.9.1 and details about
the EPIC Norfolk study were reported in section 5.3. An overview of the study design was
presented in Figure 6.2.
7.3.2 Development of metabolite scores and metabolomics analyses
Scores to predict consumption of each dairy product were based on algorithms developed
in the Fenland study. Metabolomics profiling and validation of the metabolite scores in
the EPIC Norfolk study were presented in detail in sections 6.9.2 and 6.9.5 respectively.
Briefly, to assess success of external validation we used the Area under the curve (AUC)
statistics and the significance of the contribution of metabolite scores to logistic prediction
models for dairy consumption. Metabolite scores for yoghurt and cheese failed to validate
externally as shown in Table 6.9, which means that they do not reflect consumption of
these dairy foods in the EPIC Norfolk diabetes case-cohort study.
7.3.3 Diabetes case ascertainment
Cases of incident T2D were ascertained until 31 July 2006. Two sources of ascertainment
were used combining information from self-report and participant health records. Within
the EPIC Norfolk cohort, information was collected prospectively on incident self-reported
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diagnosed diabetes or use of diabetes medications. Data were also collected from record
linkage with general practices or local hospital records, hospital admissions, and diabetes
codes from the Office of National Statistics mortality data. To minimise misclassification
of case status, only verified cases were included. Thus, self-report of physician diagnosis
alone was not considered as a confirmed case unless verified by another source internal
(e.g. medicine use) or external (record linkage) to the study.
7.3.4 Statistical analysis
The primary analysis included associations of metabolite scores generated from the 82
overlapping metabolites between the Fenland study and the case-cohort study nested within
the EPIC Norfolk study, with T2D risk. The secondary analysis included associations of
metabolite scores generated from the 82 metabolites and the OCSFAs with T2D risk in the
subset of participants with OCSFA measurements. Metabolite scores were standardised
by dividing them by their standard deviation. Top metabolite scores refer to the scores,
which included only the top metabolite signals with absolute coefficients higher than
mean+2*SD.
We used Prentice-weighted Cox proportional hazards models to estimate hazard ratios
(HRs) and their robust standard errors for the associations between the standardised
metabolite scores and T2D risk. Associations were adjusted for previously established
potential confounders. Specifically, model 1 included age, sex, educational level, socio-
economic status and family history of T2D. Model 2 was additionally adjusted for smoking,
physical activity, lipid-lowering medication, anti-hypertensive medication and hormone-
replacement therapy (HRT). Model 3 was additionally adjusted for total energy intake and
dietary factors and model 4 additionally included body mass index (BMI). The proportional-
hazards assumption was tested based on Schoenfeld residuals.
7.4 Results
7.4.1 Descriptive characteristics
Descriptive characteristics of cases and non-cases are shown in Table 7.1. On average,
cases were three years older than non-cases, included 16.4% more women, had a lower
educational level and socio-economic status, were more frequently former smokers than
non-smokers, were less active, had higher BMI, and were more frequently on lipid-lowering
and anti-hypertensive medication. At baseline, future T2D case participants were also
more frequently non-consumers of yoghurt and consumed more processed meat, sugar
sweetened beverages and alcoholic beverages than non-cases.
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Table 7.1 Descriptive characteristics of socio-demographic, lifestyle, clinical and dietary
factors in the EPIC Norfolk diabetes case cohort study*
Total T2D cases Non-cases
Participants (N) 1,440 641 799
Socio-demographic factors
Age (years) 60.1 9.0 61.8 8.2 58.8 9.4
Sex Women 48.9 58.0 41.6
Educational level (ref. Low) Medium 37.6 34.9 39.8
High 12.3 10.1 14
Socio-economic status (ref. Low) Medium 16.0 13.4 18.0
High 42.1 39.3 44.3
Lifestyle factors
Smoking status (ref. Never) Former smoker 43.0 48.8 38.3
Current smoker 12.7 12.0 13.3
Physical activity (ref. Inactive) Moderately inac-
tive
26.9 24.2 29.2
Moderately active 21.9 18.7 24.5
Active 16.7 13.9 19.0
Energy intake (kcal/d) 2,023 578 2,035 608 2,013 554
BMI (kg/m2) 27.6 4.5 29.6 4.6 26.0 3.6
Medications / Supplements
Lipid-lowering medication Yes 1.9 2.7 1.4
Anti-hypertensive medication Yes 23.6 34.2 15.1
Hormone replacement therapy Yes 16.0 11.9 19.4
Dietary supplements † Yes 54.2 58.7 50.6
Types of dairy products
Milk Energy density † 1.8 0.9 1.8 0.9 1.8 1.0
< 1 serving/d 21.5 20.4 22.4
≥ 2 serving/d 41.0 41.5 40.6
Yoghurt < 1 serving/wk 53.5 59.4 48.7
≥ 1 serving/d 7.3 6.1 8.3
Cheese < 1 serving/wk 24.8 27.9 22.3
≥ 1 serving/d 8.2 7.5 8.8
Butter < 1 serving/wk 63.4 65.2 62.0
≥ 1 serving/d 19.4 20.6 18.5
Total dairy products Energy density † 3.1 1.4 3.1 1.4 3.1 1.4
< 1 servings/d 3.9 3.9 3.9
≥ 3 servings/d 43.8 43.1 44.4
Non-dairy dietary factors (g/d)
Fruits 241.1 198.9 231.1 198.0 249.2 199.5
Vegetables 233.1 120.3 224.2 121.8 240.2 118.6
Cereals 154.4 85.5 151.7 89.3 156.7 82.3
Red meat 64.3 46.0 65.1 45.7 63.6 46.2
Processed meat 31.4 25.5 34.5 27.0 28.9 24.0
Fish 37.2 25.5 36.0 25.4 38.1 25.6
Margarines 17.2 16.7 18.1 18.2 16.5 15.4
Sweet snacks 115.9 85.9 113.9 86.3 117.5 85.6
Sugar-sweetened beverages 41.0 84.8 49.5 96.8 34.1 73.2
Coffee 385.1 337.4 364.9 317.5 401.4 351.9
Tea 636.2 370.0 630.0 373.6 641.2 367.3
Alcoholic beverages 120.7 229.9 134.6 257.2 109.5 205.0
*The mean and SD are presented for continuous variables and column percentages are presented
for categorical variables. Missing values for each variable were < 2% with total non-overlapping
missing values of 3.8% across all variables
†Energy from milk or total dairy products in 2,000 kcal of total energy intake /day
Abbreviations: T2D: type 2 diabetes
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7.4.2 Associations of metabolite scores with type 2 diabetes risk
HRs from the Cox proportional hazard models and their 95% CIs for associations of
total and top (Table 7.2) metabolite scores and T2D risk are presented separately for the
dairy types which showed evidence of external validity (milk, butter, total dairy products;
Tables 7.3, 7.4) and for those which did not (yoghurt, cheese; Tables 7.5, 7.6).
Primary results: Total and top metabolite scores without odd-chain fatty acids
The metabolite score for the binary variable of milk consumption was inversely associated
with T2D in multivariable models without adjustment for BMI [HR=0.89 (95% CI: 0.82,
0.97) per 1 SD of the total metabolite score and HR=0.77 (0.70, 0.83) per 1 SD of the top
metabolite score, Table 7.3]. Results for the metabolite scores of the continuous variable
of milk were similar, but stronger [HR=0.78 (0.72, 0.85) per 1 SD of the total metabolite
score and HR=0.75 (0.69, 0.82) per 1 SD of the top metabolite score].
The top metabolite score for butter was associated with a significant lower risk of
T2D by 28% per 1 SD of the metabolite score [HR=0.72 (0.66, 0.78)]. Although the
total metabolite score did not significantly predict butter consumption, it also showed a
significant inverse association with T2D risk.
Metabolite scores for total dairy consumption (binary and continuous variables) were
overall significantly inversely associated with T2D risk. For the scores reflecting binary
consumption, 1 SD of the top metabolite score, which significantly predicted total dairy
consumption was associated with 26% lower T2D risk [HR=0.74 (0.68, 0.80)]. Simi-
lar associations were observed for the scores of the continuous variable of total dairy
consumption.
After adjustment for BMI, all associations were attenuated, but were still significant
apart from the association between the total metabolite score for the binary variable of
milk consumption and T2D risk.
Associations for metabolite scores reflecting yoghurt and cheese consumption were
either positive or null (Table 7.4).
Secondary results: Total and top metabolite scores including odd-chain saturated
fatty acids
After inclusion of OCSFAs in the discovery analysis for the metabolite scores, results
for the scores, which significantly predicted dairy consumption were similar with results
without the OCSFAs (Table 7.5). One SD of the total and top metabolite scores for the
binary variable of milk was associated with 27% and 26% lower risk of T2D respectively
[HR=0.73 (0.65, 0.82) and 0.74 (0.66, 0.83)] in multivariable models without adjustment
for BMI. Results for the metabolite scores of the continuous variable of milk were similar.
Metabolite scores for butter were associated with 24% lower T2D risk per 1 SD of the
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top score [0.76 (0.68, 0.86)]. Metabolite scores for the binary variable of total dairy
consumption were associated with a 25% T2D risk reduction per 1 SD of the total score
[HR=0.75 (0.66, 0.84)] and 20% risk reduction per 1 SD of the top score [HR=0.80 (0.71,
0.89)]. Similar associations were observed for the scores reflecting the continuous variable
of total dairy consumption.
After adjustment for BMI associations were attenuated, but still significant.
Associations for metabolite scores reflecting yoghurt and cheese consumption were
either positive or null (Table 7.6)
































































































































































































































































































































































































































































































































































































































































































































































































































































































Table 7.3 Hazard ratios of type 2 diabetes per 1 SD of metabolite scores significantly
predicting dairy consumption in the incident diabetes case-cohort set nested within the EPIC
Norfolk study
Model HR 95% CI p
Total metabolite scores*
Milk (binary) score Socio-demographic + family history of T2D † 0.86 0.79, 0.93 < 0.001
+Smoking, physical activity, medications ‡ 0.88 0.81, 0.95 0.002
+ Diet § 0.89 0.82, 0.97 0.009
+ BMI 0.95 0.87, 1.04 0.27
Milk (continuous-energy density) score Socio-demographic + family history of T2D † 0.76 0.70, 0.82 < 0.001
+Smoking, physical activity, medications ‡ 0.78 0.72, 0.84 < 0.001
+ Diet § 0.78 0.72, 0.85 < 0.001
+ BMI 0.86 0.78, 0.94 0.001
Butter score Socio-demographic + family history of T2D † 0.56 0.52, 0.60 < 0.001
+Smoking, physical activity, medications ‡ 0.58 0.53, 0.62 < 0.001
+ Diet § 0.57 0.52, 0.62 < 0.001
+ BMI 0.62 0.57, 0.68 < 0.001
Total dairy products (binary) score Socio-demographic + family history of T2D † 0.74 0.69, 0.80 < 0.001
+Smoking, physical activity, medications ‡ 0.76 0.71, 0.83 < 0.001
+ Diet § 0.76 0.69, 0.83 < 0.001
+ BMI 0.84 0.77, 0.92 < 0.001
Total dairy products (continuous-energy density) score Socio-demographic + family history of T2D † 0.71 0.66, 0.77 < 0.001
+Smoking, physical activity, medications ‡ 0.73 0.68, 0.79 < 0.001
+ Diet § 0.72 0.66, 0.79 < 0.001
+ BMI 0.81 0.74, 0.89 < 0.001
Top metabolite scores* ∥
Milk (binary) score Socio-demographic + family history of T2D † 0.75 0.70, 0.81 < 0.001
+Smoking, physical activity, medications ‡ 0.77 0.71, 0.83 < 0.001
+ Diet § 0.77 0.70, 0.83 < 0.001
+ BMI 0.83 0.76, 0.91 < 0.001
Milk (continuous-energy density) score Socio-demographic + family history of T2D † 0.74 0.68, 0.79 < 0.001
+Smoking, physical activity, medications ‡ 0.75 0.70, 0.81 < 0.001
+ Diet § 0.75 0.69, 0.82 < 0.001
+ BMI 0.83 0.76, 0.90 < 0.001
Butter score Socio-demographic + family history of T2D † 0.69 0.64, 0.75 < 0.001
+Smoking, physical activity, medications ‡ 0.71 0.66, 0.77 < 0.001
+ Diet § 0.72 0.66, 0.78 < 0.001
+ BMI 0.77 0.70, 0.84 < 0.001
Total dairy products (binary) score Socio-demographic + family history of T2D † 0.72 0.67, 0.78 < 0.001
+Smoking, physical activity, medications ‡ 0.74 0.68, 0.80 < 0.001
+ Diet § 0.74 0.68, 0.80 < 0.001
+ BMI 0.83 0.76, 0.90 < 0.001
Total dairy products (continuous-energy density) score Socio-demographic + family history of T2D † 0.70 0.65, 0.76 < 0.001
+Smoking, physical activity, medications ‡ 0.72 0.66, 0.78 < 0.001
+ Diet § 0.71 0.65, 0.78 < 0.001
+ BMI 0.80 0.73, 0.87 < 0.001
*Metabolite scores generated from the total sample of the incident diabetes case-cohort study (N=1,440) with 641 incident diabetes
cases during 16,30 person-years of follow-up
†Models adjusted for age (continuous in years), sex, educational level (3 categories: low, medium, high), socio-economic status (3
categories: low, medium, high) and family history of T2D (2 categories: Yes, No)
‡Models additionally adjusted for smoking (3 categories: never, former, current smoker), physical activity (4 categories: inactive,
moderately inactive, moderately active, active), lipid-lowering medication (2 categories: yes, no), anti-hypertensive medication (2
categories: yes, no), hormone-replacement therapy (3 categories: yes, no, men)
§Models additionally adjusted for total energy intake (continuous in kcal/day), dietary supplement use (2 categories: yes, no),
consumption (g/day) of fruit, vegetables, total cereals, red meat, processed meat, fish, margarine, sweet snacks, sugar-sweetened
beverages, coffee, tea, alcoholic beverages
∥Top metabolites are defined as the metabolites with coefficients above mean+2*SD. The top metabolite scores for each dairy type are
listed in Table 7.2
Abbreviations: BMI: Body mass index; CI: Confidence interval; HR: Hormone-replacement therapy; T2D: Type 2 diabetes
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Table 7.4 Hazard ratios of type 2 diabetes per 1 SD of metabolite scores not significantly
predicting dairy consumption in the incident diabetes case-cohort set nested within the EPIC
Norfolk study
Model HR 95% CI p
Total metabolite scores*
Yoghurt score Socio-demographic + family history of T2D † 1.29 1.19, 1.40 < 0.001
+Smoking, physical activity, medications ‡ 1.32 1.22, 1.43 < 0.001
+ Diet § 1.32 1.22, 1.43 < 0.001
+ BMI 1.30 1.19, 1.41 < 0.001
Cheese score Socio-demographic + family history of T2D † 1.08 0.99, 1.17 0.068
+Smoking, physical activity, medications ‡ 1.11 1.02, 1.20 0.012
+ Diet § 1.13 1.04, 1.23 0.004
+ BMI 1.11 1.02, 1.21 0.014
Top metabolite scores* ∥
Yoghurt score Socio-demographic + family history of T2D † 0.94 0.87, 1.02 0.146
+Smoking, physical activity, medications ‡ 0.98 0.90, 1.06 0.556
+ Diet § 1.00 0.91, 1.09 0.915
+ BMI 1.04 0.96, 1.14 0.341
Cheese score Socio-demographic + family history of T2D † 0.87 0.80, 0.94 < 0.001
+Smoking, physical activity, medications ‡ 0.91 0.84, 0.99 0.024
+ Diet § 0.93 0.86, 1.02 0.121
+ BMI 1.01 0.93, 1.10 0.832
*Metabolite scores generated from the total sample of the incident diabetes case-cohort study (N=1,440) with
641 incident diabetes cases during 16,30 person-years of follow-up
†Models adjusted for age (continuous in years), sex, educational level (3 categories: low, medium, high),
socio-economic status (3 categories: low, medium, high) and family history of T2D (2 categories: Yes, No)
‡Models additionally adjusted for smoking (3 categories: never, former, current smoker), physical activity (4
categories: inactive, moderately inactive, moderately active, active), lipid-lowering medication (2 categories:
yes, no), anti-hypertensive medication (2 categories: yes, no), hormone-replacement therapy (3 categories: yes,
no, men)
§Models additionally adjusted for total energy intake (continuous in kcal/day), dietary supplement use (2
categories: yes, no), consumption (g/day) of fruit, vegetables, total cereals, red meat, processed meat, fish,
margarine, sweet snacks, sugar-sweetened beverages, coffee, tea, alcoholic beverages
∥Top metabolites are defined as the metabolites with coefficients above mean+2*SD. The top metabolite scores
for each dairy type are listed in Table 7.2
Abbreviations: BMI: Body mass index; CI: Confidence interval; HR: Hormone-replacement therapy; T2D:
Type 2 diabetes
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Table 7.5 Hazard ratios of type 2 diabetes per 1 SD of metabolite scores significantly predicting
dairy consumption in the OCSFA subset of the incident diabetes case-cohort set nested within
the EPIC Norfolk study
Model HR 95% CI p
Total metabolite scores *
Milk (binary) score Socio-demographic + family history of T2D † 0.69 0.62, 0.77 < 0.001
+Smoking, physical activity, medications ‡ 0.73 0.65, 0.82 < 0.001
+ Diet § 0.73 0.65, 0.83 < 0.001
+ BMI 0.79 0.70, 0.90 < 0.001
Milk (continuous-energy density) score Socio-demographic + family history of T2D † 0.68 0.62, 0.76 < 0.001
+Smoking, physical activity, medications ‡ 0.71 0.64, 0.79 < 0.001
+ Diet § 0.70 0.62, 0.78 < 0.001
+ BMI 0.75 0.67, 0.85 < 0.001
Butter score Socio-demographic + family history of T2D † 0.58 0.52, 0.65 < 0.001
+Smoking, physical activity, medications ‡ 0.60 0.53, 0.67 < 0.001
+ Diet § 0.58 0.50, 0.66 < 0.001
+ BMI 0.64 0.56, 0.73 < 0.001
Total dairy products (binary) score Socio-demographic + family history of T2D † 0.74 0.66, 0.82 < 0.001
+Smoking, physical activity, medications ‡ 0.77 0.69, 0.86 < 0.001
+ Diet § 0.75 0.66, 0.84 < 0.001
+ BMI 0.81 0.72, 0.92 0.001
Total dairy products (continuous-energy density) score Socio-demographic + family history of T2D † 0.73 0.66, 0.81 < 0.001
+Smoking, physical activity, medications ‡ 0.76 0.69, 0.85 < 0.001
+ Diet § 0.75 0.67, 0.84 < 0.001
+ BMI 0.81 0.72, 0.91 0.001
Top metabolite scores * ∥
Milk (binary) score Socio-demographic + family history of T2D † 0.73 0.66, 0.81 < 0.001
+Smoking, physical activity, medications ‡ 0.76 0.69, 0.84 < 0.001
+ Diet § 0.74 0.66, 0.83 < 0.001
+ BMI 0.79 0.71, 0.89 < 0.001
Milk (continuous-energy density) score Socio-demographic + family history of T2D † 0.77 0.69, 0.85 < 0.001
+Smoking, physical activity, medications ‡ 0.79 0.71, 0.88 < 0.001
+ Diet § 0.77 0.69, 0.87 < 0.001
+ BMI 0.81 0.72, 0.91 < 0.001
Butter score Socio-demographic + family history of T2D † 0.75 0.68, 0.83 < 0.001
+Smoking, physical activity, medications ‡ 0.77 0.70, 0.86 < 0.001
+ Diet § 0.76 0.68, 0.86 < 0.001
+ BMI 0.81 0.72, 0.91 0.001
Total dairy products (binary) score Socio-demographic + family history of T2D † 0.78 0.71, 0.87 < 0.001
+Smoking, physical activity, medications ‡ 0.81 0.73, 0.90 < 0.001
+ Diet § 0.80 0.71, 0.89 < 0.001
+ BMI 0.85 0.76, 0.95 0.005
Total dairy products (continuous-energy density) score Socio-demographic + family history of T2D † 0.78 0.71, 0.86 < 0.001
+Smoking, physical activity, medications ‡ 0.81 0.73, 0.90 < 0.001
+ Diet § 0.79 0.71, 0.89 < 0.001
+ BMI 0.85 0.75, 0.95 0.004
*Metabolite scores generated from the subset of the case-cohort study with available measurements of OCSFAs including 592
participants, 356 cases and 5,569 person-years of follow-up
†Models adjusted for age (continuous in years), sex, educational level (3 categories: low, medium, high), socio-economic status (3
categories: low, medium, high) and family history of T2D (2 categories: Yes, No)
‡Models additionally adjusted for smoking (3 categories: never, former, current smoker), physical activity (4 categories: inactive,
moderately inactive, moderately active, active), lipid-lowering medication (2 categories: yes, no), anti-hypertensive medication (2
categories: yes, no), hormone-replacement therapy (3 categories: yes, no, men)
§Models additionally adjusted for total energy intake (continuous in kcal/day), dietary supplement use (2 categories: yes, no),
consumption (g/day) of fruit, vegetables, total cereals, red meat, processed meat, fish, margarine, sweet snacks, sugar-sweetened
beverages, coffee, tea, alcoholic beverages
∥Top metabolites are defined as the metabolites with coefficients above mean+2*SD. The top metabolite scores for each dairy type are
listed in Table 7.2
Abbreviations: BMI: Body mass index; CI: Confidence interval; HR: Hormone-replacement therapy; OCSFA: Odd-chain fatty acid;
T2D: Type 2 diabetes
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Table 7.6 Hazard ratios of type 2 diabetes per 1 SD of metabolite scores not significantly
predicting dairy consumption in the OCSFA subset of the incident diabetes case-cohort
set nested within the EPIC Norfolk study
Model HR 95% CI p
Total metabolite scores *
Yoghurt score Socio-demographic + family history of T2D † 1.37 1.23, 1.52 < 0.001
+Smoking, physical activity, medications ‡ 1.35 1.21, 1.50 < 0.001
+ Diet § 1.35 1.21, 1.51 < 0.001
+ BMI 1.27 1.14, 1.43 < 0.001
Cheese score Socio-demographic + family history of T2D † 0.95 0.85, 1.06 0.354
+Smoking, physical activity, medications ‡ 1.03 0.92, 1.16 0.59
+ Diet § 1.02 0.91, 1.14 0.778
+ BMI 1.10 0.98, 1.24 0.112
Top metabolite scores * ∥
Yoghurt score Socio-demographic + family history of T2D † 1.22 1.10, 1.35 < 0.001
+Smoking, physical activity, medications ‡ 1.19 1.07, 1.32 0.001
+ Diet § 1.18 1.06, 1.32 0.004
+ BMI 1.11 0.99, 1.24 0.071
Cheese score Socio-demographic + family history of T2D † 0.92 0.83, 1.03 0.16
+Smoking, physical activity, medications ‡ 0.99 0.89, 1.11 0.866
+ Diet § 0.99 0.89, 1.11 0.927
+ BMI 1.03 0.92, 1.16 0.555
*Metabolite scores generated from the subset of the case-cohort study with available measurements of OCSFAs
including 592 participants, 356 cases and 5,569 person-years of follow-up
†Models adjusted for age (continuous in years), sex, educational level (3 categories: low, medium, high),
socio-economic status (3 categories: low, medium, high) and family history of T2D (2 categories: Yes, No)
‡Models additionally adjusted for smoking (3 categories: never, former, current smoker), physical activity (4
categories: inactive, moderately inactive, moderately active, active), lipid-lowering medication (2 categories:
yes, no), anti-hypertensive medication (2 categories: yes, no), hormone-replacement therapy (3 categories: yes,
no, men)
§Models additionally adjusted for total energy intake (continuous in kcal/day), dietary supplement use (2
categories: yes, no), consumption (g/day) of fruit, vegetables, total cereals, red meat, processed meat, fish,
margarine, sweet snacks, sugar-sweetened beverages, coffee, tea, alcoholic beverages
∥Top metabolites are defined as the metabolites with coefficients above mean+2*SD. The top metabolite scores
for each dairy type are listed in Table 7.2
Abbreviations: BMI: Body mass index; CI: Confidence interval; HR: Hormone-replacement therapy; OCSFA:
Odd-chain fatty acid; T2D: Type 2 diabetes
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7.5 Discussion
7.5.1 Summary of results and overall interpretation
Metabolite scores, which significantly predicted milk, butter and total dairy consumption
were associated with a lower risk of T2D. In contrast, metabolite scores, which predicted
yoghurt and cheese in the Fenland study, but not in the EPIC Norfolk study, were associated
with either a higher risk or no risk of T2D.
These associations might be indicative of related metabolic pathways linking dairy
consumption to the risk of T2D, but the exact interpretation is challenging. The scores
did not completely reflect dairy consumption, but only specific aspects of them, which
are limited to the set of metabolites that we used. Thus, interpretation of these findings
should be done in combination with the results from the external validation. An example of
such interpretation for total dairy products is that with an AUC of 0.68 from multivariable
prediction models and a significant contribution of the metabolite score to this prediction,
an HR of 0.83 can be interpreted as "a decrease in the risk of T2D by 17% per 1 SD of the
metabolite score, which was associated with a 68% probability of reflecting consumers of
total dairy products after accounting for socio-demographic and lifestyle parameters".
7.5.2 Findings in the context of previous evidence
Distinct from studies on associations between OCSFAs and T2D risk (section 7.1), which
reported null or inverse associations, some previous studies explored metabolomic profiles
discriminating people by diabetes status for the prediction of T2D. These studies appraised
metabolites in the context of T2D prediction and not in relation to dairy consumption.
SM-OH C14:1 identified as one of the top metabolites predicting any of the dairy
types we examined, was inversely associated with prevalent T2D in a Korean[293] and a
German population[294] and with prevalent impaired glucose tolerance status in a German
population[294].
LPC C17:0, which was one of the top signals for butter and total dairy consumption
in our study, was associated with a lower risk of T2D in a Swedish nested case-control
study[295], with a lower prevalence of T2D and impaired glucose tolerance in a German
cross-sectional study[294] and with lower levels of 2-hour glucose in a cross-sectional
Korean study[293]. LPC C17:0 contains C17:0, which was previously associated with
lower T2D incidence[228, 292].
PC ae C34:1, another top signal for butter consumption, was associated with lower
levels of 2-hour glucose in a cross-sectional Korean study[293].
SM C16:1, a top signal for milk and total dairy consumption, but not after adjustment
for other dietary factors, was associated with a lower risk of T2D[296], lower prevalence of
T2D[294, 297] and impaired glucose tolerance[294] and lower 2-hour glucose levels[293].
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However, this metabolite was inversely associated with dairy consumption, but due to the
attenuation of the signal after adjustment for other dietary factors, this metabolite might
have not contributed much to the association between the metabolite scores and T2D risk
after adjustment for dietary factors.
Overall, the inverse associations of metabolite scores for milk, butter and total dairy
products with T2D risk that we reported, are supported by previous evidence on associations
between metabolites that contributed the most to our scores and T2D risk or related
endpoints. These associations are also in accordance with associations between dairy
consumption and T2D risk as reported in meta-analyses of prospective cohort studies
for butter[14] and total dairy products[8, 12, 18, 19, 21, 22]. Most of the meta-analyses
on milk reported null associations[12, 18, 19], which might mean that sets of biological
pathways other than the potential pathway related to our results might differentially link
milk to T2D.
7.5.3 Interpretation and potential mechanisms
The interpretation of the observed inverse associations between metabolite scores predictive
of milk, butter and total dairy consumption and T2D risk is complex and should be formed
with caution. The extent to which these associations reflect the association between
self-reported dairy consumption and T2D is limited to the characteristics of the dairy
food matrix that our scores and the metabolites we used reflect. We considered potential
biological mechanisms based on the metabolites most significantly associated with one
or more types of dairy consumption. The complexity of the interpretation can be partly
reduced if we focus on the associations between the top metabolite signals and T2D risk,
as also reported from previous studies, assuming that these metabolites contributed the
most to the overall observed associations. Most top signals were PCs and SMs.
The SMs that we identified as top signals i.e. SM-OH C14:1, SM C16:1, were
associated also in other studies with a lower T2D risk. It might be helpful to consider the
fatty acids that these SMs contain, as they represent isomeric and isobaric compounds that
contain the OCSFAs C15:0 and C17:0 or the even-chain fatty acids C16:0 and C18:0. The
lipids, which were positively associated with dairy consumption mainly included OCSFAs
(LPC a C17:0) or consisted of isobaric or isomeric compounds, which included OCSFAs
(SM d16:1/17:0 and SM d18:1/15:0 for SM-OH C14:1; PC 15:0_18:1 and PC 16:1_17:0
for PC ae C34:1). The metabolites inversely associated with dairy consumption (SM
C16:1, LPC a C18:0) included mainly even-chain fatty acids. Since usually the lipids are
measured in relative amounts, it is difficult to conclude whether the associations observed
for a certain fatty acid can be attributed to that particular fatty acid or reflect its competitive
relation with other fatty acids, that have an opposite effect. For example, C16:0 and C18:0
were associated with higher insulin resistance[298, 299] and inflammation[300, 301]. In
addition to uptake from the diet, C16:0 and C18:0 are produced endogenously from de-novo
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lipogenesis, which has been associated with hepatic steatosis and insulin resistance[302].
OCSFAs cannot be produced through this pathway, but there is evidence that they can be
produced through alternative pathways from C16:0 and C18:0 (section 6.4)[233, 244, 245].
Thus, not only do OCSFAs have a neutral effect on the de-novo lipogenesis pathway, but
since part of them can be produced from C16:0 and C18:0, higher levels of these fatty
acids may imply lower levels of C16:0 and C18:0 and thus less harmful effects on β -cell
apoptosis and insulin resistance.
We reported null or positive associations of metabolite scores for yoghurt and cheese
with T2D risk. These scores failed to validate externally, so they might reflect random
noise and are not interpretable. Thus, it is not possible to provide a biological explanation
currently and the need for further research especially on these two dairy types is warranted.
7.5.4 Strengths and limitations
Our study on associations of metabolite scores predictive of dairy consumption with risk
of type 2 diabetes has several strengths. We used metabolite scores, which reflected dairy
consumption, with internal and external (for milk, butter and total dairy consumption)
validity in an independent case-cohort set nested within the EPIC Norfolk study. In this
way, we could avoid the measurement error of self-reported dietary assessment methods.
In addition, although we did not identify single metabolites as specific biomarkers to
individual dairy types, the use of scores with metabolite weights specific for each dairy
type, is a way of developing biomarkers specific for dairy types.
This study has also several limitations. Metabolite scores for yoghurt and cheese did
not show evidence of external validity in this cohort, so the associations between these
scores and T2D were not interpretable. The scores were derived from an observational
cross-sectional study using a self-reported method of dietary assessment, which might
entail more confounding and measurement error than an RCT design. It is not clear
how such error could influence our results, but it is possible for example, that due to
confounding we identified metabolites that are not causally related to dairy consumption or
we did not identify metabolites that are causally related. Nevertheless, it is also important
to acknowledge that RCTs of dietary interventions pose their own challenges such as
issues related to lack of blinding, adherence to the dietary advice, attrition and complexity
of interpretation of total energy intake or intakes of dietary compounds other than the
intervention foods.
7.5.5 Conclusion
In this study, we used a novel approach of developing and validating metabolite scores
predictive of dairy consumption, which constitutes a more promising method to identify
markers specific to individual dairy types. We observed a lower risk of T2D for metabolic
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profiles significantly associated with a higher consumption of milk, butter and total dairy
products. This study laid the foundations for the development and use of metabolite
scores as potential biomarkers of dairy consumption and as tools to unravel pathways
underpinning the link between dairy consumption and T2D. Further studies are needed
with different sets of metabolites and different study designs to identify more valid scores
predictive of dairy consumption especially for yoghurt and cheese, that we were not
able to identify and which have shown associations with cardio-metabolic health. The
combination of information from both observational and controlled studies could provide
a more comprehensive understanding on how metabolomics profiles predictive of dairy
consumption are related to T2D risk.
Chapter 8
Genetic predictors of dairy
consumption
Summary
Background and aims: Genetic variants of lactase persistence (LP) are well-known ge-
netic predictors of dairy consumption. These variants sufficiently predict milk consumption,
but not consumption of yoghurt or cheese, which contain less lactose than milk and also
contribute to an enhanced digestion of lactose. We aimed to investigate genetic predictors
of total and types of dairy products (milk, yoghurt and cheese) consumption to elucidate
the link of genetic predisposition to dairy consumption and develop potential tools for
Mendelian randomisation analyses.
Methods: We conducted genome-wide association studies on total and types of dairy
consumption in the UK Biobank. The primary dairy outcomes were milk consumed as
a drink or added to cereals (n=451,900), yoghurt (n=193,505), cheese (n=445,330) and
total dairy consumption (n=193,505). Diet was assessed with a general questionnaire
(three repeated measures available) and a questionnaire about diet in the last 24 hours
(Oxford WebQ; five repeated measures available). Information from both tools was used
to generate variables of dairy consumption. Total dairy consumption was expressed as a
continuous variable in servings/day. For dairy types, participants were split into consumers
and non-consumers. The associations of the single nucleotide polymorphism (SNP) for LP,
rs4988235, with milk and total dairy consumption were used as positive controls. Genome-
wide association analyses were conducted among white European-origin participants with
linear mixed models adjusted for age and sex.
Results: The majority of the participants were milk and cheese consumers (92.9% and
97.1% respectively). Almost half of the participants were yoghurt consumers (46.7%).
Highly significant positive associations were observed between rs4988235 and both milk
consumed as a drink and added to cereals (p=2.3 x 10-12) and total dairy consumption
(p=1.1 x 10-15) in the positive control analysis among white Europeans. We identified
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seven SNPs on chromosomes 1, 2, 4 and 12 predictive of total dairy consumption; four
SNPs on chromosome 2 predictive of milk consumption; one SNP on chromosome 1
predictive of yoghurt consumption and four SNPs on chromosomes 1, 2 and 7 predictive
of cheese consumption, which reached genome-wide significance.
Conclusion: We identified novel genetic predictors of total and types of dairy consump-
tion in addition to confirming the strong prediction of milk and total dairy consumption
by the LP SNP rs4988235. To our knowledge, no genome-wide association study on total
and types of dairy consumption has been previously reported. Based on the large sample
size of the UK Biobank, enabling the detection of genetic associations of small magnitude,
these findings lay the foundations for the use of such predictors to elucidate links of genetic
predisposition to dairy consumption. This also opens up possibilities to the use of the
identified SNPs as instrumental variables in Mendelian randomisation analyses for the
investigation of causal associations with disease endpoints. The replication of our findings
in other populations and in studies with more precise methods of dietary assessment will
further advance our understanding of the genetic predictors of dairy consumption.
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What is already known
• Prior candidate-gene research has shown that single nucleotide polymorphisms
(SNPs) for lactase persistence predict milk consumption
• No genetic predictors of yoghurt and cheese consumption have been reported
to date
• Mendelian randomisation is a useful tool to investigate causal associations
• SNPs have been used as instrumental variables in Mendelian randomisation
studies on associations between milk or total dairy consumption and cardio-
metabolic endpoints
What this research adds
• Seven SNPs predicted total dairy consumption, four SNPs predicted milk
consumption, four SNPs predicted cheese consumption and one SNP predicted
yoghurt consumption in genome-wide association studies of a large sample
(n≈450,000) of white European participants in the UK Biobank study.
• The identified SNPs open up the possibility for the elucidation of genetic pre-
disposition to dairy consumption and as instrumental variables in Mendelian
randomisation analyses on dairy consumption and disease incidence.
Publication
Trichia E, Day FR, Imamura F, Perry J, Wareham NJ, Forouhi N G. Associations of total
and types of dairy consumption with type 2 diabetes risk: a Mendelian Randomisation
study (analysis ongoing)
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NOTE: Definitions of concepts from genetic epidemiology, which are used throughout
this Chapter, are provided in the glossary of Appendix B.
8.1 Lactase persistence
The exploration of the genetic predictors of dairy consumption has been limited so far to
the investigation of genetic polymorphisms related to lactase persistence (LP). LP has been
associated with higher consumption of lactose-containing foods, especially milk[303]. A
meta-analysis of 5 observational studies reported that people with LP consumed on average
more milk by 55 g/day compared to those with the lactase non-persistence phenotype[304].
Absence of lactase persistence leads to lactose intolerance. Related mechanisms are
well-established. Lactase (lactase-phlorizin hydrolase) is an enzyme, which hydrolyses
lactose into glucose and galactose in the intestinal epithelial cells[303]. LP into adulthood
is the phenotype resulting from the heterozygosity or homozygosity for an autosomal
dominant allele, whereas decline in lactase activity after weaning is a result of a genotype
homozygous for the recessive allele[303].
The main single nucleotide polymorphisms (SNPs) identified to date in relation to
LP, are rs4988235 (C/T-13910) and rs182549 (G/A-22018) in the gene MCM6 on chro-
mosome 2, which codes for a promoter of the enzyme lactase[303]. These SNPs are
located upstream of the LCT gene, which codes for lactase[303]. In the absence of this
genetic variant, down-regulation of the lactase enzyme activity is observed leading to
lower lactose hydrolysis, absorption and higher transfer from the small intestine to the
colon[303]. This results in osmotic load and unpleasant symptoms of lactose intolerance
including abdominal discomfort, flatulence and diarrhoea and thus lower consumption of
milk[303]. In addition, colonic bacteria metabolise lactose and use the metabolic products
to produce short-chain fatty acids and hydrogen gas, which increase the aforementioned
symptoms[303].
Evidence suggests that the LP phenotype is a recent (5,000-10,000 years) result of
natural selection, while the default phenotype has been lactase non-persistence and this
selection is one of the strongest observed in the human genome[305]. It has been hypothe-
sised that LP was developed in regions that also developed dairy farming for food supply,
especially pastoral regions, i.e. regions where dairy farming was the main economic
activity. As can be seen in Figure 8.1a, there is a higher LP prevalence in northern Europe
(89-96%) compared to southern and eastern Europe (19-54%), western and northern India
(63%) compared to southern India (23%) and in pastoral regions of Africa (64% among
the pastoralists Sudanese Beni Amir) compared to non-pastoral regions (20% among the
non-pastoralists Sudanese Dounglawi), while the lowest prevalence is observed in Asia
with about 1% in China[306].
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Fig. 8.1 Global distribution of (a) lactase persistence (LP) and (b) the LP-associated -
213910*T allele. Colour scale represents magnitude of the LP frequency. Figure adapted
from Gerbault et al.[306].
Global map removed for copyright reasons. Copyright holder is Pascale Gerbault.
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This observation coincides with archaeological evidence on the spread of dairy 
farming into Europe and certain African regions[306]. It has been assumed that along 
with the introduction of dairy farming, the low exposure to sunlight in northern Europe 
and the high drought levels in Africa, contributed to higher consumption of milk and 
gradual natural selection, a phenomenon known as gene-culture co-evolution[306]. In 
addition to that, more LP SNPs have been identified for different ethnic groups, which is 
expected since rs4988235 explains LP mainly in Europe (Figure 8.1b)[306]. For 
example, rs41380347 (T/G-13915) has been identified as an LP SNP in Saudi Arabia and 
rs41525747 (C/G-13907) in Ethiopia and Sudan[307]. The multiple SNPs identified 
might also indicate that LP developed simultaneously and independently in different 
populations[307]. The long haplotype observed in relation to LP increases the possibility 
that more causal genetic variants of LP are located on it apart from the one identified in 
each population such as rs4988235 in Europeans [305]. 
The ethnicity-specific genetic differences observed for LP are also reflected in dairy 
consumption levels, as shown in the "old world" map (Europe, Africa, Australasia) in 
Figure 8.2, where milk consumption levels in 2010 were higher in northern Europe and 
some parts of Africa. A more specific example of two countries with very different milk 
Fig. 8.2 Global distribution of milk consumption in 2010, Global Dietary Database 
(https://www.globaldietarydatabase.org/country-comparisons.html, date of access: 24 
June 2018) 
Global map removed for copyright reasons. Copyright holder is Tufts University. 
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consumption levels such as the UK (260.4 g/day in 2010) and China (17.9 g/day in 
2010) is shown in Figure 8.3. 
Fig. 8.3 Milk contribution to the total amount of food consumed in the UK and China in 
2010, Global Dietary Database (https://www.globaldietarydatabase.org/ country-
comparisons.html, date of access: 24 June 2018) 
LP is a strong genetic predictor of dairy consumption, but it has some limitations. 
First, while the LP genetic variant can predict milk consumption, it is not suitable for the 
prediction of the other two main dairy types i.e. yoghurt and cheese[308]. Depending on 
the dairy type, the lactose content might not be much lower than in milk (Table 8.1), but 
fermented dairy products contain bacteria, which contribute to a more efficient 
metabolism of lactose compared to the non-fermented products[309]. Although it could 
be expected that the bacterial lactase would be deactivated when passing through the 
acidic stomach, the buffering effect of yoghurt and the bacterial cell membrane, protect 
the bacterial lactase. When yoghurt reaches the small intestine, which has a higher pH, 
the bacterial lactase is activated and contributes to the metabolism of lactose[309]. 
Second, the LP genetic variants cannot explain the large variability of symptoms of 
lactose intolerance. Although there is evidence that on average people with lactose 
intolerance can tolerate up to 12 g lactose daily[303], there is variation by genetic and 
environmental factors. These include sex (symptoms seem to be worse among women 
than men)[310], the distribution of lactose consumption throughout the day (24 g of 
lactose might be tolerated when spread throughout the day compared to acute 
consumption)[303], the consumption of lactose as part of a meal (better tolerated than 
consumed alone)[303] and composition of the gut microbiota[311]. It is therefore of 
interest to explore additional genetic predictors of dairy consumption. 
Pie charts removed for copyright reasons. Copyright holder is Tufts 
University. 
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Table 8.1 Lactose content in 100 g of different types of dairy
products[35]
Dairy products Sub-type Lactose content (%)















Apart from the understanding of potential biological pathways that may lead to consump-
tion of different dairy types, the identification of genetic predictors of dairy products could
also contribute to their use as instrumental variables in Mendelian randomisation analyses.
Mendelian randomisation is increasingly used in epidemiology to investigate causal associ-
ations using observational data and it has some similarities with the design of a randomised
controlled trial (Figure 8.4)[312, 313]. It is based on Mendel’s second law of random
inheritance of alleles by using genetic proxies of the exposure (instrumental variables), to
assess associations with a lower risk of reverse causation and confounding that are common
challenges in observational studies[313]. This method might be particularly useful when
studying dietary factors, for which long-term trials are usually not feasible.
There are several studies which used Mendelian randomisation to investigate causal
associations of dairy consumption with cardio-metabolic disease outcomes. Results
from these studies indicated a non-significant association of genetically predicted milk
consumption with type 2 diabetes (T2D)[304, 314], myocardial infarction[315] and is-
chaemic heart disease[304, 315]. Mendelian randomisation studies of associations of
milk consumption with cardio-metabolic markers, reported positive associations with
BMI[304, 308], obesity[308] and insulin[304]; null associations with the ratio of waist
to hip circumference[304], systolic (SBP) and diastolic blood pressure (DBP)[308],
Haemoglobin A1c (HbA1c), fasting and 2-hour glucose, and triglycerides[304]; and
inverse associations with low-density lipoprotein (LDL-C) and high-density lipoprotein
cholesterol (HDL-C)[304]. Likewise, for total dairy consumption, a meta-analysis of 25
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Mendelian randomisation Randomised controlled trial 
Natural randomisation by genetic 
variant (Mendel’s second law) 
Randomisation into 




variant allele Control Treatment 
Fig. 8.4 Comparison of Mendelian randomisation with randomised controlled trials. Figure
content adapted from Burgess et al[312].
Mendelian randomisation studies reported a positive association with BMI and a Mendelian
randomisation analysis of 22 studies from the CHARGE (Cohort for Heart and Ageing
Research in Genomic Epidemiology) Consortium reported non-significant associations
with SBP or hypertension[84].
All these studies used as instrumental variable the LP SNP rs4988235, as the most
established genetic predictor of milk consumption. As described above, the use of the SNP
entails several limitations. First, it can be used as a genetic proxy for milk consumption
only and not for other dairy types. Second, even for milk consumption it is subject to
within individual variability. Third, the LP SNP might not fulfil the requirements of a
valid instrumental variable, which should be independent of potential confounders of the
association under study[313]. For example, a potential confounder of the association
between genetically predicted milk consumption and BMI could be total energy intake if
we assume that lactose intolerant people might follow a more restricted diet independent
of dairy consumption than LP people. These limitations provide the rationale for further
discovery efforts to identify genetic variants for different types of dairy products.
8.3 Study aims
The aim of this study was to investigate genetic predictors of the three main dairy types i.e.
milk, yoghurt and cheese using an exploratory approach with genome-wide association
studies instead of the candidate gene approach followed in previous studies, and mainly
concerned the LP SNPs. This aim serves a dual purpose: a better understanding of the
biological pathways related to the profiles of dairy consumers and non-consumers; and
the use of the genetic predictors as instrumental variables in Mendelian randomisation
analyses.
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8.4 Methods
8.4.1 Study design and population
For the genome-wide association study (GWAS), we evaluated data from the UK Biobank,
a large scale prospective cohort study of approximately 503,000 participants, aged 40-69
years. Participants were recruited from April 2007 to July 2010 from 22 assessment centres
in England, Scotland and Wales through population-based registries and based on living
close to an assessment centre with an overall response rate of 5.5%. A subset of 20,345
people living within a 35 km radius from the Stockport study centre from a total of 103,514
participants who were invited, participated in the first repeated assessment in 2012-2013
and a subset of a similar size participated in the second repeated assessment in 2015.
Ethical approval was obtained by the National Information Governance Board for Health
and Social Care and the NHS Northwest Multicentre Research Ethics Committee (MREC).
8.4.2 Genotyping
Blood samples were stored in racks of 96 microtubes (1.2 ml) at -80°C or -196°C and placed
in 96-well plates for DNA extraction. Participants were genotyped with the Affymetrix Ax-
iom array (n≈450,000; Affymetrix GeneTitan® Mutli-Channel Instrument, Affymetrix Re-
search Services Laboratory, Santa Clara, CA, USA) or the UK BiLEVE array (n≈50,000).
Approximately the same procedures were followed for genotyping with both arrays with
small differences and with an approximately 95% overlap of SNPs included. The 5% non-
overlapping SNPs were in the Axiom array, which was an updated version of UK BiLEVE.
Two of the 96 wells were used for controls (1,000 Genomes). Each batch included ∼4,700
samples. After quality control (QC) checks, less than 5% (∼38,000) of the SNPs in the
Axiom array were set to missing, because they did not meet the QC standards. More
information on the genotyping was provided in relevant reports from the UK Biobank[316].
Genotypes not assayed were imputed using the UK10K merged with the 1,000 Genomes
Phase III reference panel and the IMPUTE2 programme, as described in more detail in a
UK Biobank report[317].
8.4.3 Dietary assessment and data processing
Two different tools were applied for the dietary assessment in the UK Biobank. The first
tool was used in the total sample and comprised a collection of frequency questions for
main food groups and items included in the general touchscreen questionnaire along with
other questions on e.g. socio-demographic factors, administered during the assessment
visit. This questionnaire was filled in by the participants in all three repeated assessments
(first: n≈500,000, second: n≈20,000, third: n≈8,000). The second tool was the Oxford
WebQ, a hybrid of a 24-hour dietary recall and a 200-item food frequency questionnaire
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(FFQ)[318] administered in a sub-sample of approximately 200,000 participants. The
WebQ was administered in approximately the last 70,000 participants at the assessment
centre at baseline. Then, it was sent via e-mail to approximately 320,000 participants who
had provided an email address and were asked to fill it in four times distributed across the
year 2011-2012 to capture seasonal variation and habitual diet. Participants were asked to
complete the WebQ on specific days, so that within day variation and differences between
weekdays and weekend days were captured. It was completed by approximately 100,000
participants in the first cycle (February 2011 - April 2011), 80,000 in the second (June
2011 - August 2011), 100,000 in the third (October 2011 - December 2011) and 100,000
participants in the fourth cycle (April 2012 - June 2012). The total number of participants,
who completed the WebQ at least once was 200,000 and some of them completed it
more than once up to five times. An overview of the administration of the touchscreen
questionnaire and the Oxford WebQ is shown in Figure 8.5 along with the number of
participants with one or more WebQs available.
Fig. 8.5 Dietary assessment timeline in the UK Biobank
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Dairy consumption from the touchscreen questionnaire
The questions from the touchscreen questionnaire related to dairy consumption were as
follows:
• "Which of the following do you never eat?" with multiple choice answers including
"Dairy products"
• "How often do you eat cheese? (include cheese in pizzas, quiches, cheese sauce etc)"
with eight possible answers: "Never", "Less than once a week", "Once a week", "2-4
times a week", "5-6 times a week", "Once or more daily", "Do not know", "Prefer
not to answer"
• "What type of milk do you mainly use?" with eight possible answers: "Full cream",
"Semi-skimmed", "Skimmed", "Soya", "Other type of milk", "Never/rarely have
milk", "Do not know", "Prefer not to answer"
Yoghurt consumption was not assessed in the touchscreen questionnaire.
Dairy consumption from the Oxford WebQ
Milk consumed with coffee, tea and cereals
Dairy products were assessed in various sections of the Oxford WebQ. For milk,
we used milk consumed with coffee, tea and cereals following the algorithms shown in
Figures 8.6-8.8 and under the assumptions listed in Table 8.2 and also as a beverage. The
primary milk phenotype was milk consumed as a drink and added to cereals.
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Fig. 8.6 Algorithm for the estimation of milk consumption from coffee as assessed from
Oxford WebQ. Superscript numbers refer to numbered assumptions of Table 8.2
Fig. 8.7 Algorithm for the estimation of milk consumption from tea as assessed from
Oxford WebQ. Superscript numbers refer to numbered assumptions of Table 8.2
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Fig. 8.8 Algorithm for the estimation of milk consumption from cereals as assessed from
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Milk consumed as a beverage
For milk consumed as a beverage, participants could choose one of the options ranging
from None, 12 ,1,2,3,4,5 to 6+ glasses of milk. If the participant chose the option 6+, it was
assumed that they consumed six glasses of milk. In a separate question, participants were
asked "Which type of milk did you use most frequently yesterday?". They had the option
to choose one of the following:
• I did not have any type of milk or milk substitute yesterday
• Semi-skimmed cow’s milk
• Skimmed cow’s milk
• Whole (full cream) cow’s milk
• Cholesterol lowering milk e.g. Flora pro.active
• Soya milk with added calcium
• Soya milk without added calcium
• Goat’s or sheep’s milk
• Rice, oat milk or other vegetable milk e.g. Rice Dream, Plamil
• Powdered milk
• I do not know which type of milk I used the most
• Other type of milk
If the participant chose any type of milk not compatible with the biological definition
provided by Codex Alimentarius as described in Chapter 1 such as soya milk with or
without calcium, rice, oat milk or other vegetable milk or "other type of milk", the milk
consumption was replaced with zero. This was done so that the associations between
SNPs related to LP and milk consumption would not be obscured. "Other type of milk"
was also replaced with zero, because processed milk low in lactose was not included in
the options, so it was assumed that there is a higher possibility that such a type of milk
would be reported as "Other type". In this way, we tried to minimise missclassification,
since currently the data do not make it possible to examine any specific answers of the
participants, when they would choose "other type of milk".
Yoghurt consumption
Yoghurt was assessed with the question "Did you eat any yoghurt or ice-cream yester-
day?". If the participant replied "Yes", they could choose one of the options ranging from
None, 12 , 1, 2 to 3+ servings/individual pots of yoghurt. If the participant chose the option
3+, it was assumed that they consumed three servings of yoghurt. One serving of yoghurt
was defined as 125 g according to the Food Standards Agency (FSA)[197].
Cheese consumption
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Cheese consumption was assessed with the question "Did you eat any cheese yester-
day?". If the participant replied "Yes", they could choose the type of cheese they consumed
from the following:
• Low fat hard cheese (e.g Edam, reduced fat Cheddar)
• Hard cheese (e.g. Cheddar, Parmesan)
• Soft cheese (e.g. Brie)
• Blue cheese (e.g. Stilton)
• Low fat spreadable cheese






and the quantity options ranging from None, 12 , 1, 2 to 3+ servings. If the participants
chose the option 3+, it was assumed that they consumed three servings. One serving of
cheese was assumed to correspond to 40 g as suggested by the FSA[197].
8.4.4 Statistical analysis
Derivation of dairy outcomes
In order to make the most of the available data, we derived the dairy variables by combining
information from both tools when possible. In this way, we combined the advantages
of both tools by using the larger sample size that the touchscreen questionnaire was
administered to and the greater detail available in the Oxford WebQ.
Continuous dairy variables from the Oxford WebQ were skewed. Log-transformation
and Box-Cox transformation were applied to adjust the distribution of the variables closer
to the normal. Distributions of milk, yoghurt and cheese variables did not approximate
the normal even after the transformations, so the binary variables of consumers and
non-consumers were used.
We created three binary variables of milk by splitting the participants into consumers
and non-consumers. The first variable included only milk consumed as a drink from the
Oxford WebQ. The second variable was derived from dichotomisation of the sum of milk
consumed as a drink and milk from coffee, tea or cereals from the Oxford WebQ. In
both cases, participants were considered consumers if they reported milk consumption
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in at least one repeated assessment. The third variable was derived from the touchscreen
questionnaire classifying as consumers those who chose either "Full cream", "Semi-
skimmed" or "Skimmed" from the relevant question in at least one repeated assessment.
This variable was updated with the answers from the Oxford WebQ. Specifically, we
re-classified the touchscreen-defined non-consumers into consumers if they had reported
milk consumption in the Oxford WebQ.
Yoghurt consumers were defined as those who reported yoghurt consumption at least
in one repeated assessment with the Oxford WebQ.
A binary variable for cheese consumption was created from the information provided
with the touchscreen questionnaire classifying as consumers those who reported cheese
consumption in at least one repeated assessment with either the touchscreen questionnaire
or the Oxford WebQ.
Total dairy consumption was estimated as the weighted average of the sum of milk,
yoghurt and cheese from the repeated measures of Oxford WebQ accounting for weekdays
and weekends. The weighted average was then winsorised to the 5th and 95th percentiles
and was Box-Cox transformed. Due to the lack of information on yoghurt, the touchscreen
questionnaire was not considered for the estimation of total dairy consumption.
The primary dairy outcomes were milk consumed as a drink and added to cereals
(Oxford WebQ), yoghurt (Oxford WebQ), cheese (touchscreen questionnaire and Oxford
WebQ) and total dairy consumption (Oxford WebQ).
Genetic analyses
Continuous variables for SNPs were used with values ranging from 0 to 2 depending on
heterozygosity (value of 1) or homozygosity for the effect (value of 2) or the alternative
allele (value of 0). Decimal points indicated genotype expectations for imputed SNPs.
Positive control analysis
Before conducting the GWAS, the association of the SNP rs4988235 with milk and
total dairy consumption was assessed as a positive control, because rs4988235 is the
most well characterised causal SNP for LP in white populations. In this positive-control
candidate-gene analysis, we fitted logistic regression models adjusted for age, sex and
the first 10 principal components to account for population stratification both in the total
sample and after exclusion of non-white participants. Data processing and positive control
analyses were performed in Stata version 14.2 (College Station, TX: StataCorp LP, 2015).
Genome-wide association studies
GWASs were performed on the six dairy phenotypes using an established pipeline
developed by members of the MRC Epidemiology Unit genetics group. Due to the
large data size, high performance computing (HPC) was used. Linear mixed regression
models were developed for the GWAS of all the phenotypes in BOLT-LMM version 2.3.2
software[319], which does not include logistic regression models. Models were adjusted
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for age and sex. Non-white participants were excluded. BOLT-LMM uses a relationship
matrix that controls for both population stratification and relatedness.
Biological interpretation
SNP GWAS hits with p<0.01 were presented in Manhattan plots generated with the
qqman package in R. Information on the annotation and related genes of the top SNP hits
was extracted from the HaploReg v4.1 database[320]. Top hits were defined as the SNPs
which reached genome-wide significance (p<5x10-8) after excluding variants with minor
allele frequency less than 0.01 and imputation quality less than 0.3 and pruning within 250
kb from the SNP with the strongest association. Information on the relevant genes was
searched for in the Gene NCBI (National Center for Biotechnology Information) database
(https://www.ncbi.nlm.nih.gov/gene/). Phenotypes, which have previously been associated
with our top signals in the UK Biobank, were identified from the Oxford Brain Imaging
Genetics (BIG) database (http://big.stats.ox.ac.uk/). Information on linkage disequilibrium
between the lactase persistence SNP rs4988235 and other SNPs of chromosome 2 was
extracted from SNiPA v3.3[321].
8.5 Results
8.5.1 Description of dairy outcomes
Starting from 502,628 participants, after exclusion of participants with no genetic data
(n=15,219), no overall dietary data (n=14), non-white participants (n=35,095) and partici-
pants with missing phenotypic information, the number of participants used in the analyses
of data from the touchscreen questionnaire were 451,900 for milk consumed as a drink
and added to cereals and 445,330 for cheese. After further excluding participants with no
dairy information from the Oxford WebQ, the number of participants further reduced to
193,505 for analyses on total dairy products, milk consumed as a drink, milk consumed
as a drink or added to coffee, tea or cereals and yoghurt (Table 8.3). The majority of the
participants were consumers of milk added to coffee, tea or cereals (90.2%), and cheese
(97.1%), whereas for milk consumed as a beverage only 6.9% were consumers and for
yoghurt almost half of the participants were consumers (46.7%; Table 8.3).
8.5.2 Positive control analysis
Results from the positive control analysis indicated highly significant positive associations
between the LP SNP rs4988235 and both the milk phenotypes and total dairy consumption
(Table 8.4). The strongest associations were observed from the logistic regression model
on milk consumed as a drink. In this case, β=0.11 could be interpreted as a higher
likelihood of being a milk consumer by 0.11 times for each 1% higher probability of
having the effect allele for LP. The likelihood was reduced to 0.06 times for milk consumed
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Table 8.3 Number of consumers and non-consumers for binary dairy phenotypes and
mean±SD for the continuous dairy phenotypes † in the UK Biobank subsets used for the
genome-wide association studies (GWAS)
Total set Subsets Data set
Dairy phenotypes N Consumers Non-consumers
Total dairy products 193,505 1.9±0.7 Oxford WebQ
Milk as a drink and added to cereals 451,900 92.9 7.1 Total ‡
Milk as drink and added to coffee, tea and cereals 193,505 90.2 9.8 Oxford WebQ
Milk as drink 193,505 6.9 93.1 Oxford WebQ
Yoghurt 193,505 46.7 53.3 Oxford WebQ
Cheese 445,330 97.1 2.9 Total ‡
† Only total dairy consumption was used as a continuous phenotype, so the mean±SD is reported for that, whereas
for the rest of the phenotypes the percentage of participants within each category of consumers and non-consumers
is reported
‡ Information combined from the touchscreen questionnaire and the Oxford WebQ
as a drink and added to coffee, tea and cereals. For total dairy products, β=0.03 for each
effect allele of lactase persistence, which is not directly interpretable due to the Box-Cox
transformation (Table 8.4).
Table 8.4 Positive control results for the associations of the lactase persistence single nu-
cleotide polymorphism (rs4988235) with milk and total dairy consumption in subsets of all
ethnicities or white people only in the UK Biobank
Dairy phenotype Model N b se p
Total dairy products † All ethnicities 206,381 0.03 1.3x10-5 9.0x10-20
White 193,505 0.03 1.4x10-5 1.1x10-15
Milk as a drink and added to cereals ‡ All ethnicities 486,045 0.08 8.5x10-5 2.9x10-17
White 451,833 0.07 9x10-5 2.3x10-12
Milk as drink and added to coffee, tea and cereals ‡ All ethnicities 206,381 0.07 0.0001 1.3x10-8
White 193,505 0.06 0.0002 1.8x10-6
Milk as drink ‡ All ethnicities 206,381 0.11 0.0002 4.6x10-14
White 193,505 0.10 0.0002 1.2x10-11
† Total dairy products were included in the analysis as a continuous variable in servings/day, so the effect estimates
are derived from linear regression models. Models were adjusted for age, sex and 10 principal components
‡ The different phenotypes for milk were included in the analysis as binary variables of consumers and non-
consumers of milk, so the effect estimates are derived from logistic regression models. Models were adjusted for
age, sex and 10 principal components.
8.5.3 Genome-wide association studies
Manhattan plots for total dairy products (Oxford WebQ) and the two dairy outcomes
derived from the combination of the touchscreen and Oxford WebQ questionnaires are
presented in Figure 8.9. Manhattan plots for the rest of the dairy outcomes derived
from the Oxford WebQ are presented in Figure 8.10. The most significant hits from the
GWAS (p<5x10-8) were observed for total dairy consumption within the subset of 193,505
participants with WebQ data, located on chromosomes 1, 2, 4 and 12 (p range: 8.6 x 10-16
- 1 x 10-8; Figure 8.9). For the main milk phenotype (consumed as a drink or added to
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cereals) significant hits were located on chromosome 2 (p range: 3.8 x 10-13 - 2 x 10-10;
Figure 8.9). The same pattern was observed for milk consumed as drink (p range: 5.7 x
10-12 - 2.3 x 10-10; Figure 8.10). SNPs for milk added to coffee, tea or cereals did not
reach genome-wide significance (Figure 8.10). Significant hits for cheese were located on
chromosomes 1, 2 and 7 (p range: 4.4 x 10-9 - 1.2 x 10-8;Figure 8.9), while for yoghurt only
one SNP on chromosome 1 reached genome-wide significance (p= 1.4 x 10-8; Figure 8.10).
Fig. 8.9 Manhattan plots of the negative logarithm of the genome-wide association studies
p values for SNPs with p<0.01 for total dairy products (continuous phenotype; Oxford
WebQ subset, N=193,505; green plot), milk consumed as drink or added to cereals (binary
phenotype; N=451,900; red plot) and cheese (binary phenotype; N=445,330; yellow plot)
in the UK Biobank. The dotted line indicates the genome-wide significance threshold of
5x10-8. GWAS: Genome-wide association study; SNP: Single nucleotide polymorphism
Information of SNPs producing p<5x10-8 is presented in Table 8.5. Seven SNPs were
identified as top signals for total dairy products, of which five were intronic; four intronic
SNPs were identified for milk consumed as a drink or added to cereals; four intronic SNPs
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Fig. 8.10 Manhattan plots of the negative logarithm of the genome-wide association
studies p values for SNPs with p<0.01 for milk consumed as drink or added to coffee,
tea or cereals (binary phenotype; N=193,505; top red plot), milk consumed as a drink
only (binary phenotype; N=193,505; bottom red plot) and yoghurt (binary phenotype;
N=193,505; blue plot) in the UK Biobank Oxford WebQ subset. The dotted line indicates
the genome-wide significance threshold of 5x10-8. GWAS: Genome-wide association
study; SNP: Single nucleotide polymorphism
were identified for milk consumed as a drink; one SNP was identified for yoghurt; and four
SNPs were identified for cheese, of which one was intronic.
To examine the specificity of the SNPs for each of the main dairy types, the associations
between SNPs, which were identified as top hits for at least one dairy type, and all the dairy
types are presented in Table A.34. Although some of the top hits for the milk phenotypes
overlap with those for total dairy products and other milk phenotypes, the top hits of the
three main dairy types i.e. milk, yoghurt and cheese do not overlap with each other, which
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Information extracted for top SNP hits and the corresponding genes is provided in
Table 8.6. Most of the SNPs are described as intronic, which means that they are in-
volved in protein expression and that they might be of regulatory importance. In addition,
genes located on chromosome 2, which included top SNP hits for total dairy consumption
and milk consumption (as a drink only or as a drink and added to cereals) are in close
proximity with each other, so there is a higher probability that they are in linkage disequi-
librium and are highly correlated. Indeed, for example, the LP SNP rs4988235 is in high
linkage disequilibrium (r2≥0.8) with SNPs from the genes DARS, MCM6 and R3HDM1
(Figure 8.11).
Table 8.6 Functional annotation and corresponding genes for the genome-wide association
study (GWAS) top single nucleotide polymorphism (SNP) hits of dairy phenotypes in the
UK Biobank †
Dairy phenotype SNP Chromosome Gene position Functional annotation Nearest gene
Total dairy products rs12409187 1 0.0979031 intronic AJAP1
rs4988235 2 1.58582 intronic MCM6
rs7570971 2 1.58509 intronic RAB3GAP1
rs3940549 2 1.58514 intronic ZRANB3
rs28815269 2 1.58915 none 104kb 5’ of CXCR4
rs11940694 4 0.613896 intronic KLB
rs35754956 12 1.46556 none 4.6kb 3’ of AC156455.1
Milk as drink and
added to cereals
rs6754311 2 1.58595 intronic DARS
rs62168795 2 1.58551 intronic R3HDM1
rs7570971 2 1.58509 intronic RAB3GAP1
rs3940549 2 1.58515 intronic ZRANB3
Milk as drink rs182549 2 1.58582 intronic MCM6
rs74775210 2 1.58521 intronic R3HDM1
rs151022760 2 1.58514 intronic ZRANB3
rs7570971 2 1.58509 intronic RAB3GAP1
Yoghurt rs35025768 1 0.707581 none 5.5kb 3’ of U6
Cheese rs1222762 1 1.26566 none 19kb 5’ of Metazoa_SRP
rs504764 2 0.697037 none RP11-89K21.1
rs10264126 7 1.44451 intronic CHCHD3
rs10245608 7 0.657781 none 68kb 3’ of AC005022.1
†Information was extracted from HaploReg v4.1[320]
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8.5.4 Exploratory work on biological interpretation
Information on the genes that carry the top SNP hits for dairy types is presented in
Table 8.7. The functional role of some of the identified genes (e.g. AJAP1, ZRANB3,
R3HDM1, RP11-89K21.1, KLB) is not clear. The most relevant gene is MCM6, which
contains the LP SNP rs4988235. No known information related to dairy consumption or





























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































As shown in Table 8.8, phenome-wide association data from the UK Biobank extracted
from the Oxford BIG database, indicated that body composition traits were associated
with top signals of total dairy products (rs4988235, rs7570971), milk consumed as a
drink or added to cereals (rs6754311, rs7570971), milk consumed as a drink (rs182549,
rs7570971) and cheese (rs1222762). Sleep duration was associated with top signals for
total dairy products (rs4988235, rs7570971), milk consumed as a drink or added to cereals
(rs6754311, rs7570971), milk consumed as a drink (rs182549, rs7570971) and cheese
(rs10264126). Alcohol consumption was associated with top signals of total dairy products
(rs11940694) and cheese (rs504764), while smoking was associated with top signals of
cheese (rs504764).



































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































234 Genetic predictors of dairy consumption
8.6 Discussion
8.6.1 Summary of results
In addition to the LP SNP rs4988235, in our GWASs we identified six SNPs in chromo-
somes 1, 2, 4 and 12 predictive of total dairy consumption, four SNPs in chromosome 2
predictive of milk consumed as a drink or added to cereals, four SNPs in chromosome 2
predictive of milk consumed as a drink, one SNP in chromosome 1 predictive of yoghurt
consumption and four SNPs in chromosomes 1, 2 and 7 predictive of cheese consumption.
Most of the SNPs identified are intronic, so probably of regulatory importance. Some
of the SNPs have been associated with body composition traits, sleep duration, alcohol
consumption and smoking in a PheWAS conducted previously in the UK Biobank.
8.6.2 Interpretation and previous evidence
Many of the SNPs that we identified as predictors of dairy consumption in our GWAS are
in close proximity to the LP SNP and fall within the genetic region that has been causally
associated with LP. Further steps that are required to make any causal inferences such
as fine mapping of the genetic loci, replication in other studies and further exploration
of potential confounders, were outside the scope and the timeline of this PhD project.
However, as previously reported, the possibility of multiple causal genetic variants is in
agreement with the long haplotype observed in relation to LP[305]. For example, the
SNP rs182549, which we identified as one of the top signals for milk consumption, was
previously associated with LP[305].
We did not identify any other studies reporting results of GWAS on dairy consumption.
However, there are some studies, which investigated associations between selected SNPs
and dairy consumption. Data from the PREDIMED-Valencia study showed that the SNP
rs1466113 in the somatostatic receptor 2 (SSTR2) gene, which was strongly associated with
BMI, was also associated with lower dairy consumption by 44 g/day for the homozygous
compared with the heterozygous genotype[322]. The association between rs1466113 and
dairy consumption was not significant in our study. Associations were also significant for
meat and total protein intake and the authors suggested that it is difficult to disentangle
the specific pathways, because somatostatin is involved in many pathways related to the
regulation of appetite[322]. The SNP rs4788099 in the gene SH2B1 located in chromo-
some 16, which was associated with the risk of obesity, was also associated with dairy
consumption in the Look AHEAD trial[323]. The association between rs4788099 and
dairy consumption was also significant in our study, although it did not reach genome-wide
significance (p=0.003). Pirastu et al. investigated associations between genes related to
taste and food preferences in populations from five countries from Eastern Europe and
Western Asia[324]. In this study, rs2229642 located in the gene ITPR3 of chromosome
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6 was significantly associated with liking of sheep-origin cheese[324]. The association
between rs2229642 and cheese consumption was not significant in our study. A more
recent study including data from the study by Pirastu et al, but also data from an Italian
and a Dutch population, reported significant associations of rs12994253 on chromosome
2 with blue cheese liking and rs4239891 of the IGL gene on chromosome 22 with plain
yoghurt liking[325]. Such associations were not significant in our GWAS on cheese and
yoghurt consumption respectively.
Genetic predictors of candidate biomarkers of dairy consumption i.e. the odd-chain
fatty acids C15:0 and C17:0, could also elucidate potential biological mechanisms related
to dairy consumption. In a GWAS on odd-chain fatty acids conducted from the CHARGE
consortium, no significant hits were observed for C15:0, whereas rs13361131 in the
gene MYO10 of chromosome 5 was significantly associated with C17:0[326]. The link
between this gene and C17:0 is not clear, but C17:0 can also be produced from alternative
endogenous pathways[208], apart from the uptake from dairy consumption. The association
between rs13361131 and dairy consumption was not significant in our study, so assuming
that the association observed in the study by the CHARGE consortium is causal, this SNP
might be linked to the alternative endogenous pathway of C17:0 production.
The failure to replicate most of the associations reported above in our study might be
partly due to differences in the research questions. For example, food preference is not an
identical phenotype to dairy consumption, even though it is one of the potential pathways
of genetic predisposition to dairy consumption apart from lactose intolerance. In addition,
the populations used in these studies included Western Asians, who might have a different
genotype compared to our population of white Europeans. Furthermore, results from the
GWAS on C17:0 might reflect pathways of endogenous production of C17:0.
The expression of the gene R3HDM1, which includes two of the SNPs identified as
top genetic predictors of milk consumption in our GWAS, was lower among patients with
coeliac disease[327]. Secondary lactose intolerance may result from coeliac disease, so
the two conditions might share some common mechanisms[328] and our observation of
associations between two SNPs in the gene R3HDM1 and milk consumption might be
related to this pathway, under the assumption that the associations were causal.
8.6.3 Strengths and limitations
To our knowledge, this is the largest and only (reported) GWAS on total and the main
types of dairy consumption. The key strength of our study was its large sample size,
enabling us to detect associations of small magnitude. While a large sample size can also
be achieved through consortia data or meta-analyses, we evaluated data from a single study
of participants with similar ancestry residing in the same country and thus exposed to the
same culture. In addition, all the data went through the same procedures of collection
and processing. These are two sources of heterogeneity often identified in meta-analyses
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of different studies and could create more noise in the effect estimates. We overcame
this problem by evaluating data from the UK Biobank. Finally, we used the main types
of dairy products i.e. milk, yoghurt and cheese as phenotypes in the GWAS to attempt
an identification of genetic predictors specific to each dairy type. Such predictors could
be used as instrumental variables in Mendelian randomisation studies on associations
between specific dairy types and disease, which are currently not available apart from milk
consumption, genetically predicted by the LP SNP.
The main limitation of this work relates to dietary assessment. The dairy phenotypes
were derived from information from the touchscreen questionnaire in the total sample
(n≈450,000), which did not assess milk consumption quantitatively and did not assess
yoghurt consumption at all. For cheese, though the question included reporting of average
frequency of consumption, it could not capture different forms of cheese with different
serving sizes. The use of the Oxford WebQ in the subset (n≈200,000) provided greater
detail compared with the touchscreen questionnaire, but the dietary assessment was based
on a single 24-hour recall in the form of a questionnaire with an a priori list of foods
consumed. Due to difficulty in adjusting the dairy distributions to approximate the normal,
we used binary phenotypes for dairy types, which might have resulted in loss of information.
Although the measurement error of self-reported methods of dietary assessment is a
common limitation in nutritional epidemiology and in our study, these methods are still
an important source of information in observational studies. For reasons of feasibility,
cost and participant burden, there is usually a trade-off between the large sample size and
the amount of detail that the methods used provide. For example, although 7-day diaries
might be more accurate and provide a greater level of detail, they are not feasible to be
used in so large studies as the UK Biobank. The use of the Oxford WebQ, which has been
validated against a single interviewer-administered 24-hour recall[318] is an example of
this trade-off.
8.6.4 Implications and recommendations for future research
The identification of genetic predictors of dairy consumption is important for three reasons:
to elucidate any genetic predisposition to dairy consumption, which might potentially
further inform clinical and public health interventions; to disentangle potential genetic
pathways linked to biological pathways underpinning associations between dairy consump-
tion and disease; and to investigate causal associations between dairy consumption and
disease in Mendelian randomisation analyses.
The replication of our results in other studies with more detailed methods of dietary
assessment e.g. 7-day food diaries and other populations is important to confirm the
prediction of dairy consumption from the SNPs we identified. The next step would be the
investigation of the SNPs that are causally related to dairy consumption, which can be
done with fine mapping and further exploration of sources of confounding and pleiotropy
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of effects. Specifically, some of the SNPs we identified as predictors of dairy consumption
were previously associated with traits related to anthropometry, respiratory function,
physical activity, alcohol and sleep in the UK Biobank. It is not clear whether the interplay
between these SNPs, dairy consumption and the traits identified in the phenome-wide
association study is a result of pleiotropy of effects, confounding or causal associations.
These possibilities should be addressed and further investigated in future studies to assess
the suitability of the identified SNPs as instrumental variables in Mendelian randomisation
analyses. Finally, the suitable SNPs can be used individually or as parts of genetic risk
scores in Mendelian randomisation analyses to investigate causal associations between
dairy consumption and disease.
8.6.5 Conclusion
We identified novel SNPs predictive of total and types of dairy products in a large UK
cohort, the UK Biobank. These SNPs might be involved in biological mechanisms related
to dairy consumption and be useful as instrumental variables in Mendelian randomisation
analyses. The replication of these results in independent cohorts and different ethnic groups
and the exploration to identify causal genetic variants will further contribute towards the




9.1 Summary of results and links to PhD aims
The overall aim of this PhD project was to contribute towards a deeper understanding of
the associations between dairy products and cardio-metabolic health. To achieve this aim,
I adopted an interdisciplinary approach including aspects from nutritional, molecular and
genetic epidemiology.
In Chapter 2, I aimed to describe the dairy consumption patterns across time from a
UK representative sample and the contribution of dairy consumption to nutrient intakes.
Following trends previously reported over the last decades, I observed that full-fat milk
consumption continued decreasing over the years from 2008-2016, whereas yoghurt
consumption increased among elderly individuals. I also observed a high contribution of
dairy products to nutrient intakes including a contribution of more than 25% to vitamin A,
vitamin B12, calcium, phosphorus, saturated fat and trans fat.
In Chapters 4 and 5, I aimed to investigate associations of total and types of dairy
consumption with cardio-metabolic markers including markers of adiposity, lipidaemia,
glycaemia, inflammation, hepatic function and blood pressure to elucidate potential path-
ways linking dairy consumption to cardio-metabolic disease. Results from cross-sectional
(Chapter 4) and prospective (Chapter 5) analyses indicated that the most relevant pathways
underpinning the association between dairy consumption and cardio-metabolic disease
would involve the development of adiposity, especially central adiposity and dyslipidaemia.
The cross-sectional findings specifically showed that low-fat dairy consumption was asso-
ciated with lower visceral adipose tissue (VAT) and lower ratio of VAT to subcutaneous
adipose tissue (SCAT), which has been associated with a higher cardio-metabolic risk
independent of body mass index (BMI) and total body fat mass[174]. The prospective
findings showed that low-fat fermented dairy products are associated with lower levels of
adiposity markers compared to other dairy types.
In Chapter 6, I aimed to develop and validate metabolite scores predictive of dairy
consumption as potential dairy biomarkers to overcome the measurement error of the self-
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reported methods of dietary assessment. I developed such metabolite scores in a discovery
set and showed significant associations of the scores with total dairy products, milk and
butter in the internal validation dataset. When I used an independent set for external
validation, only the metabolite score for total dairy products produced a significant result
for the association with total dairy consumption. For the scores for dairy subtypes, I did not
obtain significant findings, except for milk and butter, when the scores were developed with
additional inclusion of odd-chain saturated fatty acids (OCSFAs) as candidate biomarkers
of dairy consumption.
In Chapter 7, I aimed to investigate associations of the metabolite scores developed
and validated in Chapter 6 with type 2 diabetes (T2D) risk. Metabolite scores for total
dairy products, milk and butter were consistently associated with a lower risk of T2D after
accounting for socio-demographic and lifestyle factors.
Finally, in Chapter 8, I aimed to identify genetic predictors of dairy consumption in
addition to the lactase persistence variant. The discovery analysis in a large UK cohort of
approximately 500,000 people indicated single nucleotide polymorphisms predictive of
total and types of dairy products.
9.2 Interpretation of findings
Interpreting research findings involves consideration of potential biological mechanisms
supported by the observed associations under the assumption that they are true. It also
involves consideration of methodological challenges, which might influence the accuracy
of the observed associations, especially for aetiological research. Examples of aetiological
research in this PhD are the analyses in Chapters 4, 5 and 7 investigating associations
of dairy consumption with cardio-metabolic markers, and of metabolite scores predictive
of dairy consumption with T2D risk. For research related to prediction as in Chapter 6
on exploration of metabolomic predictors of dairy consumption and in Chapter 8 on
exploration of genetic predictors of dairy consumption, it is more important to consider
methodological challenges, although potential biological mechanisms can provide insight
to causal associations and underlying pathways.
9.2.1 Potential biological mechanisms
As described in Chapter 1, total and types of dairy products have been associated either
with lower or no risk of cardio-vascular disease and T2D. In order to understand the
underlying mechanisms of these associations, it is important to consider the balance of
effects of the nutrients, which constitute the dairy food matrix, on cardio-metabolic disease
and its intermediate endpoints. For example, yoghurt has been more consistently associated
with a lower risk of T2D[12, 16, 18, 19, 21] and it is of interest to understand what are
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the nutrients and features of the food matrix of yoghurt that contribute to the favourable
associations observed. Suggested features of importance are related to the fermentation
process and include the higher bioavailability of nutrients due to the acidity of yoghurt,
which decreases gastric pH[32] and the higher content of vitamin K2, which has been
associated with a lower risk of T2D[329] and coronary heart disease[330] in prospective
cohort studies.
A.Body weight and body composition
Evidence from randomised controlled trials (RCTs) supports favourable effects of total
dairy consumption on body weight and composition under conditions of energy restriction.
Specifically, total dairy consumption decreased body weight[58, 59, 61, 62], total fat
mass[58–62], waist circumference[58, 61], abdominal fat[77, 78] and visceral adipose
tissue (VAT)[78], and increased lean mass[58, 59, 61] in RCTs with energy restriction. In
accordance with this line of evidence, we observed inverse associations of low-fat dairy
consumption with VAT and the ratio of VAT to SCAT (Chapter 4) and of yoghurt and
low-fat cheese with body weight and BMI (Chapter 5) and positive associations of milk
(total, full-fat and low-fat) with body lean mass (Chapter 4). However, we also observed
positive associations between increasing high-fat dairy consumption and increasing body
weight and BMI (Chapter 5). There are several mechanisms reported in the literature,
which support beneficial effects of dairy products on body composition and they are related
to dairy protein, calcium, conjugated linoleic acid (CLA), vitamin K2 and growth hormone.
Dairy proteins, i.e. whey and casein, might be involved in pathways related to body
weight and composition. In a meta-analysis of 14 RCTs, although whey protein supplemen-
tation decreased body weight and body fat mass from baseline to follow-up, no statistically
significant differences were observed with supplementation with other types of protein or
carbohydrates[331]. In a 20-week RCT in 48 obese Japanese participants, an intervention
of 21 g of milk protein per day decreased body weight, BMI, VAT, SCAT and adiponectin
compared with an intervention of 12 g of soy protein and 9 g of milk protein, but it had no
effects on lipid and glycaemic markers[332]. The two types of dairy protein i.e. casein
and whey might have differential effects on the metabolic regulation of body weight, since
their kinetics are different with whey being absorbed and raising the blood amino acid
levels faster than casein[333].
A mechanism, which has been extensively studied, is the regulation of appetite as a
proxy of food intake. From studies which assess appetite subjectively with questions on
hunger, satiety and fullness or with the prospective food intake after the protein preload,
there are indications that whey preload decreases appetite compared with casein preload,
but results are inconclusive[178]. Veldhorst et al[179] and Alfenas et al[180], proposed
some sources of the heterogeneity of effects. In one RCT there was a decrease in appetite
with a simultaneous increase in blood amino acids after an intervention with 10% of
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energy from whey compared with 10% of energy from casein or soy protein, whereas no
differential effects were observed after an intervention with 25% of energy from whey
compared with an intervention with equal amounts of casein or soy protein[179]. The
authors suggested that a more favourable effect is observed for whey in the lower amounts
only, because in these amounts, the whey profile of amino acids, which reach the circulation,
includes higher amounts from amino acids such as leucine, isoleucine and tryptophan,
which have been associated with appetite regulation, than casein or soy protein[179]. On
the contrary, at higher intakes of the proteins, amino acids from all proteins reach the
threshold, which is necessary for the effects on appetite to become obvious[179]. The
second RCT by Alfenas et al. suggested that intervention with casein led to a lower energy
intake after seven days compared with whey, which might be an indication that whey exerts
effects on appetite in the short-term, but casein exerts such effects in the longer-term[180].
Apart from the effects of the increasing plasma amino acid levels on appetite regulation,
there is some evidence that whey protein intake is associated with gut hormone levels,
which might contribute towards the regulation of appetite and include higher levels of
cholecystokinin (CCK)[178, 334], gastric inhibitory polypeptide (GIP)[334], glucagon-
like peptide 1 (GLP-1)[178, 179, 334], glucagon[334] and peptide YY (PYY)[334] and
lower ghrelin levels[334].
Despite any differential effects between the two proteins, an RCT showed that intake
of their combination in the form of low-fat milk resulted in lower energy intake than
a whey drink or a casein drink alone[335]. In addition to these results, a cross-over
RCT showed that the type of dairy product also makes a difference in the regulation
of appetite, as consumption of low-fat milk resulted in lower appetite compared with
water, but consumption of yoghurt or cheese resulted in even lower appetite[336]. The
authors suggest that the decrease in appetite after yoghurt consumption compared with
milk consumption might be due to the higher protein content of yoghurt[336]. This was
not the case for cheese, but the authors suggested that the requirement of chewing cheese
as a solid food compared to a semi-solid food like yoghurt or a liquid food like milk, might
have led to lower appetite compared with milk consumption[336].
Calcium is another nutrient that has been extensively studied for its involvement in
adiposity-related pathways. A meta-analysis of 13 RCTs did not identify a significant
effect of calcium supplementation on body weight, but in subgroup analyses, the authors
identified a small decreasing effect when calcium was allocated in the form of supplements
rather than as part of dairy consumption[337]. The authors also identified flaws in trial
randomisation with imbalances at baseline weights, which might have obscured the true
associations[337]. A mechanism for the potential effect of calcium on decreasing body
weight and adiposity is through the increase of faecal fat excretion. In a meta-analysis
of 13 RCTs, the estimated faecal fat excretion was 5.2 (95% CI: 1.6-8.8) g per 1,241
mg dairy calcium per day [338]. Another mechanism proposed by studies of Zemel et
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al, is that dietary calcium leads to an increase in the extracellular calcium, which results
in a decrease of parathyroid hormone and 1,25-dihydroxyvitamin D and a subsequent
drop in intracellular calcium[339]. The drop in intracellular calcium levels was shown to
decrease the expression of the fatty acid synthase gene and increase lipolysis resulting
in lower triglyceride storage in adipocytes[177, 340]. Calcium may exert synergistic
effects with the gut microbiome for the regulation of body weight and body fat. Related
mechanisms include (1) the increase in gastric acid secretion by calcium leading to a
decrease in the gastric pH and the decrease of bacterial populations that are not tolerant
to acidity (e.g.Salmonella spp) but subsequent increase of those that are more tolerant
(e.g.Lactobacillus)[341], (2) maintaining intestinal integrity through the inhibition of the
production of cytotoxic substances from bile and fatty acids from colonic bacteria[342]
due to an increase in faecal fat excretion, and (3) the decrease in bacterial translocation
due to higher intestinal integrity[341].
CLA has also been associated with a lower fat mass by 0.024 kg / g of intake /
week in a meta-analysis of 18 RCTs[343]. In vitro studies on human adipocytes showed
that the decreasing effect on fat mass might be due to the suppression of transcription
factors involved in adipogenesis[344, 345]. An example of such a transcription factor
is the peroxisome proliferator-activated receptor γ (PPARγ), which is involved in the
differentiation of preadipocytes to adipocytes[344, 345].
Supplementation with Vitamin K2 decreased abdominal fat, waist circumference and
VAT, and increased adiponectin levels among participants who were good respondents to
the supplementation, as assessed by the circulating levels of carboxylated osteocalcin as a
marker of Vitamin K2[346].
The observed positive associations between milk consumption and body lean mass
could be partly explained by the effect of milk on increasing growth hormone[182, 183],
which increases bone mineral density and muscle mass[184]. The bioactive compounds in
milk that increase growth hormone in humans are not well-characterised, but an assumption
is that one relevant compound might be bovine growth hormone[182]. Milk protein also
increased growth hormone in a cross-over RCT compared to placebo[183].
B.Lipidaemia
As described in detail in section 3.2, butter increases total, low-density lipoprotein (LDL-C)
and high-density lipoprotein cholesterol (HDL-C) when compared with other types of
fat, whereas null effects on blood lipids were reported for total, low-fat or high-fat dairy
products[63]. Cheese decreased LDL-C and HDL-C when compared with butter[83].
The current PhD analyses extended previous evidence by investigating associations be-
tween dairy types and lipid markers. In line with these results, we also reported positive
associations of high-fat dairy consumption and especially butter with total and LDL-C
(Chapters 4-5). On the contrary, in our analyses low-fat dairy consumption, milk and
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yoghurt (total and low-fat; Chapter 5) were associated with lower total, LDL-C (Chapter 5)
and HDL-C (Chapter 4).
Nutrients which have been related to increases in blood lipids are saturated and trans
fat. While controlled trials have shown an increasing effect of saturated fat on total, LDL
and HDL-C, when it substitutes carbohydrates, mono- or poly-unsaturated fatty acids[200],
results from trials using different dairy types with the same saturated fat content have
shown differential effects on blood lipids[83, 347]. This implies that constituents and
matrices of different dairy products might play a role in the overall effects of these foods on
lipidaemia. These differences might be partly explained by differences in nutrient content,
but also differential processes such as fermentation or homogenisation. In addition, there
is an indication that saturated fat from dairy products contributes to a more favourable
lipid profile in terms of the LDL-C particle size, being associated with a decrease in small
size LDL-C both when measured as part of the diet and as fatty acid biomarkers in blood
(especially C15:0 and C17:0)[348].
A cross-over RCT reported that a diet with 1.5% of energy from ruminant trans fat had
a neutral effect on the lipid profiles compared with a diet with 0.8% energy from total trans
fat, whereas two diets with 3% energy from ruminant or industrial trans fat resulted in less
favourable lipid profiles[349]. Even 1.5% of energy from ruminant trans fatty acids is high
for a habitual consumption, which has been estimated to be around 0.5%, so the authors
concluded that habitual consumption of ruminant trans fatty acids should not be harmful in
relation to lipidaemia[349].
The absence of positive associations with lipids for total and other dairy types (null
associations as reported from RCTs or inverse associations as observed in this PhD) might
be explained after considering the balance of effects between saturated or trans fat with
other nutrients e.g. calcium, probiotics or the food matrix of different dairy types. For
example, calcium has been shown to decrease lipolysis and increase lipogenesis[177]. The
presence of the milk fat globule membrane has also been related to a more favourable
lipidaemic profile. In a parallel group RCT in free living participants, after an interven-
tion of a whipping cream-based snack for eight weeks total and LDL-C did not change,
in contrast to the control group, who received a butter oil-based snack with the same
amount of energy, total fat, saturated fat, carbohydrates, protein and calcium as the inter-
vention and who increased their total cholesterol by 0.3±0.49 mmol/l and their LDL-C
by 0.36±0.5 mmol/l[347]. The main difference in the two snacks was that the milk fat
globule membrane was intact in the whipping cream, but was absent in the butter oil due to
homogenisation[347]. No differential effects were observed on other lipids, glycaemic and
inflammatory markers[347]. In the same study, they also observed down-regulation of gene
expression of peripheral blood mononuclear cells in the whipping cream group which was
correlated with lower circulating cholesterol[347]. Complementary to these results, in a
cross-over RCT participants received buttermilk for four weeks and a placebo product with
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the same nutrient profile as buttermilk apart from the milk fat globule membrane nutrient
profile[350]. The intervention with buttermilk resulted in 3.1% lower total cholesterol
and 10.7% lower triglycerides compared to the intervention with the placebo, whereas the
decrease in LDL-C was significantly lower only among participants with higher LDL-C at
baseline[350]. The proposed underlying mechanism was the decrease in cholesterol ab-
sorption concluded from the correlation of the proxy markers of cholesterol absorption i.e.
phytosterol and b-sitosterol with the changes in LDL-C induced by the intervention[350].
Probiotics administered through yoghurt or capsules contributed to a decrease in total and
LDL-C, but with no effects on HDL-C or triglycerides as indicated by a meta-analysis of
13 RCTs with durations of interventions ranging from 4-10 weeks[351].
C.Glycaemia and insulinaemia
RCTs have failed to report any effects of total, low-fat or high-fat dairy products on
glycaemic markers including fasting blood glucose, insulin, haemoglobin A1c (HbA1c) or
the homoestasis model assessment for insulin resistance (HOMA-IR). In agreement with
this evidence, the majority of associations we observed between total or types of dairy
consumption and glycaemic markers were null (Chapters 4-5) apart from full-fat milk,
which was associated with an increase in HbA1c (Chapter 5). Some nutrients contained in
dairy products have been associated with lower risk of T2D and with beneficial effects on
insulin resistance, while others might exert harmful effects.
Observational studies have reported inverse associations between vitamin D intake and
T2D risk[352], but evidence from RCTs has not confirmed beneficial effects of vitamin
D supplementation on glycaemic regulation, which poses the question of causality of
observational associations[353]. Probiotics also seem to decrease fasting glucose, insulin
and HbA1c both among patients with T2D and among people with metabolic syndrome or
some of its components as reported from a meta-analysis of 18 RCTs[354]. In vitro studies
in human adipocytes have shown an increase in insulin resistance after supplementation
with CLA[344, 355]. On the contrary an animal and an in vitro study showed that vaccenic
acid (trans-18:1n-7) decreases insulin resistance by promoting insulin secretion and islet
growth through alterations in expression of mRNA[356].
D.Inflammation
Fermented dairy consumption decreased inflammatory markers overall in RCTs[134], but
low-fat or high-fat dairy consumption did not have an effect on C-reactive protein (CRP).
In this PhD I did not observe any significant associations between dairy products and
inflammatory markers. The evidence on potential mechanisms linking dairy consumption
to inflammation is not clear. CLA is one nutrient that has been reported to increase the
production of inflammatory cytokines[344, 345, 355, 357], but decrease the expression of
adiponectin[345] in in vitro studies of human tissues.
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E.Blood pressure
Evidence from RCTs indicates a beneficial effect of fermented milk on systolic (SBP)
and diastolic (DBP) blood pressure[85], but no effects for total[84], low-fat or high-fat
dairy products[63]. Milk, total and low-fat dairy products have been associated with
lower risk of hypertension in prospective cohort studies[86]. This PhD’s results of null
associations between dairy consumption and blood pressure agreed with the previously
reported associations and extended such findings to individual dairy types. Some nutrients
such as protein, calcium and potassium have been linked to beneficial effects on blood
pressure especially among hypertensive people and might thus be involved in related
mechanisms.
A meta-analysis of 33 RCTs with an average duration of 7.8 weeks showed that inter-
ventions including casein-derived lactotripeptides (valine-proline-proline and isoleucine-
proline-proline), which are mainly released during fermentation of dairy products by lacto-
bacteria, decreased both systolic (SBP) and diastolic blood pressure (DBP)[358]. The ef-
fects remained significant for SBP also after identification of publication bias[358]. In sub-
group analyses, stronger effects were observed among people with higher blood pressure
levels at baseline and in Japanese populations compared with European populations[358].
In vitro studies have shown that these peptides act on blood pressure by inhibiting the an-
giotensin I converting enzyme by approximately 50% leading to lower vasoconstriction[359].
A meta-analysis of 40 RCTs with a median duration of 2.4 months reported decreases
in SBP and DBP by 1.86 mmHg (95% CI: -2.91, -0.81) and 0.99 mmHg (-1.61, -0.37)
respectively after an average of 1,200 mg calcium supplementation daily compared with
control[360]. Effects were attenuated, but still significant when only double blind trials
were included, while effects were stronger among people with baseline calcium intakes
lower than 800 mg /day[360]. Increase in potassium intake was also shown to decrease SBP
and DBP in a meta-analysis of 21 RCTs with stronger effects observed when potassium
intake reached the range 90-120 mmol/day and significant effects were only among
hypertensive people[361]. Also, for every 10 mmol/day of magnesium intake the SBP
decreased by 4.3 mmHg (-6.3, -2.2) in a meta-analysis of 20 RCTs[362].
Overall, results from clinical trials investigating dairy nutrient effects on blood pressure
support the observed beneficial associations of dairy consumption with blood pressure
among hypertensive people and weaker or null associations among normotensive people.
F.Dairy metabolite scores and type 2 diabetes risk
Although the use of metabolite scores predictive of dairy consumption might contribute to
the elucidation of pathways linking dairy consumption to T2D risk, the specific biological
mechanisms involved are not clear and are hard to disentangle. However, some assumptions
for relevant mechanisms were discussed in more detail in section 7.5.3. Briefly, the
inverse associations observed in this PhD might reflect a set of pathways related to the
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metabolites I used to create the score and especially the top metabolites, which consist
of phosphatidylcholines (PCs) and sphingomyelins (SMs). Most of the PCs and SMs
comprised sum of isobaric and isomeric compounds, which contain the odd-chain saturated
fatty acids (OCSFAs) C15:0 and C17:0, or the even-chain fatty acids C16:0 and C18:0.
The observed associations might be a result of the balance of effects between OCSFAs and
the even-chain fatty acids. Blood C16:0 and C18:0 have been previously associated with
higher insulin resistance[298, 299], inflammation[300, 301] and T2D[228]. Considering
that fatty acids are expressed in relative amounts, and that OCSFAs can be alternatively
produced by even-chain fatty acids[208], higher concentrations of OCSFAs might reflect
lower concentrations of C16:0 and C18:0 and thus overall lipid profile, which favours
insulin sensitivity.
9.2.2 Epidemiological considerations
Accuracy of observed associations
The accuracy of an observed association can be assessed by evaluating its validity i.e.
whether the observed association reflects the true association and its precision i.e. how close
the observed association is to the true association[363]. Systematic error or bias can be a
threat to validity and random error can be a threat to precision. Validity can be understood
in terms of: internal validity that is validity of associations within the source population
of the study, and external validity or generalisability that is validity of associations in the
general population[363]. Different sources of bias, which can influence the validity of the
observed associations are selection bias, information bias and confounding.
Selection bias
Types of selection bias relevant to the studies of this PhD are sampling bias, attrition
bias, non-response bias, and collider bias[202]. From the cohorts I used in this project, the
National Diet and Nutrition Survey (NDNS) has a lower probability of involving sampling
bias compared with the other cohorts. NDNS sampling was random and representative
of the general population. On the contrary, eligibility of participants in the other three
cohorts (Fenland study, EPIC Norfolk study and UK Biobank) was not based on the
representativeness of the sample. While such bias might not have an impact on the internal
validity of the findings, it might limit the external validity. For example, more health-
conscious people of a higher educational level might have a higher probability of agreeing
to participate, thus resulting in a non-representative sample of the general population,
which might influence the external validity (generalisability)[202]. Thus, generalisability
of our findings from the cohorts other than NDNS was made with caution. Replication of
these findings in other studies will provide more confidence to generalise our results from
the source population to the general population.
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Attrition bias might appear in longitudinal studies if participants lost to follow-up have
systematically different characteristics from those who continue. A more specific effect of
attrition bias might be the healthy survivor’s effect, when participants who were healthier
were more likely to stay in the study for follow-up than those who might have developed a
disease or died. In the prospective analysis on associations between dairy consumption
and cardio-metabolic markers in the EPIC Norfolk study (Chapter 5), such bias could lead
to more optimistic results e.g. more favourable associations between dairy consumption
and cardio-metabolic markers than the true associations, which could compromise internal
validity, but also the inclusion of a healthier sample than the general population, which
could compromise the external validity. To handle this possibility, I applied weights
based on the inverse of the probability that a participant would be censored with weights
generated from prediction models for censoring and results were not materially different
from the main approach. In addition, I performed multiple imputation, which has been
shown to give equally valid results with complete-case analysis under the assumption of
data missing completely at random, but more valid results under the assumption of data
missing at random in simulation studies[168]. Multiple imputation is also a useful tool
when there are missing data due to non-response.
Non-response bias is another type of bias, which may appear if participants who do not
respond to some questions have different characteristics from participants who respond
and these characteristics might be related to the risk of disease[202]. Collider bias might
also appear in some cases when we adjust for a variable, which affects the outcome and
it is also affected by the exposure[202]. An example of collider bias that could appear
in this PhD is the one described in Chapter 5 on the bias caused by the adjustment for
the baseline outcome in longitudinal observational studies, where the baseline outcome
(e.g.baseline weight) affects the follow-up outcome (e.g follow-up weight) and might be
affected by the exposure (e.g. yoghurt) or other factors related to the exposure (e.g. an
overall healthy lifestyle)[194]. For this reason, we did not adjust for the baseline outcome
in the longitudinal analysis, but we accounted for it by using as outcome the change
between the baseline and follow-up in the analysis of change.
Information bias
Information bias might also influence the associations observed in this PhD and stems
from the error in the information acquired during the data collection[363]. Recall bias
is a form of information bias and is related to the accuracy of information provided by
participants or their proxies when they have to recall it. For example, recall bias might
be greater among elderly people due to memory issues. Most of the cohorts used in this
project consisted of adults with a proportion of them being elderly, so we cannot exclude
the possibility of recall bias. It is difficult to predict how associations might be influenced
by the presence of recall bias. Another form of information bias is social desirability bias,
which appears when participants provide the kind of information, which is more socially
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acceptable, even if it is not true[364]. In nutritional epidemiology this bias is common.
For example, many studies have observed under-reporting of total energy intake due to
under-reporting of foods high in fat and sugar among participants who are overweight or
obese[145–152]. In this PhD’s cross-sectional analysis (Chapter 4), I observed an inverse
association of high-fat dairy consumption with BMI and a positive association of low-fat
dairy consumption with BMI. This observation might be the result of social desirability bias
with participants with higher BMI reporting higher consumption of low-fat dairy products.
However, this might also be the result of participants of higher BMI actually consuming
higher amounts of low-fat dairy products. The true explanation is not certain, but these are
plausible scenarios. In any case, in subsequent cross-sectional analyses of outcomes other
than BMI, I adjusted for BMI to partly account for that observation. When classifying
participants into categories of a variable, for which information has been obtained from
self-reporting, information bias might lead to misclassification of participants, which
then can lead to spurious associations[363]. To avoid this kind of bias when classifying
participants into categories, I chose to compare extreme categories, as the probability of
misclassification between extreme categories is lower than consecutive categories. For
example, in the analysis of Chapter 6, where the aim was to identify biomarkers of total
and types of dairy consumption, I described metabolic profiles of very low consumers and
high consumers. In the genetic analyses of Chapter 8, I did not use the extreme categories
only, but I specified consumers and non-consumers of total and types of dairy products.
However, in this study, there were two dietary tools available (touchscreen questionnaire
and the Oxford WebQ 24-hour recall) and for each tool we had multiple repeated measures
of dietary assessment available. The multiple reports of consumption or no consumption
by the same participant provided the possibility to confirm the consistency of reporting of
dairy consumption. Since genetics would predict consumption over a lifetime, genetically
predicted non-consumption should be consistent across the repeated measurements, so
with at least one report of dairy consumption, participants were classified as consumers
and in this way, we theoretically decreased the effect of misclassification bias on this
analysis. Misclassification can be differential or non-differential depending on whether
it is systematically related to a participant characteristic and thus it happens towards a
specific direction or it is random and it happens in both directions[363]. An example
of differential misclassification in this PhD was that mentioned on overweight or obese
participants over-reporting total energy intake. Non-differential misclassification will lead
to attenuation of true associations[363].
Confounding
Confounding is another phenomenon that can influence internal validity of the results.
It is related to the observation of spurious associations due to failure to account for factors,
which are related to both the exposure and the outcome, but are not in the causal path-
way of the association between the exposure and the outcome and can thus obscure this
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association[363]. In RCTs, if the randomisation is successful, factors generally confound-
ing an observational association should have a similar distribution between the intervention
and the control group and should not obscure any observed effects of the intervention.
However, in observational research confounding is a major point of consideration. All
the studies used in this PhD were observational, so I tried to account for confounding
by adjusting the models for potential confounders including socio-demographic factors,
lifestyle factors and clinical factors.
In nutritional epidemiology, adjustment for energy intake is of special relevance and
several ways have been described depending on the purpose of the study[204]. For example,
if the aim of a study is to examine substitution of a nutrient/food with other nutrients/foods,
then we can adjust for total energy intake and all the nutrients/foods apart from the one
that we want to substitute our exposure with[204]. In the studies of this PhD, I was
interested in investigating the associations of total and types of dairy consumption with
markers of metabolic risk and adiposity accounting for total energy intake and other
food groups, so I adjusted for them. In this way, the comparison was for lower dairy
consumption by 1 serving/day without any substitution. Although I adjusted for several
potential confounders, the possibility of residual confounding cannot be excluded due to
either unmeasured confounders or confounders measured with some degree of error. For
example, dietary assessment with the food frequency questionnaire gives a rough estimate
of habitual consumption and is suitable for the ranking of participants, but it is prone to
the types of information bias mentioned above. Estimation of food consumption with a
degree of error leads to estimation of nutrient intakes including total energy intake with
a higher degree of error due to the additional level of assumptions and sources of error
included in the step of dietary data processing to generate nutrient intakes. Confounding
can also influence the precision of the observed associations, but it is difficult to identify
its exact impact. Precision of effect estimates is mainly influenced by random error, can
have the form of sampling error or measurement error and usually leads to attenuation of
associations[363].
Effect-measure modification is also a point to consider, which means differential
associations for different levels of a factor and which can be approximated by statistical
interaction under the assumption of no bias[363]. In the two analyses of aetiological
research of Chapters 4 and 5, I investigated potential interactions by age, sex and BMI
and when significant, I also presented results from analyses stratified by these factors.
However, no major differences were observed, but in the presence of bias, failure to observe
statistically significant interaction is not equivalent to the absence of biological interactions.
This was not something that I could test within the studies.
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Causality of observed associations
Causality is a major consideration in epidemiological studies of aetiological research.
Three of the studies included in this PhD were of aetiological character (Chapters 4, 5
and 7), while the other studies were of a descriptive (Chapter 2) or predictive (Chapters 6
and 8) character. There have been several approaches to describe and assess causality
in a study, but one approach, which is widely used in epidemiological research is the
Bradford-Hill criteria[363]. These criteria include strength of association, consistency,
specificity, temporality, biological gradient, plausibility, coherence, experimental evidence
and analogy[363]. The greater the number of these criteria that are fulfilled in a study,
the higher the probability that the associations observed are causal. However, although
these criteria can give an overall good guidance to make causal inferences, they also have
limitations.
Strength of association
According to the Bradford-Hill criteria, the stronger an association, the more probable
that it is causal. However, it is also possible that the true biological association is weak,
especially when it is about a multi-factorial outcome, such as cardio-metabolic disease,
which might have many risk factors of small effects rather than only a few with large
affects. Nevertheless, the scenario that a weak association is the result of the attenuation
due to confounding is still possible. In two of the analyses of aetiological character, where
there were multiple exposures and outcomes, I presented results in forest plots with their
95% confidence intervals, so that we could compare the magnitude of estimates and their
confidence intervals across different associations assessed under the same conditions. Such
conditions might refer to the same study design or adjustment for the same confounders.
Forest plots provided us with an overall picture of the most convincing associations out
of all that we observed, especially since it is difficult to judge in absolute terms which
associations are considered strong. In our investigation of associations between dairy
metabolite scores and T2D risk, significant associations were considered on average strong
with a risk reduction ranging from 17% to 43%.
Consistency
Consistency of associations observed under different circumstances and different
populations might be an indication of causality. The lack of consistency, though, is not
equivalent to lack of causality, because some associations might be specific to certain
populations e.g. certain ethnic groups. In this PhD analysis, I used as a positive control
the association between butter consumption and LDL-C, which has been established
from evidence of RCTs and seems to be replicated across different populations and
circumstances. The observation of a positive association, which was consistent with
previous evidence provided more confidence for the observed associations. In addition,
in both the cross-sectional (Chapter 4) and the prospective (Chapter 5) analyses, we
overall observed significant associations of dairy consumption with markers of adiposity
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or lipidaemia. This might further confirm that adiposity and lipidaemia might be more
strongly related to pathways underpinning associations between dairy consumption and
cardio-metabolic disease. In the survival analysis on associations between dairy metabolite
scores and T2D risk, we confirmed that top metabolites associated in a similar way with
T2D in other observational studies.
Specificity
The criterion of specificity refers to specific associations observed between an exposure
and an outcome. When the exposure is a dietary factor such as dairy products, it is often
not possible to identify an outcome that the exposure will be specific for. Likewise, when
a disease is multi-factorial i.e. multiple risk factors (causes) can lead to disease, such
as cardio-metabolic disease, it is often not possible to identify exposures specific to this
outcome.
Temporality
For the temporality assumption to be fulfilled, the exposure should precede the outcome.
In our prospective analysis (Chapter 5), this assumption was fulfilled, but not in our cross-
sectional analysis (Chapter 4), where the possibility of reverse causation i.e. that the
outcome affects the exposure is high. Although it is not possible to know the direction of
association and eliminate the possibility for reverse causation in a cross-sectional analysis,
it is reasonable to assume that more phenotypically obvious outcomes such as BMI might
influence the behaviour of the participants than less obvious outcomes such as visceral fat,
when it is assessed independent of BMI. To do this, we adjusted the rest of associations for
BMI, especially after the observation that low-fat dairy consumption was associated with a
higher BMI. Nevertheless, these findings are important for hypothesis generation, as for
example the association between low-fat dairy consumption and the VAT/SCAT ratio has
not been previously examined.
Biological gradient and analogy
The criteria of biological gradient, i.e. a linear dose-response association and analogy,
have been criticised. Non-linear associations can also be causal. In addition, the assumption
of analogy e.g. assumption of harmful effects of an exposure on outcome B, because
they were observed on outcome A, might contradict the assumption of specificity, that the
exposure would be specific to one outcome.
Biological plausibility, coherence and experimental evidence
Biological plausibility, coherence and experimental evidence concerning the associa-
tions we observed were discussed in the previous paragraph about evidence on potential
mechanisms.
Overall, our analyses that involve aetiological research fulfil partly or fully some of the
Bradford-Hill criteria including strength of association, consistency, temporality, biological
gradient, plausibility, coherence and experimental evidence. Based on that, although we
can be more confident of the associations we observed in terms of causality, we have to
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acknowledge the limitations of our research and we cannot be certain about causality. This
work adds to the existing evidence, but is only a part of the evidence synthesis and we
should draw conclusions based on the total body of evidence rather than individual studies.
9.3 Strengths and limitations
The overall strength of this PhD was the application of a multi-disciplinary approach inves-
tigating aspects of nutritional, molecular and genetic epidemiology that might contribute to-
wards a greater understanding of the link between dairy consumption and cardio-metabolic
disease. To describe dairy consumption patterns and their contribution to nutrient intakes in
the UK, I used a representative sample of the UK population and contributed to increased
precision of estimates by incorporating dairy consumption as part of composite foods,
which made a difference for some of the estimates.
Although RCTs are the gold standard in the ranking of evidence quality, they also
have some limitations including low sample size, short duration, questionable compliance,
impossible blinding and diversity in comparison groups as mentioned in section 3.8[63],
which makes observational studies a valuable source of research. Another limitation I
identified in the literature related to RCTs and especially in pooled results reported in meta-
analyses was that the majority of the available evidence concerned total dairy products or
total low- or high-fat dairy products rather than specific types[58–61, 63, 84]. Although
this is still informative, due to the heterogeneity of dairy products as a food group, it is
of greater interest to investigate specific dairy types. Therefore, across all the studies in
this PhD, I consistently investigated both total dairy products, but also dairy types with the
highest level of detail possible based on the limitations of the dietary assessment methods
available.
To explore potential biomarkers of dairy consumption, I developed metabolite scores,
which might better reflect and be more specific to dairy consumption than single biomarkers
and I assessed the scores for both internal and external validity, which many nutritional
metabolomics studies lack[288]. Finally, to explore potential genetic predictors of dairy
consumption, I used the largest biobank in the UK with genetic data from approximately
500,000 people, which gave us sufficient power to detect some significant genetic predictors.
This work is novel, as there are no previously published genome-wide association studies
on dairy consumption.
This PhD also had limitations. The observational nature of the studies included did not
allow us to be certain about causality of the associations observed. Replication of such
results in RCTs or Mendelian Randomisation studies might provide higher confidence
about causality. I did take the first step towards enabling Mendelian Randomisation,
which was to identify novel genetic predictors of dairy consumption additional to the
lactase persistence variant. These results can be useful as instrumental variables in future
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studies. Other limitations were related to the methodological considerations described
in section 9.2.2 including the possibility of different types of selection bias (sampling,
attrition, non-response and collider bias) and information bias (recall and social desirability
bias), as well as residual confounding despite my effort to adjust for many relevant potential
confounders. It is difficult to disentangle the effect that presence of bias and confounding
could have on the effect estimates we reported. Although I followed some approaches to
try and minimise the sources of such errors, bias can be inherent within the initial study
design and it is not possible to completely control for it. The use of self-reported methods
of dietary assessment in this PhD is more prone to information bias, and also random
measurement error and can give less valid and less precise estimates. However, nutritional
epidemiology has to rely on available methods, which are currently based on self-report.
My use of plasma fatty acids and metabolite scores from metabolomics was an attempt to
overcome some of these challenges by using objective assessment.
9.4 Implications for public health
Results from this PhD can be informative for public health research and public health
policy. In Chapter 2, I reported trends in total and types of dairy consumption over the
past eight years and the contribution of dairy products to nutrient intakes with a higher
precision in the estimates than previously reported. Monitoring food consumption patterns
in a population can inform policymakers on the compliance of the public to the dietary
guidelines, detect areas of concern and further inform public health decision-making. In
Chapters 4 and 5, I investigated associations of total and types of dairy consumption
with markers of metabolic risk and adiposity, detecting significant associations between
certain dairy types and certain markers of adiposity and lipidaemia. Although we cannot
be sure about causality of the associations that were observed, we consider our results
important for hypothesis generation, which can be further tested in RCTs. Our novel result
on the cross-sectional association between low-fat dairy consumption and VAT/SCAT
independent of BMI has not previously reported and effects of dairy consumption on body
fat distribution would be useful to be characterised in RCTs.
In Chapter 6, I developed metabolite scores predictive of dairy consumption. I was able
to validate the score for total dairy consumption and there was some evidence of validation
for the scores for milk and butter consumption, but I could not validate scores for yoghurt
and cheese. Although this study had limitations, the approach of metabolite scores rather
than single biomarkers is important, as metabolite scores can be more specific to foods,
such as dairy products, which have a lot of nutrients in common with other foods and thus
a more holistic approach reflecting dairy food matrix would be more informative. The use
of metabolite scores can have multiple implications from an objective method of dietary
assessment in nutrition research to the elucidation of potential pathways linking dairy
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consumption to disease, but also the monitoring of the nutritional status in a clinical setting.
We are still away from the application of personalised nutrition in the clinical setting based
on the metabolomic profile of patients or even more so in a public health setting based on
the profile of the people from the general population. However, when personalised nutrition
becomes a possibility and is applied in a clinical or public setting, such scores might be very
useful. Although currently biomarkers cannot completely replace self-reported methods of
dietary assessment, metabolic profiles that predict dairy consumption could complement
self-reported methods and account for their limitations. In patients who cannot report their
diet e.g. critically ill or with memory problems, biomarkers can prove even more useful
for assessment of diet and nutritional status. Complementary to metabolite scores, dairy
predictors on the genetic level related to the work we did in Chapter 8, can also be useful
for personalised nutrition apart from their usefulness in research.
9.5 Suggestions for future research
This PhD has laid the foundations for advancements in nutrition research, focusing on
the link between total and types of dairy products and cardio-metabolic disease, spanning
scientific areas of nutritional, molecular and genetic epidemiology. However, further
research should build on the findings of this PhD. Some examples are as below.
In Chapter 2, we described dairy consumption trends over the last eight years, but it is
of greater interest to monitor consumption trends over decades. Available data on dairy
consumption patterns in the UK before the National Diet and Nutrition Survey (NDNS)
are related to proxies of individual consumption such as food supply and availability or
consumption on the household level. Thus, the NDNS rolling programme will provide
valuable information in future years to continue describing and monitoring food consump-
tion patterns in the general UK population, but also specific "at risk" populations or specific
ethnic groups.
In Chapters 4 and 5, we identified some associations of total and types of dairy
consumption with certain markers of adiposity and lipidaemia. Some of them, e.g. the
positive association between butter and LDL-C, are well-characterised from prior RCTs.
However, others such as the association between low-fat dairy consumption and VAT/SCAT,
have not been previously described. Thus, it would be useful that the hypotheses generated
from this work are further tested in RCTs, but also animal or mechanistic studies for the
disentanglement of relevant pathways.
In Chapter 6, we adopted an approach developing metabolite scores predictive of dairy
consumption and validating some of them and in Chapter 7, we investigated associations
between the scores and T2D risk. Limitations of our study included the observational
design, the limited set of metabolites we used and the biological sample we used, which
might partly explain the failure to validate the scores for yoghurt and cheese. Therefore, it
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would be useful if our approach is followed in RCTs, with different sets of metabolites and
biological samples e.g. including metabolites related to the gut microbiome, which might
be additionally useful and specific for fermented products like yoghurt and cheese.
Finally, the discovery analysis described in Chapter 8 should be further replicated
in other studies, but also other populations and ethnic groups and the genetic predictors
should be applied in Mendelian Randomisation analyses for the investigation of causal
associations between dairy consumption and cardio-metabolic disease.
9.6 Conclusions
The multi-disciplinary approach followed in this PhD, which included aspects of nutritional,
molecular and genetic epidemiology, laid the foundations for a greater understanding of
the pathways underlying the associations between dairy products and cardio-metabolic
disease with a focus on adiposity and lipidaemia. It also generated hypotheses to be further
tested in studies of different designs such as the cross-sectional association of low-fat dairy
consumption with VAT/SCAT that we observed and some metabolites strongly associated
with dairy consumption such as SM-OH C14:1. This PhD also highlighted the usefulness
of some approaches such as the use of metabolite scores rather than single metabolites to
predict dairy consumption, but also their limitations, which did not allow for validation
of the scores and can be further addressed in future research. Such an approach can
be useful for future research potentially including more aspects of other disciplines and
further advancing this area of research. Finally, this PhD contributed new knowledge
on the possible genetic determinants of consumption of dairy types. Though this work
highlighted the challenges of doing genome-wide association analyses for dietary factors
that are ascertained by self-report, future replication of the work and the use of biomarkers
will further enhance this area of science. Such knowledge will also enable the investigation
of causality of association with cardio-metabolic disease.
References
[1] Naghavi M, Abajobir AA, Abbafati C, Abbas KM, Abd-Allah F, Abera SF, et al.
Global, regional, and national age-sex specific mortality for 264 causes of death,
1980–2016: a systematic analysis for the Global Burden of Disease Study 2016.
The Lancet. 2017;390(10100):1151–1210.
[2] Federation ID. IDF Diabetes Atlas, 8th edn. Brussels, Belgium: International
Diabetes Federation, 2017;.
[3] Gakidou E, Afshin A, Abajobir AA, Abate KH, Abbafati C, Abbas KM, et al.
Global, regional, and national comparative risk assessment of 84 behavioural,
environmental and occupational, and metabolic risks or clusters of risks, 1990–2016:
a systematic analysis for the Global Burden of Disease Study 2016. The Lancet.
2017;390(10100):1345–1422.
[4] Bian S, Hu J, Zhang K, Wang Y, Yu M, Ma J. Dairy product consumption and
risk of hip fracture: a systematic review and meta-analysis. BMC Public Health.
2018;18(1):165.
[5] Mozaffarian D. Dietary and Policy Priorities for Cardiovascular Disease, Diabetes,
and Obesity A Comprehensive Review. Circulation. 2016;133(2):187–225.
[6] Chen GC, Wang Y, Tong X, Szeto IM, Smit G, Li ZN, et al. Cheese consumption
and risk of cardiovascular disease: a meta-analysis of prospective studies. European
journal of nutrition. 2017;56(8):2565–2575.
[7] Guo J, Astrup A, Lovegrove JA, Gijsbers L, Givens DI, Soedamah-Muthu SS. Milk
and dairy consumption and risk of cardiovascular diseases and all-cause mortality:
dose–response meta-analysis of prospective cohort studies. Eur J Epidemiol. 2017;
p. 1–19.
[8] Schwingshackl L, Hoffmann G, Lampousi AM, Knüppel S, Iqbal K, Schwedhelm
C, et al.. Food groups and risk of type 2 diabetes mellitus: a systematic review and
meta-analysis of prospective studies; 2017.
[9] Wu L, Sun D. Consumption of Yogurt and the Incident Risk of Cardiovascular
Disease: A Meta-Analysis of Nine Cohort Studies. Nutrients. 2017;9(3).
[10] Alexander DD, Bylsma LC, Vargas AJ, Cohen SS, Doucette A, Mohamed M, et al.
Dairy consumption and CVD: a systematic review and meta-analysis. Br J Nutr.
2016;115(4):737–50.
[11] de Goede J, Soedamah-Muthu SS, Pan A, Gijsbers L, Geleijnse JM. Dairy con-
sumption and risk of stroke: a systematic review and updated dose–response meta-
analysis of prospective cohort studies. Journal of the American Heart Association.
2016;5(5):e002787.
258 References
[12] Gijsbers L, Ding EL, Malik VS, de Goede J, Geleijnse JM, Soedamah-Muthu SS.
Consumption of dairy foods and diabetes incidence: a dose-response meta-analysis
of observational studies. Am J Clin Nutr. 2016;103:1111–1124.
[13] Mullie P, Pizot C, Autier P. Daily milk consumption and all-cause mortality, coronary
heart disease and stroke: a systematic review and meta-analysis of observational
cohort studies. BMC Public Health. 2016;16(1):1236.
[14] Pimpin L, Wu JH, Haskelberg H, Del Gobbo L, Mozaffarian D. Is butter back? A
systematic review and meta-analysis of butter consumption and risk of cardiovascu-
lar disease, diabetes, and total mortality. PLoS One. 2016;11(6):e0158118.
[15] Qin LQ, Xu JY, Han SF, Zhang ZL, Zhao YY, Szeto IM. Dairy consumption and risk
of cardiovascular disease: an updated meta-analysis of prospective cohort studies.
Asia Pac J Clin Nutr. 2015;24(1):90–100.
[16] Chen M, Sun Q, Giovannucci E, Mozaffarian D, Manson JE, Willett WC, et al.
Dairy consumption and risk of type 2 diabetes: 3 cohorts of US adults and an
updated meta-analysis. BMC Med. 2014;12:215.
[17] Hu D, Huang J, Wang Y, Zhang D, Qu Y. Dairy foods and risk of stroke: a meta-
analysis of prospective cohort studies. Nutr Metab Cardiovasc Dis. 2014;24(5):460–
9.
[18] Aune D, Norat T, Romundstad P, Vatten LJ. Dairy products and the risk of type 2
diabetes: a systematic review and dose-response meta-analysis of cohort studies.
Am J Clin Nutr. 2013;98(4):1066–83.
[19] Gao D, Ning N, Wang C, Wang Y, Li Q, Meng Z, et al. Dairy products consumption
and risk of type 2 diabetes: systematic review and dose-response meta-analysis.
PLoS One. 2013;8(9):e73965.
[20] Soedamah-Muthu SS, Ding EL, Al-Delaimy WK, Hu FB, Engberink MF, Willett
WC, et al. Milk and dairy consumption and incidence of cardiovascular diseases
and all-cause mortality: dose-response meta-analysis of prospective cohort studies.
Am J Clin Nutr. 2011;93(1):158–71.
[21] Tong X, Dong JY, Wu ZW, Li W, Qin LQ. Dairy consumption and risk of type 2 dia-
betes mellitus: a meta-analysis of cohort studies. Eur J Clin Nutr. 2011;65(9):1027–
31.
[22] Elwood PC, Pickering JE, Givens DI, Gallacher JE. The consumption of milk and
dairy foods and the incidence of vascular disease and diabetes: an overview of the
evidence. Lipids. 2010;45(10):925–39.
[23] England PH. The Eatwell Guide. 2016;.
[24] Agriculture USDoH, Services H, of USD. 2015–2020 Dietary Guidelines for
Americans. 8th Edition. 2015;.
[25] Gordon T. The Diet-heart idea Outline of a history. Am J Epidemiol.
1988;127(2):220–225.
[26] de Souza RJ, Mente A, Maroleanu A, Cozma AI, Ha V, Kishibe T, et al. Intake
of saturated and trans unsaturated fatty acids and risk of all cause mortality, car-
diovascular disease, and type 2 diabetes: systematic review and meta-analysis of
observational studies. BMJ. 2015;351:h3978.
References 259
[27] Jakobsen MU, O’Reilly EJ, Heitmann BL, Pereira MA, Bälter K, Fraser GE, et al.
Major types of dietary fat and risk of coronary heart disease: a pooled analysis of 11
cohort studies. The American journal of clinical nutrition. 2009;89(5):1425–1432.
[28] Mozaffarian D, Micha R, Wallace S. Effects on Coronary Heart Disease of In-
creasing Polyunsaturated Fat in Place of Saturated Fat: A Systematic Review and
Meta-Analysis of Randomized Controlled Trials. Plos Medicine. 2010;7(3).
[29] Hooper L, Martin N, Abdelhamid A, Davey Smith G. Reduction in saturated fat
intake for cardiovascular disease. Cochrane Database Syst Rev. 2015;(6):CD011737.
[30] Organisation WH. Guidelines: Saturated fatty acids and trans-fatty acids intakes for
adults and children. 2018;.
[31] Nutrition Division F. Codex Alimentarius - Joint FAO/WHO Food Standards
Programme. 2011;.
[32] Buttriss J. Nutritional properties of fermented milk products. International Journal
of Dairy Technology. 1997;50(1):21–27.
[33] Lindmark Månsson H. Fatty acids in bovine milk fat. Food and nutrition research.
2008;52(1):1821.
[34] Dewettinck K, Rombaut R, Thienpont N, Le TT, Messens K, Van Camp J. Nutri-
tional and technological aspects of milk fat globule membrane material. International
dairy journal. 2008;18(5):436–457.
[35] Roe M, Pinchen H, Church S, Finglas P. McCance and Widdowson’s the composition
of foods seventh summary edition and updated composition of foods integrated
dataset. Nutrition Bulletin. 2015;40(1):36–39.
[36] Yantcheva B, Golley S, Topping D, Mohr P. Food avoidance in an Australian adult
population sample: the case of dairy products. Public Health Nutr. 2015; p. 1–8.
[37] Khatibzadeh S, Saheb Kashaf M, Micha R, Fahimi S, Shi P, Elmadfa I, et al.
A global database of food and nutrient consumption. Bull World Health Organ.
2016;94(12):931–934.
[38] Hobbs DA, Lovegrove JA, Givens ID. In: Watson RR, De Meester F, editors.
Chapter 5 - Dairy Products: Their Role in the Diet and Effects on Cardiovascular
Disease. AOCS Press; 2016. p. 111–129.
[39] Fagerli RA, Wandel M. Gender differences in opinions and practices with regard to
a" healthy diet". Appetite. 1999;32(2):171–190.
[40] Smith AM, Baghurst KI. Public health implications of dietary differences be-
tween social status and occupational category groups. Journal of epidemiology and
Community Health. 1992;46(4):409–416.
[41] Roos E, Prättälä R, Lahelma E, Kleemola P, Pietinen P. Modern and healthy?:
socioeconomic differences in the quality of diet. European journal of clinical
nutrition. 1996;50(11):753–760.
[42] Fraser G, Welch A, Luben R, Bingham S, Day N. The effect of age, sex, and
education on food consumption of a middle-aged English cohort—EPIC in East
Anglia. Preventive medicine. 2000;30(1):26–34.
260 References
[43] Hjartåker A, Lagiou A, Slimani N, Lund E, Chirlaque M, Vasilopoulou E, et al.
Consumption of dairy products in the European Prospective Investigation into
Cancer and Nutrition (EPIC) cohort: data from 35955 24-hour dietary recalls in 10
European countries. Public health nutrition. 2002;5(6b):1259–1271.
[44] Kelleher C, Friel S, Nolan G, Forbes B. Effect of social variation on the Irish diet.
Proceedings of the Nutrition Society. 2002;61(04):527–536.
[45] Delgado CL. Rising consumption of meat and milk in developing countries has
created a new food revolution. The journal of nutrition. 2003;133(11):3907S–3910S.
[46] Sanchez-Villegas A, Martinez J, Prättälä R, Toledo E, Roos G, Martinez-Gonzalez
M. A systematic review of socioeconomic differences in food habits in Europe: con-
sumption of cheese and milk. European journal of clinical nutrition. 2003;57(8):917–
929.
[47] Deshmukh-Taskar P, Nicklas TA, Yang SJ, Berenson GS. Does food group con-
sumption vary by differences in socioeconomic, demographic, and lifestyle factors
in young adults? The Bogalusa Heart Study. Journal of the American Dietetic
Association. 2007;107(2):223–234.
[48] Fulgoni V, Nicholls J, Reed A, Buckley R, Kafer K, Huth P, et al. Dairy consumption
and related nutrient intake in African-American adults and children in the United
States: continuing survey of food intakes by individuals 1994-1996, 1998, and the
National Health And Nutrition Examination Survey 1999-2000. Journal of the
American Dietetic Association. 2007;107(2):256–264.
[49] Boylan S, Lallukka T, Lahelma E, Pikhart H, Malyutina S, Pajak A, et al. Socio-
economic circumstances and food habits in Eastern, Central and Western European
populations. Public health nutrition. 2011;14(04):678–687.
[50] Possa G, de Castro MA, Marchioni DML, Fisberg RM, Fisberg M. Probability and
amounts of yogurt intake are differently affected by sociodemographic, economic,
and lifestyle factors in adults and the elderly—results from a population-based study.
Nutrition Research. 2015;35(8):700–706.
[51] Panahi S, Fernandez M, Marette A, Tremblay A. Yogurt, diet quality and lifestyle
factors. European journal of clinical nutrition. 2017;71(5):573.
[52] Cormier H, Thifault E, Garneau V, Tremblay A, Drapeau V, Pérusse L, et al. As-
sociation between yogurt consumption, dietary patterns, and cardio-metabolic risk
factors. European journal of nutrition. 2016;55(2):577–587.
[53] NatCen Social Research UCLMS MRC Elsie Widdowson Laboratory. National Diet
and Nutrition Survey Years 1-8, 2008/09-2015/16; 2018.
[54] Research MHN. Food Standards Agency Standard Recipes Database, 1992-2012.
UK Data Service SN: 8159. 2017;.
[55] Hulshof K, van Erp-Baart M, Anttolainen M, Becker W, Church S, Couet C, et al.
Intake of fatty acids in western Europe with emphasis on trans fatty acids: the
TRANSFAIR Study. European journal of clinical nutrition. 1999;53(2):143.
[56] Tarja Laaninen EPRS. Trans Fats - Overview of recent developments. European
Parliament. 2016;.
References 261
[57] Health Do. Nutrient analysis of a range of processed foods with particular reference
to trans fatty acids. 2013;.
[58] Geng T, Qi L, Huang T. Effects of Dairy Products Consumption on Body Weight and
Body Composition Among Adults: An Updated Meta-analysis of 37 Randomized
Control Trials. Molecular nutrition and food research. 2018;62(1).
[59] Stonehouse W, Wycherley T, Luscombe-Marsh N, Taylor P, Brinkworth G, Riley
M. Dairy Intake Enhances Body Weight and Composition Changes during Energy
Restriction in 18–50-Year-Old Adults—A Meta-Analysis of Randomized Controlled
Trials. Nutrients. 2016;8(7):394.
[60] Booth AO, Huggins CE, Wattanapenpaiboon N, Nowson CA. Effect of increas-
ing dietary calcium through supplements and dairy food on body weight and
body composition: a meta-analysis of randomised controlled trials. Br J Nutr.
2015;114(7):1013–25.
[61] Abargouei AS, Janghorbani M, Salehi-Marzijarani M, Esmaillzadeh A. Effect
of dairy consumption on weight and body composition in adults: a systematic
review and meta-analysis of randomized controlled clinical trials. Int J Obes (Lond).
2012;36(12):1485–93.
[62] Chen M, Pan A, Malik VS, Hu FB. Effects of dairy intake on body weight and fat: a
meta-analysis of randomized controlled trials. Am J Clin Nutr. 2012;96(4):735–47.
[63] Benatar JR, Sidhu K, Stewart RA. Effects of high and low fat dairy food on
cardio-metabolic risk factors: a meta-analysis of randomized studies. PLoS One.
2013;8(10):e76480.
[64] Snijder MB, van Dam RM, Stehouwer CD, Hiddink GJ, Heine RJ, Dekker JM. A
prospective study of dairy consumption in relation to changes in metabolic risk
factors: the Hoorn Study. Obesity (Silver Spring). 2008;16(3):706–9.
[65] Vergnaud AC, Peneau S, Chat-Yung S, Kesse E, Czernichow S, Galan P, et al.
Dairy consumption and 6-y changes in body weight and waist circumference in
middle-aged French adults. Am J Clin Nutr. 2008;88(5):1248–55.
[66] Rajpathak SN, Rimm EB, Rosner B, Willett WC, Hu FB. Calcium and dairy intakes
in relation to long-term weight gain in US men. The American journal of clinical
nutrition. 2006;83(3):559–566.
[67] Wang H, Troy LM, Rogers GT, Fox CS, McKeown NM, Meigs JB, et al. Longitudi-
nal association between dairy consumption and changes of body weight and waist
circumference: the Framingham Heart Study. Int J Obes (Lond). 2014;38(2):299–
305.
[68] Fumeron F, Lamri A, Abi Khalil C, Jaziri R, Porchay-Balderelli I, Lantieri O, et al.
Dairy consumption and the incidence of hyperglycemia and the metabolic syndrome:
results from a french prospective study, Data from the Epidemiological Study on
the Insulin Resistance Syndrome (DESIR). Diabetes Care. 2011;34(4):813–7.
[69] Rautiainen S, Wang L, Lee IM, Manson JE, Buring JE, Sesso HD. Dairy consump-
tion in association with weight change and risk of becoming overweight or obese in
middle-aged and older women: a prospective cohort study. The American journal
of clinical nutrition. 2016;103(4):979–988.
262 References
[70] Mozaffarian D, Hao T, Rimm EB, Willett WC, Hu FB. Changes in diet and lifestyle
and long-term weight gain in women and men. New England Journal of Medicine.
2011;364(25):2392–2404.
[71] Samara A, Herbeth B, Ndiaye NC, Fumeron F, Billod S, Siest G, et al. Dairy product
consumption, calcium intakes, and metabolic syndrome-related factors over 5 years
in the STANISLAS study. Nutrition. 2013;29(3):519–24.
[72] Rosell M, Hakansson NN, Wolk A. Association between dairy food consumption
and weight change over 9 y in 19,352 perimenopausal women. Am J Clin Nutr.
2006;84(6):1481–8.
[73] Martinez-Gonzalez MA, Sayon-Orea C, Ruiz-Canela M, de la Fuente C, Gea A, Bes-
Rastrollo M. Yogurt consumption, weight change and risk of overweight/obesity:
the SUN cohort study. Nutr Metab Cardiovasc Dis. 2014;24(11):1189–96.
[74] Wajchenberg BL. Subcutaneous and visceral adipose tissue: their relation to the
metabolic syndrome. Endocr Rev. 2000;21(6):697–738.
[75] Crichton GE, Howe PR, Buckley JD, Coates AM, Murphy KJ. Dairy consumption
and cardiometabolic health: outcomes of a 12-month crossover trial. Nutr Metab
(Lond). 2012;9:19.
[76] Rideout TC, Marinangeli CP, Martin H, Browne RW, Rempel CB. Consumption
of low-fat dairy foods for 6 months improves insulin resistance without adversely
affecting lipids or bodyweight in healthy adults: a randomized free-living cross-over
study. Nutr J. 2013;12:56.
[77] Zemel MB, Donnelly JE, Smith BK, Sullivan DK, Richards J, Morgan-Hanusa D,
et al. Effects of dairy intake on weight maintenance. Nutr Metab (Lond). 2008;5:28.
[78] Josse AR, Atkinson SA, Tarnopolsky MA, Phillips SM. Increased consumption of
dairy foods and protein during diet-and exercise-induced weight loss promotes fat
mass loss and lean mass gain in overweight and obese premenopausal women. The
Journal of nutrition. 2011;141(9):1626–1634.
[79] Van Loan MD, Keim NL, Adams SH, Souza E, Woodhouse LR, Thomas A, et al.
Dairy Foods in a Moderate Energy Restricted Diet Do Not Enhance Central Fat,
Weight, and Intra-Abdominal Adipose Tissue Losses nor Reduce Adipocyte Size
or Inflammatory Markers in Overweight and Obese Adults: A Controlled Feeding
Study. J Obes. 2011;2011:989657.
[80] Halkjaer J, Tjonneland A, Overvad K, Sorensen TI. Dietary predictors of 5-year
changes in waist circumference. J Am Diet Assoc. 2009;109(8):1356–66.
[81] Zong G, Sun Q, Yu D, Zhu J, Sun L, Ye X, et al. Dairy consumption, type 2 diabetes,
and changes in cardiometabolic traits: a prospective cohort study of middle-aged
and older Chinese in Beijing and Shanghai. Diabetes Care. 2014;37(1):56–63.
[82] Babio N, Becerra-Tomas N, Martinez-Gonzalez MA, Corella D, Estruch R, Ros E,
et al. Consumption of Yogurt, Low-Fat Milk, and Other Low-Fat Dairy Products
Is Associated with Lower Risk of Metabolic Syndrome Incidence in an Elderly
Mediterranean Population. J Nutr. 2015;145(10):2308–16.
[83] de Goede J, Geleijnse JM, Ding EL, Soedamah-Muthu SS. Effect of cheese con-
sumption on blood lipids: a systematic review and meta-analysis of randomized
controlled trials. Nutr Rev. 2015;73(5):259–75.
References 263
[84] Ding M, Huang T, Bergholdt HK, Nordestgaard BG, Ellervik C, Qi L. Dairy
consumption, systolic blood pressure, and risk of hypertension: Mendelian random-
ization study. bmj. 2017;356:j1000.
[85] Dong JY, Szeto IM, Makinen K, Gao Q, Wang J, Qin LQ, et al. Effect of probiotic
fermented milk on blood pressure: a meta-analysis of randomised controlled trials.
Br J Nutr. 2013;110(7):1188–94.
[86] Soedamah-Muthu SS, Verberne LD, Ding EL, Engberink MF, Geleijnse JM. Dairy
consumption and incidence of hypertension: a dose-response meta-analysis of
prospective cohort studies. Hypertension. 2012;60(5):1131–7.
[87] Zock PL, Katan MB. Butter, margarine and serum lipoproteins. Atherosclerosis.
1997;131(1):7–16.
[88] Brassard D, Tessier-Grenier M, Allaire J, Rajendiran E, She Y, Ramprasath V, et al.
Comparison of the impact of SFAs from cheese and butter on cardiometabolic risk
factors: a randomized controlled trial–3. The American journal of clinical nutrition.
2017;105(4):800–809.
[89] Engel S, Tholstrup T. Butter increased total and LDL cholesterol compared with
olive oil but resulted in higher HDL cholesterol compared with a habitual diet. Am
J Clin Nutr. 2015;102(2):309–15.
[90] Dias CB, Phang M, Wood LG, Garg ML. Postprandial lipid responses do not differ
following consumption of butter or vegetable oil when consumed with omega-3
polyunsaturated fatty acids. Lipids. 2015;50(4):339–47.
[91] Anderson-Vasquez HE, Perez-Martinez P, Ortega Fernandez P, Wanden-Berghe
C. Impact of the consumption of a rich diet in butter and it replacement for a
rich diet in extra virgin olive oil on anthropometric, metabolic and lipid profile in
postmenopausal women. Nutr Hosp. 2015;31(6):2561–70.
[92] Nestel PJ, Pally S, MacIntosh GL, Greeve MA, Middleton S, Jowett J, et al. Circu-
lating inflammatory and atherogenic biomarkers are not increased following single
meals of dairy foods. Eur J Clin Nutr. 2012;66(1):25–31.
[93] Svensson J, Rosenquist A, Ohlsson L. Postprandial lipid responses to an alpha-
linolenic acid-rich oil, olive oil and butter in women: a randomized crossover trial.
Lipids Health Dis. 2011;10:106.
[94] Hjerpsted J, Leedo E, Tholstrup T. Cheese intake in large amounts lowers LDL-
cholesterol concentrations compared with butter intake of equal fat content. Am J
Clin Nutr. 2011;94(6):1479–84.
[95] Perez-Martinez P, Ordovas JM, Garcia-Rios A, Delgado-Lista J, Delgado-Casado
N, Cruz-Teno C, et al. Consumption of diets with different type of fat influences
triacylglycerols-rich lipoproteins particle number and size during the postprandial
state. Nutr Metab Cardiovasc Dis. 2011;21(1):39–45.
[96] Ould Mohamedou MM, Zouirech K, El Messal M, El Kebbaj MS, Chraibi A,
Adlouni A. Argan Oil Exerts an Antiatherogenic Effect by Improving Lipids and
Susceptibility of LDL to Oxidation in Type 2 Diabetes Patients. Int J Endocrinol.
2011;2011:747835.
264 References
[97] Masson CJ, Mensink RP. Exchanging saturated fatty acids for (n-6) polyunsaturated
fatty acids in a mixed meal may decrease postprandial lipemia and markers of
inflammation and endothelial activity in overweight men. J Nutr. 2011;141(5):816–
21.
[98] Gagliardi AC, Maranhao RC, de Sousa HP, Schaefer EJ, Santos RD. Effects of
margarines and butter consumption on lipid profiles, inflammation markers and lipid
transfer to HDL particles in free-living subjects with the metabolic syndrome. Eur J
Clin Nutr. 2010;64(10):1141–9.
[99] Palomaki A, Pohjantahti-Maaroos H, Wallenius M, Kankkunen P, Aro H, Husgafvel
S, et al. Effects of dietary cold-pressed turnip rapeseed oil and butter on serum
lipids, oxidized LDL and arterial elasticity in men with metabolic syndrome. Lipids
Health Dis. 2010;9:137.
[100] Lecerf JM, Luc G, Marecaux N, Bal S, Bonte JP, Lacroix B, et al. Small, qualitative
changes in fatty acid intake decrease plasma low-density lipoprotein-cholesterol
levels in mildly hypercholesterolemic outpatients on their usual high-fat diets. Int J
Food Sci Nutr. 2009;60 Suppl 7:151–63.
[101] Jimenez-Gomez Y, Lopez-Miranda J, Blanco-Colio LM, Marin C, Perez-Martinez P,
Ruano J, et al. Olive oil and walnut breakfasts reduce the postprandial inflammatory
response in mononuclear cells compared with a butter breakfast in healthy men.
Atherosclerosis. 2009;204(2):e70–6.
[102] Nestel PJ, Chronopulos A, Cehun M. Dairy fat in cheese raises LDL cholesterol
less than that in butter in mildly hypercholesterolaemic subjects. Eur J Clin Nutr.
2005;59(9):1059–63.
[103] Gorguc M, Celik I. Effects of fresh butter consumption on the lipid profile in healthy
human male. Journal of Clinical Biochemistry and Nutrition. 2005;36(3):79–82.
[104] Bellido C, Lopez-Miranda J, Blanco-Colio LM, Perez-Martinez P, Muriana FJ,
Martin-Ventura JL, et al. Butter and walnuts, but not olive oil, elicit postprandial
activation of nuclear transcription factor kappaB in peripheral blood mononuclear
cells from healthy men. Am J Clin Nutr. 2004;80(6):1487–91.
[105] Lichtenstein AH, Erkkila AT, Lamarche B, Schwab US, Jalbert SM, Ausman LM.
Influence of hydrogenated fat and butter on CVD risk factors: remnant-like parti-
cles, glucose and insulin, blood pressure and C-reactive protein. Atherosclerosis.
2003;171(1):97–107.
[106] Thomsen C, Storm H, Holst JJ, Hermansen K. Differential effects of saturated and
monounsaturated fats on postprandial lipemia and glucagon-like peptide 1 responses
in patients with type 2 diabetes. Am J Clin Nutr. 2003;77(3):605–11.
[107] Mauger JF, Lichtenstein AH, Ausman LM, Jalbert SM, Jauhiainen M, Ehnholm C,
et al. Effect of different forms of dietary hydrogenated fats on LDL particle size.
Am J Clin Nutr. 2003;78(3):370–5.
[108] Clemente G, Mancini M, Nazzaro F, Lasorella G, Rivieccio A, Palumbo AM, et al.
Effects of different dairy products on postprandial lipemia. Nutr Metab Cardiovasc
Dis. 2003;13(6):377–83.
References 265
[109] Mekki N, Charbonnier M, Borel P, Leonardi J, Juhel C, Portugal H, et al. Butter
differs from olive oil and sunflower oil in its effects on postprandial lipemia and
triacylglycerol-rich lipoproteins after single mixed meals in healthy young men. J
Nutr. 2002;132(12):3642–9.
[110] Han SN, Leka LS, Lichtenstein AH, Ausman LM, Schaefer EJ, Meydani SN. Effect
of hydrogenated and saturated, relative to polyunsaturated, fat on immune and
inflammatory responses of adults with moderate hypercholesterolemia. Journal of
Lipid Research. 2002;43(3):445–452.
[111] Tonstad S, Strom EC, Bergei CS, Ose L, Christophersen B. Serum cholesterol
response to replacing butter with a new trans-free margarine in hypercholesterolemic
subjects. Nutr Metab Cardiovasc Dis. 2001;11(5):320–6.
[112] Denke MA, Adams-Huet B, Nguyen AT. Individual cholesterol variation in response
to a margarine- or butter-based diet: A study in families. JAMA. 2000;284(21):2740–
7.
[113] Nielsen NS, Marckmann P, Hoy C. Effect of meal fat quality on oxidation resistance
of postprandial VLDL and LDL particles and plasma triacylglycerol level. Br J
Nutr. 2000;84(6):855–63.
[114] Judd JT, Baer DJ, Clevidence BA, Muesing RA, Chen SC, Weststrate JA, et al.
Effects of margarine compared with those of butter on blood lipid profiles related to
cardiovascular disease risk factors in normolipemic adults fed controlled diets. Am
J Clin Nutr. 1998;68(4):768–77.
[115] Cox C, Sutherland W, Mann J, de Jong S, Chisholm A, Skeaff M. Effects of dietary
coconut oil, butter and safflower oil on plasma lipids, lipoproteins and lathosterol
levels. Eur J Clin Nutr. 1998;52(9):650–4.
[116] Noakes M, Clifton PM. Oil blends containing partially hydrogenated or interesteri-
fied fats: differential effects on plasma lipids. Am J Clin Nutr. 1998;68(2):242–7.
[117] Chisholm A, Mann J, Sutherland W, Duncan A, Skeaff M, Frampton C. Effect on
lipoprotein profile of replacing butter with margarine in a low fat diet: randomised
crossover study with hypercholesterolaemic subjects. BMJ. 1996;312(7036):931–4.
[118] Cox C, Mann J, Sutherland W, Chisholm A, Skeaff M. Effects of coconut oil, butter,
and safflower oil on lipids and lipoproteins in persons with moderately elevated
cholesterol levels. J Lipid Res. 1995;36(8):1787–95.
[119] Sanders K, Johnson L, O’Dea K, Sinclair AJ. The effect of dietary fat level and
quality on plasma lipoprotein lipids and plasma fatty acids in normocholesterolemic
subjects. Lipids. 1994;29(2):129–38.
[120] Kris-Etherton PM, Derr J, Mitchell DC, Mustad VA, Russell ME, McDonnell
ET, et al. The role of fatty acid saturation on plasma lipids, lipoproteins, and
apolipoproteins: I. Effects of whole food diets high in cocoa butter, olive oil,
soybean oil, dairy butter, and milk chocolate on the plasma lipids of young men.
Metabolism. 1993;42(1):121–9.
[121] Seppanen-Laakso T, Vanhanen H, Laakso I, Kohtamaki H, Viikari J. Replacement
of butter on bread by rapeseed oil and rapeseed oil-containing margarine: effects on
plasma fatty acid composition and serum cholesterol. Br J Nutr. 1992;68(3):639–54.
266 References
[122] Khaw KT, Sharp SJ, Finikarides L, Afzal I, Lentjes M, Luben R, et al. Randomised
trial of coconut oil, olive oil or butter on blood lipids and other cardiovascular risk
factors in healthy men and women. BMJ open. 2018;8(3):e020167.
[123] Jones KW, Eller LK, Parnell JA, Doyle-Baker PK, Edwards AL, Reimer RA. Effect
of a dairy- and calcium-rich diet on weight loss and appetite during energy restriction
in overweight and obese adults: a randomized trial. Eur J Clin Nutr. 2013;67(4):371–
6.
[124] Wennersberg MH, Smedman A, Turpeinen AM, Retterstol K, Tengblad S, Lipre E,
et al. Dairy products and metabolic effects in overweight men and women: results
from a 6-mo intervention study. Am J Clin Nutr. 2009;90(4):960–8.
[125] Stancliffe RA, Thorpe T, Zemel MB. Dairy attentuates oxidative and inflammatory
stress in metabolic syndrome. Am J Clin Nutr. 2011;94(2):422–30.
[126] van Meijl LE, Mensink RP. Effects of low-fat dairy consumption on markers of
low-grade systemic inflammation and endothelial function in overweight and obese
subjects: an intervention study. Br J Nutr. 2010;104(10):1523–7.
[127] Nestel PJ, Mellett N, Pally S, Wong G, Barlow CK, Croft K, et al. Effects of low-fat
or full-fat fermented and non-fermented dairy foods on selected cardiovascular
biomarkers in overweight adults. Br J Nutr. 2013;110(12):2242–9.
[128] Shin H, Yoon YS, Lee Y, Kim CI, Oh SW. Dairy product intake is inversely
associated with metabolic syndrome in Korean adults: Anseong and Ansan cohort of
the Korean Genome and Epidemiology Study. J Korean Med Sci. 2013;28(10):1482–
8.
[129] Ivey KL, Lewis JR, Hodgson JM, Zhu K, Dhaliwal SS, Thompson PL, et al. Asso-
ciation between yogurt, milk, and cheese consumption and common carotid artery
intima-media thickness and cardiovascular disease risk factors in elderly women.
Am J Clin Nutr. 2011;94(1):234–9.
[130] Pei R, Martin DA, DiMarco DM, Bolling BW. Evidence for the Effects of Yogurt
on Gut Health and Obesity. Crit Rev Food Sci Nutr. 2015; p. 0.
[131] Drehmer M, Pereira MA, Schmidt MI, Del Carmen BMM, Alvim S, Lotufo PA,
et al. Associations of dairy intake with glycemia and insulinemia, independent
of obesity, in Brazilian adults: the Brazilian Longitudinal Study of Adult Health
(ELSA-Brasil). Am J Clin Nutr. 2015;101(4):775–82.
[132] Struijk EA, Heraclides A, Witte DR, Soedamah-Muthu SS, Geleijnse JM, Toft U,
et al. Dairy product intake in relation to glucose regulation indices and risk of type
2 diabetes. Nutr Metab Cardiovasc Dis. 2013;23(9):822–8.
[133] Wallace TM, Levy JC, Matthews DR. Use and abuse of HOMA modeling. Diabetes
Care. 2004;27(6):1487–95.
[134] Bordoni A, Danesi F, Dardevet D, Dupont D, Fernandez AS, Gille D, et al. Dairy
Products and Inflammation: A Review of the Clinical Evidence. Crit Rev Food Sci
Nutr. 2015; p. 0.
[135] Cho NH, Jang HC, Choi SH, Kim HR, Lee HK, Chan JC, et al. Abnormal liver func-
tion test predicts type 2 diabetes: a community-based prospective study. Diabetes
Care. 2007;30(10):2566–8.
References 267
[136] Abbasi A, Bakker SJ, Corpeleijn E, van der AD, Gansevoort RT, Gans RO, et al.
Liver function tests and risk prediction of incident type 2 diabetes: evaluation in
two independent cohorts. PLoS One. 2012;7(12):e51496.
[137] Targher G, Marchesini G, Byrne CD. Risk of type 2 diabetes in patients with
non-alcoholic fatty liver disease: Causal association or epiphenomenon? Diabetes
Metab. 2016;42(3):142–56.
[138] Softic S, Cohen DE, Kahn CR. Role of Dietary Fructose and Hepatic De Novo
Lipogenesis in Fatty Liver Disease. Dig Dis Sci. 2016;61(5):1282–93.
[139] Jacobs S, Jager S, Jansen E, Peter A, Stefan N, Boeing H, et al. Associations of
Erythrocyte Fatty Acids in the De Novo Lipogenesis Pathway with Proxies of Liver
Fat Accumulation in the EPIC-Potsdam Study. PLoS One. 2015;10(5):e0127368.
[140] Alam S, Mustafa G, Alam M, Ahmad N. Insulin resistance in development and
progression of nonalcoholic fatty liver disease. World J Gastrointest Pathophysiol.
2016;7(2):211–7.
[141] Alberti K, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, et al.
Harmonizing the metabolic syndrome a joint interim statement of the international
diabetes federation task force on epidemiology and prevention; national heart, lung,
and blood institute; American heart association; world heart federation; interna-
tional atherosclerosis society; and international association for the study of obesity.
Circulation. 2009;120(16):1640–1645.
[142] Shin JA, Lee JH, Lim SY, Ha HS, Kwon HS, Park YM, et al. Metabolic syndrome
as a predictor of type 2 diabetes, and its clinical interpretations and usefulness. J
Diabetes Investig. 2013;4(4):334–43.
[143] Galassi A, Reynolds K, He J. Metabolic syndrome and risk of cardiovascular disease:
a meta-analysis. The American journal of medicine. 2006;119(10):812–819.
[144] Kim Y, Je Y. Dairy consumption and risk of metabolic syndrome: a meta-analysis.
Diabet Med. 2015;.
[145] Trijsburg L, Geelen A, Hollman PC, Hulshof PJ, Feskens EJ, Van’t Veer P, et al.
BMI was found to be a consistent determinant related to misreporting of energy,
protein and potassium intake using self-report and duplicate portion methods. Public
Health Nutr. 2016; p. 1–10.
[146] Jessri M, Lou WY, L’Abbe MR. Evaluation of different methods to handle misre-
porting in obesity research: evidence from the Canadian national nutrition survey.
Br J Nutr. 2016;115(1):147–59.
[147] Murakami K, Livingstone MB. Prevalence and characteristics of misreporting of
energy intake in US adults: NHANES 2003-2012. Br J Nutr. 2015;114(8):1294–303.
[148] Lutomski JE, van den Broeck J, Harrington J, Shiely F, Perry IJ. Sociodemographic,
lifestyle, mental health and dietary factors associated with direction of misreporting
of energy intake. Public Health Nutr. 2011;14(3):532–41.
[149] Nielsen BM, Nielsen MM, Toubro S, Pedersen O, Astrup A, Sorensen TI, et al. Past
and current body size affect validity of reported energy intake among middle-aged
Danish men. J Nutr. 2009;139(12):2337–43.
268 References
[150] Rasmussen LB, Matthiessen J, Biltoft-Jensen A, Tetens I. Characteristics of misre-
porters of dietary intake and physical activity. Public Health Nutr. 2007;10(3):230–7.
[151] Maurer J, Taren DL, Teixeira PJ, Thomson CA, Lohman TG, Going SB, et al. The
psychosocial and behavioral characteristics related to energy misreporting. Nutr
Rev. 2006;64(2 Pt 1):53–66.
[152] Lissner L, Troiano RP, Midthune D, Heitmann BL, Kipnis V, Subar AF, et al. OPEN
about obesity: recovery biomarkers, dietary reporting errors and BMI. Int J Obes
(Lond). 2007;31(6):956–61.
[153] Akter S, Kurotani K, Nanri A, Pham NM, Sato M, Hayabuchi H, et al. Dairy
consumption is associated with decreased insulin resistance among the Japanese.
Nutr Res. 2013;33(4):286–92.
[154] Da Silva MS, Julien P, Couture P, Lemieux S, Vohl MC, Rudkowska I. Associations
between dairy intake and metabolic risk parameters in a healthy French-Canadian
population. Appl Physiol Nutr Metab. 2014;39(12):1323–31.
[155] Panagiotakos DB, Pitsavos CH, Zampelas AD, Chrysohoou CA, Stefanadis CI.
Dairy products consumption is associated with decreased levels of inflammatory
markers related to cardiovascular disease in apparently healthy adults: the ATTICA
study. J Am Coll Nutr. 2010;29(4):357–64.
[156] Esmaillzadeh A, Azadbakht L. Dairy consumption and circulating levels of inflam-
matory markers among Iranian women. Public Health Nutr. 2010;13(9):1395–402.
[157] Engberink MF, Geleijnse JM, de Jong N, Smit HA, Kok FJ, Verschuren WM. Dairy
intake, blood pressure, and incident hypertension in a general Dutch population. J
Nutr. 2009;139(3):582–7.
[158] Bingham SA, Welch AA, McTaggart A, Mulligan AA, Runswick SA, Luben R,
et al. Nutritional methods in the European prospective investigation of cancer in
Norfolk. Public health nutrition. 2001;4(03):847–858.
[159] Mulligan AA, Luben RN, Bhaniani A, Parry-Smith DJ, O’Connor L, Khawaja AP,
et al. A new tool for converting food frequency questionnaire data into nutrient and
food group values: FETA research methods and availability. Bmj Open. 2014;4(3).
[160] O’Connor LM, Lentjes MA, Luben RN, Khaw KT, Wareham NJ, Forouhi NG.
Dietary dairy product intake and incident type 2 diabetes: a prospective study using
dietary data from a 7-day food diary. Diabetologia. 2014;57(5):909–17.
[161] De Lucia Rolfe E, Sleigh A, Finucane FM, Brage S, Stolk RP, Cooper C, et al.
Ultrasound measurements of visceral and subcutaneous abdominal thickness to
predict abdominal adiposity among older men and women. Obesity (Silver Spring).
2010;18(3):625–31.
[162] Stolk R, Wink O, Zelissen P, Meijer R, Van Gils A, Grobbee D. Validity and repro-
ducibility of ultrasonography for the measurement of intra-abdominal adipose tissue.
International Journal of Obesity and Related Metabolic Disorders. 2001;25(9).
[163] Edens MA, van Ooijen PMA, Post WJ, Haagmans MJF, Kristanto W, Sijens PE,
et al. Ultrasonography to Quantify Hepatic Fat Content: Validation by H-1 Magnetic
Resonance Spectroscopy. Obesity. 2009;17(12):2239–2244.
References 269
[164] Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of
low-density lipoprotein cholesterol in plasma, without use of the preparative ultra-
centrifuge. Clinical chemistry. 1972;18(6):499–502.
[165] Brage S, Ekelund U, Brage N, Hennings MA, Froberg K, Franks PW, et al. Hierarchy
of individual calibration levels for heart rate and accelerometry to measure physical
activity. Journal of Applied Physiology. 2007;103(2):682–692.
[166] Livingstone M, Prentice AM, Coward W, Ceesay SM, Strain JJ, McKenna PG, et al.
Simultaneous measurement of free-living energy expenditure by the doubly labeled
water method and heart-rate monitoring. Am J Clin Nutr. 1990;52(1):59–65.
[167] Wijndaele K, Brage S, Besson H, Khaw KT, Sharp SJ, Luben R, et al. Television
viewing time independently predicts all-cause and cardiovascular mortality: the
EPIC Norfolk study. Int J Epidemiol. 2010; p. dyq105.
[168] White IR, Royston P, Wood AM. Multiple imputation using chained equations:
issues and guidance for practice. Statistics in medicine. 2011;30(4):377–399.
[169] Eddings W, Marchenko Y. Diagnostics for multiple imputation in Stata. Stata
Journal. 2012;12(3):353.
[170] Verardi V, Croux C. Robust regression in Stata. 2008;.
[171] Bozdogan H. Model selection and Akaike’s information criterion (AIC): The general
theory and its analytical extensions. Psychometrika. 1987;52(3):345–370.
[172] Benjamini Y, Yekutieli D. The control of the false discovery rate in multiple testing
under dependency. Annals of statistics. 2001; p. 1165–1188.
[173] Willett WC, Howe GR, Kushi LH. Adjustment for total energy intake in epidemio-
logic studies. The American journal of clinical nutrition. 1997;65(4):1220S–1228S.
[174] Kaess B, Pedley A, Massaro J, Murabito J, Hoffmann U, Fox C. The ratio of
visceral to subcutaneous fat, a metric of body fat distribution, is a unique correlate
of cardiometabolic risk. Diabetologia. 2012;55(10):2622–2630.
[175] Pallister T, Jackson M, Martin T, Glastonbury C, Jennings A, Beaumont M, et al.
Untangling the relationship between diet and visceral fat mass through blood
metabolomics and gut microbiome profiling. International journal of obesity.
2017;41(7):1106.
[176] Christen T, Sheikine Y, Rocha VZ, Hurwitz S, Goldfine AB, Di Carli M, et al.
Increased glucose uptake in visceral versus subcutaneous adipose tissue revealed by
PET imaging. JACC Cardiovasc Imaging. 2010;3(8):843–51.
[177] Zemel MB. Role of dietary calcium and dairy products in modulating adiposity.
Lipids. 2003;38(2):139–146.
[178] Hall W, Millward D, Long S, Morgan L. Casein and whey exert different effects on
plasma amino acid profiles, gastrointestinal hormone secretion and appetite. British
Journal of Nutrition. 2003;89(02):239–248.
[179] Veldhorst MA, Nieuwenhuizen AG, Hochstenbach-Waelen A, van Vught AJ, West-
erterp KR, Engelen MP, et al. Dose-dependent satiating effect of whey relative to
casein or soy. Physiology and behavior. 2009;96(4-5):675–682.
270 References
[180] Alfenas RdCG, Bressan J, Paiva ACd. Effects of protein quality on appetite and en-
ergy metabolism in normal weight subjects. Arquivos Brasileiros de Endocrinologia
and Metabologia. 2010;54(1):45–51.
[181] Thorning TK, Raben A, Tholstrup T, Soedamah-Muthu SS, Givens I, Astrup A.
Milk and dairy products: good or bad for human health? An assessment of the
totality of scientific evidence. Food and nutrition research. 2016;60(1):32527.
[182] Rich-Edwards JW, Ganmaa D, Pollak MN, Nakamoto EK, Kleinman K, Tserendol-
gor U, et al. Milk consumption and the prepubertal somatotropic axis. Nutrition
journal. 2007;6(1):28.
[183] Van Vught A, Nieuwenhuizen A, Veldhorst M, Brummer RJ, Westerterp-Plantenga
M. The effects of dietary protein on the somatotropic axis: a comparison of
soy, gelatin,[alpha]-lactalbumin and milk. European journal of clinical nutrition.
2010;64(5):441.
[184] Carroll PV, Christ the members of Growth Hormone Research Society Scien-
tific Committee ER, Bengtsson BA, Carlsson L, Christiansen J, Clemmons D,
et al. Growth hormone deficiency in adulthood and the effects of growth hormone
replacement: a review. The Journal of Clinical Endocrinology and Metabolism.
1998;83(2):382–395.
[185] Morio B, Fardet A, Legrand P, Lecerf JM. Involvement of dietary saturated fats,
from all sources or of dairy origin only, in insulin resistance and type 2 diabetes.
Nutr Rev. 2015;.
[186] Maersk M, Belza A, Stødkilde-Jørgensen H, Ringgaard S, Chabanova E, Thomsen
H, et al. Sucrose-sweetened beverages increase fat storage in the liver, muscle, and
visceral fat depot: a 6-mo randomized intervention study–. The American journal
of clinical nutrition. 2011;95(2):283–289.
[187] Smith JD, Hou T, Hu FB, Rimm EB, Spiegelman D, Willett WC, et al. A comparison
of different methods for evaluating diet, physical activity, and long-term weight gain
in 3 prospective cohort studies. The Journal of nutrition. 2015;145(11):2527–2534.
[188] Riboli E, Kaaks R. The EPIC Project: rationale and study design. European Prospec-
tive Investigation into Cancer and Nutrition. International journal of epidemiology.
1997;26(suppl_1):S6.
[189] Day N, Oakes S, Luben R, Khaw KT, Bingham S, Welch A, et al. EPIC-Norfolk:
study design and characteristics of the cohort. European Prospective Investigation
of Cancer. Br J Cancer. 1999;80 Suppl 1:95–103.
[190] Rhee JJ, Sampson L, Cho E, Hughes MD, Hu FB, Willett WC. Comparison of
methods to account for implausible reporting of energy intake in epidemiologic
studies. American journal of epidemiology. 2015; p. kwu308.
[191] Wareham NJ, Jakes RW, Rennie KL, Schuit J, Mitchell J, Hennings S, et al. Validity
and repeatability of a simple index derived from the short physical activity ques-
tionnaire used in the European Prospective Investigation into Cancer and Nutrition
(EPIC) study. Public Health Nutr. 2003;6(04):407–413.
[192] Fitzmaurice GM WJ Laird NM. WHO CDC PREVENTION, Applied longitudinal
analysis. Hoboken; 2004.
References 271
[193] Lydersen S. Statistical review: frequently given comments. Annals of the rheumatic
diseases. 2014; p. annrheumdis–2014–206186.
[194] Glymour MM, Weuve J, Berkman LF, Kawachi I, Robins JM. When is baseline
adjustment useful in analyses of change? An example with education and cognitive
change. Am J Epidemiol. 2005;162(3):267–78.
[195] Rothman KJ. No adjustments are needed for multiple comparisons. Epidemiology.
1990;1(1):43–6.
[196] Seaman S, White I. Inverse probability weighting with missing predictors of
treatment assignment or missingness. Communications in Statistics-Theory and
Methods. 2014;43(16):3499–3515.
[197] Agency FS. Food portion sizes. 2002;.
[198] Kinross JM, von Roon AC, Holmes E, Darzi A, Nicholson JK. The human gut
microbiome: implications for future health care. Current gastroenterology reports.
2008;10(4):396–403.
[199] Adolfsson O, Meydani SN, Russell RM. Yogurt and gut function. The American
Journal of Clinical Nutrition. 2004;80(2):245–256.
[200] Mensink RP, Zock PL, Kester AD, Katan MB. Effects of dietary fatty acids and
carbohydrates on the ratio of serum total to HDL cholesterol and on serum lipids
and apolipoproteins: a meta-analysis of 60 controlled trials. The American journal
of clinical nutrition. 2003;77(5):1146–1155.
[201] Micha R, King IB, Lemaitre RN, Rimm EB, Sacks F, Song X, et al. Food sources of
individual plasma phospholipid trans fatty acid isomers: the Cardiovascular Health
Study. Am J Clin Nutr. 2010;91(4):883–93.
[202] Hernan MA, Hernandez-Diaz S, Robins JM. A structural approach to selection bias.
Epidemiology. 2004;15(5):615–25.
[203] Paeratakul S, Popkin BM, Kohlmeier L, Hertz-Picciotto I, Guo X, Edwards LJ.
Measurement error in dietary data: implications for the epidemiologic study of the
diet-disease relationship. Eur J Clin Nutr. 1998;52(10):722–7.
[204] Willett W. Nutritional epidemiology. Oxford University Press; 2012.
[205] Fraser GE, Yan R. A multivariate method for measurement error correction using
pairs of concentration biomarkers. Ann Epidemiol. 2007;17(1):64–73.
[206] Pfrimer K, Vilela M, Resende CM, Scagliusi FB, Marchini JS, Lima NK, et al.
Under-reporting of food intake and body fatness in independent older people: a
doubly labelled water study. Age Ageing. 2015;44(1):103–8.
[207] Scalbert A, Brennan L, Manach C, Andres-Lacueva C, Dragsted LO, Draper J,
et al. The food metabolome: a window over dietary exposure. Am J Clin Nutr.
2014;99(6):1286–308.
[208] Jenkins B, West JA, Koulman A. A review of odd-chain fatty acid metabolism and
the role of pentadecanoic acid (C15: 0) and heptadecanoic acid (C17: 0) in health
and disease. Molecules. 2015;20(2):2425–2444.
272 References
[209] Tserng KY, Kliegman R, Miettinen EL, Kalhan S. A rapid, simple, and sensitive
procedure for the determination of free fatty acids in plasma using glass capillary
column gas-liquid chromatography. Journal of lipid research. 1981;22(5):852–858.
[210] Persson XMT, Błachnio-Zabielska AU, Jensen MD. Rapid measurement of plasma
free fatty acid concentration and isotopic enrichment using LC/MS. Journal of lipid
research. 2010;51(9):2761–2765.
[211] Wolk A, Vessby B, Ljung H, Barrefors P. Evaluation of a biological marker of dairy
fat intake. Am J Clin Nutr. 1998;68(2):291–5.
[212] Smedman AE, Gustafsson IB, Berglund LG, Vessby BO. Pentadecanoic acid in
serum as a marker for intake of milk fat: relations between intake of milk fat and
metabolic risk factors. Am J Clin Nutr. 1999;69(1):22–9.
[213] Wolk A, Furuheim M, Vessby B. Fatty acid composition of adipose tissue and
serum lipids are valid biological markers of dairy fat intake in men. J Nutr.
2001;131(3):828–33.
[214] Baylin A, Kabagambe EK, Siles X, Campos H. Adipose tissue biomarkers of fatty
acid intake. Am J Clin Nutr. 2002;76(4):750–7.
[215] Brevik A, Veierod MB, Drevon CA, Andersen LF. Evaluation of the odd fatty acids
15:0 and 17:0 in serum and adipose tissue as markers of intake of milk and dairy fat.
Eur J Clin Nutr. 2005;59(12):1417–22.
[216] Rosell M, Johansson G, Berglund L, Vessby B, Faire Ud, Hellénius ML. The
relation between alcohol intake and physical activity and the fatty acids 14: 0, 15: 0
and 17: 0 in serum phospholipids and adipose tissue used as markers for dairy fat
intake. British Journal of Nutrition. 2007;93(1):115–121.
[217] Sun Q, Ma J, Campos H, Hu FB. Plasma and erythrocyte biomarkers of dairy fat
intake and risk of ischemic heart disease. Am J Clin Nutr. 2007;86(4):929–37.
[218] Krachler B, Norberg M, Eriksson JW, Hallmans G, Johansson I, Vessby B, et al.
Fatty acid profile of the erythrocyte membrane preceding development of Type 2
diabetes mellitus. Nutr Metab Cardiovasc Dis. 2008;18(7):503–10.
[219] Thiébaut AC, Rotival M, Gauthier E, Lenoir GM, Boutron-Ruault MC, Joulin
V, et al. Correlation between serum phospholipid fatty acids and dietary intakes
assessed a few years earlier. Nutrition and cancer. 2009;61(4):500–509.
[220] Saadatian-Elahi M, Slimani N, Chajès V, Jenab M, Goudable J, Biessy C, et al.
Plasma phospholipid fatty acid profiles and their association with food intakes: re-
sults from a cross-sectional study within the European Prospective Investigation into
Cancer and Nutrition. The American journal of clinical nutrition. 2009;89(1):331–
346.
[221] Mozaffarian D, Cao H, King IB, Lemaitre RN, Song X, Siscovick DS, et al. Trans-
palmitoleic acid, metabolic risk factors, and new-onset diabetes in U.S. adults: a
cohort study. Ann Intern Med. 2010;153(12):790–9.
[222] Aslibekyan S, Campos H, Baylin A. Biomarkers of dairy intake and the risk of heart
disease. Nutr Metab Cardiovasc Dis. 2012;22(12):1039–45.
References 273
[223] Mozaffarian D, de Oliveira Otto MC, Lemaitre RN, Fretts AM, Hotamisligil G,
Tsai MY, et al. trans-Palmitoleic acid, other dairy fat biomarkers, and incident
diabetes: the Multi-Ethnic Study of Atherosclerosis (MESA). Am J Clin Nutr.
2013;97(4):854–61.
[224] de Oliveira Otto MC, Nettleton JA, Lemaitre RN, Steffen LM, Kromhout D, Rich
SS, et al. Biomarkers of dairy fatty acids and risk of cardiovascular disease in the
Multi-ethnic Study of Atherosclerosis. J Am Heart Assoc. 2013;2(4):e000092.
[225] Yakoob MY, Shi P, Hu FB, Campos H, Rexrode KM, Orav EJ, et al. Circulating
biomarkers of dairy fat and risk of incident stroke in U.S. men and women in 2 large
prospective cohorts. Am J Clin Nutr. 2014;100(6):1437–47.
[226] Santaren ID, Watkins SM, Liese AD, Wagenknecht LE, Rewers MJ, Haffner SM,
et al. Serum pentadecanoic acid (15:0), a short-term marker of dairy food intake, is
inversely associated with incident type 2 diabetes and its underlying disorders. Am
J Clin Nutr. 2014;100(6):1532–40.
[227] Guertin KA, Moore SC, Sampson JN, Huang WY, Xiao Q, Stolzenberg-Solomon
RZ, et al. Metabolomics in nutritional epidemiology: identifying metabolites
associated with diet and quantifying their potential to uncover diet-disease relations
in populations. Am J Clin Nutr. 2014;100(1):208–17.
[228] Forouhi NG, Koulman A, Sharp SJ, Imamura F, Kroger J, Schulze MB, et al.
Differences in the prospective association between individual plasma phospholipid
saturated fatty acids and incident type 2 diabetes: the EPIC-InterAct case-cohort
study. Lancet Diabetes Endocrinol. 2014;2(10):810–8.
[229] Nestel PJ, Straznicky N, Mellett NA, Wong G, De Souza DP, Tull DL, et al. Spe-
cific plasma lipid classes and phospholipid fatty acids indicative of dairy food
consumption associate with insulin sensitivity. Am J Clin Nutr. 2014;99(1):46–53.
[230] Abdullah MM, Cyr A, Lepine MC, Labonte ME, Couture P, Jones PJ, et al. Rec-
ommended dairy product intake modulates circulating fatty acid profile in healthy
adults: a multi-centre cross-over study. Br J Nutr. 2015;113(3):435–44.
[231] Albani V, Celis-Morales C, Marsaux CF, Forster H, O’Donovan CB, Woolhead C,
et al. Exploring the association of diary product intake with the fatty acids C15:0
and C17:0 measured from dried blood spots in a multi-population cohort: findings
from the Food4Me study. Mol Nutr Food Res. 2015;.
[232] Yakoob MY, Shi P, Willett WC, Rexrode KM, Campos H, Orav EJ, et al. Cir-
culating Biomarkers of Dairy Fat and Risk of Incident Diabetes Mellitus Among
US Men and Women in Two Large Prospective Cohorts. Circulation. 2016; p.
CIRCULATIONAHA. 115.018410.
[233] Weitkunat K, Schumann S, Nickel D, Hornemann S, Petzke KJ, Schulze MB, et al.
Odd-chain fatty acids as a biomarker for dietary fiber intake: a novel pathway
for endogenous production from propionate, 2. The American journal of clinical
nutrition. 2017;105(6):1544–1551.
[234] Jenkins BJ, Seyssel K, Chiu S, Pan PH, Lin SY, Stanley E, et al. Odd Chain Fatty
Acids; New Insights of the Relationship Between the Gut Microbiota, Dietary Intake,
Biosynthesis and Glucose Intolerance. Scientific Reports. 2017;7:44845.
274 References
[235] Laursen ASD, Dahm CC, Johnsen SP, Schmidt EB, Overvad K, Jakobsen MU.
Adipose tissue fatty acids present in dairy fat and risk of stroke: the Danish Diet,
Cancer and Health cohort. European journal of nutrition. 2018; p. 1–11.
[236] Hodson L, Skeaff CM, Fielding BA. Fatty acid composition of adipose tissue and
blood in humans and its use as a biomarker of dietary intake. Progress in lipid
research. 2008;47(5):348–380.
[237] Arab L, Akbar J. Biomarkers and the measurement of fatty acids. Public health
nutrition. 2002;5(6a):865–871.
[238] Lankinen M, Schwab U. Biomarkers of dairy fat. Am J Clin Nutr. 2015;101(5):1101–
2.
[239] Ratnayake WM. Concerns about the use of 15:0, 17:0, and trans-16:1n-7 as biomark-
ers of dairy fat intake in recent observational studies that suggest beneficial effects of
dairy food on incidence of diabetes and stroke. Am J Clin Nutr. 2015;101(5):1102–3.
[240] Siler SQ, Neese RA, Hellerstein MK. De novo lipogenesis, lipid kinetics, and whole-
body lipid balances in humans after acute alcohol consumption–. The American
journal of clinical nutrition. 1999;70(5):928–936.
[241] Wu Z, Palmquist D. Synthesis and biohydrogenation of fatty acids by ruminal
microorganisms in vitro. Journal of Dairy Science. 1991;74(9):3035–3046.
[242] Vlaeminck B, Fievez V, Cabrita A, Fonseca A, Dewhurst R. Factors affecting
odd-and branched-chain fatty acids in milk: A review. Animal feed science and
technology. 2006;131(3-4):389–417.
[243] Horning MG, Martin DB, Karmen A, Vagelos P. Fatty acid synthesis in adipose
tissue. J biol Chem. 1961;236:669–672.
[244] Massart-Leën A, Roets E, Peeters G, Verbeke R. Propionate for fatty acid syn-
thesis by the mammary gland of the lactating goat. Journal of Dairy Science.
1983;66(7):1445–1454.
[245] French E, Bertics S, Armentano L. Rumen and milk odd-and branched-chain fatty
acid proportions are minimally influenced by ruminal volatile fatty acid infusions.
Journal of dairy science. 2012;95(4):2015–2026.
[246] Jaudszus A, Kramer R, Pfeuffer M, Roth A, Jahreis G, Kuhnt K. trans Palmi-
toleic acid arises endogenously from dietary vaccenic acid. Am J Clin Nutr.
2014;99(3):431–5.
[247] Djousse L. Is plasma pentadecanoic acid a reasonable biomarker of dairy consump-
tion? J Am Heart Assoc. 2013;2(4):e000393.
[248] Gama M, Bizzo H, Antoniassi R. Analytical shortcomings and other considerations
related to the identification of biomarkers of dairy fat intake. European journal of
clinical nutrition. 2017;71(8):1022.
[249] Kell DB, Oliver SG. Here is the evidence, now what is the hypothesis? The
complementary roles of inductive and hypothesis-driven science in the post-genomic
era. Bioessays. 2004;26(1):99–105.
References 275
[250] Dunn WB, Broadhurst DI, Atherton HJ, Goodacre R, Griffin JL. Systems level
studies of mammalian metabolomes: the roles of mass spectrometry and nuclear
magnetic resonance spectroscopy. Chemical Society Reviews. 2011;40(1):387–426.
[251] Herrero M, Simó C, García-Cañas V, Ibáñez E, Cifuentes A. Foodomics: MS-
based strategies in modern food science and nutrition. Mass spectrometry reviews.
2012;31(1):49–69.
[252] Guasch-Ferré M, Bhupathiraju SN, Hu FB. Use of Metabolomics in Improving
Assessment of Dietary Intake. Clinical chemistry. 2018;64(1):82–98.
[253] Bertram HC, Hoppe C, Petersen BO, Duus JO, Molgaard C, Michaelsen KF. An
NMR-based metabonomic investigation on effects of milk and meat protein diets
given to 8-year-old boys. Br J Nutr. 2007;97(4):758–63.
[254] Pedersen SM, Nielsen NC, Andersen HJ, Olsson J, Simrén M, Öhman L, et al. The
serum metabolite response to diet intervention with probiotic acidified milk in irrita-
ble bowel syndrome patients is indistinguishable from that of non-probiotic acidified
milk by 1H NMR-based metabonomic analysis. Nutrients. 2010;2(11):1141–1155.
[255] Pedersen SMM, Nebel C, Nielsen NC, Andersen HJ, Olsson J, Simren M, et al.
A GC-MS-based metabonomic investigation of blood serum from irritable bowel
syndrome patients undergoing intervention with acidified milk products. European
Food Research and Technology. 2011;233(6):1013–1021.
[256] Hjerpsted JB, Ritz C, Schou SS, Tholstrup T, Dragsted LO. Effect of cheese and
butter intake on metabolites in urine using an untargeted metabolomics approach.
Metabolomics. 2014;10(6):1176–1185.
[257] Zheng H, Yde CC, Clausen MR, Kristensen M, Lorenzen J, Astrup A, et al.
Metabolomics investigation to shed light on cheese as a possible piece in the French
paradox puzzle. J Agric Food Chem. 2015;63(10):2830–9.
[258] Zheng H, Yde CC, Dalsgaard TK, Arnberg K, Mølgaard C, Michaelsen KF, et al.
Nuclear magnetic resonance-based metabolomics reveals that dairy protein fractions
affect urinary urea excretion differently in overweight adolescents. European Food
Research and Technology. 2015;240(3):489–497.
[259] Meikle PJ, Barlow CK, Mellett NA, Mundra PA, Bonham MP, Larsen A, et al.
Postprandial Plasma Phospholipids in Men Are Influenced by the Source of Dietary
Fat–3. The Journal of nutrition. 2015;145(9):2012–2018.
[260] Zheng H, Lorenzen JK, Astrup A, Larsen LH, Yde CC, Clausen MR, et al. Metabolic
effects of a 24-week energy-restricted intervention combined with low or high dairy
intake in overweight women: an NMR-based metabolomics investigation. Nutrients.
2016;8(3):108.
[261] Pallister T, Haller T, Thorand B, Altmaier E, Cassidy A, Martin T, et al. Metabolites
of milk intake: a metabolomic approach in UK twins with findings replicated in two
European cohorts. European journal of nutrition. 2017;56(7):2379–2391.
[262] Munger LH, Trimigno A, Picone G, Freiburghaus C, Pimentel G, Burton KJ, et al.
Identification of urinary food intake biomarkers for milk, cheese, and soy-based
drink by untargeted GC-MS and NMR in healthy humans. Journal of proteome
research. 2017;16(9):3321–3335.
276 References
[263] Lees HJ, Swann JR, Wilson ID, Nicholson JK, Holmes E. Hippurate: the natural
history of a mammalian–microbial cometabolite. Journal of proteome research.
2013;12(4):1527–1546.
[264] Moons KG, Altman DG, Reitsma JB, Ioannidis JP, Macaskill P, Steyerberg EW,
et al. Transparent Reporting of a multivariable prediction model for Individual
Prognosis or Diagnosis (TRIPOD): explanation and elaboration. Annals of internal
medicine. 2015;162(1):W1–W73.
[265] Lind MV, Savolainen OI, Ross AB. The use of mass spectrometry for analysing
metabolite biomarkers in epidemiology: methodological and statistical considera-
tions for application to large numbers of biological samples. European journal of
epidemiology. 2016;31(8):717–733.
[266] Wishart DS. Metabolomics: applications to food science and nutrition research.
Trends in Food Science and Technology. 2008;19(9):482–493.
[267] Pham-Tuan H, Kaskavelis L, Daykin CA, Janssen HG. Method development in high-
performance liquid chromatography for high-throughput profiling and metabonomic
studies of biofluid samples. Journal of Chromatography B. 2003;789(2):283–301.
[268] Sumner LW, Amberg A, Barrett D, Beale MH, Beger R, Daykin CA, et al. Proposed
minimum reporting standards for chemical analysis. Metabolomics. 2007;3(3):211–
221.
[269] Dunn WB, Broadhurst D, Begley P, Zelena E, Francis-McIntyre S, Anderson N,
et al. Procedures for large-scale metabolic profiling of serum and plasma using gas
chromatography and liquid chromatography coupled to mass spectrometry. Nat
Protoc. 2011;6(7):1060–83.
[270] Trygg J, Gullberg J, Johansson AI, Jonsson P, Antti H, Marklund SL, et al. Extraction
and GC/MS analysis of the human blood plasma metabolome. Analytical Chemistry.
2005;77(24):8086–8094.
[271] Wang LY, Summerhill K, Rodriguez-Canas C, Mather I, Patel P, Eiden M, et al.
Development and validation of a robust automated analysis of plasma phospholipid
fatty acids for metabolic phenotyping of large epidemiological studies. Genome
medicine. 2013;5(4):39.
[272] IUPAC I. IUPAC-IUB Joint Commission on Biochemical Nomenclature (JCBN).
Nomenclature and symbolism for amino acids and peptides. Recommendations
1983. Biochem J. 1984;219(2):345–373.
[273] van den Berg RA, Hoefsloot HC, Westerhuis JA, Smilde AK, van der Werf MJ.
Centering, scaling, and transformations: improving the biological information
content of metabolomics data. BMC genomics. 2006;7(1):142.
[274] Saccenti E, Hoefsloot HC, Smilde AK, Westerhuis JA, Hendriks MM. Reflec-
tions on univariate and multivariate analysis of metabolomics data. Metabolomics.
2014;10(3):0.
[275] Hendriks MM, van Eeuwijk FA, Jellema RH, Westerhuis JA, Reijmers TH, Hoefs-
loot HC, et al. Data-processing strategies for metabolomics studies. TrAC Trends
in Analytical Chemistry. 2011;30(10):1685–1698.
References 277
[276] Alsberg BK, Goodacre R, Rowland JJ, Kell D. Classification of pyrolysis mass spec-
tra by fuzzy multivariate rule induction-comparison with regression, K-nearest neigh-
bour, neural and decision-tree methods. Analytica Chimica Acta. 1997;348(1):389–
407.
[277] Bryan K, Brennan L, Cunningham P. MetaFIND: A feature analysis tool for
metabolomics data. BMC bioinformatics. 2008;9(1):470.
[278] Fan Y, Murphy TB, Byrne JC, Brennan L, Fitzpatrick JM, Watson RWG. Applying
random forests to identify biomarker panels in serum 2D-DIGE data for the detection
and staging of prostate cancer. Journal of proteome research. 2011;10(3):1361–1373.
[279] Touw WG, Bayjanov JR, Overmars L, Backus L, Boekhorst J, Wels M, et al. Data
mining in the Life Sciences with Random Forest: a walk in the park or lost in the
jungle? Briefings in Bioinformatics. 2012; p. bbs034.
[280] Acharjee A, Finkers R, Visser RG, Maliepaard C. Comparison of regularized re-
gression methods for omics data. Metabolomics. 2013;3(126):2153–0769.1000126.
[281] Chen T, Cao Y, Zhang Y, Liu J, Bao Y, Wang C, et al. Random forest in clinical
metabolomics for phenotypic discrimination and biomarker selection. Evidence-
Based Complementary and Alternative Medicine. 2013;2013.
[282] Hoerl AE, Kennard RW. Ridge regression: Biased estimation for nonorthogonal
problems. Technometrics. 1970;12(1):55–67.
[283] Tibshirani R. Regression shrinkage and selection via the lasso. Journal of the Royal
Statistical Society Series B (Methodological). 1996; p. 267–288.
[284] Kyung M, Gill J, Ghosh M, Casella G. Penalized regression, standard errors, and
Bayesian lassos. Bayesian Analysis. 2010;5(2):369–411.
[285] Zou H, Hastie T. Regression shrinkage and selection via the elastic net, with
applications to microarrays. JR Stat Soc Ser B. 2003;67:301–20.
[286] Pedregosa F, Varoquaux G, Gramfort A, Michel V, Thirion B, Grisel O, et al.
Scikit-learn: Machine learning in Python. Journal of machine learning research.
2011;12(Oct):2825–2830.
[287] Kluyver T, Ragan-Kelley B, Pérez F, Granger BE, Bussonnier M, Frederic J, et al.
Jupyter Notebooks-a publishing format for reproducible computational workflows.
In: ELPUB;. p. 87–90.
[288] Brennan L. The nutritional metabolomics crossroads: how to ensure success for
dietary biomarkers; 2017.
[289] Kröger J, Zietemann V, Enzenbach C, Weikert C, Jansen EH, Döring F, et al.
Erythrocyte membrane phospholipid fatty acids, desaturase activity, and dietary fatty
acids in relation to risk of type 2 diabetes in the European Prospective Investigation
into Cancer and Nutrition–Potsdam Study. Am J Clin Nutr. 2010; p. ajcn. 005447.
[290] Patel PS, Sharp SJ, Jansen E, Luben RN, Khaw KT, Wareham NJ, et al. Fatty
acids measured in plasma and erythrocyte-membrane phospholipids and derived by
food-frequency questionnaire and the risk of new-onset type 2 diabetes: a pilot study
in the European Prospective Investigation into Cancer and Nutrition (EPIC)–Norfolk
cohort. Am J Clin Nutr. 2010; p. ajcn. 29182.
278 References
[291] Hodge AM, English DR, O’dea K, Sinclair AJ, Makrides M, Gibson RA, et al.
Plasma phospholipid and dietary fatty acids as predictors of type 2 diabetes: in-
terpreting the role of linoleic acid–. The American journal of clinical nutrition.
2007;86(1):189–197.
[292] Imamura F, Fretts A, Marklund M, Ardisson Korat AV, Yang WS, Lankinen M, et al.
Fatty acid biomarkers of dairy fat consumption and incidence of type 2 diabetes: a
pooled analysis of prospective cohort studies. PLoS Med. 2018; p. (in press)–(in
press).
[293] Lee HS, Xu T, Lee Y, Kim NH, Kim YJ, Kim JM, et al. Identification of puta-
tive biomarkers for type 2 diabetes using metabolomics in the Korea Association
REsource (KARE) cohort. Metabolomics. 2016;12(12):178.
[294] Wang-Sattler R, Yu Z, Herder C, Messias AC, Floegel A, He Y, et al. Novel
biomarkers for pre-diabetes identified by metabolomics. Mol Syst Biol. 2012;8:615.
[295] Shi L, Brunius C, Lehtonen M, Auriola S, Bergdahl IA, Rolandsson O, et al. Plasma
metabolites associated with type 2 diabetes in a Swedish population: a case–control
study nested in a prospective cohort. Diabetologia. 2018; p. 1–13.
[296] Floegel A, Stefan N, Yu Z, Muhlenbruch K, Drogan D, Joost HG, et al. Identifica-
tion of serum metabolites associated with risk of type 2 diabetes using a targeted
metabolomic approach. Diabetes. 2013;62(2):639–48.
[297] Fall T, Salihovic S, Brandmaier S, Nowak C, Ganna A, Gustafsson S, et al. Non-
targeted metabolomics combined with genetic analyses identifies bile acid synthesis
and phospholipid metabolism as being associated with incident type 2 diabetes.
Diabetologia. 2016;59(10):2114–24.
[298] van den Berg SA, Guigas B, Bijland S, Ouwens M, Voshol PJ, Frants RR, et al.
High levels of dietary stearate promote adiposity and deteriorate hepatic insulin
sensitivity. Nutr Metab (Lond). 2010;7:24.
[299] Reynoso R, Salgado LM, Calderon V. High levels of palmitic acid lead to insulin
resistance due to changes in the level of phosphorylation of the insulin receptor and
insulin receptor substrate-1. Mol Cell Biochem. 2003;246(1-2):155–62.
[300] Anderson EK, Hill AA, Hasty AH. Stearic acid accumulation in macrophages in-
duces toll-like receptor 4/2-independent inflammation leading to endoplasmic reticu-
lum stress-mediated apoptosis. Arterioscler Thromb Vasc Biol. 2012;32(7):1687–95.
[301] Weigert C, Brodbeck K, Staiger H, Kausch C, Machicao F, Haring HU, et al.
Palmitate, but not unsaturated fatty acids, induces the expression of interleukin-6
in human myotubes through proteasome-dependent activation of nuclear factor-
kappaB. J Biol Chem. 2004;279(23):23942–52.
[302] Postic C, Girard J. Contribution of de novo fatty acid synthesis to hepatic steatosis
and insulin resistance: lessons from genetically engineered mice. J Clin Invest.
2008;118(3):829–38.
[303] Corgneau M, Scher J, Ritie-Pertusa L, Le Dt, Petit J, Nikolova Y, et al. Recent ad-
vances on lactose intolerance: Tolerance thresholds and currently available answers.
Critical reviews in food science and nutrition. 2017;57(15):3344–3356.
References 279
[304] Yang Q, Lin SL, Au Yeung SL, Kwok MK, Xu L, Leung GM, et al. Genetically
predicted milk consumption and bone health, ischemic heart disease and type 2
diabetes: a Mendelian randomization study. Eur J Clin Nutr. 2017;.
[305] Bersaglieri T, Sabeti PC, Patterson N, Vanderploeg T, Schaffner SF, Drake JA, et al.
Genetic signatures of strong recent positive selection at the lactase gene. Am J Hum
Genet. 2004;74(6):1111–20.
[306] Gerbault P, Liebert A, Itan Y, Powell A, Currat M, Burger J, et al. Evolution of
lactase persistence: an example of human niche construction. Philos Trans R Soc
Lond B Biol Sci. 2011;366(1566):863–77.
[307] Ingram CJ, Mulcare CA, Itan Y, Thomas MG, Swallow DM. Lactose digestion and
the evolutionary genetics of lactase persistence. Hum Genet. 2009;124(6):579–91.
[308] Hartwig FP, Horta BL, Smith GD, de Mola CL, Victora CG. Association of
lactase persistence genotype with milk consumption, obesity and blood pressure: a
Mendelian randomization study in the 1982 Pelotas (Brazil) Birth Cohort, with a
systematic review and meta-analysis. International journal of epidemiology. 2016;
p. dyw074.
[309] Savaiano DA. Lactose digestion from yogurt: mechanism and relevance. Am J Clin
Nutr. 2014;99(5 Suppl):1251S–5S.
[310] Corella D, Arregui M, Coltell O, Portoles O, Guillem-Saiz P, Carrasco P, et al.
Association of the LCT-13910C>T polymorphism with obesity and its modula-
tion by dairy products in a Mediterranean population. Obesity (Silver Spring).
2011;19(8):1707–14.
[311] Pimentel G, Burton KJ, Rosikiewicz M, Freiburghaus C, von Ah U, Münger LH,
et al. Blood lactose after dairy product intake in healthy men. British Journal of
Nutrition. 2017;118(12):1070–1077.
[312] Burgess S, Thompson SG. Mendelian randomization: methods for using genetic
variants in causal estimation. CRC Press; 2015.
[313] Lawlor DA, Harbord RM, Sterne JA, Timpson N, Davey Smith G. Mendelian
randomization: using genes as instruments for making causal inferences in epidemi-
ology. Statistics in medicine. 2008;27(8):1133–1163.
[314] Bergholdt HK, Nordestgaard BG, Ellervik C. Milk intake is not associated with low
risk of diabetes or overweight-obesity: a Mendelian randomization study in 97,811
Danish individuals. Am J Clin Nutr. 2015;102(2):487–96.
[315] Bergholdt HK, Nordestgaard BG, Varbo A, Ellervik C. Milk intake is not associated
with ischaemic heart disease in observational or Mendelian randomization analyses
in 98,529 Danish adults. Int J Epidemiol. 2015;44(2):587–603.
[316] Biobank U. Genotyping and quality control of UK Biobank, a large-scale, exten-
sively phenotypes prospective resource. 2015;.
[317] Biobank U. Genotype imputation and genetic association studies of UK Biobank.
2015;.
280 References
[318] Liu B, Young H, Crowe FL, Benson VS, Spencer EA, Key TJ, et al. Development
and evaluation of the Oxford WebQ, a low-cost, web-based method for assessment
of previous 24 h dietary intakes in large-scale prospective studies. Public health
nutrition. 2011;14(11):1998–2005.
[319] Loh PR, Kichaev G, Gazal S, Schoech AP, Price AL. Mixed-model association for
biobank-scale datasets. Nature genetics. 2018; p. 1.
[320] Ward LD, Kellis M. HaploReg: a resource for exploring chromatin states, conser-
vation, and regulatory motif alterations within sets of genetically linked variants.
Nucleic Acids Res. 2012;40(Database issue):D930–4.
[321] Arnold M, Raffler J, Pfeufer A, Suhre K, Kastenmüller G. SNiPA: an interactive,
genetic variant-centered annotation browser. Bioinformatics. 2015;31(8):1334–
1336.
[322] Sotos-Prieto M, Guillen M, Guillem-Saiz P, Portoles O, Corella D. The rs1466113
polymorphism in the somatostatin receptor 2 gene is associated with obesity and
food intake in a Mediterranean population. Ann Nutr Metab. 2010;57(2):124–31.
[323] McCaffery JM, Papandonatos GD, Peter I, Huggins GS, Raynor HA, Delahanty
LM, et al. Obesity susceptibility loci and dietary intake in the Look AHEAD Trial.
Am J Clin Nutr. 2012;95(6):1477–86.
[324] Pirastu N, Robino A, Lanzara C, Athanasakis E, Esposito L, Tepper BJ, et al.
Genetics of food preferences: a first view from silk road populations. J Food Sci.
2012;77(12):S413–8.
[325] Pirastu N, Kooyman M, Traglia M, Robino A, Willems SM, Pistis G, et al. A
Genome-Wide Association Study in isolated populations reveals new genes associ-
ated to common food likings. Rev Endocr Metab Disord. 2016;17(2):209–19.
[326] de Oliveira Otto MC, Lemaitre RN, Sun Q, King IB, Wu JHY, Manichaikul
A, et al. Genome-wide association meta-analysis of circulating odd-numbered
chain saturated fatty acids: Results from the CHARGE Consortium. PLoS One.
2018;13(5):e0196951.
[327] Garcia-Etxebarria K, Jauregi-Miguel A, Romero-Garmendia I, Plaza-Izurieta
L, Legarda M, Irastorza I, et al. Ancestry-based stratified analysis of Im-
munochip data identifies novel associations with celiac disease. Eur J Hum Genet.
2016;24(12):1831–1834.
[328] Murray JA. The widening spectrum of celiac disease. The American Journal of
Clinical Nutrition. 1999;69(3):354–365.
[329] Beulens JW, Grobbee DE, Sluijs I, Spijkerman AM, Van Der Schouw YT. Dietary
phylloquinone and menaquinones intakes and risk of type 2 diabetes. Diabetes care.
2010;33(8):1699–1705.
[330] Gast GCM, de Roos NM, Sluijs I, Bots ML, Beulens JW, Geleijnse JM, et al. A
high menaquinone intake reduces the incidence of coronary heart disease. Nutrition,
Metabolism and Cardiovascular Diseases. 2009;19(7):504–510.
[331] Miller PE, Alexander DD, Perez V. Effects of whey protein and resistance exercise
on body composition: a meta-analysis of randomized controlled trials. Journal of
the American College of Nutrition. 2014;33(2):163–175.
References 281
[332] Takahira M, Noda K, Fukushima M, Zhang B, Mitsutake R, Uehara Y, et al. Random-
ized, double-blind, controlled, comparative trial of formula food containing soy pro-
tein vs. milk protein in visceral fat obesity. -FLAVO study. Circ J. 2011;75(9):2235–
43.
[333] Boirie Y, Dangin M, Gachon P, Vasson MP, Maubois JL, Beaufrère B. Slow and fast
dietary proteins differently modulate postprandial protein accretion. Proceedings of
the National Academy of Sciences. 1997;94(26):14930–14935.
[334] Giezenaar C, Trahair LG, Luscombe-Marsh ND, Hausken T, Standfield S, Jones KL,
et al. Effects of randomized whey-protein loads on energy intake, appetite, gastric
emptying, and plasma gut-hormone concentrations in older men and women. The
American journal of clinical nutrition. 2017;106(3):865–877.
[335] Lorenzen J, Frederiksen R, Hoppe C, Hvid R, Astrup A. The effect of milk proteins
on appetite regulation and diet-induced thermogenesis. European journal of clinical
nutrition. 2012;66(5):622–627.
[336] Law M, Lee YT, Vien S, Luhovyy BL, Anderson GH. The effect of dairy products
consumed with high glycemic carbohydrate on subjective appetite, food intake,
and postprandial glycemia in older adults. Applied Physiology, Nutrition, and
Metabolism. 2017;42(11):1210–1216.
[337] Trowman R, Dumville JC, Hahn S, Torgerson DJ. A systematic review of the
effects of calcium supplementation on body weight. British Journal of Nutrition.
2006;95(06):1033–1038.
[338] Christensen R, Lorenzen JK, Svith CR, Bartels E, Melanson E, Saris W, et al. Effect
of calcium from dairy and dietary supplements on faecal fat excretion: a meta-
analysis of randomized controlled trials. Obesity reviews. 2009;10(4):475–486.
[339] Zemel MB, Shi H, Greer B, Dirienzo D, Zemel PC. Regulation of adiposity by
dietary calcium. The FASEB Journal. 2000;14(9):1132–1138.
[340] Zemel M, Richards J, Mathis S, Milstead A, Gebhardt L, Silva E. Dairy augmenta-
tion of total and central fat loss in obese subjects. International journal of obesity.
2005;29(4):391–397.
[341] Bovee-Oudenhoven I, Termont D, Weerkamp AH, Faassen-Peters M, Van der
Meer R. Dietary calcium inhibits the intestinal colonization and translocation of
Salmonella in rats. Gastroenterology. 1997;113(2):550–557.
[342] Schepens MA, ten Bruggencate SJ, Schonewille AJ, Brummer RJM, van der Meer
R, Bovee-Oudenhoven IM. The protective effect of supplemental calcium on colonic
permeability depends on a calcium phosphate-induced increase in luminal buffering
capacity. British Journal of Nutrition. 2012;107(7):950–956.
[343] Whigham LD, Watras AC, Schoeller DA. Efficacy of conjugated linoleic acid for
reducing fat mass: a meta-analysis in humans. Am J Clin Nutr. 2007;85(5):1203–
1211.
[344] Brown JM, Boysen MS, Jensen SS, Morrison RF, Storkson J, Lea-Currie R, et al.
Isomer-specific regulation of metabolism and PPARγ signaling by CLA in human
preadipocytes. Journal of lipid research. 2003;44(7):1287–1300.
282 References
[345] Brown JM, Boysen MS, Chung S, Fabiyi O, Morrison RF, Mandrup S, et al. Conju-
gated Linoleic Acid Induces Human Adipocyte Delipidation Autocrine/Paracrine
regulation of MEK/ERK signaling by adipocytokines. Journal of Biological Chem-
istry. 2004;279(25):26735–26747.
[346] Knapen M, Jardon K, Vermeer C. Vitamin K-induced effects on body fat and weight:
results from a 3-year vitamin K2 intervention study. European journal of clinical
nutrition. 2018;72(1):136.
[347] Rosqvist F, Smedman A, Lindmark-Månsson H, Paulsson M, Petrus P, Straniero S,
et al. Potential role of milk fat globule membrane in modulating plasma lipoproteins,
gene expression, and cholesterol metabolism in humans: a randomized study. The
American journal of clinical nutrition. 2015;102(1):20–30.
[348] Sjogren P, Rosell M, Skoglund-Andersson C, Zdravkovic S, Vessby B, de Faire U,
et al. Milk-derived fatty acids are associated with a more favorable LDL particle
size distribution in healthy men. The Journal of nutrition. 2004;134(7):1729–1735.
[349] Motard-Belanger A, Charest A, Grenier G, Paquin P, Chouinard Y, Lemieux S, et al.
Study of the effect of trans fatty acids from ruminants on blood lipids and other risk
factors for cardiovascular disease. Am J Clin Nutr. 2008;87(3):593–9.
[350] Conway V, Couture P, Richard C, Gauthier S, Pouliot Y, Lamarche B. Impact
of buttermilk consumption on plasma lipids and surrogate markers of cholesterol
homeostasis in men and women. Nutrition, Metabolism and Cardiovascular Diseases.
2013;23(12):1255–1262.
[351] Guo Z, Liu X, Zhang Q, Shen Z, Tian F, Zhang H, et al. Influence of consumption
of probiotics on the plasma lipid profile: a meta-analysis of randomised controlled
trials. Nutrition, Metabolism and Cardiovascular Diseases. 2011;21(11):844–850.
[352] Pittas AG, Lau J, Hu FB, Dawson-Hughes B. The role of vitamin D and calcium
in type 2 diabetes. A systematic review and meta-analysis. The Journal of Clinical
Endocrinology and Metabolism. 2007;92(6):2017–2029.
[353] Autier P, Mullie P, Macacu A, Dragomir M, Boniol M, Coppens K, et al. Effect
of vitamin D supplementation on non-skeletal disorders: a systematic review of
meta-analyses and randomised trials. The Lancet Diabetes and Endocrinology.
2017;5(12):986–1004.
[354] Wang X, Juan QF, He YW, Zhuang L, Fang YY, Wang YH. Multiple effects of
probiotics on different types of diabetes: a systematic review and meta-analysis
of randomized, placebo-controlled trials. Journal of Pediatric Endocrinology and
Metabolism. 2017;30(6):611–622.
[355] Chung S, Brown JM, Provo JN, Hopkins R, McIntosh MK. Conjugated linoleic acid
promotes human adipocyte insulin resistance through NFκB-dependent cytokine
production. Journal of Biological Chemistry. 2005;280(46):38445–38456.
[356] Wang X, Gupta J, Kerslake M, Rayat G, Proctor SD, Chan CB. Trans-11 vaccenic
acid improves insulin secretion in models of type 2 diabetes in vivo and in vitro.
Molecular nutrition and food research. 2016;60(4):846–857.
[357] Kennedy A, Overman A, LaPoint K, Hopkins R, West T, Chuang CC, et al.
Conjugated linoleic acid-mediated inflammation and insulin resistance in human
adipocytes are attenuated by resveratrol. Journal of lipid research. 2009;50(2):225–
232.
References 283
[358] Fekete AA, Givens DI, Lovegrove JA. Casein-derived lactotripeptides reduce
systolic and diastolic blood pressure in a meta-analysis of randomised clinical trials.
Nutrients. 2015;7(1):659–681.
[359] Nakamura Y, Yamamoto N, Sakai K, Okubo A, Yamazaki S, Takano T. Purification
and characterization of angiotensin I-converting enzyme inhibitors from sour milk.
Journal of dairy science. 1995;78(4):777–783.
[360] Van Mierlo L, Arends L, Streppel M, Zeegers M, Kok F, Grobbee D, et al. Blood
pressure response to calcium supplementation: a meta-analysis of randomized
controlled trials. Journal of human hypertension. 2006;20(8):571–580.
[361] Aburto NJ, Hanson S, Gutierrez H, Hooper L, Elliott P, Cappuccio FP. Effect of
increased potassium intake on cardiovascular risk factors and disease: systematic
review and meta-analyses. 2013;.
[362] Jee SH, Miller ER, Guallar E, Singh VK, Appel LJ, Klag MJ. The effect of
magnesium supplementation on blood pressure: a meta-analysis of randomized
clinical trials. American Journal of Hypertension. 2002;15(8):691–696.
[363] Rothman KJ, Greenland S, Lash TL. Modern epidemiology. 2008;.
[364] Hebert JR, Clemow L, Pbert L, Ockene IS, Ockene JK. Social desirability bias
in dietary self-report may compromise the validity of dietary intake measures.




This Appendix includes supplemental tables and figures related to results from
• Chapter 2 (section A.1, pages 285-288)
• Chapters 4 (section A.2, pages 289-304)
• Chapters 5 (section A.3, pages 299-316)
• Chapters 6 (section A.4, pages 317-357)
• Chapters 8 (section A.5, pages 358-359)
A.1 Chapter 2
The following tables include descriptive statistics (mean, standard error, median and IQR)
of total and types of dairy consumption among adults <65 years and elderly participants

































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































A.2 Chapter 4 289
A.2 Chapter 4
290 Supplemental results
Table A.4 Associations of total and types of dairy consumption with clinical markers of
body weight and composition from multiple linear regression models †
BMI (kg/m2) Waist (cm) Waist / Hip cir-
cumference
Mean (SD) 26.9 (4.8) 91.0 (13.5) 0.9 (0.1)
Participants (N) 12,064 12,058 12,043
Dairy consumption (servings †/d) b 95% CI b 95% CI b 95% CI
Milk
Demographic, energy ‡ 0.1 0.01 0.2 0.09 -0.19 0.37 0 0 0
+ SES, lifestyle, diet 0.264 0.16 0.36 0.48 0.19 0.77 0 0 0
+ BMI -0.153 -0.29 0 0 0 0
Yoghurt
Demographic, energy ‡ 0.06 -0.1 0.22 -0.21 -0.7 0.27 -0.01 -0.01 0
+ SES, lifestyle, diet 0.14 -0.03 0.31 0.39 -0.1 0.88 0 0 0
+ BMI -0.22 -0.46 0.02 0 0 0
Cheese
Demographic, energy ‡ -0.19 -0.42 0.04 -0.34 -0.93 0.26 0 -0.01 0
+ SES, lifestyle, diet 0.06 -0.15 0.27 0.15 -0.41 0.71 0 0 0.01
+ BMI 0.14 -0.14 0.43 0 0 0
Fermented dairy products
Demographic, energy ‡ -0.04 -0.16 0.09 -0.26 -0.62 0.09 0 -0.01 0
+ SES, lifestyle, diet 0.11 -0.03 0.24 0.29 -0.08 0.66 0 0 0
+ BMI -0.07 -0.26 0.12 0 0 0
Full-fat milk
Demographic, energy ‡ -0.41 -0.58 -0.24 -1.15 -1.61 -0.69 0 -0.01 0
+ SES, lifestyle, diet -0.13 -0.31 0.05 -0.61 -1.08 -0.13 0 -0.01 0
+ BMI -0.303 -0.56 -0.04 0.003 -0.01 0
Low-fat milk
Demographic, energy ‡ 0.16 0.06 0.26 0.25 -0.04 0.54 0 0 0
+ SES, lifestyle, diet 0.284 0.18 0.38 0.55 0.25 0.84 0 0 0
+ BMI -0.14 -0.28 0.01 0 0 0
Full-fat yoghurt
Demographic, energy ‡ -1.38 -1.78 -0.97 -3.6 -4.81 -2.4 -0.02 -0.03 -0.01
+ SES, lifestyle, diet -0.453 -0.85 -0.06 -0.85 -1.99 0.3 0 -0.01 0
+ BMI -0.01 -0.53 0.52 0 0 0.01
Low-fat yoghurt
Demographic, energy ‡ 0.25 0.08 0.43 0.24 -0.28 0.75 0 -0.01 0
+ SES, lifestyle, diet 0.223 0.04 0.41 0.56 0.03 1.08 0 0 0
+ BMI -0.25 -0.51 0.01 0 0 0
High-fat cheese
Demographic, energy ‡ -0.63 -0.93 -0.33 -0.83 -1.59 -0.07 0 -0.01 0
+ SES, lifestyle, diet -0.11 -0.39 0.17 0.14 -0.56 0.84 0 0 0.01
+ BMI 0.393 0.03 0.75 0 0 0
Low-fat cheese
Demographic, energy ‡ 0.44 0.1 0.79 0.38 -0.51 1.27 0 -0.01 0.01
+ SES, lifestyle, diet 0.28 -0.03 0.59 0.18 -0.69 1.05 0 0 0.01
+ BMI -0.25 -0.75 0.25 0 -0.01 0
Butter
Demographic, energy ‡ -0.06 -0.17 0.05 -0.17 -0.49 0.14 0 0 0
+ SES, lifestyle, diet 0.153 0.03 0.27 0.22 -0.12 0.57 0 0 0
+ BMI -0.1 -0.26 0.06 0 0 0
Ice-cream
Demographic, energy ‡ 0.83 0.38 1.28 2.45 1.13 3.76 0.01 0 0.02
+ SES, lifestyle, diet 0.733 0.31 1.15 2.2 1.06 3.34 0.01 0 0.02
+ BMI -0.01 -0.6 0.57 0 0 0.01
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Table A.4 (continued)
BMI (kg/m2) Waist (cm) Waist / Hip cir-
cumference
Mean (SD) 26.9 (4.8) 91.0 (13.5) 0.9 (0.1)
Participants (N) 12,064 12,058 12,043
Dairy consumption (servings †/d) b 95% CI b 95% CI b 95% CI
Low-fat fermented dairy products
Demographic, energy ‡ 0.12 -0.02 0.26 -0.1 -0.5 0.31 0 -0.01 0
+ SES, lifestyle, diet 0.163 0.01 0.31 0.33 -0.09 0.75 0 0 0
+ BMI -0.2 -0.41 0.01 0 0 0
High-fat dairy products
Demographic, energy ‡ -0.18 -0.26 -0.1 -0.46 -0.69 -0.23 0 0 0
+ SES, lifestyle, diet 0.02 -0.08 0.12 -0.09 -0.36 0.19 0 0 0
+ BMI -0.08 -0.21 0.05 0 0 0
Low-fat dairy products
Demographic, energy ‡ 0.13 0.05 0.21 0.09 -0.14 0.33 0 0 0
+ SES, lifestyle, diet 0.224 0.13 0.31 0.44 0.19 0.69 0 0 0
+ BMI -0.153 -0.27 -0.03 0 0 0
Total dairy products
Demographic, energy ‡ 0.02 -0.04 0.08 -0.07 -0.26 0.12 0 0 0
+ SES, lifestyle, diet 0.214 0.13 0.28 0.39 0.16 0.61 0 0 0
+ BMI -0.123 -0.23 -0.01 0 0 0
†Associations are per serving/day (Milk: 1 average glass (200g); Yoghurt: 125g carton; Cheese:
medium serving (40g); Single cream: 1 tablespoon (15g); Double cream: 1 tablespoon (30g);
Butter: 1 teaspoon (10g); Ice-cream: 1 average scoop/tub (60g) as defined by Food Standards
Agency 2002)[197]
‡Model 1: age (years), sex, test-site (Cambridge, Ely, Wisbech), ethnicity (white, non-white), total
energy intake (kcal/d), mutual adjustment for dairy products; Model 2: Model 1 + educational level
(low, medium, high), age when full-time education finished (years), socio-economic status based
on occupation (low: technical/semi-routine and routine occupations; medium: lower managerial /
intermediate occupations; high: professional/higher managerial occupations), income (<£20,000,
£20,000-40,000, >£40,000), marital status (single, married, widowed/separated), smoking status
(never, former, current smoker), pack-years of smoking, energy expenditure due to physical activity
(kj/kg/d), lipid-lowering medication (Yes, No), anti-hypertensive medication (Yes, No), hormone-
replacement therapy (Yes, No, Men). Model 3: Model 2 + intakes (g/d) of fruit, vegetables (not
including potatoes), potatoes, legumes, processed cereals, whole-grain cereals, poultry and eggs,
red meat, processed meat, fish, sauces, margarine, nuts, sweet snacks, sugar-sweetened beverages,
artificially sweetened beverages, fruit juice, regular coffee, decaffeinated coffee, tea, alcoholic
























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Table A.7 Associations of total and types of dairy consumption with cardio-metabolic

















N 11,253 11,523 11,989 11,988 11,897
Nutrient % change 95% CI b 95% CI b 95% CI b 95% CI b 95% CI
Protein -0.02 -0.05 0 0.39 0.17 0.61 0.04 -0.01 0.08 -0.02 -0.03 -0.01 0.04 -0.01 0.08
Total sugars -0.02 -0.04 0 0.39 0.17 0.61 0.05 0.01 0.1 -0.02 -0.03 -0.01 0.04 0 0.08
Lactose -0.03 -0.05 -0.01 0.39 0.17 0.61 0.06 0 0.11 -0.02 -0.03 -0.01 0.04 -0.01 0.09
Total fat -0.03 -0.04 -0.02 0.38 0.23 0.53 0.02 -0.03 0.07 -0.02 -0.03 -0.01 0.03 -0.02 0.07
Saturated fat -0.03 -0.04 -0.02 0.38 0.23 0.53 0.02 -0.03 0.07 -0.02 -0.03 -0.01 0.02 -0.02 0.07
Monounsaturated fat -0.03 -0.04 -0.02 0.38 0.23 0.53 0.02 -0.03 0.07 -0.02 -0.03 -0.01 0.03 -0.02 0.07
Calcium -0.03 -0.05 0 0.39 0.17 0.61 0.04 -0.01 0.09 -0.02 -0.03 -0.01 0.04 -0.01 0.08
Potassium -0.03 -0.05 0 0.38 0.16 0.6 0.05 -0.01 0.11 -0.02 -0.03 -0.01 0.03 -0.02 0.09
Magnesium -0.02 -0.05 0 0.38 0.16 0.6 0.03 -0.02 0.09 -0.02 -0.03 -0.01 0.04 -0.01 0.09
Phosphorous -0.03 -0.05 0 0.39 0.17 0.61 0.04 -0.01 0.08 -0.02 -0.03 -0.01 0.04 -0.01 0.08
Zinc -0.03 -0.05 0 0.39 0.17 0.61 0.04 -0.01 0.08 -0.02 -0.03 -0.01 0.04 -0.01 0.08
Selenium -0.03 -0.05 0 0.39 0.17 0.61 0.04 -0.01 0.08 -0.02 -0.03 -0.01 0.04 -0.01 0.08
Vitamin A -0.03 -0.04 -0.02 0.38 0.23 0.53 0.01 -0.04 0.06 -0.02 -0.03 -0.01 0.02 -0.03 0.06
Vitamin B12 -0.02 -0.04 0 0.39 0.17 0.61 0.03 -0.02 0.09 -0.02 -0.03 -0.01 0.04 -0.01 0.08
†Significant associations were selected after False Discovery Rate correction ; Serving sizes as defined by the
Food Standards Agency 2002[197]: Milk: 1 average glass (200g); Yoghurt: 125g carton; Cheese: medium serving
(40g); Single cream: 1 tablespoon (15g); Double cream: 1 tablespoon (30g); Butter: 1 teaspoon (10g); Ice-cream:
1 average scoop/tub (60g) ; Dairy nutrients intakes were calculated from the food frequency questionnaire using
in-house software
Abbreviations: SCAT: Subcutaneous Adipose Tissue; VAT: Visceral Adipose Tissue
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Table A.9 Associations of total and types of dairy consumption with markers of hepatic
function from multiple linear regression models
Hepatic fat score ALT (IU/l) GGT (IU/l)
Mean (SD) 4.3 (1.3) 28.9 (16.6) 34.8 (35.3)
Participants (N) 10,108 11,982 11,986
Dairy consumption (servings †/d) b ‡ 95% CI % change § 95% CI % change § 95% CI
Milk
Demographic, energy ∥ 0 -0.02 0.01 1.36 0.38 2.35 0.89 -0.08 1.87
+ SES, lifestyle, diet 0 -0.01 0.01 2.09 0.98 3.22 1.69 0.62 2.78
+ BMI -0.01 -0.02 0.01 1.27 0.21 2.35 1.17 0.15 2.21
Yoghurt
Demographic, energy ∥ 0 -0.02 0.02 1.04 -0.52 2.63 -2.91 -4.53 -1.26
+ SES, lifestyle, diet 0.01 -0.02 0.03 0.46 -1.22 2.17 -0.58 -2.29 1.17
+ BMI 0 -0.02 0.02 0.1 -1.6 1.83 -1.27 -2.97 0.45
Cheese
Demographic, energy ∥ -0.01 -0.03 0.02 -1.55 -3.65 0.6 -0.78 -2.72 1.19
+ SES, lifestyle, diet 0 -0.03 0.02 -1.11 -3.25 1.08 0.57 -1.44 2.62
+ BMI 0 -0.02 0.03 -1.05 -3.17 1.11 0.93 -1.07 2.96
Fermented dairy products
Demographic, energy ∥ 0 -0.02 0.01 0.01 -1.16 1.2 -2.02 -3.19 -0.84
+ SES, lifestyle, diet 0 -0.01 0.02 -0.16 -1.47 1.17 -0.1 -1.38 1.19
+ BMI 0 -0.02 0.02 -0.36 -1.67 0.96 -0.36 -1.61 0.91
Full-fat milk
Demographic, energy ∥ -0.02 -0.04 0 -0.52 -2.35 1.35 -1.03 -2.79 0.77
+ SES, lifestyle, diet -0.02 -0.04 0.01 1.26 -0.73 3.29 -0.18 -2.14 1.82
+ BMI -0.01 -0.04 0.01 1.51 -0.39 3.45 0.21 -1.59 2.04
Low-fat milk
Demographic, energy ∥ 0 -0.01 0.01 1.57 0.57 2.57 1.1 0.12 2.1
+ SES, lifestyle, diet 0 -0.01 0.01 2.14 1.02 3.27 1.79 0.72 2.88
+ BMI -0.01 -0.02 0.01 1.265 0.19 2.34 1.23 0.2 2.27
Full-fat yoghurt
Demographic, energy ∥ -0.07 -0.13 -0.02 0.46 -4.29 5.44 -10.91 -14.43 -7.24
+ SES, lifestyle, diet -0.03 -0.09 0.02 2.01 -2.92 7.19 -4.39 -8.29 -0.32
+ BMI -0.02 -0.07 0.04 2.91 -2.13 8.21 -3.16 -6.87 0.7
Low-fat yoghurt
Demographic, energy ∥ 0.01 -0.01 0.03 1.11 -0.5 2.75 -1.71 -3.47 0.07
+ SES, lifestyle, diet 0.01 -0.01 0.03 0.31 -1.4 2.05 -0.06 -1.88 1.79
+ BMI 0 -0.02 0.02 -0.19 -1.93 1.57 -1.01 -2.8 0.81
High-fat cheese
Demographic, energy ∥ -0.02 -0.05 0.02 -3.22 -5.8 -0.57 -0.9 -3.16 1.42
+ SES, lifestyle, diet -0.01 -0.05 0.02 -2.15 -4.91 0.7 0.77 -1.7 3.32
+ BMI 0 -0.04 0.03 -1.48 -4.21 1.32 1.44 -1.02 3.96
Low-fat cheese
Demographic, energy ∥ 0.01 -0.03 0.05 1.06 -2.23 4.45 -0.58 -3.92 2.87
+ SES, lifestyle, diet 0.01 -0.03 0.05 0.27 -2.92 3.57 0.28 -2.99 3.66
+ BMI 0.01 -0.03 0.05 -0.47 -3.69 2.85 0.17 -3.13 3.58
Butter
Demographic, energy ∥ 0 -0.01 0.01 0.54 -0.63 1.72 -0.69 -1.77 0.41
+ SES, lifestyle, diet 0 -0.01 0.02 1.46 0.16 2.78 -0.61 -1.78 0.58
+ BMI 0 -0.02 0.01 1.05 -0.16 2.29 -0.84 -1.96 0.29
Ice-cream
Demographic, energy ∥ 0.02 -0.03 0.07 1.64 -2.41 5.87 -4.1 -7.97 -0.08
+ SES, lifestyle, diet 0.01 -0.04 0.06 0.85 -3.24 5.1 -3.18 -6.98 0.77
+ BMI -0.02 -0.07 0.03 -2.37 -5.98 1.38 -5.62 -9.28 -1.8
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Table A.9
Hepatic fat score ALT (IU/l) GGT (IU/l)
Mean (SD) 4.3 (1.3) 28.9 (16.6) 34.8 (35.3)
Participants (N) 10,108 11,982 11,986
Dairy consumption (servings †/d) b ‡ 95% CI % change § 95% CI % change § 95% CI
Low-fat fermented dairy products
Demographic, energy ∥ 0 -0.02 0.02 0.91 -0.4 2.25 -2.35 -3.69 -0.99
+ SES, lifestyle, diet 0.01 -0.01 0.02 0.32 -1.1 1.76 -0.34 -1.77 1.12
+ BMI 0 -0.02 0.02 -0.08 -1.52 1.38 -0.86 -2.29 0.58
High-fat dairy products
Demographic, energy ∥ -0.01 -0.01 0 0.06 -0.79 0.92 -0.64 -1.45 0.18
+ SES, lifestyle, diet 0 -0.02 0.01 1.26 0.21 2.33 -0.42 -1.4 0.57
+ BMI -0.01 -0.02 0.01 1.24 0.23 2.26 -0.31 -1.24 0.63
Low-fat dairy products
Demographic, energy ∥ 0 -0.01 0.01 1.26 0.46 2.07 -0.09 -0.88 0.71
+ SES, lifestyle, diet 0 -0.01 0.01 1.42 0.49 2.37 1.04 0.15 1.94
+ BMI -0.01 -0.02 0.01 0.79 -0.11 1.71 0.56 -0.3 1.42
Total dairy products
Demographic, energy ∥ 0 -0.01 0.01 0.83 0.19 1.47 -0.43 -1.06 0.21
+ SES, lifestyle, diet 0 -0.01 0.01 1.63 0.79 2.48 0.29 -0.5 1.09
+ BMI -0.01 -0.02 0 1.03 0.22 1.85 -0.1 -0.86 0.66
†Associations are per serving/day (Milk: 1 average glass (200g); Yoghurt: 125g carton; Cheese: medium serving
(40g); Single cream: 1 tablespoon (15g); Double cream: 1 tablespoon (30g); Butter: 1 teaspoon (10g); Ice-cream: 1
average scoop/tub (60g) as defined by Food Standards Agency 2002)[197]
‡Beta coefficient and 95% CI derived from poisson regression
§% change used for log-transformed outcomes after back-transformation (exponentiation) and defined as [(eb-
1)*100]%
parallelModel 1: age (years), sex, test-site (Cambridge, Ely, Wisbech), ethnicity (white, non-white), total energy
intake (kcal/d), mutual adjustment for dairy products; Model 2: Model 1 + educational level (low, medium, high),
age when full-time education finished (years), socio-economic status based on occupation (low: technical/semi-
routine and routine occupations; medium: lower managerial / intermediate occupations; high: professional/higher
managerial occupations), income (<£20,000, £20,000-40,000, >£40,000), marital status (single, married, wid-
owed/separated), smoking status (never, former, current smoker), pack-years of smoking, energy expenditure
due to physical activity (kj/kg/d), lipid-lowering medication (Yes, No), anti-hypertensive medication (Yes, No),
hormone-replacement therapy (Yes, No, Men).; Model 3: Model 2 + intakes (g/d) of fruit, vegetables (not including
potatoes), potatoes, legumes, processed cereals, whole-grain cereals, poultry and eggs, red meat, processed meat,
fish, sauces, margarine, nuts, sweet snacks, sugar-sweetened beverages, artificially sweetened beverages, fruit juice,
regular coffee, decaffeinated coffee, tea, alcoholic beverages, plasma vitamin C levels (µmol/l), dietary supplement
use (Yes, No).; Model 4: Model 3 + BMI (kg/m2)
Abbreviations: ALT: Alanine Transaminase; GGT: Gamma-Glutamyl Transferase
302 Supplemental results
Table A.10 Associations of total and types of dairy consumption with blood pressure, CRP









Mean (SD) 123.5 (15.8) 74.5 (10.2) 2.9 (5.5) 7.1 (3.8)
Participants (N) 12,063 12,062 9,438 9,642
Dairy consumption (servings †/d) b 95% CI b 95% CI % change ‡ 95% CI % change ‡ 95% CI
Milk
Demographic, energy § -0.28 -0.6 0.05 -0.28 -0.53 -0.04 3.69 0.2 7.3 -1.23 -2.44 0
+ SES, lifestyle, diet 0.11 -0.26 0.48 -0.15 -0.41 0.12 6.16 2.26 10.21 -1.52 -2.87 -0.16
+ BMI 0 -0.35 0.36 -0.23 -0.49 0.02 3.09 -0.22 6.51 -0.96 -2.28 0.39
Yoghurt
Demographic, energy § -0.25 -0.85 0.36 -0.33 -0.78 0.12 -6.58 -12.91 0.2 1.56 -0.78 3.96
+ SES, lifestyle, diet 0.01 -0.58 0.6 0.14 -0.36 0.64 5.06 -2.08 12.73 0.54 -1.79 2.92
+ BMI -0.2 -0.78 0.38 -0.18 -0.63 0.27 1.84 -3.88 7.9 1.91 -0.39 4.25
Cheese
Demographic, energy § -0.78 -1.48 -0.07 -0.57 -1.05 -0.09 2.13 -5.38 10.24 1.88 -0.81 4.63
+ SES, lifestyle, diet -0.21 -0.94 0.52 -0.22 -0.72 0.28 8.46 0.33 17.25 2.13 -0.61 4.95
+ BMI -0.28 -0.99 0.43 -0.23 -0.72 0.26 5.12 -1.62 12.31 2.44 -0.18 5.13
Fermented dairy products
Demographic, energy § -0.48 -0.9 -0.05 -0.43 -0.75 -0.12 -2.86 -7.47 1.97 1.7 0.04 3.38
+ SES, lifestyle, diet -0.08 -0.53 0.37 -0.02 -0.37 0.34 6.5 1.09 12.19 1.21 -0.56 3.01
+ BMI -0.23 -0.67 0.2 -0.2 -0.54 0.13 3.2 -1.22 7.83 2.134 0.38 3.92
Full-fat milk
Demographic, energy § -1.15 -1.76 -0.53 -0.66 -1.18 -0.14 2.28 -3.97 8.93 -1.1 -3.3 1.16
+ SES, lifestyle, diet -0.53 -1.21 0.14 -0.43 -0.96 0.1 5.48 -1.44 12.89 -1.41 -3.83 1.08
+ BMI -0.29 -0.91 0.32 -0.22 -0.71 0.28 5.69 -0.14 11.86 -2.02 -4.32 0.33
Low-fat milk
Demographic, energy § -0.19 -0.52 0.14 -0.25 -0.5 0 3.84 0.31 7.5 -1.24 -2.48 0
+ SES, lifestyle, diet 0.14 -0.23 0.51 -0.13 -0.4 0.14 6.19 2.28 10.24 -1.53 -2.88 -0.16
+ BMI 0.02 -0.34 0.38 -0.23 -0.49 0.02 2.95 -0.37 6.37 -0.9 -2.23 0.46
Full-fat yoghurt
Demographic, energy § -2.21 -3.73 -0.69 -1.29 -2.43 -0.15 -35.88 -46.68 -22.88 8.1 1.44 15.2
+ SES, lifestyle, diet -0.72 -2.34 0.9 -0.03 -1.18 1.13 -11.07 -26.01 6.89 3.82 -2.85 10.94
+ BMI -0.43 -1.91 1.05 0.09 -1.02 1.21 -0.02 -14.92 17.5 1.69 -4.45 8.22
Low-fat yoghurt
Demographic, energy § 0.04 -0.61 0.7 -0.19 -0.67 0.3 -1.92 -8.86 5.55 0.74 -1.69 3.24
+ SES, lifestyle, diet 0.1 -0.52 0.72 0.17 -0.36 0.69 7.18 -0.49 15.43 0.16 -2.25 2.63
+ BMI -0.17 -0.78 0.44 -0.22 -0.69 0.25 2.04 -3.9 8.35 1.93 -0.45 4.37
High-fat cheese
Demographic, energy § -1.31 -2.26 -0.36 -0.93 -1.54 -0.31 0.65 -8.61 10.85 4.18 0.7 7.78
+ SES, lifestyle, diet -0.39 -1.4 0.63 -0.44 -1.09 0.21 9.46 -1.45 21.58 4.6 1.04 8.28
+ BMI -0.26 -1.24 0.73 -0.22 -0.88 0.44 10.13 0.42 20.79 3.77 0.43 7.23
Low-fat cheese
Demographic, energy § -0.05 -1.09 0.99 -0.06 -0.79 0.66 4.35 -7.76 18.04 -1.46 -5.51 2.76
+ SES, lifestyle, diet 0 -1.02 1.02 0.06 -0.67 0.8 7.23 -4.49 20.39 -1.11 -5.29 3.24
+ BMI -0.31 -1.29 0.67 -0.24 -0.96 0.47 -0.39 -9.23 9.3 0.68 -3.35 4.87
Butter
Demographic, energy § -0.49 -0.89 -0.09 -0.27 -0.54 0.01 0.29 -3.56 4.29 -1.07 -2.48 0.36
+ SES, lifestyle, diet -0.11 -0.58 0.36 -0.01 -0.32 0.3 2.07 -2.29 6.62 -1.2 -2.8 0.43
+ BMI -0.19 -0.64 0.26 -0.09 -0.39 0.22 -1.09 -4.82 2.78 -0.06 -1.69 1.6
Ice-cream
Demographic, energy § -0.4 -1.73 0.92 0.3 -0.57 1.17 13.52 -1.94 31.42 -2.61 -7.91 2.99
+ SES, lifestyle, diet 0.02 -1.29 1.34 0.56 -0.34 1.46 10.59 -4.41 27.95 -1.74 -7.02 3.83
+ BMI -0.62 -1.97 0.73 0.03 -0.87 0.93 0.78 -13.39 17.26 1.46 -4.17 7.42










Mean (SD) 123.5 (15.8) 74.5 (10.2) 2.9 (5.5) 7.1 (3.8)
Participants (N) 12,063 12,062 9,438 9,642
Dairy consumption (servings †/d) b 95% CI b 95% CI % change ‡ 95% CI % change ‡ 95% CI
Low-fat fermented dairy products
Demographic, energy § -0.23 -0.72 0.27 -0.29 -0.65 0.07 -3.89 -9.19 1.73 0.92 -0.97 2.85
+ SES, lifestyle, diet 0 -0.5 0.5 0.1 -0.3 0.5 5.72 -0.3 12.09 0.29 -1.66 2.28
+ BMI -0.23 -0.71 0.26 -0.2 -0.57 0.17 1.57 -3.17 6.55 1.69 -0.26 3.67
High-fat dairy products
Demographic, energy § -0.67 -0.97 -0.37 -0.4 -0.62 -0.18 -0.07 -3.03 2.98 -0.47 -1.54 0.6
+ SES, lifestyle, diet -0.23 -0.62 0.15 -0.16 -0.42 0.11 1.76 -1.95 5.62 -0.4 -1.71 0.93
+ BMI -0.19 -0.56 0.19 -0.11 -0.37 0.14 0.48 -2.7 3.77 0.05 -1.26 1.38
Low-fat dairy products
Demographic, energy § -0.23 -0.51 0.05 -0.28 -0.48 -0.07 1.37 -1.53 4.36 -0.52 -1.54 0.51
+ SES, lifestyle, diet 0.07 -0.25 0.39 -0.08 -0.31 0.15 6.09 2.74 9.55 -0.84 -2 0.32
+ BMI -0.07 -0.37 0.24 -0.224 -0.44 0 2.86 0.03 5.77 -0.06 -1.21 1.1
Total dairy products
Demographic, energy § -0.42 -0.64 -0.19 -0.31 -0.47 -0.15 0.75 -1.61 3.17 -0.56 -1.39 0.27
+ SES, lifestyle, diet -0.01 -0.31 0.29 -0.06 -0.26 0.15 4.47 1.37 7.68 -0.88 -1.94 0.19
+ BMI -0.14 -0.43 0.16 -0.18 -0.37 0.02 1.08 -1.52 3.74 0.11 -0.95 1.19
†Associations are per serving/day (Milk: 1 average glass (200g); Yoghurt: 125g carton; Cheese: medium serving (40g); Single cream: 1
tablespoon (15g); Double cream: 1 tablespoon (30g); Butter: 1 teaspoon (10g); Ice-cream: 1 average scoop/tub (60g) as defined by
Food Standards Agency 2002)[197]
‡% change used for log-transformed outcomes after back-transformation (exponentiation) and defined as [(eb-1)*100]%
SModel 1: age (years), sex, test-site (Cambridge, Ely, Wisbech), ethnicity (white, non-white), total energy intake (kcal/d), mutual
adjustment for dairy products; Model 2: Model 1 + educational level (low, medium, high), age when full-time education finished
(years), socio-economic status based on occupation (low: technical/semi-routine and routine occupations; medium: lower managerial /
intermediate occupations; high: professional/higher managerial occupations), income (<£20,000, £20,000-£40,000, >40,000), marital
status (single, married, widowed/separated), smoking status (never, former, current smoker), pack-years of smoking, energy expenditure
due to physical activity (kj/kg/d), lipid-lowering medication (Yes, No), anti-hypertensive medication (Yes, No), hormone-replacement
therapy (Yes, No, Men).; Model 3: Model 2 + intakes (g/d) of fruit, vegetables (not including potatoes), potatoes, legumes, processed
cereals, whole-gran cereals, poultry and eggs, red meat, processed meat, fish, sauces, margarine, nuts, sweet snacks, sugar-sweetened
beverages, artificially sweetened beverages, fruit juice, regular coffee, decaffeinated coffee, tea, alcoholic beverages, plasma vitamin C
levels (µmol/l), dietary supplement use (Yes, No).; Model 4: Model 3 + BMI (kg/m2)
Abbreviations: CRP: C-Reactive Protein
304 Supplemental results
Table A.11 Associations of total and types of dairy consump-




Mean (SD) -0.002 (0.62)
Participants (N) 11,931
Dairy consumption (servings †/d) b 95% CI
Milk
Demographic, energy ‡ 0.02 0.01 0.04
+ SES, lifestyle, diet 0.04 0.03 0.06
Yoghurt
Demographic, energy ‡ -0.01 -0.04 0.01
+ SES, lifestyle, diet 0.03 0 0.05
Cheese
Demographic, energy ‡ -0.02 -0.05 0.02
+ SES, lifestyle, diet 0.02 -0.01 0.05
Fermented dairy products
Demographic, energy ‡ -0.01 -0.03 0
+ SES, lifestyle, diet 0.03 0.01 0.04
Full-fat milk
Demographic, energy ‡ -0.02 -0.05 0.01
+ SES, lifestyle, diet 0.01 -0.02 0.04
Low-fat milk
Demographic, energy ‡ 0.03 0.01 0.04
+ SES, lifestyle, diet 0.04 0.03 0.06
Full-fat yoghurt
Demographic, energy ‡ -0.2 -0.27 -0.13
+ SES, lifestyle, diet -0.04 -0.1 0.02
Low-fat yoghurt
Demographic, energy ‡ 0.01 -0.02 0.04
+ SES, lifestyle, diet 0.04 0.01 0.06
High-fat cheese
Demographic, energy ‡ -0.06 -0.11 -0.02
+ SES, lifestyle, diet 0 -0.04 0.04
Low-fat cheese
Demographic, energy ‡ 0.05 0.01 0.1
+ SES, lifestyle, diet 0.05 0.01 0.09
Butter
Demographic, energy ‡ -0.01 -0.03 0
+ SES, lifestyle, diet 0.01 -0.01 0.03
Ice-cream
Demographic, energy ‡ 0.08 0.02 0.13
+ SES, lifestyle, diet 0.07 0.02 0.13




Mean (SD) -0.002 (0.62)
Participants (N) 11,931
Dairy consumption (servings †/d) b 95% CI
Low-fat fermented dairy products
Demographic, energy ‡ 0 -0.02 0.02
+ SES, lifestyle, diet 0.03 0.01 0.05
High-fat dairy products
Demographic, energy ‡ -0.02 -0.03 -0.01
+ SES, lifestyle, diet 0 -0.01 0.02
Low-fat dairy products
Demographic, energy ‡ 0.02 0 0.03
+ SES, lifestyle, diet 0.04 0.02 0.05
Total dairy products
Demographic, energy ‡ 0 -0.01 0.01
+ SES, lifestyle, diet 0.03 0.01 0.04
†Associations are per serving/day (Milk: 1 average glass (200g); Yoghurt:
125g carton; Cheese: medium serving (40g); Single cream: 1 tablespoon
(15g); Double cream: 1 tablespoon (30g); Butter: 1 teaspoon (10g); Ice-
cream: 1 average scoop/tub (60g) as defined by Food Standards Agency
2002)[197]
‡Model 1: age (years), sex, test-site (Cambridge, Ely, Wisbech), ethnicity
(white, non-white), total energy intake (kcal/d), mutual adjustment for
dairy products; Model 2: Model 1 + educational level (low, medium,
high), age when full-time education finished (years), socio-economic
status based on occupation (low: technical/semi-routine and routine occu-
pations; medium: lower managerial / intermediate occupations; high: pro-
fessional/higher managerial occupations), income (<£20,000, £20,000-
40,000, >£40,000), marital status (single, married, widowed/separated),
smoking status (never, former, current smoker), pack-years of smok-
ing, energy expenditure due to physical activity (kj/kg/d), lipid-lowering
medication (Yes, No), anti-hypertensive medication (Yes, No), hormone-
replacement therapy (Yes, No, Men).; Model 3: Model 2 + intakes (g/d)
of fruit, vegetables (not including potatoes), potatoes, legumes, processed
cereals, whole-grain cereals, poultry and eggs, red meat, processed meat,
fish, sauces, margarine, nuts, sweet snacks, sugar-sweetened beverages,
artificially sweetened beverages, fruit juice, regular coffee, decaffeinated
coffee, tea, alcoholic beverages, plasma vitamin C levels (µmol/l), dietary











































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Table A.14 Associations of the change in total and types of dairy consumption with the
change in HbA1c, blood pressure and a z-score for metabolic risk from baseline to the first











Mean (SD) of change 1.6 (6.1) 0.5 (14.9) -0.1 (10.5) 0.01 (0.34)
Participants (N) 6,224 14,210 14,231 6,033
Dairy consumption (servings/d) ‡ b 95% CI b 95% CI b 95% CI b 95% CI
Milk
Demographic, lifestyle, energy § 0.07 -0.18 0.31 -0.08 -0.52 0.36 0.11 -0.21 0.42 0.002 -0.02 0.02
+ Diet ∥ 0.1 -0.14 0.35 -0.1 -0.55 0.35 0.1 -0.22 0.43 0.003 -0.02 0.02
+ BMI # 0.1 -0.14 0.34 -0.13 -0.56 0.31 0.09 -0.24 0.41
Yoghurt
Demographic, lifestyle, energy § 0.1 -0.4 0.61 -0.16 -1.03 0.7 -0.38 -1.03 0.27 -0.01 -0.05 0.02
+ Diet ∥ 0.16 -0.35 0.66 -0.09 -0.98 0.81 -0.29 -0.96 0.38 -0.01 -0.04 0.03
+ BMI # 0.21 -0.29 0.71 0.14 -0.71 0.98 -0.14 -0.78 0.5
Cheese
Demographic, lifestyle, energy § -0.11 -0.67 0.46 -0.04 -0.94 0.86 -0.15 -0.79 0.49 -0.03 -0.06 0.01
+ Diet ∥ -0.08 -0.64 0.48 -0.01 -0.92 0.89 -0.13 -0.78 0.51 -0.02 -0.06 0.01
+ BMI # -0.04 -0.6 0.52 0.08 -0.8 0.96 -0.07 -0.69 0.56
Butter
Demographic, lifestyle, energy § 0.02 -0.22 0.27 0.37 -0.03 0.76 0.23 -0.08 0.53 -0.002 -0.02 0.01
+ Diet ∥ 0.01 -0.24 0.25 0.35 -0.07 0.76 0.22 -0.09 0.53 -0.001 -0.02 0.02
+ BMI # 0 -0.24 0.24 0.3 -0.12 0.72 0.19 -0.12 0.51
Full-fat milk
Demographic, lifestyle, energy § 0.54 0.08 1 0.1 -0.79 0.99 0.24 -0.4 0.87 0.02 -0.01 0.05
+ Diet ∥ 0.55 0.09 1.01 0.07 -0.83 0.96 0.2 -0.43 0.83 0.02 -0.02 0.05
+ BMI # 0.52 0.06 0.97 -0.1 -0.98 0.78 0.07 -0.54 0.69
Low-fat milk
Demographic, lifestyle, energy § 0 -0.26 0.27 -0.05 -0.62 0.52 0.12 -0.25 0.49 0.002 -0.02 0.02
+ Diet ∥ 0.04 -0.23 0.31 -0.05 -0.62 0.51 0.12 -0.25 0.49 0.003 -0.02 0.02
+ BMI # 0.04 -0.23 0.31 -0.09 -0.65 0.48 0.1 -0.26 0.47
Full-fat yoghurt
Demographic, lifestyle, energy § -0.06 -1.7 1.59 1.33 -1.77 4.43 0.14 -1.95 2.23 0.02 -0.08 0.13
+ Diet ∥ -0.02 -1.67 1.64 1.32 -1.8 4.44 0.08 -2.04 2.2 0.03 -0.07 0.14
+ BMI # -0.01 -1.68 1.66 1.29 -1.75 4.32 0.05 -2.02 2.13
Low-fat yoghurt
Demographic, lifestyle, energy § 0.22 -0.36 0.8 -0.2 -1.04 0.65 -0.37 -0.95 0.22 -0.02 -0.06 0.02
+ Diet ∥ 0.26 -0.3 0.82 -0.12 -0.97 0.72 -0.27 -0.87 0.33 -0.01 -0.05 0.03
+ BMI # 0.33 -0.23 0.89 0.16 -0.66 0.99 -0.07 -0.66 0.51
High-fat cheese
Demographic, lifestyle, energy § -0.08 -0.81 0.65 1.33 0 2.65 0.75 -0.21 1.7 0.01 -0.05 0.06
+ Diet ∥ -0.05 -0.76 0.67 1.27 -0.05 2.6 0.67 -0.28 1.62 0.01 -0.05 0.06
+ BMI # -0.11 -0.81 0.6 0.83 -0.44 2.1 0.36 -0.54 1.26
Low-fat cheese
Demographic, lifestyle, energy § -0.13 -1 0.73 -1.26 -2.84 0.31 -1.06 -2.23 0.1 -0.04 -0.1 0.03
+ Diet ∥ -0.09 -0.96 0.79 -1.19 -2.78 0.39 -0.98 -2.18 0.22 -0.03 -0.1 0.03
+ BMI # 0.02 -0.86 0.9 -0.63 -2.17 0.9 -0.58 -1.77 0.61
Ice-cream
Demographic, lifestyle, energy § 0.12 -0.58 0.82 -0.26 -1.41 0.89 -0.36 -1.21 0.5 -0.002 -0.05 0.05
+ Diet ∥ 0.14 -0.55 0.84 -0.35 -1.5 0.81 -0.35 -1.22 0.52 -0.003 -0.05 0.05
+ BMI # 0.14 -0.55 0.84 -0.48 -1.62 0.65 -0.43 -1.27 0.41
Fermented dairy products
Demographic, lifestyle, energy § -0.03 -0.38 0.32 -0.27 -0.95 0.41 -0.37 -0.83 0.08 -0.03 -0.05 -0.004
+ Diet ∥ 0 -0.36 0.35 -0.24 -0.94 0.47 -0.33 -0.79 0.14 -0.02 -0.04 0.001
+ BMI # 0.04 -0.32 0.39 -0.06 -0.74 0.63 -0.2 -0.64 0.24
High-fat dairy products
Demographic, lifestyle, energy § 0.06 -0.15 0.26 0.22 -0.11 0.55 0.18 -0.03 0.39 -0.002 -0.01 0.01
+ Diet ∥ 0.06 -0.15 0.27 0.19 -0.15 0.54 0.16 -0.06 0.38 -0.001 -0.01 0.01
+ BMI # 0.04 -0.17 0.25 0.11 -0.23 0.46 0.11 -0.12 0.34
Low-fat dairy products
Demographic, lifestyle, energy § 0.01 -0.17 0.19 -0.11 -0.43 0.21 -0.04 -0.27 0.2 -0.01 -0.02 0.01
+ Diet ∥ 0.04 -0.14 0.23 -0.09 -0.42 0.24 -0.01 -0.24 0.23 -0.004 -0.02 0.01
+ BMI # 0.06 -0.12 0.25 -0.01 -0.33 0.31 0.05 -0.18 0.28












Mean (SD) of change 1.6 (6.1) 0.5 (14.9) -0.1 (10.5) 0.01 (0.34)
Participants (N) 6,224 14,210 14,231 6,033
Dairy consumption (servings/d) ‡ b 95% CI b 95% CI b 95% CI b 95% CI
Total dairy products
Demographic, lifestyle, energy § 0.005 -0.14 0.15 -0.01 -0.23 0.22 0 -0.16 0.16 -0.002 -0.01 0.01
+ Diet ∥ 0.03 -0.12 0.17 -0.01 -0.24 0.22 0.003 -0.16 0.17 0 -0.01 0.01
+ BMI # 0.03 -0.12 0.17 -0.001 -0.23 0.22 0.01 -0.15 0.18
† HbA1c: Haemoglobin A1c
‡ Servings as defined by Food Standards Agency 2002[197]: Milk- 1 average glass (200g); Yoghurt- 125g carton;
Cheese- medium serving (40g); Single cream- 1 tablespoon (15g); Double cream- 1 tablespoon (30g); Butter- 1
teaspoon (10g); Ice-cream- 1 average scoop/tub (60g)
§ Linear regression model 1: age (years), sex, educational level (low, medium, high), age at completion of full-time
education (years), marital status (single, married, widowed or separated), socio-economic status based on occupation
(low: technical/semi-routine and routine occupationsl medium: lower managerial / intermediate occupationsl; high:
professional / higher managerial occupations), individual follow-up time (years), physical activity level (inactive,
moderately inactive, moderately active, active), smoking status (never, former and current smoker), lipid-lowering
medication (Yes, No), anti-hypertensive medication (Yes, No), hormone-replacement therapy (Yes, No, Men), total
energy intake (kcal/day)
∥ Linear regression model 2: Model 1 + intakes (g/d) of fruit, vegetables, potatoes, legumes, nuts, processed
cereals, whole-grain cereals, poultry and eggs, red meat, processed meat, fish, sauces, margarine, sweet snacks,
sugar-sweetened beverages, artificially sweetened beverages, fruit juice, coffee, tea and alcoholic beverages and
dietary supplement use (Yes, No)






































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































A.4 Chapter 6 327
Table A.20 Coefficients of predictors in decreasing order of magnitude of the
absolute values* for milk and total dairy products as derived from elastic net
linear prediction models † in the discovery set of the Fenland study with all 174
metabolites included
Milk Total dairy products
Order # Predictor Coefficient Predictor Coefficient
1 SM-OH C14:1 0.078 SM-OH C14:1 0.11
2 SM C16:1 -0.055 LPC a C18:0 -0.073
3 LPC a C18:0 -0.034 LPC a C17:0 0.072
4 PC aa C28:1 0.033 SM C16:1 -0.053
5 LPC a C17:0 0.026 PC aa C28:1 0.037
6 Pro 0.023 SM C24:0 -0.026
7 SM C24:0 -0.022 SM C16:0 -0.024
8 LPC a C20:3 0.02 PC aa C32:1 0.017
9 C0 0.019 t4OHPro -0.015
10 LPC a C18:2 -0.019 Pro 0.014
11 Orn -0.018 PC ae C34:1 0.013
12 C141 -0.017 PC ae C38:4 0.013
13 PC aa C40:5 0.017 C51 0.012
14 Ile -0.016 C141 -0.012
15 His -0.014 C182 -0.012
16 PC aa C38:1 -0.014 PC aa C38:1 -0.012
17 Cit 0.013 PC ae C34:3 -0.012
18 SM C16:0 -0.013 His -0.011
19 Creatinine 0.012 LPC a C14:0 0.011
20 t4OHPro -0.012 PC aa C40:5 0.011
21 C51 0.012 Ile -0.01
22 C6C41DC -0.012 PC ae C36:4 -0.01
23 PC aa C38:3 0.012 PC aa C26:0 -0.009
24 Thr -0.011 PC aa C34:4 -0.009
25 PC aa C32:3 -0.011 PC aa C40:4 0.009
26 PC aa C34:4 -0.011 PC ae C38:2 -0.009
27 Trp 0.01 Ala -0.008
28 SDMA -0.01 alpha-AAA 0.008
29 Spermidine 0.009 PC ae C36:2 0.008
30 LPC a C16:1 0.009 PC ae C44:3 -0.008
31 PC aa C24:0 -0.009 SM C24:1 -0.008
32 PC aa C40:4 0.009 AcOrn 0.007
33 PC ae C30:2 -0.009 Kynurenine 0.006
34 PC ae C34:3 -0.009 PC aa C42:1 -0.006
328 Supplemental results
Table A.20 (continued)
Milk Total dairy products
Order # Predictor Coefficient Predictor Coefficient
35 SM-OH C22:1 -0.009 PC ae C30:2 -0.006
36 C181OH 0.008 C8 -0.005
37 Lys 0.007 PC aa C32:3 -0.005
38 alpha-AAA 0.007 PC ae C30:0 0.005
39 PC aa C32:0 0.007 PC ae C38:0 -0.005
40 PC aa C42:0 0.007 Arg 0.004
41 SM -OH C22:2 0.007 Trp 0.004
42 Taurine 0.006 c4OHPro -0.004
43 C161 0.006 C51DC -0.004
44 C16OH 0.006 C16 0.004
45 PC ae C40:2 -0.006 SM-OH C16:1 0.004
46 PC ae C40:5 -0.006 Orn -0.003
47 PC ae C44:3 -0.006 Val 0.003
48 C12 -0.005 Sarcosine -0.003
49 PC aa C40:3 -0.005 Spermidine 0.003
50 PC ae C38:4 0.005 C5MDC -0.003
51 PC ae C44:5 0.005 LPC a C16:1 0.003
52 SM C20:2 0.005 LPC a C26:1 -0.003
53 Sarcosine -0.004 PC aa C42:5 -0.003
54 C142 -0.004 SDMA -0.002
55 Ala -0.003 C3DCMC5OH -0.002
56 Asp 0.003 C142 -0.002
57 Ser -0.003 C18 -0.002
58 C41 -0.003 LPC a C26:0 -0.002
59 C51DC -0.003 PC ae C34:0 0.002
60 C3DCMC5OH -0.003 Taurine 0.001
61 C18 -0.003 C0 0.001
62 PC aa C40:2 0.003 C4 0.001
63 PC ae C42:5 0.003 C61 -0.001
64 Arg 0.002 C102 -0.001
65 Glu -0.002 C142OH -0.001
66 Gly -0.002 LPC a C18:2 -0.001
67 Phe -0.002 LPC a C28:0 -0.001
68 C16 0.002 PC ae C36:1 0.001
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Table A.20 (continued)
Milk Total dairy products
Order # Predictor Coefficient Predictor Coefficient
69 C182 -0.002 PC ae C42:4 -0.001
70 PC aa C36:2 -0.002 SM -OH C22:2 0.001
71 PC ae C34:1 0.002 Asn 0
72 PC ae C44:6 0.002 Asp 0
73 Gln 0.001 Cit 0
74 Leu 0.001 Gln 0
75 Kynurenine 0.001 Glu 0
76 Serotonin -0.001 Gly 0
77 C2 -0.001 Leu 0
78 PC aa C36:6 -0.001 Lys 0
79 PC aa C42:1 -0.001 Met 0
80 PC aa C42:4 0.001 Phe 0
81 PC ae C38:0 -0.001 Ser 0
82 PC ae C40:6 -0.001 Thr 0
83 PC ae C42:4 -0.001 Tyr 0
84 Asn 0 PEA 0
85 Met 0 Creatinine 0
86 Tyr 0 Met-SO 0
87 Val 0 Serotonin 0
88 PEA 0 C2 0
89 AcOrn 0 C3 0
90 Met-SO 0 C31 0
91 c4OHPro 0 C3OH 0
92 C3 0 C41 0
93 C31 0 C3DCC4OH 0
94 C3OH 0 C5 0
95 C4 0 C5DCC6OH 0
96 C3DCC4OH 0 C6C41DC 0
97 C5 0 C7DC 0
98 C5DCC6OH 0 C9 0
99 C5MDC 0 C10 0
100 C61 0 C101 0
101 C7DC 0 C12 0
102 C8 0 C12DC 0
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Table A.20 (continued)
Milk Total dairy products
Order # Predictor Coefficient Predictor Coefficient
103 C9 0 C121 0
104 C10 0 C14 0
105 C101 0 C141OH 0
106 C102 0 C161 0
107 C12DC 0 C161OH 0
108 C121 0 C162 0
109 C14 0 C162OH 0
110 C141OH 0 C16OH 0
111 C142OH 0 C181 0
112 C161OH 0 C181OH 0
113 C162 0 LPC a C20:4 0
114 C162OH 0 LPC a C16:0 0
115 C181 0 LPC a C18:1 0
116 LPC a C14:0 0 LPC a C20:3 0
117 LPC a C20:4 0 LPC a C24:0 0
118 LPC a C26:1 0 LPC a C28:1 0
119 LPC a C16:0 0 PC aa C24:0 0
120 LPC a C18:1 0 PC aa C30:0 0
121 LPC a C24:0 0 PC aa C32:0 0
122 LPC a C26:0 0 PC aa C32:2 0
123 LPC a C28:0 0 PC aa C34:1 0
124 LPC a C28:1 0 PC aa C34:2 0
125 PC aa C26:0 0 PC aa C34:3 0
126 PC aa C30:0 0 PC aa C36:0 0
127 PC aa C32:1 0 PC aa C36:1 0
128 PC aa C32:2 0 PC aa C36:2 0
129 PC aa C34:1 0 PC aa C36:3 0
130 PC aa C34:2 0 PC aa C36:4 0
131 PC aa C34:3 0 PC aa C36:5 0
132 PC aa C36:0 0 PC aa C36:6 0
133 PC aa C36:1 0 PC aa C38:0 0
134 PC aa C36:3 0 PC aa C38:3 0
135 PC aa C36:4 0 PC aa C38:4 0
136 PC aa C36:5 0 PC aa C38:5 0
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Table A.20 (continued)
Milk Total dairy products
Order # Predictor Coefficient Predictor Coefficient
137 PC aa C38:0 0 PC aa C38:6 0
138 PC aa C38:4 0 PC aa C40:1 0
139 PC aa C38:5 0 PC aa C40:2 0
140 PC aa C38:6 0 PC aa C40:3 0
141 PC aa C40:1 0 PC aa C40:6 0
142 PC aa C40:6 0 PC aa C42:0 0
143 PC aa C42:2 0 PC aa C42:2 0
144 PC aa C42:5 0 PC aa C42:4 0
145 PC aa C42:6 0 PC aa C42:6 0
146 PC ae C30:0 0 PC ae C30:1 0
147 PC ae C30:1 0 PC ae C32:1 0
148 PC ae C32:1 0 PC ae C32:2 0
149 PC ae C32:2 0 PC ae C34:2 0
150 PC ae C34:0 0 PC ae C36:0 0
151 PC ae C34:2 0 PC ae C36:3 0
152 PC ae C36:0 0 PC ae C36:5 0
153 PC ae C36:1 0 PC ae C38:1 0
154 PC ae C36:2 0 PC ae C38:3 0
155 PC ae C36:3 0 PC ae C38:5 0
156 PC ae C36:4 0 PC ae C38:6 0
157 PC ae C36:5 0 PC ae C40:1 0
158 PC ae C38:1 0 PC ae C40:2 0
159 PC ae C38:2 0 PC ae C40:3 0
160 PC ae C38:3 0 PC ae C40:4 0
161 PC ae C38:5 0 PC ae C40:5 0
162 PC ae C38:6 0 PC ae C40:6 0
163 PC ae C40:1 0 PC ae C42:0 0
164 PC ae C40:3 0 PC ae C42:1 0
165 PC ae C40:4 0 PC ae C42:2 0
166 PC ae C42:0 0 PC ae C42:3 0
167 PC ae C42:1 0 PC ae C42:5 0
168 PC ae C42:2 0 PC ae C44:5 0
169 PC ae C42:3 0 PC ae C44:6 0
170 SM C18:0 0 SM C18:0 0
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Table A.20 (continued)
Milk Total dairy products
Order # Predictor Coefficient Predictor Coefficient
171 SM C18:1 0 SM C18:1 0
172 SM C24:1 0 SM C20:2 0
173 SM-OH C16:1 0 SM-OH C22:1 0
174 Hexose 0 Hexose 0
age 0.001 age 0.001
sex 0 sex 0
test site 0.04 test site 0
smoking status 0 smoking status 0






HRT 0 HRT -0.027
BMI 0.001 BMI 0.003
intercept 0.738 intercept 1.236
*The metabolites are presented in order of decreasing absolute value of the elastic net
coefficients, whereas the rest of the predictors used in the models are presented in the
end, along with the model intercept
†Coefficients are derived from the main models, which include age, sex, test site,
smoking status, physical activity, lipid lowering medication, hormone-replacement
therapy, body mass index and the metabolites
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Table A.21 Coefficients of predictors for total and types of dairy products as derived from
logistic and linear prediction models without penalisation* in the discovery set of the
Fenland study with all 174 metabolites included








Ala -114.667 -13.475 -272.273 -29.816 -254.369 -0.005 -0.011
Arg 138.858 -134.948 133.374 163.449 293.77 0.005 0.008
Asn -68.203 101.301 265.649 -114.776 -95.209 0.002 -0.003
Asp 79.938 -143.259 -143.113 -167.316 6.22 0.008 0.003
Cit 217.879 -30.699 -120.486 -55.147 185.831 0.019 0.005
Gln 120.646 -107.698 257.596 -88.471 -120.86 0.006 0.003
Glu -146.368 -174.856 238.954 110.061 -110.022 -0.007 0.003
Gly -162.413 -41.122 232.249 -99.369 -3.678 -0.007 -0.003
His -116.733 162.942 112.922 125.97 -112.583 -0.025 -0.019
Ile -305.317 -287.471 -199.094 164.266 -192.457 -0.029 -0.011
Leu 119.675 54.409 19.436 -92.748 231.49 0.009 0
Lys 52.997 108.234 -6.18 -231.907 134.562 0.009 -0.001
Met -50.335 16.108 -58.387 4.079 165.469 -0.001 0.004
Orn -212.742 -56.118 -136.096 208.394 -319.858 -0.024 -0.01
Phe 8.1 -14.929 -45.55 -68.665 -111.789 -0.004 -0.004
Pro 288.195 61.108 33.729 33.32 301.759 0.025 0.019
Ser -239.987 -105.311 116.561 87.977 58.985 -0.007 0.001
Thr -337.071 -134.345 390.399 39.275 -97.674 -0.014 -0.003
Trp 126.052 34.491 -80.467 -22.419 -6.987 0.016 0.01
Tyr 158.529 67.617 324.211 90.692 204.321 -0.009 -0.005
Val 109.365 202.219 -32.321 153.94 103.31 0.005 0.011
PEA -112.661 -97.367 15.244 81.432 -93.432 0.005 -0.006
AcOrn -13.053 60.063 -3.605 9.254 84.733 0.005 0.011
SDMA -52.077 107.967 265.523 138.199 -118.346 -0.016 -0.008
alpha-AAA 211.429 112.383 -67.363 93.254 309.625 0.01 0.013
Creatinine 370.359 -186.038 -269.782 -114.552 -49.829 0.019 0.001
Kynurenine 41.504 264.978 411.408 -32.441 223.1 0.003 0.009
Met-SO -17.544 49.816 -39.717 -61.007 -106.667 -0.002 0.001
c4OHPro -159.829 -218.793 -340.114 15.958 -320.429 0.007 -0.003
t4OHPro -192.465 -190.873 -368.287 109.232 -349.233 -0.02 -0.017
Sarcosine -64.447 -178.76 -119.204 -35.498 -159.711 -0.007 -0.006
Serotonin -110.115 180.739 118.909 -20.343 100.979 -0.009 -0.004
Spermidine 24.932 24.054 -214.372 -81.657 15.86 0.01 0.006
Taurine 158.915 274.595 -34.42 -179.552 -47.456 0.014 0.006
C0 203.499 61.137 -400.74 -186.54 40.207 0.03 0.009
C2 -52.768 158.584 204.657 60.924 -170.337 -0.015 -0.001
C3 240.648 163.589 -124.265 78.88 201.873 0 -0.002
C31 -58.48 49.34 -112.066 -126.674 -16.199 0.003 0.001
C3OH -26.434 -25.083 -44.613 -15.015 -83.802 0.004 0.007
C4 -22.514 65.431 176.318 -66.388 124.846 -0.001 0.004
C41 -106.797 36.085 -123.297 31.886 169.077 -0.011 -0.005
C3DCC4OH 74.47 -103.906 -69.564 -58.939 -18.041 0.007 0.005
C5 -16.339 -200.036 -51.192 101.783 -13.522 -0.005 -0.005
C51 101.55 152.446 337.695 -149.948 175.579 0.02 0.019
C51DC 34.714 -51.445 86.093 3.683 -174.873 -0.007 -0.009
C5DCC6OH -31.554 8.747 -15.95 38.715 107.51 -0.002 0.008
C5MDC -28.313 94.217 -252.746 -11.629 1.949 0 -0.008
C3DCMC5OH -25.762 148.113 5.736 -127.635 -365.39 -0.007 -0.006
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Table A.21 (continued)








C6C41DC -183.242 -71.93 -97.666 51.848 -18.284 -0.015 -0.004
C61 177.754 -72.791 38.026 5.182 47.496 -0.003 -0.007
C7DC 103.013 70.146 -160.22 100.094 6.215 -0.004 -0.004
C8 -76.435 19.912 -180.556 3.4 -27.735 -0.001 -0.02
C9 -55.864 -267.99 106.371 449.273 117.885 -0.005 0.003
C10 -121.246 -129.112 95.936 86.786 63.638 0.008 0.02
C101 7.525 -76.313 -329.793 -61.522 -80.278 -0.003 -0.004
C102 15.399 281.207 -219.422 -307.257 -30.574 0.001 -0.002
C12 -78.086 -103.467 174.781 65.868 -27.406 -0.016 0.001
C12DC -27.037 51.681 62.917 -84.705 -50.048 -0.002 -0.007
C121 101.936 -13.754 -69.486 94.568 166.088 0.024 0.017
C14 -16.288 137.686 63.978 -28.281 48.656 -0.005 -0.005
C141 -321.08 -212.4 18.972 138.301 -202.158 -0.038 -0.043
C141OH 58.149 124.764 112.809 29.759 179.609 0.009 0.008
C142 -214.237 -11.128 -48.01 -171.086 -200.098 -0.008 0.002
C142OH -36.288 69.588 -94.904 -204.579 -76.891 -0.003 -0.008
C16 -13.425 -159.109 111.708 115.849 188.154 0.008 0.014
C161 171.775 169.786 -35.09 -114.5 86.347 0.014 0.005
C161OH 2.733 33.538 184.432 130.001 43.964 -0.003 -0.003
C162 47.027 11.172 148.796 4.889 -25.603 0.008 0.006
C162OH 80.154 -87.243 -184.01 -64.985 -40.119 -0.005 -0.006
C16OH 111.623 -98.32 7.052 60.284 23.019 0.012 0.007
C18 -186.578 -247.864 -109.864 94.934 51.461 -0.013 -0.016
C181 27.052 40.092 -86.832 110.078 21.614 0.022 0.014
C181OH 127.515 -120.905 159.677 -100.554 -29.075 0.014 0.008
C182 -213.787 212.664 -68.011 -289.607 -164.108 -0.013 -0.017
LPC a C14:0 49.831 156.808 82.745 315.916 349.517 0.003 0.023
LPC a C16:1 131.846 261.269 19.095 -106.093 91.787 0.023 0.014
LPC a C17:0 301.307 212.685 319.973 529.748 627.877 0.047 0.078
LPC a C18:0 -245.195 -181.951 -272.12 -146.079 -288.527 -0.084 -0.109
LPC a C18:2 -66.423 46.646 23.73 -104.068 -295.201 -0.004 -0.01
LPC a C20:4 -82.388 -62.959 -23.984 6.551 -159.621 -0.024 -0.019
LPC a C26:1 4.977 50.625 -19.131 -73.184 -116.458 0.008 -0.006
LPC a C16:0 -152.474 14.741 -132.106 -191.498 -133.411 0.031 0.019
LPC a C18:1 -150.626 -59.249 -6.834 2.424 -212.825 -0.039 -0.002
LPC a C20:3 288.567 174.476 20.038 -221.398 52.742 0.053 0.035
LPC a C24:0 52.847 217.899 -50.295 -149.671 -207.996 0.003 0.006
LPC a C26:0 7.631 -39.894 -96.265 -218.713 5.238 -0.016 -0.02
LPC a C28:0 -16.184 -204.872 32.396 -84.411 -32.691 0.005 -0.008
LPC a C28:1 49.144 -14.277 133.169 39.566 108.733 0.005 0.001
PC aa C24:0 -162.25 2.989 -107.473 147.446 -98.112 -0.016 0.01
PC aa C26:0 -136.585 -80.869 -119.218 -128.985 -138.136 0.004 -0.006
PC aa C28:1 503.434 432.294 495.201 244.064 684.642 0.049 0.045
PC aa C30:0 74.702 99.178 136.299 107.856 308.67 -0.004 0.007
PC aa C32:0 66.485 -44.203 -35.785 -405.311 31.768 0.03 0.002
PC aa C32:1 116.232 -34.698 64.232 114.284 241.624 -0.019 0.006
PC aa C32:2 50.379 55.974 65.367 64.852 84.372 -0.012 -0.01
PC aa C32:3 -236.695 -99.975 187.832 174.746 -103.076 -0.017 -0.012
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PC aa C34:1 -64.81 -41.998 -15.677 134.115 -4.386 -0.077 -0.06
PC aa C34:2 -8.147 -95.577 59.575 -51.906 -151.657 0.056 0.053
PC aa C34:3 39.807 108.114 43.255 -97.771 -73.787 0.015 -0.001
PC aa C34:4 -256.17 -2.866 -79.285 -86.082 -2.704 -0.009 -0.023
PC aa C36:0 95.409 293.322 -24.181 -49.858 53.782 0.003 0.013
PC aa C36:1 -168.328 -273.277 -190.801 126.253 -147.337 -0.002 0.034
PC aa C36:2 -83.421 -231.993 -113.024 23.365 -314.384 -0.032 -0.076
PC aa C36:3 -3.038 150.776 12.887 -44.812 -16.271 -0.097 -0.025
PC aa C36:4 -205.502 36.497 100.489 -28.916 -55.046 0.025 0.006
PC aa C36:5 26.752 -77.053 206.543 -49.924 -71.22 -0.006 0.007
PC aa C36:6 -11.028 27.215 57.816 -87.771 39.911 -0.009 -0.011
PC aa C38:0 24.387 24.711 -275.554 3.704 -171.602 0.001 0.004
PC aa C38:1 -318.283 32.438 -304.206 -112.167 -165.86 -0.016 -0.015
PC aa C38:3 150.75 63.725 -119.523 -182.357 38.953 0.123 0.056
PC aa C38:4 29.089 -133.196 -36.61 1.106 -82.059 -0.019 -0.003
PC aa C38:5 101.731 -84.287 64.526 8.775 16.641 0.011 0.057
PC aa C38:6 -106.984 119.779 -1.532 -79.14 -73.677 0.04 0.002
PC aa C40:1 -96.367 -148.197 -11.904 -10.189 -92.649 0.001 -0.002
PC aa C40:2 37.183 48.834 75.215 -136.209 -34.436 0.007 0.002
PC aa C40:3 -88.189 123.852 208.157 -32.901 -309.669 -0.01 -0.002
PC aa C40:4 124.818 -56.752 104.129 -131.08 -53.615 0.01 0.014
PC aa C40:5 241.932 119.175 -192.569 154.818 216.519 0.018 0.018
PC aa C40:6 -64.232 -86.319 -270.365 -75.467 -129.512 0.015 -0.002
PC aa C42:0 199.518 -2.94 129.749 -210.786 79.599 0.01 0.003
PC aa C42:1 188.373 -128.814 -4.48 -89.575 -175.1 -0.005 -0.01
PC aa C42:2 -6.744 -66.036 -82.987 -1.306 42.784 0.004 0.002
PC aa C42:4 131.745 64.288 274.578 58.033 -145.028 0.006 0.004
PC aa C42:5 -29.754 50.557 -49.462 -94.453 -144.499 -0.004 -0.007
PC aa C42:6 159.578 -136.132 90.825 -74.674 182.958 0.001 -0.002
PC ae C30:0 65.42 67.919 311.435 268.234 477.881 -0.003 0.009
PC ae C30:1 -205.506 -224.57 -34.223 28.164 -168.72 0.003 0.008
PC ae C30:2 -324.466 -60.325 17.856 224.694 76.93 -0.018 -0.013
PC ae C32:1 76.428 -59.248 42.164 -179.459 71.961 0.006 0.009
PC ae C32:2 17.128 41.098 -29.929 92.802 -20.842 -0.013 -0.013
PC ae C34:0 -51.378 -161.654 193.323 235.898 443.687 -0.011 -0.001
PC ae C34:1 75.654 29.526 141.95 191.758 297.453 0.005 0.003
PC ae C34:2 84.873 16.964 43.723 137.104 112.915 0.011 0.011
PC ae C34:3 -148.926 -96.512 -326.246 -70.832 -284.456 -0.017 -0.017
PC ae C36:0 -116.249 1.657 9.972 29.567 -34.523 0 0.003
PC ae C36:1 122.628 -25.564 -12.09 193.576 295.701 -0.001 -0.002
PC ae C36:2 96.48 95.98 379.403 323.72 394.67 0.001 0.021
PC ae C36:3 -130.428 -112.485 -134.584 -92.281 -78.435 -0.002 -0.013
PC ae C36:4 -94.951 -152.295 -300.519 108.909 -115.575 -0.03 -0.037
PC ae C36:5 -96.162 -104.031 -209.859 94.049 -96.563 0.024 0.022
PC ae C38:0 -128.577 17.302 88.267 -129.921 -258.796 -0.013 -0.016
PC ae C38:1 -42.561 46.616 27.752 86.113 13.483 0.085 0.066
PC ae C38:2 9.927 -40.816 191.757 -72.577 -123.012 -0.067 -0.064
PC ae C38:3 53.421 -6.092 -137.04 155.775 255.896 0.006 0.004
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PC ae C38:4 223.922 -5.959 183.265 292.494 291.573 0.031 0.035
PC ae C38:5 -172.989 -96.414 -181.112 20.863 -136.315 -0.013 -0.003
PC ae C38:6 35.019 -86.387 -259.037 -97.569 -32.46 0.01 -0.001
PC ae C40:1 175.288 14.325 -8.019 -174.137 -127.142 0.006 -0.001
PC ae C40:2 -122.843 -219.348 -139.464 94.137 -111.175 -0.011 -0.042
PC ae C40:3 -45.62 -168.171 -45.024 13.639 -260.18 0.053 0.095
PC ae C40:4 26.389 189.489 28.392 -61.577 -6.592 0.071 0.02
PC ae C40:5 -141.58 25.599 170.397 -9.498 -39.109 -0.041 -0.01
PC ae C40:6 -89.874 125.544 92.175 1.295 16.143 -0.024 -0.01
PC ae C42:0 91.107 52.725 230.646 95.71 11.647 0.001 0.002
PC ae C42:1 62.131 123.29 -152.916 -174.634 1.722 -0.115 -0.069
PC ae C42:2 120.295 -23.409 109.642 -0.829 15.268 0.019 -0.047
PC ae C42:3 22.882 -155.173 -59.759 44.614 -110.443 0.02 0.009
PC ae C42:4 -106.958 235.781 61.978 -72.419 -87.545 -0.051 -0.003
PC ae C42:5 214.603 -93.557 134.274 -5.532 135.241 0.005 0.001
PC ae C44:3 -200.426 -139.425 55.915 -96.164 -169.005 -0.01 -0.012
PC ae C44:5 3.199 -207.978 -63.355 25.178 -152.543 0.009 0.002
PC ae C44:6 230.697 285.709 -124.623 -189.553 -6.388 0.005 0
SM C16:0 -157.731 -268.587 -177.076 -205.661 -303.774 -0.022 -0.032
SM C16:1 -382.606 60.633 -260.1 -205.841 -338.261 -0.061 -0.062
SM C18:0 236.856 -26.366 -94.665 -103.763 31.364 0.009 0.006
SM C18:1 -297.83 130.968 -275.4 -6.182 -142.573 -0.006 -0.004
SM C20:2 190.243 -28.957 89.175 57.587 -19.563 0.012 0.002
SM C24:0 -341.698 -303.44 -63.071 -119.424 -452.158 -0.024 -0.027
SM C24:1 -103.48 -177.096 -142.692 -283.462 -409.743 -0.002 -0.01
SM-OH C14:1 678 409.681 602.433 472.175 941.878 0.083 0.118
SM-OH C16:1 163.775 82.308 312.934 365.193 480.346 -0.005 0.007
SM-OH C22:1 -245.526 -50.245 74.389 49.342 -51.791 -0.017 -0.006
SM -OH C22:2 185.849 64.066 134.661 107.042 293.475 0.013 0.007
Hexose 200.258 -76.054 168.219 -124.193 -97.978 0.007 -0.001
age -4.633 33.647 -105.29 -11.999 28.849 0 0.001
sex -153.416 192.655 246.222 -1.679 9.28 -0.064 0.052
test site 526.453 -33.063 -308.135 -619.958 61.863 0.043 0.003
smoking status -137.922 -749.571 86.539 149.909 -97.312 -0.005 0
physical activity -16.901 -13.011 8.995 -5.743 -4.103 0 0
lipid-lowering -107.525 -85.375 30.8 -55.882 -33.292 -0.026 -0.036
HRT 209.915 -609.862 -378.867 86.267 44.105 -0.039 -0.015
BMI -7.934 26.87 137.865 -59.713 114.371 -0.001 0.003
intercept 4.998 -50.365 27.672 14.464 12.11 0.964 1.163
*Coefficients are derived from the main models, which include age, sex, test site, smoking status, physical activity, lipid
lowering medication, hormone-replacement therapy, body mass index and the metabolites










































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Table A.23 Coefficients of predictors in decreasing order of mag-
nitude of the absolute values* for milk and total dairy products as
derived from elastic net linear prediction models† in the discovery
set of the Fenland study with the 82 overlapping metabolites with
the diabetes case-cohort sub-study of the EPIC Norfolk study
Milk Total dairy products
Order # Predictor Coefficient Predictor Coefficient
1 SM-OH C14:1 0.104 SM-OH C14:1 0.141
2 SM C16:1 -0.058 LPC a C18:0 -0.072
3 LPC a C20:3 0.041 LPC a C17:0 0.071
4 LPC a C18:0 -0.034 SM C16:1 -0.058
5 Phe 0.026 SM C16:0 -0.038
6 SM C16:0 -0.026 trans-OH-Pro -0.024
7 C0 0.025 C18:2 -0.018
8 PC aa C38:5 0.025 Phe 0.017
9 LPC a C17:0 0.024 PC ae C34:1 0.016
10 Ile -0.021 His -0.015
11 His -0.02 PC aa C32:1 0.015
12 LPC a C18:2 -0.02 C14:1 -0.014
13 Orn -0.019 PC ae C36:2 0.014
14 LPC a C16:1 0.019 SM C24:1 -0.013
15 SM-OH C22:1 -0.019 LPC a C14:0 0.012
16 trans-OH-Pro -0.017 C16 0.011
17 creatinine 0.016 PC aa C34:2 -0.011
18 C6 -0.016 C5:1 0.01
19 C14:1 -0.016 C8 -0.01
20 PC aa C32:0 0.016 LPC a C18:2 -0.01
21 PC aa C36:5 -0.016 Ala -0.009
22 Cit 0.015 kynurenine 0.009
23 C16 0.015 Ile -0.008
24 Ser -0.014 Ac-Orn 0.008
25 SDMA -0.014 alpha-AAA 0.008
26 LPC a C20:4 -0.014 LPC a C20:3 0.008
27 PC aa C32:2 -0.014 SM-OH C22:1 -0.008
28 C5:1 0.013 PC ae C34:2 -0.007
29 LPC a C18:1 -0.013 Tyr 0.006
30 Thr 0.012 C5-M-DC -0.006
31 taurine 0.011 PC aa C32:2 -0.006
32 SM-OH C22:2 0.01 Arg 0.005
33 PC aa C36:4 -0.009 Thr 0.005
34 SM C18:1 -0.009 Val -0.005
35 Lys 0.008 SDMA -0.005
36 PC aa C30:0 -0.008 sarcosine -0.005
37 PC aa C36:1 -0.008 C18 -0.005
38 PC ae C34:1 0.008 LPC a C16:1 0.005
39 SM C18:0 0.008 PC aa C36:5 -0.004
40 Asp 0.007 C0 0.003
41 Gln 0.007 Asp 0.002
42 alpha-AAA 0.007 Cit 0.002
43 C12 -0.007 Orn -0.002
44 Leu 0.006 taurine 0.002
45 sarcosine -0.006 SM-OH C22:2 0.002
46 C2 -0.006 hexose -0.002
47 C18:2 -0.006 Ser -0.001
48 Gly -0.005 Asn 0
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Table A.23 (continued)
Milk Total dairy products
Order # Predictor Coefficient Predictor Coefficient
49 Trp -0.005 Gln 0
50 kynurenine 0.005 Glu 0
51 PC ae C34:2 -0.005 Gly 0
52 Ala -0.004 Leu 0
53 Glu -0.004 Lys 0
54 Pro -0.004 Met 0
55 C18 -0.004 Pro 0
56 Arg 0.003 Trp 0
57 Tyr 0.003 creatinine 0
58 Ac-Orn 0.003 Met-SO 0
59 serotonin -0.003 serotonin 0
60 C4-OH 0.002 C2 0
61 SM C24:1 -0.002 C3 0
62 C4 -0.001 C4 0
63 C5-M-DC -0.001 C4-OH 0
64 Asn 0 C6 0
65 Met 0 C10 0
66 Val 0 C12 0
67 Met-SO 0 C14 0
68 C3 0 LPC a C20:4 0
69 C8 0 LPC a C16:0 0
70 C10 0 LPC a C18:1 0
71 C14 0 PC aa C30:0 0
72 LPC a C14:0 0 PC aa C32:0 0
73 LPC a C16:0 0 PC aa C34:1 0
74 PC aa C32:1 0 PC aa C36:1 0
75 PC aa C34:1 0 PC aa C36:2 0
76 PC aa C34:2 0 PC aa C36:3 0
77 PC aa C36:2 0 PC aa C36:4 0
78 PC aa C36:3 0 PC aa C38:4 0
79 PC aa C38:4 0 PC aa C38:5 0
80 PC ae C36:1 0 PC ae C36:1 0
81 PC ae C36:2 0 SM C18:0 0
82 hexose 0 SM C18:1 0
age 0.001 age 0.001
sex 0 sex 0
test site 0.042 test site 0
smoking status -0.004 smoking status 0
physical activity 0 physical activity 0
lipid-lowering 0 lipid-lowering 0
HRT -0.003 HRT -0.028
BMI 0.001 BMI 0.004
intercept 0.753 intercept 1.229
*The metabolites are presented in order of decreasing absolute value of the elastic net
coefficients, whereas the rest of the predictors used in the models are presented in the
end, along with the model intercept
†Coefficients are derived from the main models, which include age, sex, test site,
smoking status, physical activity, lipid lowering medication, hormone-replacement
therapy, body mass index and the metabolites
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Table A.24 Coefficients of predictors for total and types of dairy consumption as derived
from logistic and linear prediction models without penalisation* in the discovery set of the
Fenland study with the 82 overlapping metabolites with the diabetes case-cohort sub-study
of the EPIC Norfolk study








Ala -143.198 -64.385 -222.506 -13.584 -180.01 -0.005 -0.01
Arg 102.863 -32.195 109.613 181.474 272.256 0.004 0.008
Asn 24.06 114.728 266.29 -66.098 -123.062 0.001 -0.002
Asp 185.378 -234.109 -25.095 -102.595 19.501 0.009 0.004
Cit 203.809 -96.813 -98.783 -25.375 54.178 0.019 0.005
Gln 274.874 -109.97 165.836 -62.224 -201.428 0.009 0.005
Glu -145.642 -199.445 279.685 120.973 -20.849 -0.007 0.001
Gly -136.595 -51.062 285.891 -23.52 -42.357 -0.007 -0.004
His -135.65 285.559 60.437 -66.114 -147.783 -0.025 -0.021
Ile -355.023 -251.954 -186.261 119.865 -179.133 -0.028 -0.009
Leu 200.616 29.299 39.634 -93.706 166.572 0.009 0
Lys 82.517 212.537 -36.287 -301.793 88.642 0.009 -0.003
Met -119.524 151.609 -38.632 -70.469 157.095 -0.002 0.001
Orn -186.071 -67.515 -65.998 233.687 -320.898 -0.02 -0.005
Phe 287.902 90.389 35.253 74.043 399.086 0.028 0.022
Pro -141.136 -206.124 172.771 178.437 5.531 -0.006 0.002
Ser -419.58 -101.194 314.448 41.986 -66.766 -0.016 -0.004
Thr 108.146 47.888 -124.655 -106.31 -38.739 0.015 0.008
Trp 173.413 73.394 288.358 100.846 155.143 -0.012 -0.008
Tyr 134.041 162.386 -96.591 239.259 112.402 0.008 0.014
Val -149.039 -142.483 0.252 37.567 -113.412 0.003 -0.009
Ac-Orn -6.873 107.434 24.685 -20.06 62.816 0.005 0.011
SDMA -35.102 50.987 154.119 166.84 -106.907 -0.017 -0.009
alpha-AAA 165.264 132.012 -58.213 116.278 297.413 0.009 0.011
creatinine 268.785 -198.651 -365.098 -122.46 -57.686 0.018 0.001
kynurenine 57.473 309.143 424.232 0.471 289.037 0.006 0.012
Met-SO 59.006 19.278 -6.195 -22.181 -50.095 0 0.001
trans-OH-Pro -449.838 -513.987 -629.298 118.232 -454.737 -0.017 -0.025
sarcosine -56.738 -183.022 -1.957 13.748 -82.831 -0.007 -0.007
serotonin -155.792 130.609 39.352 -76.589 48.062 -0.007 -0.003
taurine 132.586 301.053 -146.507 -184.242 -58.585 0.015 0.006
C0 213.612 4.828 -466.513 -151.6 41.214 0.032 0.01
C2 18.769 187.212 58.19 71.748 -162.489 -0.01 0.006
C3 220.007 79.017 -117.944 112.887 165.978 -0.004 -0.007
C4 -36.715 1.236 80.884 -90.735 118.254 -0.003 0.001
C4-OH 65.767 -73.698 -19.459 -140.085 -83.43 0.005 0.006
C5:1 207.869 236.072 305.677 -234.622 234.399 0.016 0.014
C5-M-DC 3.706 55.736 -275.6 -52.23 -85.592 -0.003 -0.01
C6 -79.542 -135.688 -58.323 81.349 -29.21 -0.017 -0.005
C8 -69.302 74.544 -251.173 7.656 -24.392 -0.01 -0.025
C10 -99.185 -71.754 7.051 39.404 52.412 0.016 0.023
C12 -69.399 -69.705 95.968 20.611 -18.649 -0.013 0.003
C14 102.44 114.726 91.443 -62.646 76.546 -0.003 -0.005
C14:1 -281.027 -241.69 -64.148 84.54 -197.973 -0.019 -0.028
C16 114.085 -222.309 76.383 186.718 179.984 0.021 0.022
C18 -157.098 -271.604 -114.565 212.189 66.967 -0.007 -0.012
C18:2 -223.682 291.298 -57.803 -430.611 -329.483 -0.008 -0.018
LPC a C14:0 56.283 195.572 248.358 396.581 405.686 0 0.023
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LPC a C16:1 97.78 261.993 115.53 -93.16 105.055 0.024 0.003
LPC a C17:0 345.707 274.542 458.102 631.874 742.721 0.032 0.076
LPC a C18:0 -233.945 -164.559 -340.655 -224.129 -354.051 -0.067 -0.097
LPC a C18:2 -138.403 10.938 -49.501 -110.814 -325.018 -0.011 -0.013
LPC a C20:4 -116.933 -184.359 -107.993 -0.758 -232.628 -0.027 -0.016
LPC a C16:0 -205.259 -4.856 -151.217 -264.12 -209.627 0.022 0.009
LPC a C18:1 -177.67 -109.484 -10.173 30.141 -249.642 -0.026 0.01
LPC a C20:3 435.634 127.195 13.56 -178.954 146.221 0.056 0.023
PC aa C30:0 22.171 153.285 297.543 142.761 301.5 -0.013 0.001
PC aa C32:0 79.444 50.057 -51.247 -530.323 -42.55 0.024 0.003
PC aa C32:1 91.947 -3.814 77.889 101.316 286.851 -0.004 0.017
PC aa C32:2 -36.134 54.99 109.41 40.356 106.996 -0.019 -0.023
PC aa C34:1 -101.395 -115.201 -52.799 63.029 -76.25 0.007 0.003
PC aa C34:2 -100.014 -163.653 -3.562 -162.961 -241.636 -0.001 -0.01
PC aa C36:1 -154.716 -329.106 -227.963 123.277 -162.61 -0.013 -0.012
PC aa C36:2 -123.584 -310.97 -249.56 -127.575 -442.529 0.013 0.009
PC aa C36:3 73.226 40.598 -3.917 -105.874 -75.227 -0.014 -0.012
PC aa C36:4 -289.719 -99.454 -24.099 -51.021 -211.335 -0.021 -0.004
PC aa C36:5 -106.71 166.754 29.327 -203.104 -182.154 -0.028 -0.021
PC aa C38:4 28.582 -242.468 -179.69 -104.857 -224.233 0.012 0.006
PC aa C38:5 107.769 26.643 -69.764 -183.344 -114.367 0.043 0.025
PC ae C34:1 151.597 25.273 166.8 358.062 373.816 0.009 0.013
PC ae C34:2 -18.566 -76.865 -110.281 217.646 103.343 -0.011 -0.013
PC ae C36:1 107.664 16.167 79.216 300.626 394.359 -0.005 -0.001
PC ae C36:2 115.588 93.876 428.374 399.754 523.118 0.005 0.028
SM C16:0 -162.654 -263.869 -160.722 -120.393 -379.806 -0.032 -0.044
SM C16:1 -339.491 57.665 -188.616 -195.507 -414.27 -0.055 -0.059
SM C18:0 245.664 13.04 -39.94 24.299 87.156 0.02 0.013
SM C18:1 -256.47 173.658 -191.415 82.302 -131.605 -0.022 -0.013
SM C24:1 -236.518 -191.344 -106.072 -376.263 -526.657 -0.003 -0.013
SM-OH C14:1 817.199 494.282 742.892 750.773 1,174.93 0.109 0.148
SM-OH C22:1 -172.573 -24.445 87.84 85.343 -32.746 -0.024 -0.015
SM-OH C22:2 243.775 138.598 184.16 72.305 243.677 0.013 0.006
hexose 125.309 -112.988 189.883 -179.92 -164.593 0.003 -0.006
age -4.34 37.505 -68.865 -32.526 11.867 0.001 0.001
sex -213.742 213.438 268.874 -47.195 -67.027 -0.067 0.029
test site 609.148 -154.403 -313.191 -519.754 47.965 0.044 0.002
smoking status -99.732 -792.127 -9.686 186.147 -133.895 -0.006 0
physical activity -14.39 -3.683 0.278 -2.883 7.42 0 0
lipid-lowering -68.158 -89.035 41.098 -44.65 -9.875 -0.024 -0.027
HRT 207.045 -633.632 -432.651 104.984 104.299 -0.041 -0.02
BMI 6.672 30.794 142.298 -27.835 55.053 0 0.004
intercept -22.918 -44.009 18.185 4.086 -7.308 0.941 1.17
*Coefficients are derived from the main models, which include age, sex, test site, smoking status, physical activity, lipid
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Fig. A.1 Receiver operating characteristic (ROC) curves and corresponding areas under
the curve (AUC) for prediction models of metabolite scores reflecting (A) milk, (B)
yoghurt, (C) cheese, (D) butter and (E) total dairy consumption in the internal validation
set (n=4,246) using all the 174 metabolites. Socio-demographic, lifestyle model: age, sex,
test site, smoking status, physical activity, lipid lowering medication, hormone-replacement
therapy and body mass index; Top metabolite score: metabolites with coefficients with
absolute values >mean+2*SD
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Table A.26 Coefficients of predictors in decreasing order of magnitude
of the absolute values* for milk and total dairy consumption as derived
from elastic net linear prediction models † in the discovery set of the
Fenland study with the 82 overlapping metabolites and the odd-chain
saturated fatty acids with the diabetes case-cohort set nested within the
EPIC Norfolk study
Milk Total dairy products
Order # Predictor Coefficient Predictor Coefficient
1 SM-OH C14:1 0.108 SM-OH C14:1 0.162
2 SM C16:1 -0.077 SM C16:1 -0.091
3 LPC a C16:1 0.054 C15:0 0.045
4 LPC a C18:2 -0.037 LPC a C16:1 0.041
5 SM-OH C22:1 -0.023 LPC a C18:0 -0.034
6 LPC a C14:0 -0.021 PC aa C32:2 -0.028
7 creatinine 0.019 SM C16:0 -0.028
8 LPC a C20:3 0.018 LPC a C17:0 0.023
9 LPC a C18:0 -0.017 trans-OH-Pro -0.019
10 Ala -0.013 PC aa C34:1 0.018
11 Lys 0.012 Tyr 0.014
12 taurine 0.012 PC aa C30:0 0.013
13 C14:1 -0.012 Ser -0.011
14 PC aa C34:2 -0.011 C5:1 0.011
15 Tyr 0.01 LPC a C16:0 -0.009
16 C5:1 0.01 PC aa C32:0 -0.008
17 Val -0.009 SM-OH C22:1 -0.008
18 trans-OH-Pro -0.009 hexose -0.008
19 PC aa C32:2 -0.009 C14:1 -0.007
20 PC aa C38:4 0.009 PC aa C32:1 0.007
21 Orn -0.008 PC aa C36:1 -0.007
22 Phe 0.008 creatinine 0.006
23 SDMA -0.008 serotonin 0.006
24 hexose -0.008 taurine 0.006
25 Asn -0.007 LPC a C18:2 -0.006
26 Cit 0.007 PC ae C36:2 0.006
27 C0 0.007 Leu -0.005
28 PC aa C32:0 -0.007 C3 -0.005
29 Gly 0.006 C18 -0.005
30 Pro -0.006 PC aa C34:2 -0.005
31 C2 -0.006 Thr -0.004
32 SM-OH C22:2 0.006 Ala -0.003
33 C15:0 0.005 Asp 0.003
34 Glu -0.005 SM C24:1 -0.003
35 Trp 0.004 SM-OH C22:2 0.003
36 serotonin 0.004 Glu -0.002
37 C18:2 0.004 Phe 0.002
38 LPC a C17:0 0.004 sarcosine 0.002
39 Ser -0.003 C18:2 -0.002
40 Thr -0.003 SM C18:1 0.002
41 alpha-AAA 0.003 Asn -0.001
42 C8 -0.003 Gln -0.001
43 C18 -0.003 Ac-Orn 0.001
44 PC aa C36:5 -0.003 C0 0.001
45 PC ae C34:1 0.003 C4-OH -0.001
46 Met-SO 0.002 PC aa C36:4 0.001
47 C3 0.002 C17:0 0
48 PC aa C36:1 -0.002 Arg 0
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Table A.26 (continued)
Milk Total dairy products
Order # Predictor Coefficient Predictor Coefficient
49 SM C18:0 -0.002 Cit 0
50 His -0.001 Gly 0
51 Met 0.001 His 0
52 PC aa C38:5 0.001 Ile 0
53 C17:0 0 Lys 0
54 Arg 0 Met 0
55 Asp 0 Orn 0
56 Gln 0 Pro 0
57 Ile 0 Trp 0
58 Leu 0 Val 0
59 Ac-Orn 0 SDMA 0
60 kynurenine 0 alpha-AAA 0
61 sarcosine 0 kynurenine 0
62 C4 0 Met-SO 0
63 C4-OH 0 C2 0
64 C5-M-DC 0 C4 0
65 C6 0 C5-M-DC 0
66 C10 0 C6 0
67 C12 0 C8 0
68 C14 0 C10 0
69 C16 0 C12 0
70 LPC a C20:4 0 C14 0
71 LPC a C16:0 0 C16 0
72 LPC a C18:1 0 LPC a C14:0 0
73 PC aa C30:0 0 LPC a C20:4 0
74 PC aa C32:1 0 LPC a C18:1 0
75 PC aa C34:1 0 LPC a C20:3 0
76 PC aa C36:2 0 PC aa C36:2 0
77 PC aa C36:3 0 PC aa C36:3 0
78 PC aa C36:4 0 PC aa C36:5 0
79 PC ae C34:2 0 PC aa C38:4 0
80 PC ae C36:1 0 PC aa C38:5 0
81 PC ae C36:2 0 PC ae C34:1 0
82 SM C16:0 0 PC ae C34:2 0
83 SM C18:1 0 PC ae C36:1 0
84 SM C24:1 0 SM C18:0 0
age 0.001 age 0.001
sex 0 sex 0
test site 0.027 test site -0.006
smoking status 0.005 smoking status 0.012
physical activity 0 physical activity 0
lipid-lowering 0 lipid-lowering 0
HRT 0 HRT -0.034
BMI 0.002 BMI 0.005
intercept 0.727 intercept 1.182
*The metabolites are presented in order of decreasing absolute value
of the elastic net coefficients, whereas the rest of the predictors used in
the models are presented in the end, along with the model intercept
†Coefficients are derived from the main models, which include age, sex,
test site, smoking status, physical activity, lipid lowering medication,
hormone-replacement therapy, body mass index and the metabolites
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Table A.27 Coefficients of predictors for total and types of dairy consumption as derived
from logistic and linear prediction models without penalisation* in the discovery set of the
Fenland study with the 82 overlapping metabolites and the odd-chain saturated fatty acids
with the diabetes case-cohort set nested within the EPIC Norfolk study








C15:0 443.509 328.304 959.961 744.317 1,027.88 -0.001 0.039
C17:0 82.421 297.792 202.873 88.382 284.113 -0.002 -0.004
Ala -271.581 55.321 -27.927 176.974 -204.174 -0.014 -0.003
Arg -93.496 -151.176 -193.711 90.311 -80.403 -0.004 -0.004
Asn -164.492 272.711 237.779 -257.337 142.176 -0.012 -0.004
Asp 210.722 -115.677 -32.838 254.939 327.843 0.004 0.005
Cit 283.941 -53.671 224.898 -120.623 168.491 0.013 0.002
Gln 126.655 -60.888 -241.004 -2.555 -94.849 0.003 -0.003
Glu 9.352 -257.356 -80.664 250.159 90.604 -0.011 -0.009
Gly 10.569 215.733 229.914 -290.172 -173.758 0.011 0
His 141 128.964 340.011 -38.737 -52.426 -0.008 -0.001
Ile -126.546 -267.954 -112.663 91.123 -111.962 0.021 0.021
Leu -14.68 -35.655 -148.194 -10.837 -137.034 0 -0.011
Lys 189.899 215.418 -302.813 -76.33 84.847 0.019 0.008
Met -70.894 -212.273 5.316 -129.018 40.514 0.002 -0.009
Orn -19.895 -172.792 -141.811 112.895 48.146 -0.015 0
Phe 220.827 -95.612 6.095 22.108 62.792 0.009 0.01
Pro -291.827 -76.989 66.065 83.365 33.937 -0.008 0
Ser -213.515 -124.87 -58.359 -112.416 -264.003 -0.009 -0.013
Thr -137.723 141.796 94.078 53.264 -446.445 -0.006 -0.007
Trp 186.324 8.644 100.964 -166.863 135.661 0.007 -0.002
Tyr 374.589 251.808 147.439 251.673 235.258 0.018 0.023
Val -239.251 -70.101 2.299 -107.552 -269.057 -0.029 -0.014
Ac-Orn -146.654 178.755 117.933 35.782 -152.845 0 0.003
SDMA 15.088 149.699 72.049 206.072 -40.048 -0.014 -0.003
alpha-AAA 8.853 151.22 -26.065 -44.684 75.915 0.006 0.004
creatinine 313.395 -176.43 -451.026 106.048 77.394 0.026 0.014
kynurenine 245.017 -81.755 -7.354 206.474 137.66 -0.002 0.001
Met-SO -65.114 -176.48 253.273 -168.553 -15.228 0.005 -0.001
trans-OH-Pro -207.047 -80.291 -831.721 -5.997 -488.35 -0.013 -0.023
sarcosine -25.742 111.835 105.101 -16.274 97.756 0.001 0.004
serotonin 20.651 420.964 298.005 -3.975 302.175 0.006 0.009
taurine 142.344 217.022 -267.702 -197.406 181.212 0.015 0.007
C0 58.644 110.72 -348.054 29.727 2.406 0.015 0.018
C2 -189.338 458.488 177.293 -19.166 9.646 -0.014 0
C3 78.535 24.581 -322.924 -64.308 58.143 0.001 -0.02
C4 13.803 333.057 292.267 -40.734 38.666 0.002 0.004
C4-OH 115.855 152.11 -174.505 -57.758 -9.273 0.002 -0.006
C5:1 111.504 159.056 63.937 -233.919 343.3 0.012 0.015
C5-M-DC 128.979 169.61 -74.594 -4.951 -45.817 -0.003 0
C6 8.41 -68.323 -136.294 -31.096 87.185 0.011 0
C8 -21.288 21.06 59.123 90.258 -12.881 -0.013 0.008
C10 -29.921 -112.19 73.522 46.566 51.98 -0.002 -0.017
C12 -101.84 -118.581 123.157 71.429 48.104 0.004 0.016
C14 13.207 -18.361 -17.051 91.612 97.219 -0.003 0.001
C14:1 -185.475 -40.923 -77.054 -121.889 -236.972 -0.023 -0.022
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Table A.27 (continued)








C16 22.23 -37.394 -75.075 9.309 220.947 0.014 0.01
C18 -138.952 -345.413 -104.466 276.222 -127.191 -0.012 -0.014
C18:2 -104.265 -71.765 -232.925 -261.754 -356.565 0.013 0
LPC a C14:0 -289.231 321.66 379.965 216.924 343.797 -0.038 0.002
LPC a C16:1 398.396 205.315 125.539 -215.482 126.214 0.076 0.045
LPC a C17:0 221.248 182.669 264.079 459.257 515.653 0.031 0.039
LPC a C18:0 -105.151 -16.45 -122.539 -124.504 -185.042 -0.039 -0.023
LPC a C18:2 -301.503 -51.143 175.266 -14.818 -154.686 -0.049 -0.014
LPC a C20:4 69.177 -161.103 -138.501 -138.073 12.114 -0.007 -0.017
LPC a C16:0 -150.954 36.484 -48.713 -151.12 -133.881 -0.016 -0.049
LPC a C18:1 -143.254 -121.772 160.814 66.655 69.307 0.004 0.031
LPC a C20:3 411.744 115.281 -10.041 -5.891 232.816 0.034 0.004
PC aa C30:0 -183.54 198.699 651.294 160.563 293.378 0.016 0.027
PC aa C32:0 -117.383 34.1 -3.259 -333.213 -200.051 -0.021 -0.02
PC aa C32:1 266.229 9.075 310.469 27.636 143.165 -0.024 0.005
PC aa C32:2 -191.157 -13.635 181.429 -11.19 2.195 -0.009 -0.044
PC aa C34:1 7.549 -179.861 79.568 76.592 37.707 0.012 0.035
PC aa C34:2 -297.787 -198.348 -1.19 -27.635 -410.006 -0.008 -0.008
PC aa C36:1 -167.039 -319.803 -49.372 23.865 -130.47 -0.014 -0.033
PC aa C36:2 -119.776 -120.775 -164.997 0.712 -343.533 0.016 0.006
PC aa C36:3 173.691 106.966 -173.268 -65.535 -82.697 -0.009 0
PC aa C36:4 57.851 79.675 -189.691 -150.504 -219.718 0.005 0.023
PC aa C36:5 -284.475 203.446 15.08 -69.217 -91.577 -0.018 -0.009
PC aa C38:4 208.445 -57.73 -327.062 -271.348 -255.354 0.012 0.001
PC aa C38:5 159.641 -45.419 -101.684 -149.425 -78.466 0.026 0.008
PC ae C34:1 308.353 -160.497 71.32 416.825 399.795 0.012 -0.001
PC ae C34:2 -124.343 -220.531 -320.647 148.243 -24.179 -0.001 -0.006
PC ae C36:1 75.656 7.887 97.735 404.559 183.971 -0.002 0.002
PC ae C36:2 134.963 -14.916 274.035 438.122 334.658 -0.015 0.01
SM C16:0 -50.588 -151.915 -95.85 -308.129 -231.74 0.012 -0.024
SM C16:1 -382.357 55.32 -150.801 -392.819 -415.522 -0.104 -0.119
SM C18:0 41.742 24.843 -301.395 134.233 76.575 -0.026 -0.02
SM C18:1 -180.361 199.658 -28.895 -1.177 -138.53 0.019 0.026
SM C24:1 -202.582 -225.907 79.561 4.045 -161.269 0.003 -0.003
SM-OH C14:1 837.69 453.076 459.712 615.332 1,018.34 0.127 0.18
SM-OH C22:1 -140.431 -279.242 -1.234 135.262 56.4 -0.032 -0.017
SM-OH C22:2 66.914 257.571 12.264 -3.195 313.29 0.01 0.006
hexose -240.446 136.508 -136.433 -109.164 -132.01 -0.012 -0.009
age 40.018 9.26 -47.134 -35.111 54.457 0.001 0.001
sex -313.638 357.837 355.415 -183.808 -105.009 0.073 0.205
test site 493.899 -149.587 -667.295 -425.189 -122.968 0.028 -0.011
smoking status -5.387 -676.405 25.127 253.235 29.993 0.01 0.015
physical activity 57.504 -40.73 -60.443 48.692 62.196 0 0
lipid-lowering -94.309 27.962 14.843 -118.142 -33.692 -0.051 -0.041
HRT 186.497 -837.976 -691.876 58.152 2.391 0.03 0.06
BMI -19.891 -5.402 71.992 31.235 123.081 0.002 0.005
intercept -84.536 -25.941 1.017 -55.642 -42.235 0.54 0.686
*Coefficients are derived from the main models, which include age, sex, test site, smoking status,
physical activity, lipid lowering medication, hormone-replacement therapy, body mass index and
the metabolites
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Table A.28 Areas under the curve in the discovery and internal validation sets for the different
dairy prediction models
Discovery set Internal validation set
N 6,035 4,246
Milk
Socio-demographic, lifestyle factors* 0.59 0.59
Metabolite score † 0.71 0.66
Top metabolite score ‡ 0.61 0.61
Socio-demographic, lifestyle factors, metabolite score* 0.73 0.68
Socio-demographic, lifestyle factors, top metabolite score* † 0.64 0.63
Yoghurt
Socio-demographic, lifestyle factors* 0.67 0.67
Metabolite score † 0.7 0.66
Top metabolite score ‡ 0.63 0.62
Socio-demographic, lifestyle factors, metabolite score* 0.72 0.7
Socio-demographic, lifestyle factors, top metabolite score* † 0.69 0.68
Cheese
Socio-demographic, lifestyle factors* 0.62 0.67
Metabolite score † 0.73 0.69
Top metabolite score ‡ 0.67 0.65
Socio-demographic, lifestyle factors, metabolite score* 0.75 0.73
Socio-demographic, lifestyle factors, top metabolite score* † 0.69 0.71
Butter
Socio-demographic, lifestyle factors* 0.6 0.59
Metabolite score † 0.73 0.72
Top metabolite score ‡ 0.68 0.67
Socio-demographic, lifestyle factors, metabolite score* 0.74 0.73
Socio-demographic, lifestyle factors, top metabolite score* † 0.7 0.69
Total dairy products
Socio-demographic, lifestyle factors* 0.56 0.59
Metabolite score † 0.83 0.79
Top metabolite score ‡ 0.78 0.77
Socio-demographic, lifestyle factors, metabolite score* 0.83 0.81
Socio-demographic, lifestyle factors, top metabolite score* † 0.79 0.78
*Socio-demographic and lifestyle factors include age, sex, test site, smoking status, physical activity, lipid lowering medication,
hormone-replacement therapy and body mass index
†Metabolite score created from the 82 metabolites overlapping with the metabolites of the external validation set
‡Top metabolite scores were derived from the top mean+2*SD of the absolute values of the elastic net coefficients from the main
models, which included age, sex, test site, smoking status, physical activity, lipid lowering medication, hormone-replacement therapy,
body mass index and the metabolites



































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Table A.30 Areas under the curve of the logistic models* with or without the fatty acids
C15:0, C17:0, trans-16:1n-7 and the metabolite score (174 metabolites) for total and types
of dairy products










Yes 0.68 0.68 Yes 0.66 0.65
Yoghurt Fatty acids Yoghurt Fatty acids





Yes 0.7 0.71 Yes 0.7 0.7
Cheese Fatty acids Cheese Fatty acids





Yes 0.72 0.73 Yes 0.73 0.72
Butter Fatty acids Butter Fatty acids





Yes 0.74 0.74 Yes 0.73 0.72
Total dairy products Fatty acids Total dairy products Fatty acids





Yes 0.8 0.81 Yes 0.8 0.8
*All models include age, sex, test site, smoking status, physical activity, lipid lowering medication, hormone-replacement
therapy and body mass index
†The top metabolite score includes only the top metabolite signals defined as the metabolites with absolute values of
coefficients >mean+2*SD
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Table A.31 Areas under the curve of the logistic models* with or without the odd-
chain saturated fatty acids C15:0, C17:0 and the metabolite score (82 metabolites
†) for total and types of dairy products in the external validation set of the EPIC
Norfolk diabetes case-cohort study)










Yes 0.63 0.63 Yes 0.63 0.64
Yoghurt Fatty acids Yoghurt Fatty acids





Yes 0.70 0.70 Yes 0.70 0.70
Cheese Fatty acids Cheese Fatty acids





Yes 0.70 0.71 Yes 0.70 0.70
Butter Fatty acids Butter Fatty acids





Yes 0.63 0.78 Yes 0.63 0.77
Total dairy products Fatty acids Total dairy products Fatty acids





Yes 0.67 0.76 Yes 0.71 0.77
*All models include age, sex, test site, smoking status, physical activity, lipid lowering medication,
hormone-replacement therapy and body mass index
†Metabolites approximately matched between the discovery (targeted) set and the external validation
(untargeted) set
‡The top metabolite score includes only the top metabolite signals defined as the metabolites with
absolute values of coefficients >mean+2*SD
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Table A.32 Change in the ranking of top
metabolite signals (>absolute mean+2SD) af-









1 SM(OH) C141 5 4
2 SM C161 34 32
3 PC aa C281 12 9
4 C141 11 7
5 Ile 120 115
6 LPCa C180 49 43
7 LPCa C203 21 14
Yoghurt
1 c4OHPro 15 14
2 SM(OH) C141 2 0
3 SM C240 11 8
4 SM C160 90 86
5 PC aa C281 4 1
6 taurine 1 5
7 PC ae C404 94 87
8 C9 27 19
Cheese
1 SM(OH) C141 2 1
2 PC ae C364 28 26
3 C0 21 18
4 PC aa C424 30 26
5 Trp 96 91
6 LPC a C170 32 26
7 C51 57 50
8 PC ae C362 10 2
9 LPC a C180 13 4
10 C5MDC 112 102
Butter
1 SM(OH) C141 1 0
2 PC aa C320 40 38
3 C9 5 2
4 PC ae C341 9 5
5 LPC a C170 6 1
6 LPC a C140 15 9
7 SM(OH) C161 2 5
8 PC ae C340 4 4
9 C102 48 39
Total dairy products
1 SM(OH) C141 1 0
2 SM C161 163 161
3 LPC a C180 35 32
4 LPC a C170 9 5
5 SM C241 18 13
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Table A.33 Change in the ranking of top metabolite
signals (>absolute mean+2SD) after adjusting for di-








1 SM(OH) C141 5 -
2 LPCa C203 34 -
3 SM C161 12 -
Yoghurt
1 SM(OH) C141 1 0
2 t4OHPro 14 12
3 C18 16 13
4 LPC a C170 42 38
Cheese
1 SM(OH) C141 1 0
2 t4OHPro 28 26
3 LPC a C180 21 18
4 C0 30 26
Butter
1 SM(OH) C141 1 0
2 PC ae C341 5 3
3 LPC a C170 4 1
4 LPC a C140 7 3
5 PC aa C320 70 65
Total dairy products
1 SM(OH) C141 1 0
2 SM C161 163 161
3 LPC a C180 35 32
4 LPC a C170 9 5
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A.5 Chapter 8


























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Glossary of genetic terms
The following definitions of genetic terms were extracted from the website of NSW Centre
for Genetics Education (http://www.genetics.edu.au/publications-and-resources/glossary)
and are provided to facilitate the reader to understand key concepts of genetic epidemiology
included in Chapter 8.
Allele: There are usually two copies of a gene. These two copies are called alleles. In
some cases, one or both alleles will be mutated or altered in some way.
Autosomal: Of the autosome i.e. any chromosome that is not a sex chromosome (that
is not an X or Y chromosome). In humans, the autosomes are the numbered chromosomes
and are given the numbers 1-22. Chromosome 1 is the largest and 22 is the smallest.
Chromosome: A threadlike structure found in the nucleus of all the body cells (except
red blood cells) consisting of DNA and proteins. Each chromosome can be thought of as a
string of beads where every bead represents a gene.
Dominant: Every cell contains two copies of each gene. Where only one of the gene
copies or allele is mutated, and the other allele is ’correct’, but the person is affected by a
genetic condition due to that mutation, the mutation is described as dominant. The mutated
gene is said to be dominant over the other ’correct’ copy of the gene. A condition or
characteristic caused by a dominant gene mutation only requires one of the genes to be
mutated for the person to be affected.
Gene: The basic unit of heredity; a segment of DNA which contains the information
for a specific characteristic or function.
Genome: The complete set of genes carried by an individual or a cell.
Genotype: The genetic constitution of an individual
Heterozygote: An individual who has two different alleles at a particular gene locus,
one on each chromosome of a pair. One allele is usually normal and the other abnormal.
Such an individual may also be referred to as a carrier.
Homozygote: Refers to an individual in whom the two alleles or gene copies contain
identical information. An individual can be homozygous for the correct copies of the gene
or can be homozygous for the mutated copies of the gene.
364 Glossary of genetic terms
Intron: The part of the genetic sequence that is not translated into the final gene
product or message.
Linkage: The tendency for genes or segments of DNA which are located close together
on the same chromosome to be inherited together.
Phenotype: The physical and/or biochemical characteristics of a person, an animal or
other organism which are determined by their genetic make-up and/or environment.
Recessive: Every cell contains two copies of each gene. Each gene contains the
information for a particular gene product, such as a protein. If a gene is mutated, the gene
no longer codes for the gene product. Where an individual has one gene copy or allele
mutated and the other copy ’correct’, the cell will only be producing half the amount of
gene product. If this does not result in any condition for the individual, the mutation is
described as being hidden or ’recessive’ to the correct copy of the gene. An individual
with this genetic constitution is said to be a ’carrier’ of a recessive gene mutation. For a
recessive gene mutation to result in a particular characteristic or a condition, both copies
of the genes must be mutated.
Single Nucleotide Polymorphism (SNP): A DNA sequence variation that involves a
change in a single nucleotide. Variations in the genetic code at the level of one nucleotide
may be useful in certain applications such as assessing the patterns of inheritance via
genetic linkage studies, or forensic DNA testing or DNA fingerprinting.
 
 
